


*The Safety, Efficacy, and Cost Effectiveness
of Therapeutic Apheresis*

July 1983

NTIS order #PB84-114842



Recommended Citation:

Health Technology Case Study 23: The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis (Washington, D. C.: U.S. Congress, Office of Technology Assessment, OTA-HCS-23, June 1983). This case study was performed as a part of OTA's assessment of ***Medical Technology and Costs of the Medicare Program***.

Library of Congress Catalog Card Number 83-600554

For sale by the Superintendent of Documents,
U.S. Government Printing Office, Washington, D.C. 20402

Preface

The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis is Case Study #23 in OTA's Health Technology Case Study Series. It was prepared in response to a request by the Senate Finance Committee, Subcommittee on Health, and is part of OTA's project on *Medical Technology and Costs of the Medicare Program*, requested by the House Committee on Energy and Commerce and its Subcommittee on Health and the Environment. A listing of other case studies in the series is included at the end of this preface.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA's overall project on *The Implications of Cost-Effectiveness Analysis of Medical Technology*. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in various fields. Selection criteria were developed to ensure that case studies provide the following:

- examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);
- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e.g., cost);
- examples of technologies with associated high costs either because of high volume (for low-cost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies either are prepared by OTA staff, are commissioned by OTA and performed under contract by experts (generally in academia), or are written by OTA staff on the basis of contractors' papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, "comments are provided to authors, along with OTA's suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least 30, and sometimes by 80 or more outside reviewers. These reviewers may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA of each case study's scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.

Health Technology Case Study Series^a

Case Study series number	Case study title; author(s); OTA publication number	Case Study Series number	Case study title; author(s); OTA publication number^b
1	Formal Analysis, Policy Formulation, and End-Stage Renal Disease; Richard A. Rettig (OTA-BP-H-9(1)) ^c		Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12))
2	The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning; Judith L. Wagner (OTA-BP-H-9(2))	13	Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13))
3	Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3))	14	Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14))
4	Cost Effectiveness of Automated Multichannel Chemistry Analyzers; Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(4))	15	Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15))
5	Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5))	16	The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16))
6	The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications; Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6))	17	Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (OTA-BP-H-9(17))
7	Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7))	18	The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^d
8	The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8))	19	Assessment of Four Common X-Ray Procedures; Judith L. Wagner (OTA-BP-H-9(19)) ^e
9	The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9))	20	Mandatory Passive Restraint Systems in Automobiles: Issues and Evidence; Kenneth E. Warner (OTA-BP-H-15(20)) ^f
10	The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10))	21	Selected Telecommunications Devices for Hearing-Impaired Persons; Virginia W. Stern and Martha Ross Redden (OTA-BP-H-16(21)) ^g
11	Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11))	22	The Effectiveness and Costs of Alcoholism Treatment; Leonard Saxe, Denise Dougherty, Katharine Esty, and Michelle Fine (OTA-CS-H-22)
12	Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area;	23	The Safety, Efficacy, and Cost Effectiveness of Therapeutic Apheresis; John C. Langenbrunner (Office of Technology Assessment)

^aAvailable for sale by the Superintendent of Documents, U. S. Government Printing Office, Washington, D. C., 20402, and by the National Technical Information Service, 5285 Port Royal Road, Springfield, Va., 22161. Call OTA's Publishing Office (224-8996) for availability and ordering information.

^bOriginal publication numbers appear in parentheses.

^cThe first 17 cases in the series were 17 separately issued cases in *Background Paper #2: Case Studies of Medical Technologies*, prepared in conjunction with OTA's August 1981 report *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

^dBackground Paper #3 to *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

^eBackground Paper #5 to *The Implications of Cost-Effectiveness Analysis of Medical Technology*.

^fBackground Paper #1 to OTA's May 1982 report *Technology and Handicapped People*.

Background Paper #2 to *Technology and Handicapped People*.

OTA Staff for Case Study #23

H. David Banta, Assistant *Director*, *OTA Health and Life Sciences Division*

Clyde J. Behney, *Health Program Manager*

John C. Langenbrunner, *Study Director*

Anne Kesselman Bums, *Project Director*

Cynthia King, *Analyst*

Pamela Simerly, *Research Assistant*

Kerry Britten Kemp, *Division Editor*

Virginia Cwalina, *Administrative Assistant*

Jennifer Nelson, *Secretary*

Mary Walls, *Secretary*

OTA Publishing Staff

John C. Holmes, *Publishing Officer*

John Bergling Kathie S. Boss Debra M. Datcher Joe Henson

Glenda Lawing Linda Leahy Donna Young

Advisory Panel on Medical Technology and Costs of the Medicare Program

Stuart Altman, *Panel Chair*
Dean, Florence Heller School, Brandeis University

Frank Baker
Vice President
Washington State Hospital Association

Mary Marshall
filegate
Virginia House of Delegates

Robert Blendon
Senior Vice President
The Robert Wood Johnson Foundation

Walter McNerney
Northwestern University

Jerry Cromwell
President
Health Economics Research
Chestnut Hill., Mass.

Morton Miller
President
National Health Council
New York, N. Y.

Karen Davis
Johns Hopkins University
School of Hygiene and Public Health

James Mongan
Executive Director
Truman Medical Center
Kansas City, Mo.

Robert Derzon
Vice President
Lewin & Associates
Washington, D. C'.

Seymour Perry
Institute for Health Policy Analysis
Washington, D. C.

Howard Frazier
Director
Center for the Analysis of Health Practices
Harvard school of Public Health

Robert Sigmond
Blue Goss of Greater Philadelphia

Clifton Gaus
Center for Health Policy Stud-es
Washington, D.C.

Anne Somers
Department of Evironment and
Community and Family Medicine
Rutgers University

Jack Hadley
Urban Institute
Washington, D. C.

Kate Ireland
Chairman, Board of Governors
Frontier Nursing Service
Wendover, Ky.

Paul Torrens
UCLA School of Public Health

Judith Lave
Graduate School of Public Health
University of Pittsburgh

Keith Weikel
Group Vice President
AMI
McLean, Va.

Contents

<i>Chapter</i>	<i>Page</i>
Glossary	ix
CHAPTER 1: INTRODUCTION AND SUMMARY	3
Background and Scope of the Case Study.....	3
Summary	4
Apheresis: Definitions, Descriptions and Developments	4
Scientific and Medical Aspects of Apheresis: Issues and Evidence	5
Cost Effectiveness and Reimbursement Policy: Issues and Evidence	6
Implications for Policy.....	7
Organization of the Case Study	7
CHAPTER 2: APHERESIS: DEFINITIONS, DESCRIPTIONS, AND DEVELOPMENTS..	11
Historical Development	12
The Scientific and Medical Basis for Use	15
The Treatment Process	16
Organizational Settings and Staffing	16
Frequency, Intensity, and Duration of Blood Component Exchange	16
Circulatory Access and Replacement Fluids.....	17
Drug Therapy Used With Apheresis.	17
Equipment Technology	18
Centrifugal Systems	18
Membrane Separation Devices	19
Future Technological Directions	19
FDA Device Regulation	21
CHAPTER 3: SCIENTIFIC AND MEDICAL ASPECTS OF APHERESIS: ISSUES AND EVIDENCE	25
Methodological Issues	25
Treatment Design	25
Research Design	26
Patient Selection	27
Outcome Measures	27
Safety: A Review of the Evidence	29
Efficacy and Effectiveness: A Review of the Evidence	30
Protein-Related Diseases	31
Antibody-Related Diseases	32
Immune-Complex Related Diseases.....	37
Cell-Related Diseases	39
Conclusions and Directions for Research	40
CHAPTER4: COST EFFECTIVENESS AND REIMBURSEMENT POLICY: ISSUES AND EVIDENCE	45
Cost Effectiveness	45
Estimating Costs	47
Cost Studies	49
Third-Party Reimbursement	50
Federal Policies	50
Private Sector Policies	52
Conclusions	53
CHAPTER 5: IMPLICATIONS FOR POLICY	57
<i>Appendixes</i>	
A. Health Program Advisory Committee and Acknowledgments	61
B. Apheresis for Hemolytic-Uremic Syndrome	63
C. Apheresis for Inhibitors to Factor VIII.....	68
D. Apheresis in Guillain-Barre Syndrome	72

E. The Cause and Pathological Development of Autoimmune Diseases	76
F. American Red Cross Blood Services Bibliography	77
References	159

Tables

<i>Table No.</i>	<i>Page</i>
1. Reported Use of Therapeutic Apheresis	14
2. Automated Blood Cell Separation Systems	20
3. Selected Diseases Treated With Apheresis	31
4. Therapeutic Apheresis for Miscellaneous Immunological Diseases and Diseases of Unknown Cause	39
5. Present Apheresis Research Activity.	41
6. Ten General Principles of Analysis	46
7. Estimating Costs of Apheresis Therapy	48
B-1. Apheresis Experience Among Patients Diagnosed With Hemolytic-Uremic Syndrome	65
B-2. Variability in Effectiveness of Plasma Exchange Therapy for Hemolytic-Uremic Syndrome as Expressed in Selected Outcome Measures	66
C-1. Apheresis Experience Among Patients Diagnosed With Inhibitor to Factor VIII...	68
C-2. Effectiveness of Apheresis for Factor VIII Inhibitors.	69

Glossary

Air-emboli: A bubble of air obstructing a blood vessel.

Anaphylaxis: An unusual or exaggerated allergic reaction.

Antibodies: The chemicals in the human body's defense system that identify foreign substances, lock onto them, and trigger the body's immune attack on foreign substances. The body makes more than a million antibodies, each different and each capable of recognizing and attacking only one substance—one type virus, one type of bacteria, and so on.

Anticoagulant: Substances inhibiting normal blood clotting.

Antigen: A large molecule, usually a protein or carbohydrate, which when introduced in the body stimulates the production of an antibody that will react specifically with the antigen.

Atrophy: A wasting away; a diminution of the size of a cell, tissue, organ, or part.

Autoimmune: Directed against the body's own tissue.

In autoimmune diseases, pathological antibodies are produced that attack the body's own normal tissue, such as kidney cells in glomerulonephritis or the nerve/muscle junction in myasthenia gravis.

Cost-benefit analysis (CBA): An analytical technique that compares the costs of a project or technological application to the resultant benefits, with both costs and benefits expressed by the same measure. This measure is nearly always monetary.

Cost-effectiveness analysis (CEA): An analytical technique that compares the costs of a project or of alternative projects to the resultant benefits, with costs and benefits/effectiveness expressed by different measures. Costs are usually expressed in dollars, but terms such as "lives saved," "disability avoided," "quality-adjusted life years saved," or any other relevant objectives. Also, when benefits/effectiveness are difficult to express in a common metric, they may be presented as an "array."

CEA/CBA: A composite term referring to a family of analytical techniques that are employed to compare costs and benefits of programs or technologies. The terms as used in this case study means "cost-effectiveness analysis/cost-benefit analysis."

Cytapheresis: A type of therapeutic apheresis involving the selective removal of specific blood cells (red cells, white cells, and/or platelets).

Cytotoxic: A specific toxic action on cells of special organs.

Discounting: A procedure used in economic analysis to reduce to present value those costs and effects that occur in future years. Discounting is based on two premises: 1) individuals prefer to receive benefits today rather than in the future, and 2) resources in-

vested today in alternative programs could earn a return over time.

Drug: Any chemical or biological substance that may be applied to, ingested by, or injected into humans, in order to prevent, treat, or diagnose disease or other medical conditions.

Effectiveness: Same as efficacy (see below) except that it refers to average or actual conditions of use.

Efficacy: The probability of benefit to individuals in a defined population from a medical technology applied for a given medical problem under ideal conditions of use.

Erythrocytapheresis: A type of cytapapheresis involving the removal of red cells.

Extracorporeal: Outside the body, as in extracorporeal tubing for membrane apheresis equipment.

Glomerulonephritis: A variety of nephritis characterized by inflammation of the capillary loops in the glomeruli of the kidney.

Granulocytes: Any cell containing granules, especially a leukocyte containing certain types of granules in its cytoplasm.

Hemolysis: Separation of the hemoglobin from the red cells and its appearance in the plasma.

Hybridoma: A hybrid cell resulting from the fusion of two cells: a lymphocyte producing an antibody and a myeloma (or tumor cell), which grows well in culture and allows hybridoma to be established permanently. The antibodies from a given hybridoma are identical ("monoclonal").

Hyperviscosity: Excessive thickness of blood.

Hypocalcemia: Reduction of the blood calcium below normal.

Immune complexes: Antigen-antibody complexes that can be deposited in tissue. In immune-complex related diseases, such as rheumatoid arthritis, this deposition occurs and produces severe inflammation and tissue damage.

Immunoglobulin: A protein of animal origin endowed with known antibody activity. Immunoglobulins function as specific antibodies and are responsible for the humoral aspects of immunity. They are found in the serum and in other body fluids and tissues. There are five basic classes of immunoglobulins—IgA, IgD, IgE, IgG, and IgM.

Immunosuppressive: The artificial prevention or diminution of the immune response.

Incidence: In epidemiology, the number of cases of disease, infection, or some other event having its onset during a prescribed period of time, in relation to the unit of population in which it occurs. Incidence is a measure of morbidity or other events as they happen over a period of time.

Inpatient care: Care that includes an overnight stay in a medical facility.

Leukocytes: The white cells of blood.

Leukapheresis: A type of cytapheresis involving the reduction of excess white cells, as in leukemia.

Locke's solution: A solution of sodium chloride, calcium chloride, potassium chloride, sodium bicarbonate, and dextrose.

Lymphapheresis: A type of cytapheresis involving the removal of lymphocytes (certain white cells) without depletion of plasma components, making any plasma replacement, therefore, unnecessary.

Lymphocytes: A type of leukocyte, chiefly a product of lymphoid tissue, which participates in humoral and cell-mediated immunity.

Lymphokines: The biologically active soluble factor produced by white blood cells.

Lymphoplasmapheresis: A type of cytapheresis involving a combination of lymphopheresis and plasmapheresis: the removal of both lymphocytes and plasma, usually during a single procedure, and requiring the use of replacement fluids.

Medicaid: A Federal program that is administered and operated individually by each participating State government that provides medical benefits to certain low-income persons in need of health and medical care.

Medical technology: The drugs, devices, and medical and surgical procedures used in medical care.

Medicare: A nationwide, federally administered health insurance program authorized in 1965 to cover the cost of hospitalization, medical care, and some related services for eligible persons over age 65, persons receiving Social Security Disability Insurance payments for 2 years, and persons with end-stage renal disease. Medicare consists of two separate but coordinated programs—hospital insurance (Part A) and supplementary medical insurance (Part B). Health insurance protection is available to insured persons without regard to income.

Monoclonal antibodies: Antibodies derived from a single source or clone of cells which recognize only one kind of antigen.

Myeloma: A malignant disease in which tumor cells of the antibody-producing system synthesize excessive amounts of specific proteins.

Outpatient care: Care that does not include an overnight stay in the facility in which care is provided.

Paraproteinemias: Presence in the blood of a paraprotein (immunoglobulin produced by a clone of neoplastic plasma cells proliferating abnormally), such as a cryoglobulin or a macroglobulin, in amounts not normally observed.

Pathogen: A specific causative agent of disease.

Plasma: The fluid portion of blood in which particulate components are suspended.

Plasma exchange: An often used therapeutic application of apheresis, in which a large volume (up to

5 liters) of plasma is removed and replaced by an equivalent volume of fluids such as fresh frozen human plasma, plasma substitute, or combination of albumin, calcium, and normal saline, depending on the need of the individual patient. Some researchers make a distinction between *plasma exchange* and *plasma infusion*. In the former case, plasma is removed and replaced by a colloid solution, commonly albumin, fresh frozen plasma, or simple donor plasma. Although the plasma replacement in early cases was initiated only for purposes of expansion of the blood vessel "intravascular" volume, later investigators suggested that the administration of fresh frozen plasma had an independent therapeutic effect. This led some investigators to administer it without apheresis; this is described in the literature as plasma infusion.

Plasma perfusion: A multiple separation technique in therapeutic apheresis whereby the patient's plasma is first isolated from the cellular elements and subsequently passed through a filtration medium (either absorptive columns or membranes) to remove unwanted plasma components. The filtered plasma is then returned to the patient along with the cells.

Plasmapheresis: Strictly defined, a type of apheresis that involves the removal of small amounts of plasma. The primary use of this procedure is in the collection of source plasma for subsequent processing into serum fractions, and it has been traditionally found in blood banks and in the plasma collection industry.

Platelets: Oval-shaped structures found in the blood of all mammals and chiefly known for their role in blood coagulation.

Plateletapheresis: A type of cytapheresis involving the reduction of abnormally high levels of platelets.

Prevalence: In epidemiology, the number of cases or disease, infected persons, or persons with disabilities or some other condition present at a particular time, in relation to the size of the population. Prevalence is a measure of morbidity at a point in time.

Proteins: The functional and structural components of cells.

Purpura: A group of disorders characterized by purplish or brownish-red discoloration, easily visible through the epidermis, caused by hemorrhage into the tissues.

Randomized clinical trial (RCT): An experimental design involving the random assignment of human subjects either to an experimental group (in which subjects receive the treatment being studied) or to a control group (in which subjects do not receive the treatment being studied). Also referred to as "randomized controlled clinical trial" or "controlled clinical trial."

Registry: The collection of health or medically related data typically abstracted from a specific document (e.g., medical record or death certificate) using cri-

teria that are applied retrospectively. In practical terms, registries generally cover discrete political or geographic areas.

Reliability: A measure of the consistency of a method in producing results. A reliable test gives the same results when applied more than once under the same conditions. Also called “precision.”

Remission: Abatement or diminution of the symptoms of a disease.

Risk: A measure of the probability of an adverse or untoward outcome and the severity of the resultant harm to health of individuals in a defined population and associated with use of a medical technology applied for a given medical problem under specified conditions of use.

Safety: A judgment of the acceptability of risk (see above) in a specified situation.

Technology: The application of organized knowledge to practical ends.

Technology assessment: A comprehensive form of policy research that examines the technical, economic,

and social consequences of technological applications. It is especially concerned with unintended, indirect, or delayed social impacts. In health policy, the term has also come to mean any form of policy analysis concerned with medical technology, especially the evaluation of efficacy and safety. The comprehensive form of technology assessment is then termed “comprehensive technology assessment.”

Validity: A measure of the extent to which an observed situation reflects the “true” situation. *Internal validity* is a measure of the extent to which study results reflect the true relationship of a “risk factor” (e.g., treatment or technology) to the outcome of interest in study subjects. *External validity* is a measure of the extent to which study results can be generalized to the population that is represented by individuals in the study, assuming that the characteristics of that population are accurately specified.

Vasculitis: Inflammation of a blood vessel.

Introduction and Summary

Introduction and Summary

BACKGROUND AND SCOPE OF THE CASE STUDY

For several centuries, one of the chief therapeutic methods besides the administration of herbs was to attempt to remove noxious substances from the body—either by a general purging, often with drastic laxatives, or still more dramatically, by bloodletting. It has been said that several important persons, Louis XIII of France and George Washington, for instance, were probably killed by such therapy (43,137).

In the past decade, the medical community has increasingly used therapeutic apheresis, * a technology** initially mindful of the ancient practice of bloodletting. In therapeutic apheresis, a patient's plasma and/or blood cellular parts are separated and then removed from the blood and replaced by substitute plasma or a related physiological solution. It is believed that abnormal or harmful substances or cells are thereby removed, leading to a cure or arrest of the disease. Results reported in the scientific literature have been dramatic, and apheresis is being used to treat an increasing number of medical conditions. Skepticism over the validity of such claims and also the high costs of apheresis, however, have touched off recent controversies over this procedure's use.

Therapeutic apheresis is not a new procedure but the extent of its use has grown, and may continue to grow, substantially and rapidly. From 1977 through 1980, procedure volume increased

more than 500 percent, from around 5,000 to over 40,000 procedures per year (108). These estimates were developed retrospectively, because there has been no formal reporting system. In the late 1970's, the rate of growth far outpaced the estimates. The now defunct National Center for Health Care Technology, for example, originally estimated use in 1979 at "hundreds of procedures," only to learn later that the actual procedure volume that year hovered around 16,000 (34). This phenomenal rate of growth between 1977 and 1980 led in turn to general estimates of a half million procedures per year by 1985. Very recently, however, these estimates have been revised downward because of increased concern by health care professionals and third-party payers alike over the technology's safety, effectiveness, and costs (35).

At present, apheresis is primarily accepted as an acute therapy in a small group of relatively obscure diseases, and the number of patients undergoing treatment totals approximately 20,000 (70). Like another new technology of recent years, the computer, therapeutic apheresis might in some respects be characterized as a "solution looking for problems." This is evidenced by the fact that apheresis is being evaluated as a chronic treatment modality for several major diseases, including rheumatoid arthritis, multiple sclerosis, and certain forms of cancer. These disorders represent a potential patient population of hundreds of thousands of cases in this country. Because patient benefits for these disorders have often been only partial, temporary, or equivocal, the emergence of efficacy and, especially, cost concerns is not surprising.

The costs of apheresis have, in fact, become a particularly volatile issue. Therapeutic apheresis may be found to have great potential for reducing illness and death. The potential number of medical conditions and size of the patient population that could be covered, in combination with the costs of apheresis treatment (\$400 to \$1,200

● There is some debate over the proper terms for the procedures described in this case study. The term "plasmapheresis" has been used in the medical literature since 1914. Some argue that the more technically correct and appropriate noun to describe the separation and removal of blood components is "apheresis" (see, e.g., 67). In any case, the reader should be aware that the terms "plasmapheresis" and "apheresis" are used rather interchangeably in the literature as well as in common usage (73).

● *The Office of Technology Assessment (OTA) defines **technology** as the practical application of organized knowledge. The term **medical technology**, as used in this case study, is a drug, device, or medical or surgical procedure used in medical care. (The term may also apply to the organizational and supportive systems within which medical care is delivered, but those systems are not the focus of this case study.) (95).

per treatment, with a significant number of treatments needed per patient), however, point to a possibly vast expenditure of funds on apheresis—in the billions of dollars. This cost issue has been further highlighted because some Americans already question the resource expenditures of over \$1 billion per year for each of three established therapies: coronary bypass surgery, kidney dialysis and transplants, and treatment of newborns in neonatal intensive care units (2).

Major market opportunities for equipment, supplies, and services have been forecast for apheresis technology in the next decade. As a result, therapeutic apheresis has been the subject of investor interest and increased industry participation. Vigorous research, development, and marketing activities have been undertaken by companies in the United States, Europe, and Japan. Major American participants include Haemonetics Corp., International Business Machines (IBM), Baxter Travenol, Cobe Laborato-

ries, Parker-Hannifin, Cordis-Dow, and Millipore Corp. These companies have developed several new therapeutic techniques in response to perceptions of a need to reduce present costs. These techniques are discussed in later chapters, although a description or analysis of the industry or market that has developed around the technology of therapeutic apheresis is beyond the scope of this study.

This case study was prepared as part of OTA's project on "Medical Technology and Costs of the Medicare Program." The entire project is being conducted in response to requests by the House Committee on Energy and Commerce and its Subcommittee on Health, and the Subcommittee on Health of the Senate Committee on Finance. This particular portion of the project responds to a specific request by the Senate Finance Committee's Subcommittee on Health for scientifically based information on the effectiveness of therapeutic apheresis.

SUMMARY

Apheresis: Definitions, Descriptions, and Developments*

Apheresis is a procedure in which blood is separated into its basic components (red cells, white cells, platelets, and plasma), and one or more of these is selectively removed from the blood. It is applied therapeutically for the purpose of curing, alleviating, or treating a disease or its symptoms. The procedure can take several forms, though it is usually accomplished by removing venous whole blood from the body, separating the blood into cellular and noncellular (plasma) parts or "fractions," and returning the cellular fraction to the patient. Just as in kidney dialysis, blood flows from a patient to a machine where it is treated and then returned to the patient by way of an extracorporeal (i.e., outside the body) blood tubing set.

The idea of apheresis first originated in 1914, but it was not until World War II that human

apheresis was considered and used as a means of meeting the increased demand for plasma. Over the last 20 years, **the collection and processing of donor plasma has evolved into a major industry as the demand for plasma fractions, such as albumin, has increased. The first successful therapeutic** use of apheresis was reported in the late 1950's, and during the next few years, reports appeared on the application of apheresis to several diseases. Recent advances during the past decade in basic research, in equipment, and in the technique of apheresis have provided a rationale for carrying out apheresis on a much larger scale and in a wider variety of diseases. To date, apheresis has been used in the treatment of over 75 diseases, and an additional 41 diseases have been identified as possible candidates for this therapy.

The rationale for performing apheresis is to remove one or more components of blood that conceivably contain and carry pathogenic substances linked to a patient's disease process. Various diseases have been increasingly associated with these "abnormal" blood components in the circulation, and these components are believed to

* A number of the scientific and medical terms used in this case study are defined in the Glossary.

initiate or aggravate the disease condition. Apheresis typically has been used in diseases involving excessive levels of three main types of substances found in blood components: plasma protein, antibodies, and immune complexes. Physicians reason that if they can properly identify and remove these problem substances, the disease process may be controlled and the patient's clinical condition should improve. Unfortunately, the effects of apheresis are not well understood. The volume and frequency of blood component exchanges have not been well established, and for the most part, benefits remain anecdotal and difficult to reproduce. Effects of therapeutic apheresis are not generally believed to be curative, but are usually of a temporary nature. Often the procedure is used in conjunction with other treatments, especially drug therapy.

Apheresis treatment is provided almost exclusively through large medical school hospitals and community/Red Cross blood banks. A few commercial, freestanding, independent centers have been established during the past 2 or 3 years, although it appears that this trend may be moderating.

Approximately 5 percent of therapeutic apheresis procedures are performed manually by removing whole blood, spinning it down in a stationary centrifuge, and returning the cellular components to the patient. For most apheresis procedures, however, automated centrifuge equipment is used. Some new major developments in hardware, including adsorption columns and semipermeable membranes that function as molecular sieves, are now either undergoing clinical tests or about to be marketed for general use. These advances in equipment may, in the course of the next decade, be improved or even overshadowed by advances in basic biomedical research or by emerging developments such as biotechnology.

Scientific and Medical Aspects of Apheresis: Issues and Evidence

By almost any standard, treatment by apheresis is still in relatively early stages of development—there are no ideal protocols based on a complete

understanding of reasons for its efficacy.* As a result, much of the existing literature on the effectiveness of apheresis is not of very good methodological quality. The great majority of the reported studies are case reports without any conclusive control groups, blinding, randomization, or other techniques used in controlled clinical trials. Even if standardized protocols could be developed, scientific research on the effectiveness of apheresis might be difficult or undesirable to conduct. Ethical and practical problems have hindered the implementation of randomized clinical trials and other controlled research. Furthermore, the assessment of individual treatments is difficult because apheresis procedures are often provided in combination with drug therapy or other treatment regimens.

Measures of outcome have been a recurring critical issue, as well, because such measures have varied enormously, both across and within disease indications. Outcome measures have sometimes focused on improvement in clinical signs and symptoms, other times focused on biologic and chemical parameters, and in other instances been lacking, not specified, or ill-defined. The reliability and validity** of outcome measures are also problematic because of the nature of several illnesses treated by apheresis which are characterized by abrupt and pronounced changes that may or may not be attributable to therapeutic effects.

Finally, the interpretation of many studies of apheresis that are available is hindered because only particular types of patients, i.e., the “worst cases,” tend to receive apheresis treatments (as a last resort after other conventional therapies fail). Because of these various limitations of the available research evidence, indications about the safety, efficacy, and effectiveness of apheresis are necessarily limited. Nevertheless, some tentative conclusions and directions for treatment can be discerned.

**Efficacy* is the health benefit as measured under controlled conditions such as those in a randomized clinical trial. *Effectiveness* is the health benefit as measured under average conditions of use.

***Reliability* is a measure of consistency of a method in producing results. A reliable test gives the same results when applied more than once under the same conditions. *Validity* is a measure of the extent to which a situation that is observed in a study is reflective of the true situation.

Apheresis appears to be a relatively safe procedure, though it is not without at least short-term risks. The long-term risks of removing useful blood components have been termed “worrisome” and are unclear at best. Apheresis device equipment can also be termed effective in the sense that the technology accomplishes the intended removal of plasma and cells. However, there is very little definitive evidence documenting the widespread success of the technology in actually improving health. The use of apheresis has been generally acknowledged as an effective treatment application for acute therapy in a small group of relatively obscure diseases. These include acquired myasthenia gravis, primary macroglobulinemia (Waldenström’s) and hyperglobulinemias, including multiple myeloma. There is certainly suggestive evidence, too, that therapeutic apheresis is successful in arresting the disease process for some patients with other specific disease conditions. Convincing proof of clinical efficacy, however, is still lacking in the wider variety of diseases in which this treatment is being used.

Large prospective randomized trials, many of them funded by the National Institutes of Health, have been organized for several disease applications in which apheresis therapy has been used, in order to more precisely define what advantages, if any, these treatments may have. Further research will be needed to both compare present treatment approaches with new and emerging blood filtration methods and to test related scientific advances (e.g., the use of monoclonal antibodies).

Cost Effectiveness and Reimbursement Policy: Issues and Evidence

In addition to the issues of health status or other health outcome related effects (i.e., safety, efficacy, and effectiveness) of apheresis, efficiency issues must also be addressed. Two important methods used to assess the costs and benefits of therapeutic apheresis, and develop comparisons among effects, costs, and benefits are cost-benefit analysis (CBA) and cost-effectiveness analysis (CEA). CBA is used to develop comparisons of the benefits of treatments against the resources they consume, with both benefits and costs expressed in dollars. It is difficult to conduct a CBA

for apheresis, because even though the therapy has reportedly lessened suffering and helped prolong lives, reliable estimates of these benefits have yet to be determined and quantified. CEAs are used to evaluate the relative cost of alternative treatments per unit of effectiveness (typically specified in nonmonetary terms). CEAs for apheresis have not yet been conducted because sufficient data on outcomes for apheresis and alternative treatments are lacking.

Nevertheless, the task of evaluating treatments can include the context of costs, for which there have been several general estimates. National expenditure estimates on apheresis therapy, which is currently performed on only selected patients, range from \$3.2 million to \$240 million. **If, however, apheresis therapy is extended in the future to the wider array of diseases to which it has been only experimentally applied thus far, total treatment costs could range from \$650 million to over \$7 billion per year.**

Third-party payment will be an important influence on future adoption, use, and economic effects of therapeutic apheresis, through the funding and reimbursement policies of both private and government insurance programs. Reimbursement policies, like other aspects of therapeutic apheresis, have been the subject of some debate because of the competing factors of cost and therapeutic promise. The development of most of these policies has been recent. On September 15, 1981, the Health Care Financing Administration issued its first national instructions for apheresis, announcing coverage under the Medicare Program for only a small group of relatively rare disease indications.* Medicaid coverage regulations vary from State to State because of changes in Federal funding policies, which provide States with some latitude in deciding how Federal funds are spent. Other governmental programs, such as the Department of Defense’s CHAMPUS, as well as pri-

● On Apr. 20, 1983, Public Law 98-21 provided for extensive changes in Medicare reimbursement policies for hospital-based care. Under the statute, whose provisions will be phased in over 3 years, hospitals will receive a flat fee per patient, set prospectively, on the basis of patient diagnosis in one or more of 467 diagnosis-related groups (DRGs). It is unclear at this point how the DRG-based payment system will affect the adoption and use of apheresis. What is certain, however, is that information on the effectiveness of this treatment will be even more important as physicians and patients face increasingly scarce resources.

vate medical insurers, also vary on which disease indications should be covered, probably stemming from a less than consistent scrutiny of the evidence on safety and efficacy. A widening of Medicare and private insurer coverage of therapeutic apheresis for specific life-threatening complications (e.g., rheumatoid vasculitis) is probable in the near future. But direct cost estimates and the potential cost of possibly premature diffusion alone make it unlikely and unwise that third-party payers will support any broad extension of benefits for apheresis treatment until more valid data is generated. Until evidence is available, therapeutic apheresis will largely be viewed as an experimental technique, not to be considered as a part of routine care. In light of such a situation, present research and clinical trials being carried out assume even greater importance.

Implications for Policy

Several recurring issues in need of further study or resolution arise during an examination of apheresis technology. One issue, which arises because the technology is still in the development stage, is what the appropriate patient criteria for use are, what the appropriate timing of intervention in the course of a disease is, and whether the procedure to be followed in performing therapeutic apheresis is adequately standardized. Such questions are basic in the development of a technology, and research to address these questions is needed, as it forms a necessary foundation for the conduct of well-controlled testing and clinical

trials. Interim apheresis registries could track conditions of use and form a knowledge base for development of well-controlled studies.

A second issue, which arises where conditions of use have been sufficiently standardized, is the lack of and need for well-designed clinical trials of apheresis. There has been a recent infusion of government and foundation funding to offset the high costs of such trials. Should costs continue to be a problem, one alternative might be to have third-party payers, including Medicare, selectively reimburse for therapeutic apheresis in return for clinical data. If implemented properly, this alternative could substantially increase the quality of information available for public and private reimbursement coverage decisions. Evidence of the technology's cost effectiveness could result in yielding substantial budgetary savings. Even if the results of such trials were disappointing, they could lead the way to unexpected advances in research.

A third issue is the possibly transitional nature of apheresis technology. Advances in apheresis equipment, advances in related areas of basic biomedical research, and emerging parallel developments such as biotechnology, indicate that policies affecting therapeutic apheresis must be considered in the larger context of present scientific and technological flux. Considerable attention will be needed to establish the most rational and productive balance between development and support of apheresis technology and that of basic and applied research toward other technologies of similar or more favorable promise.

ORGANIZATION OF THE CASE STUDY

This case study is organized into five chapters. **Chapter 2 provides definitions and descriptions of the various types of apheresis technology, along with perspectives on the history and etiology of apheresis use.** It also describes the current treatment process and future trends, especially as they involve changes in apheresis equipment devices.

Chapter 3 reviews research on the scientific and medical aspects of therapeutic apheresis. Included is a description of methodological issues involved in therapeutic apheresis evaluation. The evidence on the safety, efficacy, and effectiveness of the procedure for the wide range of specific diseases and conditions is examined. The results of three

methodological reviews of therapeutic apheresis for treatment of hemolytic uremic syndrome, acquired Factor-VIII inhibitor, and Guillain-Barre syndrome, prepared for this case study, are also discussed. (The full reviews are presented as apps. B, C, and D.)

Chapter 4 focuses on reimbursement and cost-effectiveness issues. Data and estimates on the costs and benefits of providing therapeutic apheresis and policy issues of the current system are considered in relation to safety and efficacy data regarding treatment. In chapter 5, implications for policy are provided in light of several recurring issues that emerge from an assessment of this technology.

There are six appendixes to this case study. Appendix A acknowledges the valuable assistance of the Health Program Advisory Committee and several other individuals for their review and advice in putting together this report. Appendixes B, C, and D contain the previously mentioned methodological reviews, while appendix E briefly discusses the cause and pathological development of autoimmune diseases. A full bibliography of the scientific literature on therapeutic apheresis, compiled by the American Red Cross and organized by disease categories, is included in appendix F. (The bibliography specific to this case study can be found in the References section following the appendixes.)

2.

Apheresis: Definitions, Descriptions, and Developments

Apheresis: Definitions; Descriptions, and Developments

Apheresis is a procedure in which blood is separated into its basic components (red cells, white cells, platelets, and plasma), and one or more of these is selectively removed from the blood. It is applied therapeutically for the purpose of curing, alleviating, or treating a disease and/or its symptoms. The procedure is usually accomplished by removing venous whole blood from the body, separating the blood into cellular and noncellular (plasma) parts or “fractions,” and returning the cellular fraction to the patient (59,86). **Just as with kidney dialysis, blood flows from a patient to a machine** where it is treated and then returned to the patient by way of an extracorporeal (i.e., outside the body) blood tubing set (39). *

In simplest terms, apheresis involves separating “bad blood” from good. Blood comprises four basic components: red cells, white cells, platelets, and plasma. A typical adult male has **3 trillion red cells in the blood**. The red cells deliver oxygen throughout the body and carry carbon dioxide back to the lungs, where it is exhaled. For every 800 red cells, the blood contains about 1 white cell. The several types of white cells (leukocytes) play key roles in the immunological defense system (lymphocytes), fight infections (granulocytes), and respond to foreign materials. Platelets, of which there are about 1 for every 20 blood cells, are spherical or oval bodies that help the blood to clot. Lastly, plasma, which contains large quantities of proteins, ions, and organic and inorganic molecules, makes up about 55 percent of blood volume, and is the straw-colored, fluid portion of circulating blood. The rationale for performing apheresis is to remove one or more of these components of blood that conceivably contain specific pathogenic substances linked to a patient’s disease process (2).

● In kidney dialysis, however, the dialysis device does not separate the blood’s cellular and plasma components of blood, but rather removes only unwanted metabolites and waste products from the blood (39).

A variety of diseases have been associated with abnormal proteins or blood components in the circulation, which are believed to initiate or aggravate the disease condition. Apheresis typically has been used in diseases involving three main types of abnormal levels of blood components: plasma protein, antibodies, and immune complexes.

Protein-related diseases involve either excessive levels of proteins in plasma (e.g., the macroglobulins in Waldenstrom’s syndrome) or excessive levels of other substances which are “carried” in the blood by the plasma proteins (e.g., thyroid hormone in thyrotoxicosis). The antibody-related diseases are often termed “autoimmune” diseases. Normally, antibodies are produced by the immune system to attack foreign substances (“antigens”) such as bacteria. However, in autoimmune diseases, pathological antibodies are produced which attack the body’s own normal tissue, such as kidney cells in glomerulonephritis or the nerve/muscle junction in myasthenia gravis. **Immune complexes** are antigen-antibody complexes that can be deposited in tissue. In immune-complex related diseases, such as rheumatoid arthritis, this deposition occurs and produces severe inflammation and tissue damage (117).

The therapeutic goal of apheresis is to decrease the levels (through removal) of these abnormal components in the circulating blood. Physicians reason that if they can properly identify and remove these problem substances, the disease process may be controlled and the patient’s clinical condition should improve.

Unfortunately, the effects of apheresis are not well understood. For the most part, its benefits remain anecdotal and difficult to reproduce. Its effects are not generally believed to be curative; rather, they are usually of a temporary nature. Often the procedure is used in conjunction with other treatments, especially drug therapy, making it difficult to assess the effectiveness of

apheresis therapy. The scientific and medical applications of apheresis and corresponding levels of efficacy and effectiveness gained from such treatment are discussed at length in chapter 3.

Apheresis can take several forms: plasmapheresis, plasma exchange, plasma perfusion, cytappheresis, lymphapheresis, and lymphoplasmaphoresis. Strictly defined, plasmapheresis involves the removal of small amounts of plasma. The primary use of this procedure is in the collection of source plasma for subsequent processing into serum fractions, as has been traditionally found in blood banks and in the plasma collection industry.

The plasma separation process, however, has been increasingly used over the last decade for therapeutic uses. The therapeutic application most often includes two general techniques. In **plasma exchange**, a large volume (up to 5 liters) of plasma is removed and replaced by an equivalent volume of fluids such as fresh frozen human plasma, a plasma substitute, or combinations of albumin, calcium, and normal saline, depending on the need of the individual patient. * **Plasma perfusion** refers to a multiphase separation technique in which the patient's plasma is first isolated from the cellular elements and subsequently passed through a filtration medium (either adsorptive columns or membranes) to remove unwanted plasma components. The filtered plasma is then returned

*It is important to note that some researchers also make a distinction between **plasma exchange and plasma infusion**. In the former case, plasma is removed and replaced by a **colloid** solution, commonly albumin, fresh frozen plasma, or simple donor plasma. Although the plasma replacement in early cases was initiated only for purposes of expansion of the blood vessel "intravascular" volume, later authors suggested that the administration of fresh frozen plasma had an independent therapeutic effect. This led some investigators to administer it without **apheresis**; this is described in the literature as plasma infusion.

HISTORICAL DEVELOPMENT

The idea of apheresis (from the Greek, **aphair-esis**, meaning "taking away") first originated in 1914 with a group headed by John J. Abel at Johns Hopkins Medical School (1), which attempted to develop an artificial kidney in dogs. In the course

to the patient along with the cells (39,108). Only recently has equipment for this technique been approved for general therapeutic use by the Food and Drug Administration (FDA) (see "Equipment Technology" section later in this chapter for a more complete discussion of plasma perfusion).

Another form of therapeutic apheresis is **cytappheresis**, the selective removal of specific blood cells (red cells, white cells, and/or platelets). Cytapheresis is usually subdivided according to **plateletapheresis** (the reduction of abnormally high levels of platelets), **leukapheresis** (the reduction of excess white cells, as in leukemia), and **erythrocytapheresis** (the removal of red cells) (105). Cytapheresis can also include **lymphapheresis**, the removal of lymphocytes (certain white cells) without depletion of plasma components, making any plasma replacement, therefore, unnecessary. **Lymphoplasmaphoresis** is a combination of lymphapheresis and plasmapheresis: the removal of both lymphocytes and plasma, usually during a single procedure, and requiring the use of replacement fluids.

There are different types of hardware used for performing apheresis. One is a centrifugal type machine that spins the blood in a chamber and uses centrifugal force to separate the heavier parts of the blood from the lighter ones. The filter type uses a flat sheet or hollow fiber porous membrane to separate the larger blood components from the smaller. This type is only capable of removing plasma from the cellular portion of the blood: plasma and plasma proteins easily pass through the pores in the membrane but the red cells, white cells, platelets, and large protein molecules are too large to pass. Thus, the filter-type device can only perform plasmapheresis. Although the centrifugal type of device is more versatile, the filter type has fewer moving parts and is easier to operate (39).

of this work, they investigated the effect "of the repeated removal of considerable quantities of blood, replacing the plasma by Locke's solution," and infused the mixture back into the dogs. They showed that dogs were able to tolerate the ex-

change of substantial volumes of plasma and coined the term “plasmapheresis” to describe the procedure. They suggested that “if this method can be employed without harmful consequences it is probable that it could be applied in a bolder manner in a greater variety of morbid states than the time honored but often debatable” medical practice of bloodletting (67).

For 30 years, plasmapheresis was used mainly in experimental animals, to study the metabolism of plasma proteins (67). The possibility of human plasmapheresis was first considered during World War II as a means of meeting the increased demand for plasma. A trial conducted in 1944 demonstrated the feasibility of weekly plasma donations. Over the last 20 years, the collection and processing of donor plasma has evolved into a major industry as the demand for plasma fractions, such as albumin, has increased (108).

The first successful therapeutic use of plasmapheresis was reported in the late 1950's in the management of macroglobulinemia (thickened blood due to the accumulation of proteins) and multiple myeloma, a malignant tumor of the bone marrow. During the next few years, reports appeared on the application of plasmapheresis to several other diseases, including rheumatoid arthritis in which a circulating “plasma factor” was implicated. In these treatments, a small volume of plasma was removed and replaced only with isotonic saline solution. The procedure was slow and limited by the tendency to deplete all plasma proteins (both beneficial and harmful) if conducted too often (108).

Over the past 10 years, however, several types of cell separators have been developed which can efficiently separate large quantities of red cells,

white cells, platelets, and plasma either continuously or on an intermittent basis. In the late 1960's, International Business Machines (IBM) Corp. developed the first cell separator in a collaborative effort with the National Cancer Institute. A second type of device was subsequently developed commercially by Haemonetics, Corp., of Massachusetts (80,108).

During the early 1970's cell separators were mainly used by blood banks to harvest white cells and platelets, and to collect plasma and plasma fractions intended for transfusions or research. But as apheresis evolved more toward a therapeutic application in the mid 1970's, the equipment-embodied cell-separator technology was easily and rapidly modified for therapeutic use.

The medical literature has reflected this burgeoning interest in therapeutic apheresis. In 1981, there were approximately four times as many articles on the subject appearing in Index Medicus as there were in the 1970's (85). To date, apheresis has been used in the treatment of over 75 diseases, and an additional 41 diseases have been identified as possible candidates for this therapy (22,117). Table 1 presents a listing of diseases in which the use of therapeutic apheresis has been reported in the medical literature.

The growing interest in therapeutic apheresis is further exemplified by the emergence of professional societies, scientific meetings, and journals devoted entirely to this subject. The membership in the American Society for Apheresis has increased dramatically, for example, and the journals, *Plasma Therapy and Transfusion Technology* and *Journal of Clinical Apheresis* have initiated publication only within the last 5 years (43,49,145).

Table I.—Reported Use of Therapeutic Apheresis

Acute necrotizing hemorrhagic encephalomyelitis	Hepatic coma
Acute disseminated encephalomyelitis	Herpes gestations
Acute post-streptococcal glomerulonephritis	Hodgkins disease
Acute rheumatic fever	Hypercholesterolemia
Addison's disease	Hyperglobulinemic purpura
Adenocarcinoma of the colon	Hypersensitivity pneumonitis
Adenocarcinoma of the breast	Hypersensitivity angiitis
Allergic granulomatosis and angiitis	Hypertension
Amyloidosis	Hypertriglyceridemia
Amiotrophic lateral sclerosis (ALS)	Hyperviscosity syndrome
Ankylosing spondylitis	Idiopathic membranous glomerulopathy
Aplastic anemia	Idiopathic thrombocytopenic purpura (ITP)
Atopic dermatitis	Idiopathic hypoparathyroidism
Atrophic gastritis type A	Insulin resistant diabetes mellitus due to anti-receptor antibody
Autoimmune infertility & gonadal insufficiency	Juvenile onset diabetes mellitus
Autoimmune hemolytic anemia (AIHA)	Lipoid nephrosis
Autoimmune hypogammaglobulinemia	Lymphomas
Autoimmune neutropenia	Malignant melonoma
Behcet's syndrome	Mixed connective tissue disease
Bone marrow transplant	Multiple sclerosis
Bronchial asthma	Multiple myeloma
Bronchogenic carcinoma	Myasthenia gravis
Bullous pemphigoid	Necrotizing cutaneous angitis
Cardiac allograft rejection	Neuroblastoma
Chronic membranoproliferative hypocomplementemic glomerulonephritis	Other neoplasms
Chronic active hepatitis	Pemphigus vulgaris
Circulating anticoagulant (Anti-Factor VIII)	Pernicious anemia
Cold agglutinins	Poisoning or overdose (paraquat, mushroom, digitalis)
Colon carcinoma	Polyarteritis nodosa
Crohn's disease	Polymyositis
Cryogenic fibrosing alveolitis	Post-transfusion purpura
Cryoglobulinemia	Primary cardiomyopathy
Cutaneous vasculitis	Primary biliary cirrhosis
Dermatitis herpetiformis	Proliferative/membranoproliferative glomerulonephritis
Dermatomyositis	Psoriasis
Discoid lupus erythematosus	Pure red cell aplasia
Disseminated intravascular coagulation (DIC)	Rapidly progressive glomerulonephritis
Dressier's syndrome	Raynaud's disease
Eaton-Lambert syndrome	Refsum's syndrome
Endomyocardial fibrosis	Reiter's disease
Erythema multiform	Renal allograft rejection
Fabry's disease	Reye's syndrome
Felty's syndrome	Rhesus iso-immunization
Gastric carcinoma	Rheumatoid arthritis
Gaucher's disease	Sarcoidosis
Giant cell arteritis	Scleroderma
Glomerulonephritis in subacute bacterial endocarditis	Sjogren's syndrome
Goodpasture's syndrome	Subacute bacterial endocarditis
Graft versus host disease	Systemic lupus erythematosus (SLE)
Graves' disease	Takayasu's arteritis
Graves' ophthalmopathy	Thrombotic thrombocytopenic purpura (ITP)
Guillain-Barre syndrome	Thyroid storm
Acute	Ulcerative colitis
Chronic	Viral hepatitis
Relapsing	Waldenstrom's macroglobulinemia
Hashimoto's thyroiditis	Wegener's granulomatosis
Hemolytic uremic syndrome	White cell isoantibodies
Henoch-Schonlein purpura	

SOURCE: Off Ice of Technology Assessment, 1983.

THE SCIENTIFIC AND MEDICAL BASIS FOR USE¹

For therapeutic use, apheresis technology came along at an opportune time—when there is a growing support for the theories that a large number of chronic conditions occur because the antibodies of the immune system, instead of attacking foreign substances as they are supposed to, attack the body's own tissues. This results in a build-up of so-called immune complexes, which are carried in the blood (34).

Indeed, many diseases that appear to respond to apheresis seem to have common elements: they reflect failures in the immune system, the body's defense network of sorts, which is designed to protect the individual against viruses, foreign cells, and some poisons. The cells of the immune system circulate in the blood and lymph systems and also reside in specialized tissues such as the thymus, spleen, and lymph nodes. There are two principle modes of immunity: humoral immunity and cell-mediated immunity. Humoral immunity is realized through antibodies, which are proteins produced by lymphocytes and which circulate in the blood system. They represent the major defense against bacterial infections. Cellular immunity is realized through lymphokines (also lymphocyte products) which are responsible for a variety of phenomena including influencing migration of inflammatory cells, allergic responses, dilation of the blood vessels, rejection of tissue grafts, and other foreign matter.

The foreign agents eliciting immune responses are called *antigens*, which may be circulating proteins or other types of molecules, or also substances on the surfaces of bacteria or foreign tissue. When individuals are exposed to an antigen, their lymphocytes respond by making antibodies specifically directed against the antigen. The antibodies have binding sites which attach to the antigen, and together they form aggregates called *immune complexes*. These complexes cir-

culate in the bloodstream and are subsequently processed and removed from the body by cells located in the liver, spleen, and other organs. It is in this manner that foreign agents are eliminated.

The formation of immune complexes triggers many other reactions. One of these is activation of the *complement system*, a set of proteins found in the blood. Complement products can kill cells with antigens on them, such as bacteria. They also attract inflammatory cells to the area where the antigen-antibody reactions are taking place, and these cells assist in clearing the antigens.

Antigens also stimulate specific lymphocytes, *Tlymphocytes*, to proliferate and then differentiate. Some T lymphocytes differentiate into "helper cells" which assist the lymphocytes in making antibodies; some differentiate into "killer" lymphocytes which can kill foreign cells having antigen on their surface; and some cells differentiate into "suppressor cells" which regulate the immune response by inhibiting further antibody production against the specific antigen.

The exact nature and extent of the immune response depend on many factors: the type of antigen, its route of entry into the body, the genetic makeup and state of health of the host, the types of antibodies made, and the relative proportions of helper, killer, and suppressor cells generated. A fundamental property of an individual's immune system is that it distinguishes between the antigens on the body's own tissues and those on foreign agents. Unfortunately, this system occasionally breaks down, and individuals mount immune responses, most often antibody production, directed against their own tissues. The diseases that result from such a disorder are referred to as "autoimmune diseases."

The cause and pathological development of autoimmune diseases are thought to be due to several mechanisms: *inactivation reactions*, *cytotoxic reactions*, immune complex deposition, *anaphylaxis*, and *delayed hypersensitivity*. These mechanisms are briefly discussed in appendix E.

¹Unless otherwise noted, this section is condensed from Frost & Sullivan, Inc., *In-Vivo Hemodetoxification and Hemoprocessing Markets in the U. S.*, New York, June 1981.

THE TREATMENT PROCESS

Until the advent of automated devices, the process of apheresis was exhausting and time-consuming, requiring 4 to 5 hours, for example, to remove about 1 quart of plasma. It was a tedious manual procedure in which the patient's blood was drawn one bag at a time, separated in a centrifuge so that the target components could be removed and the remaining blood returned to the patient before drawing another bag. Now, automated cell separators reduce the procedure to a simple, straightforward exchange which can be completed in 2 to 4 hours. The patient is connected to the cell separator, which draws the blood, separates the components, and returns the rest of the blood to the patient. The volume exchange for each procedure is calculated for each patient according to size and the type of treatment modality desired (73).

Organizational Settings and Staffing

Apheresis treatment is provided almost exclusively through large medical school hospitals and community/Red Cross blood banks. A few commercial, freestanding, independent centers have been established during the past 2 or 3 years; however, it appears that this trend maybe moderating.

Most of the existing therapeutic apheresis programs originally evolved in conjunction with the donor facilities at community and hospital blood banks. However, some of the larger institutions have since established independent hemapheresis units (which undertake and perform hemodialysis and other blood filtration procedures in addition to apheresis) that perform leukapheresis and plateletapheresis in addition to plasma exchange.

The hemapheresis center is normally staffed by nurses with special (usually "on-the-job") training in the operation of the cell separator equipment, administration of replacement fluids, circulatory access techniques, and the treatment of apheresis complications. The operation of the unit is directed by a physician, often a hematologist.

In most centers the actual procedure is conducted by one or two apheresis nurses. Usually a physician (who is often the center director) is

required to be immediately available in the event that complications should develop. In many of the smaller facilities the supervising physician is in direct attendance during the procedure, while in the larger apheresis centers he or she is generally on call within the unit (49,108).

Frequency, Intensity, and Duration of Blood Component Exchange

The volume and frequency of blood component exchange depend to a large degree on the disease being treated as well as the individual patient response. To date, temporal considerations have been more influenced by factors such as circulatory access and scheduling than by uniform protocols, because the metabolism, kinetics, and pathogenicity of the abnormal blood component constituents removed by apheresis have not been largely established (144). Therapy regimes that have evolved from clinical studies vary as a result. Frequency of treatment ranges from an average of 3 procedures in the management of myeloma to approximately 16 treatments per year for patients with chronic myasthenia gravis (though severely debilitating rheumatoid arthritis may require up to 30 treatments in the first year, with that number decreasing thereafter (47). The average for all reported diseases treated by apheresis ranges from approximately 5 to 15 treatments per year per patient, at a volume of 3.2 liters (the range is 2.0 to 4.5 liters per treatment) (108).

A survey of hospital and community blood banks by Scoville Associates (108) indicated, however, an average of only 5.6 treatments per patient during 1980. Average volume per exchange was 2.8 liters (1.5 to 3.5 liters). The difference in treatment schedules was hypothesized to stem from several factors. For example, the hospital and blood bank averages included schedules for just 30 different disorders, many of which were treated on an acute basis only. Also, a major objective in acute treatment settings is to obtain rapid patient response, and several centers reported that they usually terminated apheresis after three to four procedures if improvement is not apparent.

Circulatory Access and Replacement Fluids

The initial step in the apheresis procedure involves the removal of whole blood from the patient for subsequent separation. Blood vessel access is not (because of relative infrequency) as critical in this procedure as it is, for example, in chronic hemodialysis in end-stage renal disease applications. The preferred access site is a simple puncture into the vein at the elbow. Such access is adequate for most patients even with extended series of exchanges.

The cellular elements and replacement fluids are normally returned to a vein in the other arm. Other return sites include the femoral vein, forearm, or through a small vein in the hand or foot. Sometimes repeated apheresis treatment requires surgeons or other qualified staff to make a shunt or fistula, a sort of permanent “tap,” between an artery and a vein to give them ready access to the circulatory system. Clotting and site infections can be significant complications in the use of such taps.

Crystalloid solutions (saline, Ringer’s solution, Hartman’s solution) are normally used routinely as replacement fluid in small volume apheresis procedures. These involve removal of 1 to 2 liters of plasma every 2 to 3 weeks as in some cases of hyperviscosity syndrome. Crystalloid solutions have the advantage of low cost. Larger volume exchanges run the risk of protein depletion, and as a rule, require the use of colloid replacement fluids such as albumin, fresh frozen plasma (FFP), or plasma protein fraction (PPF). Guidelines have been established by FDA for safe levels of plasma donation without protein replacement in the average size adult.

The typical plasma exchange schedule, however, involves the removal of between 2 to 3 liters of plasma at a frequency of two to four times per week, and protein replacement is routinely utilized in these cases. In general, little is known about the correlation between specific disease states and the effectiveness of various replacement fluids.

Fluid volume removal is normally replaced on an equal basis. Since continued exchange will remove the replacement fluids as well as the pa-

tient’s own plasma, many centers are now beginning to use a technique whereby saline or dextran is administered at the beginning of the procedure, and the protein replacement portion (FFP, PPF, or albumin) is infused toward the end of the exchange, thus saving some depletion of the more expensive colloid solutions. This proportion of protein solution to total replacement fluid generally ranges between 30 to 50 percent (2,108).

Drug Therapy Used With Apheresis

Apheresis used alone has often provided only transient results because cells making deleterious antibodies may not be affected. In fact, a “rebound effect” can sometimes occur when apheresis is used by itself, where posttherapy antibody levels are even higher than initial levels. Apheresis has, as a result, often been more effective when used in combination with immunosuppressive, cytotoxic, and anti-inflammatory drugs. Examples of these include cyclophosphamide, azathioprine, and steroids (e.g., prednisone). In specific diseases these drugs may be used individually, but they are often administered together.

Steroids have many complex physiological effects, and the effects of those that are responsible for suppressing inflammation, immune responses, and symptoms of autoimmune diseases are not completely understood. The basis of action of cytotoxic drugs is that they kill lymphocytes, and thus antibody production is decreased.

With corresponding drug therapy, then, the low levels of circulating antibodies and immune complexes rapidly achieved by apheresis may be maintained, since the rebound effect and the production of antibodies by lymphocytes are inhibited by the drugs. Other internal repair mechanisms can then intercede, correcting or repairing damage induced by the immune complexes or antibodies. For example, in myasthenia gravis, lowering the concentrations of antibodies allows new muscle membrane proteins to be synthesized. Removal of circulating immune complexes may also “desaturate” the immune complex clearing mechanisms in lymphoid tissues and allow them to function better.

For some diseases, apheresis, in combination with the drugs, has been claimed to result in complete remission. For others, long-term benefits have been reported. On the other hand, some diseases thought to be autoimmune have not been improved with apheresis. Ultimately, the suc-

cessful treatment of autoimmune diseases will hopefully rely on more specific therapies, because these drugs are not without complications and can deplete sets of cells required for other vital bodily functions (42). Chapter 3 more fully discusses scientific and medical issues of apheresis.

EQUIPMENT TECHNOLOGY

Centrifugal Systems

Approximately percent of therapeutic apheresis procedures are performed manually by removing whole blood, spinning it down in a stationary centrifuge and returning the cellular components to the patient as is done in source plasma collection. Manual apheresis has the advantage of requiring relatively inexpensive equipment. However, its use is limited to the removal of small volumes of plasma (1.0 liter or less) due to the inconvenience and additional time requirements as compared to automated techniques. The rate of plasma removal using manual procedures runs approximately 2.5 hours per liter as compared to 1.2 hours per liter for automated cell separation equipment. Also, the use of a "non-closed" (manual) system runs a higher risk of infection and presents the possibility of returning the wrong red cells to the patient.

Most apheresis procedures are earned out using automated centrifuge equipment. There are two basic types of automated centrifuge devices currently in use for apheresis: the intermittent flow centrifuge (IFC) and the continuous flow centrifuge (CFC). Both systems provide a significant advantage over manual apheresis because large volumes of plasma maybe processed quickly with less risk to the patient. IFC devices are manufactured and sold by Haemonetics Corp. The Haemonetics Model 30 is used for a majority of the therapeutic plasma exchange procedures performed in the United States. This equipment was originally designed for the collection of leukocytes and platelets, but has been found to be effective for large-scale plasma exchange, lymphoplasma-pheresis, and lynmphapheresis as well (57,108).

Generally, in the IFC system, blood is drawn from a blood vessel in the arm and pumped through tubing into a disposable bowl placed in the well of the centrifuge. Several lines are also connected to the bowl leading to collection bags. Anticoagulant is introduced into the lines to be mixed with the donor/patient blood. As centrifugation begins, plasma is the first fraction of blood to be separated and collected into a container. Platelets and white cells are separated later in the process and are then diverted to other containers. When the process is completed, the pump action reverses and the red cells remaining in the bowls are reinfused into the patient via a blood vessel in the other arm. When the bowl is empty the whole procedure is repeated according to the effect desired (42).

The first CFC device, developed in the late 1960's by IBM in conjunction with the National Cancer Institute, involved a rotating seal which enabled the continuous infusion of whole blood and removal of separated components from a rotating centrifuge bowl. This basic CFC design was commercialized by IBM as the Model 2990 and by American Instrument Co. (now a division of Travenol Labs) as the Aminco Centrifuge. A few of these devices are still in use throughout the United States, but most have been replaced by the Haemonetics 30 or the second generation IBM Model 2997, which employs a ring-shaped separation channel in place of the previous centrifuge bowl (108).

Fenwal Laboratories (Division of Travenol Labs) has developed a series of CFC instruments (CS-3000 and Centrifuge II) in which the blood and separated components pass to and from the

separation chamber through continuous tubing, without the requirement of a rotating seal. A counter rotating mechanism is employed which enables the tubing to be continuously unwound without twisting or coiling (108).

The **disposable** equipment associated with apheresis varies according to the technique used. In the mechanical plasma separation application, disposables consist of tubing to connect the patient to the equipment and vice versa. A disposable bowl is fitted into the centrifuge and the separation takes place, then various bags are connected to the bowl to collect plasma and/or cellular components. Since the cellular components extracted during therapeutic apheresis are not intended for reuse in other patients, the disposables are simpler and less costly than those used in most blood banking operations (42).

Some new major developments in hardware are now undergoing clinical tests. These include adsorption columns and semipermeable membranes that function as molecular sieves.

Membrane Separation Devices

Membrane separation devices have evolved as parallel flow (or flat sheet) or hollow fiber configurations similar to those found in basic types of hemodialyzers. Membrane blood separators can only filter plasma from cellular components (as opposed to centrifugal systems that can also be used for specific cell separation (cytapheretic) applications as well as for plasma exchange). Membrane systems, however, are expected to allow simpler, more rapid and more precise treatment. They are currently being reviewed by FDA (see the "FDA Device Regulation" section of this chapter) for use in this country.

The **disposable** associated with membrane apheresis represent the heart of the plasma separation process. The plasma separation membrane replaces the centrifuge in this process. Tubing is used to form the extracorporeal circuit, very much as in dialysis (42).

Membrane disposables are expected to be initially priced higher than those required for centrifugal machines, but it should be noted that in Europe, especially in West Germany, many clini-

cians use Asahi-brand hollow fiber membranes in preference to centrifugal systems despite the higher costs. Membrane systems, in fact, are dominant in the European and Japanese markets, accounting for 70 to 80 percent of the procedures performed. If membrane systems become accepted in U.S. markets, manufacturing costs could decrease substantially to reflect economies of scale, although prices are not expected to approach those for similar membranes used for dialysis (\$15 to \$25 per patient). Apheresis membranes will be initially more expensive because they are more delicate and their quality constraints will be more demanding in terms of pore size and wall thickness consistency (117).

Future Technological Directions

Current apheresis therapy most often entails plasma replacement, which is not only expensive but also removes normal as well as adverse plasma constituents. Therefore, future systems will likely emphasize more selective removal of undesirable components and return of the patient's own plasma, probably by one of the following techniques. (In most instances, however, the specific unwanted target components underlying the usefulness of plasma exchange have not yet been precisely identified.)

Cryoprecipitation.— Certain macromolecules in the plasma will precipitate (come out of suspension) when exposed to cold temperatures. When applied in conjunction with apheresis, the patient's plasma is circulated through a cold environment, where cryoprecipitation occurs. These precipitants are removed by filtration, and then the remaining plasma and cells are returned to the patient. Other macromolecules in addition to unwanted immune complexes are removed by this procedure. However, most normal plasma proteins, especially albumin, are retained. Parker-Hannifin Co.'s Cryomax system (see table 2) is likely to be the first selective entry.

Mechanical Double Filtration.— Another approach to avoiding the replacement of plasma in therapeutic apheresis is double filtration for

⁴This section is drawn from L. F., Rothschild, **Unterberg**, Towbin, "Therapeutic Apheresis," New York, 1981.

Table 2.—Automated Blood Cell Separation Systems

Manufacturer	Models	Introduced	Approximate machine cost	Approximate disposables	Components separated	Membrane type
<i>Continuous-flow centrifuge</i>						
Fenwal (Travenol/Baxter)	CS-3000	1979	\$32,000	\$65-\$80	Cells, plasma	None
IBM Biomedical	Centrifuge II 2997	1981 1977	\$19,700 \$31,000	\$65-\$80 \$65-\$60	Cells, plasma Cells, plasma	None None
<i>Intermittent-flow centrifuge</i>						
Haemonetics	30	1973	\$21,600	\$65-\$80	Cells, plasma	None
	V-50	1980	\$28,800	\$30-\$49	Cells, plasma	None
	PEX	1980	\$25,600	\$49 avg.	Cells, plasma	None
<i>Continuous-flow membrane</i>						
Cobe Laboratories	Centry TPE	March 1982	\$30,000	\$80-\$90	Plasma only	Sheet
Parker-Hannifin	Cryomax	1983 (expected)	\$30,000	\$390	Plasma only	Hollow fiber
Fenwal (Travenol/Baxter)	PS-400	Late 1981 in Europe	\$20,000	\$75-\$200	Plasma only	Hollow fiber
Organon-Teknika (Netherlands)	Curesis	NA	NA	NA	Plasma only	Hollow fiber
Asahi (Japan)	Plasmaflo@	(expected)	NA	\$175-\$400	Plasma only	Hollow fiber
Fresenius (West Germany)	Plasmaflux@	NA	NA	NA	Plasma only	Hollow fiber
Toray (Japan)	Plasmax	NA	NA	NA	Plasma only	Hollow fiber

^aDisposables cost estimates are exclusive of other disposable items such as needles, saline bags, transfer pecks, and priming solutions which may also be used in conjunction with apheresis treatments.
NA - Not available.

SOURCES: L. F. Rothschild, Unterberg, Towbin, 1981; Friedman, American Red Cross, 1982; Collins, Cobe Labs, 1982; Clurys, Du Pent, 1982.

albumin recovery. This type of system is essentially similar to the Cryomax approach, but the plasma fraction is not chilled to produce precipitation. After the plasma is separated from the cellular fractions by a membrane, it is passed through another membrane with smaller pores that allow only smaller proteins, especially albumin, to pass while retaining the larger macromolecules including immunoglobulins. The albumin fraction is then combined with the cellular fraction and returned to the patient. Albumin recovery systems are under investigation by several groups around the world.

Hemoperfusion.— This approach involves the passage of whole blood through an adsorption column (e.g., activated charcoal) to remove the unwanted substance(s) somewhat more selectively. This technique has been used primarily for detoxification in acute chemical or drug poisonings, and is being investigated for use in renal and liver failure. It offers desired speed in emergency cases, but for broader usage is not as promising as plasma perfusion (described below) due to un-

wanted cellular adherence to the columns and potential release of particles from columns.

Adsorptive Plasma Perfusion. -This technique should permit considerably greater selectivity in plasma component removal. It involves separation of plasma from cells, passage of the plasma through an adsorptive column (which specifically removes the unwanted substance), and return of the plasma and cells to the patient. Beneficial results in recurrent breast cancer treated with plasma exchange with on-line adsorptive column treatment have been recently claimed. Future development of adsorptive plasma perfusion may well involve columns containing monoclonal antibodies produced to specifically bind and, thus, selectively remove undesirable constituents.

Artificial Antibodies.—As previously discussed, antibodies are synthesized by lymphoid tissue to bind to and inactivate antigens (generally foreign substances). Antibodies are made to bind very selectively to specific antigens like a key in a lock. Unwanted plasma antibodies could be re-

moved by allowing them to bind to: 1) their natural antigenic “lock,” which is held within a column (“antigenic columns”); or 2) an artificially produced antibody to the patient’s normal and unwanted antibody, which is held within a column through which the plasma passes (“antibody column”), i.e., the unwanted antibody serves as an antigen to another manufactured antibody.

Artificial antibodies are currently produced for use in diagnostic tests using the immune response of goats or other animals especially for radioimmunoassays, a technique that allows an accurate measurement of biological and pharmacological substances in the bloodstream and other fluids of the body. Recent advances in gene splicing technology have given rise to monoclonal antibody or hybridoma (hybrid cell) techniques which allow the production of more specific antibodies at less cost than conventional procedures.

Based on current technology, economic factors may delay the development of monoclonal antibody columns for on-line plasma processing, except in certain diseases with only a few definable types of unwanted factors. Other diseases may require a constellation of distinct antigens or antibodies held within a column. Another potential problem for immunological adsorption columns concerns the quantity of unwanted substance to be removed. If, for example, large quantities of immune complexes must be removed, large quantities of antibodies would be needed in the columns. It is currently uncertain whether monoclonal production would be inexpensive enough to allow **columns** with large quantities of manufactured antibodies to be economically feasible.

FDA Device Regulation

FDA regulations currently governing centrifugal cell separators on the market only concern blood banking applications. The centrifugal apheresis devices have been classified into Class III (premarket approval or PMA) for use with donors in the preparation of blood products,³ although data indicate many clinicians are using them for therapy. Machines introduced prior to

the Medical Device Amendments in 1976 have “grandfathered” approval, while centrifugal machines introduced after 1976 have gained FDA premarket approval by being considered by FDA to be substantially equivalent to pre-1976 devices.

The membrane-based devices being developed, and mostly being tested in clinical trials, were not permitted to simply file a premarket notification with FDA. * They are considered essentially new devices for which investigational device exemptions (IDEs) are required. IDEs are granted with sufficient demonstration of safety, after which the clinical protocols can then proceed. Results of the clinical trials are used in filing for premarket approval. No attempts to reclassify separators as Class II devices, which would only require the manufacturers to meet certain product performance standards specifications, are being pursued at present. It has been speculated that the industry, on its own initiative in the future, could develop such standards for FDA approval (117).

In October 1981, the Gastroenterology-Urology Device Section of FDA’s General Medical Devices Panel reviewed the Cobe Centry TPE System for total plasma exchange and recommended approval of the device for therapeutic applications. On March 16, 1982, FDA granted the premarket approval.

A second and third membrane apheresis PMA (Parker-Hannifin’s Cryomax model and Asahi’s Plasmaflo model) were reviewed and recommended for approval by FDA’s General Medical Devices Panel in late 1982. These models are expected to receive FDA’s premarket approval and to be generally marketed in early 1983 (21). In addition, there are currently in excess of 20 IDEs for conducting clinical investigations with apheresis membrane devices which are manufactured by five different manufacturers (39).

● Sec. 510(k) of the 1976 Medical Device Amendments requires any distributor of a medical device intended to be marketed for the first time to file a notice with FDA at least 90 days in advance to permit the **agency** to decide whether the device is determined to be “substantially equivalent” to devices already on the market before the passage of the 1976 amendments or, if not found to be substantially equivalent, whether the device needs **premarket** approval to assure safety and efficacy.

³21 CFR 864.9245.

Scientific and Medical Aspects of Apheresis: Issues and Evidence

Scientific and Medical Aspects of Apheresis: Issues and Evidence

Various types of apheresis procedures have been performed on a clinical basis for many years, but the number of patients and types of diseases treated have risen significantly in the last 5 years. This increase is partially due to increased understanding of the disease and partially due to engineering advances in equipment technologies. By almost any standard, treatment by apheresis is still in relatively early stages of development—there are no ideal protocols based on a thorough understanding of reasons for its efficacy. Nevertheless, there is an increasing flow of clinical data, sometimes describing dramatic patient improvement, supporting the view that apheresis is a rapidly emerging technology with significant promise (117). Such evidence of treatment effectiveness^{*} is even today, however, often based on unsystematically collected data. Because of the

^{*}**Effectiveness** is the health benefit as measured under average conditions of use. **Efficacy** is the health benefit as measured under controlled conditions such as those in a randomized clinical trial (104).

METHODOLOGICAL ISSUES

An assessment of any medical technology depends, in part, on the development of a strategy for identifying technologies to be evaluated, and on the development of clear-cut standards for the quality of the evidence that should be considered (104,147). **Proper research methods, as a result, become essential to the evaluation of a technology. Careful and systematic investigations are the essential ingredients in establishing that observed effects are due to the medical intervention. Poorly and haphazardly conducted research studies are plagued with problems of validity and generalizability, and these same issues continue to hinder attempts to perform assessments based on such research (85).**

paucity of high-quality research, conclusions about the safety, efficacy, and effectiveness of apheresis are necessarily limited, although some tentative conclusions and directions for treatment can be discerned.

The present chapter analyzes the methodological problems in conducting apheresis research and examines available evidence of the safety, efficacy, and effectiveness of apheresis. Following a discussion of methodological issues, several major reviews of apheresis research will be summarized and evaluated. This chapter will further include the findings of a primary literature review and assessment of apheresis in the treatment of three diseases—namely, hemolytic uremic syndrome, acquired Factor-VIII inhibitor, and Guillain-Barré *syndrome*—where preliminary reports and evidence have been “promising” in utilizing apheresis as a therapeutic approach (57). (A full discussion of these findings can be found in apps. B, C, and D.) Present and future research directions for apheresis will be considered last.

To be valid, and to permit generalizations to be drawn, there must be clarity about what is being tested, what is being compared, which subject populations are involved in the research, and what is being measured. Operationally, these four factors refer to treatment design, research design, patient selection, and outcomes (102,104).

Treatment Design

Treatment design involves the extent to which clarity about the “active ingredients” of the procedure being tested can be achieved. Questions to be answered include whether the procedure involves a single treatment, a combination of treat-

ments, or a combination of treatment and non-treatment factors. Often, because apheresis procedures involve a complex interplay of many factors (i.e., are “multivariant”), resulting research is confounded by inability to separate effects (85,117). The extent to which researchers can measure the impact of any one component of the procedure is limited when all patients receive or have access to multiple components concurrently. Clarity of design is essential to being able to attribute outcomes to particular treatments or packages of treatments.

Because it is an experimental therapy, the use of apheresis has not been standardized. Protocols in various studies have varied considerably. Variables include type of replacement fluid, patient selection criteria, other medications, extended respirator and intensive care therapy, and intensity of plasma exchange (i.e., frequency and volume exchanged in each treatment). Many different protocols have been used for apheresis, even in the treatment of a single disease, so that variation in procedures undoubtedly has led to variation in results (117). These variations make it difficult if not impossible to achieve some level of comparison between studies.

For example, apheresis is often used as an “adjuvant” or auxiliary therapy to immunosuppressive since drug therapy is required to inhibit the rebound reaction (see ch. 2). Although apheresis is used as an adjuvant therapy to anti-inflammatory, immunosuppressive, or cytotoxic drugs, this fact should not be viewed as a threat to its validity: any improvement in the course of disease would not be attributable to the pharmacological agents alone, but rather to the combined (or synergistic) effects of apheresis and drug therapy. There could be a validity problem, however, with the application of the treatment when the concomitant drug therapy varies across studies. When there is differential improvement by type of drug used, the integrity of the definition of treatment is called into question. Even though treatments are presented in the literature in a similar fashion, they may, in fact, operate quite differently. It may be the case that the combined (or synergistic) effects of apheresis and drug therapy may vary according to the strength of the drug and the frequency with which it is administered (85).

Even if standardized protocols could be developed, however, it may be difficult or undesirable to administer them. This is particularly problematic if, for research purposes, assignment to one group or another is required. Use of sham treatment in control groups, for example, could very well cause this group of patients to suffer some of the side effects of apheresis, raising the ethical question of subjecting them to a potentially harmful technique. (See the next section, “Safety: A Review of the Evidence,” for a discussion of the safety and risk issues of apheresis.) Another obvious ethical concern is whether treatment can be denied patients in near-fatal, disease states in which apheresis has served as the treatment of last resort. A third issue is the difficulty of setting up a controlled trial for some rare autoimmune diseases such as Goodpasture’s syndrome, which strikes only 2 out of 100,000 people in the United States every year (22,34). Even with autoimmune diseases of more common occurrence, such as systemic lupus erythematosus, presentation of disease symptoms can occur with such broad variety that setting up controlled trials for these conditions can become equally difficult (49).

A last treatment design problem has to do with possible placebo effects of the therapy itself. For example, among the several explanations discussed in the literature for improvement of patients undergoing apheresis was the possible psychotherapeutic effects of such therapy. Few studies have involved double blind protocols (with sham apheresis) which are necessary to eliminate the possibility of “placebo improvements” (85, 117,138).

Research Design

A valid research design, perhaps most importantly, requires systematic comparison. At minimum, these comparisons involve the same group of patients measured before and after treatment; optimally, they involve two or more randomly assigned groups tested before and after treatment (147). The latter design is usually called a true experiment (25,122) or, in health care research, a randomized clinical trial (RCT). The advantage of this design, in comparison to nonrandom selection design, is that differences in outcomes can

be attributed more confidently to the treatment, rather than preexisting differences in the sample populations tested (102,104).

Evaluating existing research on apheresis therapy poses difficulties in any attempt to draw valid conclusions. Other than references to prior treatment regimens, comparative data on treatment groups are typically not available. The great majority of the reported studies are case reports without any concurrent control groups, blinding, randomization, or other techniques used in controlled clinical trials.

Because of operational and ethical difficulties discussed with treatment design issues (see last section), even well-controlled trials of apheresis have often suffered from small sample sizes. A small sample size for RCTS, for example, can undermine what would otherwise be considered a strong methodological study (85).

Related to the issue of appropriate research design is that multivariate analyses (useful for examining differences by such factors as age, sex, disease state, and levels of disability) are largely unavailable. Studies which statistically control outcome data have not been conducted because such analyses require large patient populations and present difficulties both in data collection and analysis. Their absence from the literature, along with the lack of controlled research, hinders informed development of treatment strategies tailored to subpopulation needs (102,104).

Apheresis researchers, however, seek to generate systematic experimental designs with comparison group information and multiple, longitudinal outcome measures. This is reflected by the increasing number of well-controlled studies both recently reported and presently being carried-out (see “Conclusions and Directions for Future Research” section of this chapter).

Patient Selection

Patient selection refers to decisions concerning eligibility for treatment, selection for participation in research, and availability for follow-up research. If the general population of apheresed patients is not represented in the research samples because of particular characteristics (e.g., poorer

prognosis, differing remittive drug regimens), the generalizability of the research findings is limited and selection bias is bound to occur (102,104).

Perhaps the most severe sampling problem in apheresis studies stems from the use of the therapy as a last resort, i.e., for the “worst cases.” Typically, apheresis therapy has been initiated when patients diagnosed with a specific disease do not respond to other conventional therapies, including drug therapies and other forms of dialysis such as hemodialysis or peritoneal dialysis. The application of apheresis in the most severe cases of rheumatoid arthritis with multiple complications, for example, has been reported to correspond to what Warner (141) has labeled the “desperation reaction,” where patients and their physicians are highly motivated to try any promising therapy because continued painful symptoms or death is the likely outcome without the therapy and there is no effective alternative treatment available. High motivation can likely play an important role in the patient’s response to a number of subjectively determined outcome criteria, producing overly optimistic results (85). At the same time, if only the “worst cases” are selected for apheresis, its potential effectiveness may be underestimated because of its initiation at too late a stage in the disease process.

There is further the problem of statistical regression. According to Wortman and Saxe (147) “statistical regression arises when patients are chosen because of their extreme value on a laboratory test or other measure relevant to treatments.” Investigators have found that subjects with high pre-treatment measures tend to have lower scores after the treatment-when, in fact, no change has taken place. This is the statistical regression effect and it can deceive clinicians into believing that apheresis has been effective when it really has not (85).

Outcome Measures

A recurring critical issue in any attempt to analyze the effectiveness of a medical technology is the selection of **appropriate endpoints for evaluating the success or failure of the intervention. The way in which outcomes of apheresis therapies are measured significantly affects interpretation of apheresis therapy research.**

Measures of assessment of outcome have varied enormously, both across and within disease indication categories. Appropriate outcome measures have at times focused on clinical improvement (i.e., improvement in signs and symptoms) often with reports of dramatic change. Clinical improvement measures, as defined in some apheresis studies, however, have been relatively “soft” or subjective endpoints where researchers fail to establish standards for any of the criteria, but rather look for general improvement across series of measures (85). In other instances, outcome measures are lacking, not specified, or ill-defined in the written reports.

Even when clinical outcome measures are well defined, it is important that the appropriate measure is used. When an outcome measure such as mortality is used to evaluate the effectiveness of apheresis therapy for hemolytic-uremic syndrome (characterized by a decay of general kidney function), for example, the benefits of apheresis may be substantially understated. Plasma exchange may, for instance, bring about a temporary improvement in the patient’s clinical status, but other intervening factors may ultimately cause the patient’s death. Most clinicians, however, would probably agree that the ultimate objective of apheresis therapy is to increase the likelihood of survival, which suggests that survival (or mortality) is an important outcome measure of the efficacy of apheresis and should not be disregarded. The need for chronic dialysis, on the other hand, could be a more appropriate outcome measure for determining the ultimate success of plasma exchange in the treatment of hemolytic-uremic syndrome, since renal failure is a major element of the syndrome (146).

Interpretation of clinical improvement for many diseases treated by apheresis is further confounded by the variability produced by a basic “remitting-exacerbating” nature of the illness. Specifically, rheumatoid arthritis, systemic lupus erythematosus, myasthenia gravis, and Guillain-Barré syndrome patients frequently experience abrupt and

pronounced improvements or worsening of the illness, and such spontaneous change can easily be mistaken for therapeutic effect. This leads to greater variability in results in clinical studies and to difficulty in interpreting the results (115,117).

Outcome measures have also focused on hematologic and biochemical parameters, such as nerve conduction tests, and immunological changes. These measures have not necessarily demonstrated any correlation to clinical responses, though. Sometimes they have preceded or coincided with clinical changes, while for other disease indications, they have shown no association to a clinical response. In short, such outcome measures may be necessary but insufficient indicators of the efficacy of apheresis (146). Simon (127), for example, recently reported the case of a woman with pemphigus vulgaris (a sometimes fatal skin disease), where apheresis allowed the disappearance of both skin and tissue-fixed antibodies, but in which the patient continued to have manifestations of the disease and subsequently died.

Perhaps hematologic and biochemical parameters could be combined in some way as co-measures with clinical improvement outcomes. The problem of combining multiple evaluation criteria and assessing the significance of the results is a difficult one. For example, researchers may choose to assign different weights to each outcome measure which would lead to disagreement and perhaps a lack of consensus on the effectiveness of apheresis therapy for certain disease indications (146).

Finally, outcome measures probably suffer from the lack of systematic documentation of adverse effects. As a new technology is developed, used, and reported, researchers and practitioners may also champion the technology for a variety of personal and professional reasons (104). Apheresis therapy reporting may have been biased by the tendency to report the more successful uses of the new therapy (115).

SAFETY: A REVIEW OF THE EVIDENCE

The paucity of well-controlled trials creates difficulties for an unreserved assessment that apheresis is a safe procedure. Doubts about short- and long-term safety have neither been confirmed nor dispelled. Plasmapheresis, in its use for plasma collection in blood banking, has been demonstrated as a relatively safe procedure. Apheresis in its other forms does appear to carry some degree of risk, however, and results in a number of complications, especially when applied repeatedly for therapeutic applications (42).

Observational studies have generally asserted the procedure to be relatively safe and well tolerated by most patients, especially when performed by experienced personnel. Close and continual monitoring of the patient (at least during initial treatments that establish individual tolerance levels), however, is usually recommended to ensure that any complications be treated immediately should they occur. Unlike hemodialysis, where patients receive their blood back almost unchanged, there is much more room for error and miscalculation, because of the newness of the replacement mixture (80).

Borberg (13) reported that in 205 plasma exchange procedures, 4 serious reactions (anaphylaxis, collapse) and 23 moderate reactions (chills, stiffness, low blood calcium, fever) occurred. He further stated that the incidence of side effects was significantly reduced as the apheresis staff gained experience with the procedure.

Wenz and Barland (144) conducted a 10-year historical survey on plasma exchange and reported it to be a relatively safe procedure when performed by experienced personnel. Among the risks reported were massive extracorporeal blood clotting and viral hepatitis. However, there have been no clinical problems with hemorrhagic tendencies despite decreases (30 percent) in platelet counts following plasma exchange. Coagulation parameters returned to normal levels within 4 to 24 hours following the exchange.

In another study of the safety issue, Sutton, et al. (130), reported that of 887 plasma exchange procedures performed over a 3-year period, minor complications (chills, hypotension) occurred in

less than 7 percent of the exchanges. Citrate (an anticoagulant) toxicity (paresthesia and nausea) occurred in 5 to 15 percent of the exchanges. Sutton, et al. (130), did not see an increased risk of infection in these patients despite low levels of the third component of complement and immunoglobulins following the exchanges and the concurrent use of immunosuppressive drugs. In addition only two episodes of minor bleeding were reported, a further argument that patients receiving this type of therapy may not be predisposed to bleeding (145).

Generally, the major risks associated with apheresis may be grouped according to:

- **Problems of technique.** —Manual apheresis may run a risk of infection and also presents the possibility of returning the wrong cells to the patient. Automated centrifuge machines may create problems with hemolysis, platelet loss, or air-emboli entering the patient's bloodstream.
- **Complications associated with fluid transfer.** —Improper control of fluid balance may result in hypertension or cardiac arrhythmias in patients undergoing plasma exchange. The infusion of large volumes of intravenous fluids at room temperature may lead to hypothermia or chill reactions.
- **Side effects with replacement fluids.** —Each of the major types of protein replacement carries particular risks. The use of fresh frozen plasma may introduce hepatitis. Immunological reactions, including chills, skin eruptions, wheezing, and stiffness may occur in patients who are allergic to certain antigens in transfused plasma. The use of plasma protein fraction or albumin may cause hypotensive reactions or may result in platelet loss (108).

Long-term effects of fluid replacement are also worrisome. Removing lymphocytes and large volumes of plasma repeatedly could decrease immunocompetence levels, increasing the probability of patients' susceptibility to pneumonia and the like. A related concern is the risk of removing the cells that carry long-term immunological memory-B-cell

lymphocytes. Apheresis could make patients susceptible to some childhood disease they had been immune to formerly. Such diseases are often more serious for adults than children (57,80).

- **Anticoagulant reactions.** —The use of large amounts of citrate may result in hypocalcemia (low blood calcium) which requires the addition of calcium to the replacement fluids. The use of heparin as an anticoagulant can result in significant platelet loss (thrombocytopenia) if the procedure is extended over long periods (108).
- **Immunosuppressive drug reactions.** —As already discussed in chapter 2, the apheresis procedure is often accompanied by an immunosuppressive drug treatment regimen. These drugs are not without complications,

either. Since they are relatively nonspecific, the immune system in general is suppressed, and consequently patients on these drugs are prone to infection. These potent drugs can also damage vital organs, sometimes resulting in life-threatening inflammation and fibrosis of lungs, heart, intestines, or kidneys (42).

While all the above situations can result in serious complications, particularly for severely ill patients, many of these problems appear to occur rarely and often can be overcome by prompt diagnosis and attention. There have been six known fatalities among the thousands of apheresis procedures reported performed during the last 10 years (108).

EFFICACY AND EFFECTIVENESS: A REVIEW OF THE EVIDENCE

Ideally, for any procedure, criteria should exist for the selection of patients; the intensity, frequency, and duration of the procedure; the choice of replacement fluids; the immunological parameters to be followed; and the clinical evaluation of the effects of the procedure. However, after a decade of use no firm guidelines for apheresis have been established (144).

Despite the lack of well-controlled and generalizable research on the efficacy and effectiveness of apheresis, there is a vast literature that describes and analyzes treatment effects. Because it is highly anecdotal, discussion of the evidence has sometimes been confined to speculation and generalities. **Still, the amount of research has dramatically increased and its quality has improved in recent years.**

This section presents and analyzes the evidence from several reviews of available literature. The discussion includes the scientific and medical assessments conducted by the National Center for Health Care Technology (NCHCT or Center) for Medicare coverage and reimbursement policy, *

● The National Center for Health Care Technology (now succeeded by the Office of Health Technology Assessment) in the Department of Health and Human Services has been authorized by law since

and a number of assessments undertaken by medical associations and specialty societies. This section further presents evidence from original assessments completed for this case study on three disease indications for which apheresis therapy has been used experimentally, with somewhat favorable and hopeful results.

Medical applications and effects of apheresis are usually classified according to medical discipline, such as neurology and hematology, or according to the type of abnormal blood component removal (i.e., protein, antibody, immune complex, or cell). This section will utilize the latter approach. Table 3 classifies various diseases by both categories. For protein, antibody, and immune-complex component removal, the apheresis modality generally employed is plasma exchange, with lymphapheresis and lymphoplasmapheresis used to a lesser extent.

1978 to advise on issues related to the evaluation of health care technologies for reimbursement purposes by the Health Care Financing Administration and other third-party payers. For a complete discussion concerning this process the reader is referred, for example, to references 103, 104,

Table 3.—Selected Diseases Treated With Apheresis

Medical discipline	Plasma exchange			
	Protein related	Antibody related	Immune complex related	Cytapheresis
Hematology	Waldenstrom's macroglobulinemia	Idiopathic thrombocytopenic purpura (ITP) Factor VIII antibody Rh disease	Thrombotic thrombocytopenic purpura (ITP) ^b	Sickle cell Polycythemia
Rheumatology	—	—	Rheumatoid arthritis (RA) ^a Systemic lupus erythematosus (SLE) Scleroderma Other	Rheumatoid arthritis
Neurology	—	Guillain-Barré syndrome (GBS) Myasthenia gravis (MG) Multiple sclerosis (MS) ^a Polymyositis	—	Multiple sclerosis
Oncology Nephrology	Multiple myeloma —	Transplant rejection Goodpasture's syndrome (GS)	Other cancers Progressive nephritis Glomerulonephritis	Some leukemias
Other	Toxins Poisons Hypercholesterolemia Thyrotoxicosis Primary biliary cirrhosis Hypertriglyceridemia	—	—	—

^aPreferred apheresis therapy not yet decided; clinical studies have employed plasmapheresis, Plasma exchange, lymphapheresis, and/or lymphoplasmapheresis.
^bDiscussed in this chapter Under "Antibody Related Diseases."

SOURCE: Adapted from L. F. Rothschild, Unterberg, Towbin, 1981.

Protein-Related Diseases

As discussed in chapter 2, protein-related diseases involve either excessive levels of proteins in plasma or excessive levels of other substances which are "carried" in the blood by the plasma proteins.

Hyperviscosity Syndrome

The earliest therapeutic use of plasmapheresis was in the management of hyperviscosity syndrome associated with paraproteinemias. This group of diseases is characterized by the production of enormous amounts of protein molecules known as immunoglobulins, which are endowed with known antibody activity. *Waldenstrom's macroglobulinemia* results in the overproduction of one type of immunoglobulin-IgM and an increase in plasma viscosity or thickening leading to ocular, neurological, and cardiovascular problems. *Multiple myeloma*, a malignant tumor of the bone marrow, involves excessive production of other types of immunoglobulins—IgG, IgA,

IgE, or IgD—and may result in various symptoms including hyperviscosity syndrome, excessive bleeding, and renal failure. *Cryoglobulinemia* is characterized by the presence of abnormal immunoglobulins which "precipitate" or form antibody-antigen complexes in temperatures below 37 C. Symptoms include neurologic abnormalities, purpura, and "skin ulcers" (108).

Clinical studies as early as 1960 have generally confirmed the effectiveness of massive plasma exchanges in treating the hyperviscosity syndrome. A major reason for these findings is that patients' symptoms have classically correlated with levels of viscosity and direct removal of substances. Observers have rarely been led astray, with symptoms normally following the lowering of the viscosity levels in these disease states (58,108,127).

In Waldenstrom's syndrome, there seems to be little dispute that apheresis is an effective palliative measure in the removal of excess protein. In severe cases, it probably represents the only effective

treatment modality (42,117). With multiple myeloma, apheresis has been demonstrated to be effective in the acute treatment of crises associated with this condition. Improvement is temporary, but it can permit chemotherapeutic attempts to bring the disease under control. In terminal patients who fail to respond to chemotherapy, apheresis is finding use as a palliative measure to manage hyperviscosity symptoms. The disease is ultimately fatal, but apheresis has improved and prolonged the quality of life for some patients (117). Several groups have reported definite responses from apheresis for treating the symptoms of cryoglobulinemia, but there are no known results of controlled studies for this indication (58,108).

In February 1981, NCHCT in response to a Medicare coverage issue request, recommended that, as a safe and effective therapy, apheresis be covered in the “treatment of primary macroglobulinemia (Waldenstrom) and hyperglobulinemias, including multiple myeloma. These indications would include hyperviscosity states and cryoglobulinemias associated with these conditions” (54). The American College of Physicians, through its Clinical Efficacy Assessment Project (for more information see, for example, 104), also seems ready to concur. In a draft statement (4) prepared for NCHCT, they call apheresis an “efficacious and standard therapy in the treatment of hyperviscosity syndromes such as those secondary to Waldenstrom’s macroglobulinemia and multiple myeloma.”

Hypercholesterolemia

Likewise, apheresis has been used to remove other direct substances in the plasma such as cholesterol. **Familial hypercholesterolemia** is a common, usually inherited disease characterized by increases in plasma cholesterol leading to nodules of cholesterol forming on the skin or within the nervous system and to premature closing of the arteries. The use of apheresis has been undertaken at several hemapheresis centers with varying results. There has also been some anecdotal evidence of cholesterol levels being lowered and resulting clinical improvements in patients suffering from disorders related to **primary biliary**

cirrhosis, characterized by enlargement of the liver and retention of bile (108).

Protein Bound Factors

Certain classes of hormones, toxins and poisons have also been found to be bound to plasma proteins, and this has provided the rationale for the use of apheresis in treating the life-threatening symptoms that often result from the presence of excessive concentrations of these substances. Again, the removal of these substances has often correlated with clinical success, but controlled studies have not been earned out. In most of these conditions, however, apheresis is utilized only as a short-term, emergency measure (108,127).

Thyrotoxicosis is a condition that results from excessive production of hormone by the thyroid gland. Removal of the substance by apheresis has been reported to alleviate crisis symptoms (a crisis stage is referred to as a **thyroid storm**).

Hepatic coma is thought to be due to the accumulation of protein bound toxins in the bloodstream as a result of acute liver failure arising from a number of causes such as acute viral hepatitis, cancer, or reaction to anesthesia. Plasma exchange, and more recently plasma perfusion, have been observed to be effective in reducing toxins until the liver has had a chance to regenerate itself. Plasma exchange regimes, though, remain highly variable for treatment of hepatic coma (108).

Refsum's disease is a chronic, hereditary disease characterized by ocular disorder, loss of sensory and motor function, and dry scaly skin. Equivocal responses in individual cases have been reported (80).

Lastly, apheresis has been used in the treatment of poisonings. The procedure has been thought to be particularly applicable to those toxins that are not removed by dialysis, such as mushroom-poisoning. Protocols have varied widely, according to setting and according to type and amount of poison (108,144).

Antibody-Related Diseases

As discussed in chapter 2, these diseases are often termed “autoimmune” diseases, in which

pathological antibodies are produced and, in turn, attack the body's own normal tissues. Researchers began to look to apheresis for treatment of this class of diseases because of the success in removing substances associated with hyperviscosity. It was hypothesized that by removing the antibodies which were thought to mediate the disease process, clinical results would correlate in a fashion similar to those found when immunoglobulins were removed for hyperviscosity symptoms (127). The two examples in this category with the most data are myasthenia gravis and Goodpasture's syndrome, both discussed in this section.

Neurological Disorders

Apheresis has been applied in the treatment of several diseases of the nervous system. Apheresis research has been pushed on by the discovery that many of the neurologic diseases have immune components and perhaps may have an antibody associated with them that may be removed (127). Myasthenia gravis (MG) is characterized by severe muscular weakness (without atrophy) and progressive fatigue. The symptoms are generally thought to result from an autoimmune attack on acetylcholine receptors in muscles. Because apheresis removes the anti-acetylcholine receptor antibodies from plasma, it has been evaluated with approximately 125 patients at five major clinical centers over the past 4 years. Results have shown significant short-term improvements in selected MG patients in clinical studies. The therapy is generally becoming considered appropriate in severe cases as well as for patients who exhibit progressive myasthenia symptoms despite treatment with corticosteroids. It has also been favorably reviewed as being beneficial in the long term and among the most promising applications of plasma exchange in autoimmune disease (42,108,177,144). Additional presumptive evidence of effectiveness is the Health Care Financing Administration's (HCFA) reimbursement of apheresis for acquired MG since September 1981. While NCHCT never issued a formal assessment recommending coverage of this indication, it did specify in November 1980 that it had "no objection" to HCFA'S preparation of a national coverage instruction for apheresis in treating acquired MG (56).

Multiple *sclerosis* (MS) is a chronic neurological disease characterized by patches of hardened tissue in the brain or the spinal cord producing partial or complete paralysis, jerking muscle tremor, and a variety of other symptoms and signs. The cause of MS is unknown, but there is some evidence to indicate that the presence of increased amounts of immunoglobulins and antibodies in the nervous system may contribute to the disease. It has been suggested and reported that two types of apheresis procedures—plasma exchange and lymphapheresis—may be effective in controlling MS through removal of toxic blood factors (108,117).

Preliminary studies involving very small numbers of patients have reported significant improvement in the majority of "progressive MS" patients treated with plasma exchange. Several factors, however, make any conclusions from these studies tentative: 1) a plasma factor "specific" for the disease, such as an antibody, has yet to be identified; 2) the disease has a relapsing and remitting nature which makes conclusions from small samples extremely tenuous; and 3) immunosuppressive therapy, reported to be useful in MS by itself, accompanied plasma exchange in the studies (so that the effect of plasma exchange alone could not be determined) (117). An assessment of MS was conducted by NCHCT in response to a Medicare coverage issue, and reviewed both published and ongoing research. The Center concurred with the findings of the National Institute of Neurological and Communicative Diseases and Stroke (NIH) and the National Multiple Sclerosis Society that there is currently inadequate justification for the routine use of any form of apheresis in the management of MS. Although apheresis is still considered experimental, however, the Center noted several controlled clinical trials about to begin or underway that should help clarify the appropriate role for apheresis in the treatment of MS (91).

Guillain-Barré syndrome (GBS) is a viral inflammatory disorder of the brain, characterized by a great increase in the protein in the cerebrospinal fluid and in accompanying loss of sensory and motor function. The condition may be acute or chronic, and is sometimes fatal. Several cases of GBS have been associated with swine flu vaccinations (108,117).

A primary review, including a methodological assessment, of the apheresis literature in the treatment of GBS was prepared as part of this study. Case reports and small-scale, mostly uncontrolled trials provide suggestive evidence that apheresis may be effective for some patients with GBS. Because of the low mortality and good prognosis for most patients with GBS, however, the safety of the procedure and indications for its use need to be delineated prior to nonexperimental use of plasma exchange in GBS.

The conditions for use of plasma exchange in acute GBS have been sufficiently standardized to enable a controlled clinical trial of the procedure. The potential cost saving and potential for shortened disability make well-designed controlled studies of this therapy important. Controlled studies currently in progress should be adequate to provide data which address the essential clinical questions. Until the results of these studies are available, though, the use of plasma exchange in GBS can only be considered an experimental procedure (115). The full review and assessment of apheresis for the treatment of GBS is presented in appendix D.

Another neurological disorder for which apheresis has been reported (108) as a treatment approach is **amyotrophic lateral sclerosis** (ALS), a progressive disease marked by muscular weakness and atrophy. Norris, et al. (89), noted some improvement in three of ten ALS patients who underwent plasma exchange sessions. This has not been confirmed by other studies, however, and no rationale yet exists as to why it should be effective (43).

Lastly, two neuromuscular disorders, polymyositis and **dermatomyositis**, have been reported (108) as responsive clinically to apheresis therapy. Both disorders, characterized by progressive muscular inflammation and weakness, have been linked to antimuscle antibodies. The evidence in both disorders, however, is anecdotal. The American College of Physicians (4) has called apheresis an “investigational therapy” in the treatment of patients with polymyositis, but has also stated that it “maybe indicated . . . in patients in the severe, imminently fatal polymyositis . . . who are resistant to all other therapies.”

Renal Diseases

Goodpasture's syndrome (GS) is characterized by a combination of glomerulonephritis (kidney disease) and pulmonary hemorrhage. The incidence of GS is approximately 4,000 to 5,000 cases annually in the United States. GS is believed to be caused by an antibody directed against glomerular (kidney) and alveolar (lung) basement membranes and is characterized by a rapidly failing course terminating in asphyxia from lung hemorrhage or in death from renal failure. Historically, the treatment of GS has involved immunosuppressive/anti-inflammatory drugs with only modest success. The mortality rate for this disorder has typically run about 75 percent (22,108).

It is possible that apheresis removes enough circulating antibodies to alter the course of the disease, but reports are mixed. Again, there have been no controlled trials, but case studies and literature reviews claim that apheresis has been effective for those patients with mild to moderate renal dysfunction, but who are suffering acute pulmonary complications or who are experiencing rapidly progressive kidney deterioration (4,108,117,144). It has been speculated that early diagnosis and apheresis therapy could prevent irreversible renal failure (42).

The American Medical Association has also supported apheresis in use of treatment of GS though it has not specified under what conditions (s). The American College of Physicians, however, has called apheresis an “investigational” therapy for GS, stating that studies to date have failed to demonstrate improved survival among patients with this disease receiving apheresis (4). A more thorough review and assessment of the use of apheresis for GS was completed in early 1983 by the Office of Health Technology Assessment (OHTA) in response to a Medicare coverage policy issue. The OHTA assessment reported the beneficial effects of plasma exchange for some groups of GS patients. However, probably because of the absence of prospective RCTs, OHTA recommended plasma exchange only be considered standard therapy for “life threatening forms” of GS (94).

In a related area of renal disorders, rejection of the donor kidney remains the major problem in renal transplantation. Acting on the hypothesis that rejection is due in part to a circulating antibody directed against the vascular endothelium, several groups have used intensive plasma exchange to treat renal *allograft rejection*. Scoville Associates (108) has reported that apheresis is apparently effective in controlling approximately 50 percent of acute rejection episodes, and that the graft survival period has been lengthened when apheresis is used in a combination therapy regimen with steroids versus use of steroid therapy alone. The role of apheresis in the management of acute renal transplant rejection (particularly in those cases which do not respond to steroid therapy) has been called promising, though, more well-controlled studies need to be undertaken at this point (30).

Blood Disorders

Another disorder for which *use* of apheresis has generated some initial response and promise has been in treatment of patients with *antibodies to Factor VII*. Apheresis has been investigated as a potential therapy for patients with antibodies or inhibitors to Factor VIII during the past 10 years. Factor VIII is a substance in the blood involved in hemostasis (i.e., the normal process of blood clotting for control of bleeding). Patients with the most common type of hemophilia lack Factor VIII and are at risk of developing Factor VIII antibodies when given supplemental, exogenous Factor VIII to help control bleeding episodes. It has been estimated that as many as 20 percent of such patients may develop this condition. Factor VIII inhibitors can also arise spontaneously in other patients. This so-called idiopathic or acquired inhibitor to Factor VIII can occur in women in their first year after giving birth, persons with rheumatoid arthritis, the elderly, and persons suffering a variety of other disorders (57,146).

As part of this case study, a primary literature review, analysis, and evaluation were undertaken for treatment of this disorder with apheresis. Nine studies were reviewed and both immediate and long-term findings were tallied. For 16 of the 18 patients at risk due to severe bleeding from surgery, the immediate clinical results were uniformly

successful. In all cases hemostasis was achieved, and the patient fully recovered from the acute episode. Nine patients were reported to have poor long-term results, but several patients were reported to have achieved a permanent reduction in Factor VIII inhibitor antibodies without the need for additional therapy. Importantly, though, the overall quality of the research evidence was found to be poor: the studies were all pretrial clinical reports (generally of one patient), there was no agreed upon treatment, the goals of the studies differed, and, with so few patients, the issue of sample bias should not be discounted (146). The complete assessment of apheresis in the treatment of antibodies to Factor VIII is presented in appendix C.

Antibodies to Factor VIII are encountered in a number of hematological (and nonhematological) disorders. Likewise, a host of hematological disorders are thought to be related to a gone-awry immune mechanism, and as a result, several blood disorders have been treated with apheresis, including thrombotic thrombocytopenic purpura, hemolytic-uremic syndrome, idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and rhesus hemolytic disease.

Thrombotic thrombocytopenic purpura (TTP) is an interesting example of a disorder for which apheresis appears to be of benefit as a lifesaving measure although the rationale for its use is still very speculative. It is a condition involving the development of diffuse, small blood clots and a deficiency of platelets. Its cause is unknown but may be related to a disordered immune mechanism acting directly on the platelets or on the blood vessels, or on both concurrently. Apheresis has been reported to have benefits in several cases, possibly by removing circulating immune complexes or an antiplatelet antibody. * Results of apheresis for TTP have been encouraging with up to 80 percent response rates reported in some studies. The American College of Physicians' assessment (4) is typical of several reviews and of the research community (7,42,108,117,125,127, 144) in stating that "apheresis in conjunction with

*Because of TTP's possible relation to immune complexes, this disorder is sometimes grouped under the immune-complex related disease category, and could logically be included in the next section's discussion ("Immune-Complex Related Diseases") as well.

exchange transfusions, corticosteroids and platelet inhibitors, appears to be efficacious and standard in the treatment of thrombotic thrombocytopenic purpura.” The American College of Physicians noted further that, “Despite the fact that trials indicating efficacy were uncontrolled, the reductions in mortality in patients with TTP compared to those not receiving apheresis were so significant that apheresis appears to be beneficial.” Simon (128) has also claimed that selective use of apheresis can also decrease morbidity, hospital stays, long-term chronic dialysis, and maintain a productive lifestyle for patients longer. NCHCT (92) conducted an assessment of TTP for Medicare coverage policy, and noted the reported beneficial effects, but cautioned that the quality of research was plagued by the complete absence of controlled clinical trials to confirm these findings. (Some have argued that such trials are impossible given the sudden and life-threatening intensity of the disorder’s onset.) NCHCT, because of the life-threatening nature of TTP, stated that the use of apheresis (specifically, plasmapheresis and plasma exchange) “seems justified when other conventional therapies have failed.”

Hemolytic-uremic syndrome (HUS) is characterized by a decay of kidney function, destruction of red cells, and a dramatically reduced level of circulating platelets. It shares a number of features with TTP. In fact, HUS has been considered by some clinicians to be a variant of TTP, this being supported by overlapping clinical and pathologic characteristics and the possibility of similar precipitating events. There is no objective method at present to distinguish HUS from TTP, although in the case of the former, the kidney is typically the main and often only target organ, children are primarily affected, and the prognosis is generally much better (71,146).

A primary literature review and assessment was conducted by Wortman and Murt (85) for this case study on the use of apheresis in the treatment of HUS. Data from the eight communications that have appeared in the literature during the past 3 years are presented on a total of 11 patients, but each case is described individually. Only one of the communications suggests that plasma exchange has limited effectiveness on the disease process (11). However, the authors in this article

add that the clinical benefit may have been compromised because apheresis was performed during a recurrent phase of the illness (which is recognized as being associated with poor prognosis). The remaining seven studies are almost uniformly favorable in suggesting that apheresis contributes to clinical improvement although there is no explanation provided about which measures are used to gauge this improvement. Several authors add the caveat that apheresis be initiated during the early stages of the disease in order to realize its full benefit (132). Parries, et al. (106), caution that apheresis alone is associated with complications (e.g., hepatitis) and that these risks should be weighed against the potential benefits of apheresis.

As might be expected with a total reporting of 11 patients, the research base is too small and incomplete to endorse apheresis as a treatment for HUS. Furthermore, the studies contain no comparison groups, while treatment designs and outcome measures varied widely, further limiting the ability to make any conclusion or recommendation. A full discussion of this assessment is found in appendix B.

Rhesus hemolytic disease (Rh disease) of the newborn is characterized by fetal anemia, jaundice, enlargement of the liver and spleen and general edema. Approximately 65 percent of untreated cases result in stillbirth or infant mortality. The disease is caused by Rh antibodies produced in maternal blood which may cross the placenta and destroy fetal red blood cells. Antibodies, directed against an Rh positive fetus, develop in an Rh negative mother following a previous pregnancy in which the fetus was Rh positive or following transfusion of Rh positive blood (108).

Murt (85) has reported that between 1968 and 1981, 13 studies were published on the effects of apheresis in the management of severe Rh disease. The quality of the research studies is quite poor: all 13 studies are observational, and all but one are reports of individual case studies. The number of patients in these studies ranges from 1 to 96 and the median is 3. Only 3 of the 13 studies have given plasma exchange an unfavorable review, and 2 of these studies are the initial published reports of the use of apheresis in treating pregnant women with Rh disease (14,112).

There are a host of other autoimmune hematological disorders treated by apheresis. Such disorders include autoimmune hemolytic *anemia* and *idiopathic thrombocytopenic purpura*. They are caused by antibodies which characteristically attack and lead to the destruction of valuable blood components. These diseases have been treated with some success with apheresis, but the reports are anecdotal (42).

Immune-Complex Related Diseases

In immune-complex related diseases, antigen-antibody complexes can be deposited in tissue and produce severe inflammation and tissue damage. Just as researchers and clinicians reasoned that protein plasma substance removal could be extended to antibody removal, circulating immune complexes began to be experimentally removed through apheresis methods.

Renal Disorders

This further extension to immune complexes was particularly notable in England and Australia where there was an initial interest by nephrologists in the application of apheresis for rapidly progressive *glomerulonephritis (GN)* (127). Characterized by a rapid deterioration of renal function, GN appears to arise from two mechanisms. The first mechanism stems from the deposition of immune complexes which are formed in the circulation and subsequently lodge in the glomeruli (small structures in the kidney which contain capillary blood vessels surrounded by a thin membrane which acts as a filter for the separation of urine). The second mechanism, the much rarer, arises when an antibody is generated against the kidney, which sets in process a chain of inflammatory events leading to GN. Plasma exchange for rapidly progressive GN has been evaluated as a therapy mode with rather uncertain results (90,108). Several case studies have been published reporting the clinical success of patients treated with concurrent plasma exchange and immunosuppressive drug therapy. However, there is some speculation that similar results may be obtainable with immunosuppressive drug therapy alone (108, 128). Apheresis in rapidly progressive GN has also been associated with a high degree of infection caused by a variety of unusual pathogens (42).

NCHCT was requested by HCFA in May 1981 to conduct an assessment of the safety and clinical effectiveness of “membranous and proliferative glomerulonephritides” for Medicare coverage and reimbursement policy (38). Due to budgetary and staff cutbacks, that assessment was not issued until early 1983 by NCHCT’s successor organization, the Office of Health Technology Assessment (28). The OHTA assessment concluded that for rarer types of GN (antibody related), it appeared that plasma exchange “favorably affected” GN, and “should be recommended as standard therapy” for these conditions. However, for those more common cases of GN associated with immune complex mechanisms, OHTA concluded that the role of apheresis is “much less clear-cut and should be investigated further” (94).

Connective Tissue Disorders

The advocated clinical successes in GN led to investigative and experimental usage of apheresis in a whole host of connective tissue diseases which were thought to be possibly related to immune complex deposition in tissues and often correlated with levels of circulating immune complexes (127).

Systemic lupus erythematosus (SLE) is a chronic and often fatal disease characterized by pathological changes in the vascular system, manifested in skin rashes, fever, arthritis, and heart, lung, and kidney damage (108). Preliminary reviews indicate that apheresis has produced “striking short term clinical improvement” in some patients with high levels of circulating immune complexes before treatment. However, other patients with SLE, but not high levels of circulating immune complexes before treatment, have also responded to therapy. Study results have also been confounded by poorly controlled immunosuppressive and anti-inflammatory drug therapy accompanying apheresis (117, 128). As with apheresis in the treatment of rapidly progressive GN, HCFA requested NCHCT in May 1981 to assess the safety and clinical effectiveness of apheresis therapy for SLE as a candidate technology for Medicare coverage and reimbursement. That assessment, now under the aegis of OHTA, has not yet been completed (28). The American College of Physicians (4) and the American Society of Hematology (7) have both judged apheresis for SLE as “in-

vestigational” only, noting that no adequately controlled scientific studies have established its efficacy. Both groups, however, cautiously allow for the possibility of use in critically ill SLE patients who fail to respond to conventional drug therapy.

Rheumatoid arthritis (RA) is a chronic disease of the joints marked by inflammation and atrophy of the bones. In late stages, deformity and immobility develop. While it is unclear at present which plasma factors are involved in RA (immunoglobulins, immune complexes, lymphokines, etc.), several medical centers have reported beneficial effects of plasma exchange or related procedures: lymphapheresis and lymphoplasmapheresis. Several apheresis protocols have been reported. Clinical responses have been claimed in the remission of symptoms that lasts several months (117). Rothwell, et al. (118), however, reported no statistically different clinical response in a controlled study that had one group receive plasma exchange and drug therapy while a second group received drug therapy only.

Because RA affects approximately 7 million individuals in the United States, with no known cure, the question of apheresis treatment benefits has become a somewhat volatile issue. Over the past 2 years, the Council on Scientific Affairs of the American Medical Association, the American Rheumatism Association, the American College of Physicians (who consulted with the American Society of Hematology and the American Society of Oncology, as well), and NCHCT have all formally considered the evidence. All have concurred that apheresis for treatment of RA is an experimental therapy but have suggested its possible use in serious, life-threatening complications of RA, such as vasculitis, cryoglobulinemia, or hyperviscosity syndrome (59,86). In a separate assessment, NCHCT explicitly recommended apheresis in the management of life-threatening **rheumatoid vasculitis*** as a treatment of last resort and possibly lifesaving intervention when more conventional therapies have failed. The Center stated that such “pro-

cedures are usually reserved for those patients who have failed to respond to more conventional therapies and it is usually combined with them” (93).

There is also some current debate about the proper mix of apheresis therapy and drug therapy for RA and about the relative effects of plasma exchange and lymphocyte removal. Studies are still needed to define the role of each therapy in the management of severe RA. Wallace, et al. (139), have recently reported the results of a double-blind, controlled study of lymphoplasmapheresis versus sham apheresis in RA for 14 patients. The results proved mixed. Whereas some measures of disease severity improved significantly in the treated group as compared with the control group, others did not. All reported benefits of therapy were temporary (12).

Cutaneous vasculitis, an additional connective tissue disorder treated with therapeutic apheresis, is characterized by inflammation of the small blood vessels of the skin. Temporary clinical responses have been reported in the literature. There are no known controlled studies (108).

Skin Disorders

Several dermatologic diseases which are thought to involve immune mechanisms have indicated a response to therapeutic apheresis. **Pemphigus vulgaris** is a rare disorder characterized by bubblelike lesions on the surface of the skin. Remissions have been reported with apheresis, but there are no published clinical trials (2,108,144). Single cases of clinical responses to **herpes gestationis**, a subepidermal blistering condition of pregnancy, and **psoriasis**, a chronic, genetically determined dermatitis, have also been reported (108).

Cancers

Therapeutic apheresis in the treatment of multiple myeloma was discussed earlier in this chapter. Several reports have also described recent attempts to treat various forms of other cancers with plasma exchange. Animal studies have suggested that the growth of the tumors is related to deficiencies in the immune process (144). The rationale for apheresis is that the removal of immune

*Rheumatoid vasculitis is marked by a destruction and necrosis of sections of the body, particularly toes and fingers and areas served by small vessels that are inflamed.

complexes or blocking factors might improve immune responsiveness to tumors. Preliminary results have been mixed and further evaluation will be required. A refinement of plasma exchange, involving modification of plasma (by circulating it through protein-A columns) has recently been reported to produce benefits in several forms of cancer, including breast cancer (117).

At the beginning of this century, hopes for developing vaccines for treatment and specific diagnostic tests for cancer were based on remarkable advances in immunology and their successful application to many infectious diseases. Early efforts to relate immunology and cancer failed because of a lack of understanding of the complexity of the immune response. In recent decades, however, investigations have discovered a probable role of the immune system in both the development and spread of tumor cells (108). **At present, apheresis for cancer is experimental, but it could broaden the fundamental understanding between malignancy and the immune response (144).**

Miscellaneous Disorders

Table 4 presents a list of diseases either believed to be of immunological origin or of unknown cause for which plasma exchange has been experimentally employed as a therapy and positive clinical responses reported. Typically, in each disease category, plasma exchange procedures have involved only a small sample group anywhere from 1 to 30 patients and there have been no control or comparison groups against which to measure treatment results. Evidence, then, is

Table 4.—Therapeutic Apheresis for Miscellaneous immunological Diseases and Diseases of Unknown Cause

Miscellaneous immunological diseases

Graves' disease
Crohn's disease
Severe asthma
Insulin-resistant diabetes
Scleroderma

Diseases *of unknown cause*

Hypertension (idiopathic only)
Raynaud's phenomenon
Idiopathic pulmonary hemosiderosis

SOURCE: Adapted from Scoville Associates, 1981.

anecdotal and awaits additional research before reliable conclusions can be drawn regarding the potential role of apheresis for these disorders (42,80,108,144).

Cell-Related Diseases

The use of apheresis (specifically cytapapheresis) therapy has been anecdotally reported to be quite beneficial in the treatment of diseases involving excess or abnormal blood cellular components. While not common, certain clinical situations may benefit from the removal and lowering of a platelet count or white blood cell count in a patient. Very high white counts, such as in **granulocytic leukemia**, can cause immediate and severe crises with cerebral hemorrhaging, and possibly death. Emergency removal of white cells can be lifesaving while chemotherapy is initiated, although chronic treatment has generally failed to alter the outcome of the diseases. **Sickle cell disease** (SCD) is characterized by red blood cells (RBCs) containing abnormal hemoglobin. The "sickling" of RBCs in capillaries impairs blood flow and can produce severe complications. Exchange transfusion (removal of RBCs followed by replacement with normal RBCs) has been reported to produce beneficial results in SCD crises. Also, long-term use of platelet removal and white cell removal in the treatment of autoimmune diseases, including multiple sclerosis and rheumatoid arthritis, have also been reported, and research in those areas continues.

Although not for therapeutic purposes, cytapapheresis applied to healthy donors also has important clinical applications in the preparation of component concentrates. Many diseases involve decreased levels of white cells or platelets. Cancer chemotherapy, as well, often depresses bone marrow production of white cells and platelets so that transfusions of the deficient components are clinically beneficial. Recent refinements in blood separator devices make it practical to collect large numbers of platelets or white cells from a single donor rather than pooling separate components from multiple donors. This is of considerable benefit in minimizing the risk of donor/recipient antigenic incompatibility and hepatitis transmission (117).

CONCLUSIONS AND DIRECTIONS FOR RESEARCH

Clearly, a variety of diseases—often rare—have been treated by apheresis in circumstances where conventional therapy has not been beneficial. There is a great deal of enthusiasm among researchers and clinicians who wish to explore all the possibilities for therapeutic apheresis. Medical journals are replete with anecdotal reports of physicians' trying apheresis as a last resort in a wide range of diseases. These cases, however, do not provide a strong systematic base for recommending the widespread use of apheresis as a mature and effective technology.

Apheresis appears to be a relatively safe procedure, though it is not without at least short-term risks. The long-term risks of removing useful blood components have been termed "worrisome" and are unclear at best (80). Apheresis device equipment can also be termed effective in the sense that the technology accomplishes the intended removal of plasma and cells.

However, there have been very few well-controlled studies documenting the efficacy of the technology in actually improving health (53). More specifically, there have been few situations in which isolated pathogenic proteins, antibodies, immune complexes, and blood cells were removed and unequivocal clinical results observed. The use of apheresis has been generally acknowledged as an effective treatment application for acute therapy in a small group of relatively obscure diseases. These include acquired myasthenia gravis, primary macroglobulinemia (Waldenström's), and hyperglobulinemias, including multiple myeloma. There is certainly suggestive evidence, too, that therapeutic apheresis is successful in arresting the disease process for some patients under some disease conditions. Convincing proof of clinical efficacy, however, is still lacking in the wider variety of diseases in which this treatment is being used.

Any interpretation of clinical results has been further hampered by the lack of standardized application of this therapy. Criteria for patient selection and treatment schedules for many disease applications still need to be developed. The relative roles of exchange, drugs, and supportive care need to be further defined and clarified.

The problem of standardized application of apheresis is not surprising in considering that the scientific rationale for use of the technology to treat a specific disease category is sometimes very weak. Because the disease-causing mechanisms remain largely unknown, speculation has necessarily determined the intensity of the apheresis schedule, the volume exchanged, and whether there should be concomitant removal of cellular components with or without the addition of immunosuppressive drugs. Each of these aspects of apheresis has been the subject of much discussion and disagreement (12).

Though some researchers say it is "too early" to do controlled trials because doctors have not yet determined the theoretically best treatments to be tested, research in apheresis seems to be in transition. In an effort to document the value of therapeutic apheresis, large prospective randomized trials have been organized for several disease applications in which apheresis therapy has not been shown to be either clearly effective or ineffective (2,12). Although some of this research is being done without direct government support, a substantial portion of experimental and clinical trial work is being undertaken with the help of the National Institutes of Health (NIH). Because of the high costs of these studies, it is not surprising—or unreasonable—that public moneys support such a significant number of them. Table 5 presents a listing of major ongoing research studies.

In order to precisely define what advantages, if any, apheresis would have, controlled trials need to address the safety and efficacy issues discussed in this chapter of present apheresis technologies. Long-term studies will also be needed to detect any additional unforeseen or unspecified questions of safety, as well as effectiveness. Importantly, future research must also compare the present treatment modalities with new and emerging approaches such as plasma filtration through specific affinity columns (with the return of the patient's own plasma) or related scientific advances such as the use of monoclonal antibodies (see "Future Technological Directions" section in ch. 2 for a discussion of these treatment approaches). Many researchers and observers in

both the public and private sectors speculate that therapeutic apheresis as now applied will be replaced over the next 10 years by either advances in equipment-embodied apheresis technology or basic scientific research into the causes of various

diseases (53). If the present applications of therapeutic apheresis are indeed in such a period of flux, great care must be taken to target research and clinical efforts into the most promising and beneficial technology-related developments.

Table 5.—Present Apheresis Research Activity

Location	Principal investigator	Disease indication
<i>Major NIH Stud/as</i>		
SUNY—Stony Brook	Gorevic, Peter	Cryoglobulinemia
Washington University	Shonfeld, G.	Familial hypercholesterolemia
Cincinnati General Hospital	Stein, Evan	Familial hypercholesterolemia
Johns Hopkins University	Kwiterovich, Peter	Hypercholesterolemia, xanthomatosis, atherosclerosis
NIADDK, NIH	Balow, J. E.	Goodpasture's syndrome
Walter Reed Army Medical Center	Johnson, John	Goodpasture's syndrome and rapidly progressive glomerulonephritis
University of Cincinnati	Pollak, Victor	Glomerulonephritis
Massachusetts General	Coggins, Cecil	Glomerulonephritis
NIADDK, NIH	Klippel, J. H.	Systemic lupus erythematosus
Rush-Presbyterian St. Lukes	Lewis, Edmund	Systemic lupus erythematosus
Cincinnati General Hospital	Kashvap, Moti	Systemic lupus erythematosus
Rush-Presbyterian St. Lukes	Lewis, Edmund	Lupus nephritis
George Washington University	Lachin, John	Lupus nephritis
University of Iowa	Hunsicker, Lawrence	Lupus nephritis
University of Pennsylvania	Schumacher, H.	Rheumatoid arthritis
NIADDK, NIH	Wilder, R. L.	Rheumatoid arthritis
Scripps Clinic and Research Foundation	Vaughan, John	Rheumatoid arthritis
Columbia University	Jacobs, Jerry	Rheumatoid arthritis
Mayo Foundation	Bunch, Thomas W.	Rheumatoid arthritis
SUNY at Brooklyn	Diamond, Herbert S.	Rheumatoid arthritis
Columbia University	Chess, Leonard	Rheumatic disease
Boston Children's Hospital	Weiner, Howard	Multiple sclerosis
University of Utah Medical Center	Petajan, Jack	Multiple sclerosis
Peter Bent Brigham Hospital	Weiner, Howard	Multiple sclerosis
Johns Hopkins Hospital	McKhann, Guy	Guillain-Barré syndrome
Miami Veterans Medical Center	Lian, Eric	Thrombotic thrombocytopenic purpura
University of Rochester	Marder, Victor	Idiopathic thrombocytopenic purpura
Cincinnati General Hospital	Glueck, Charles	Lipoprotein metabolism
Columbia University	Edelson, Richard	Pemphigus
Johns Hopkins University	Moser, Hugo	Refsum's disease
NCI, NIH	Stevenson, H. C.	Cancer
NCI, NIH	Schiffer, C. A.	Leukemia
University of Texas	Tindall, Richard	Neuromuscular disorder
University of New Mexico, Albuquerque	Simon, Toby	Neonatal adaptation
Columbia University	Grossman, Marc	Porphyria cutanea tarda
Columbia University	Jaffe, Israeli	Connective tissue disorder
Columbia University	Resor, Stanley	Dermatomyositis, polymyositis, and polyneuropathy
Tufts University	Agnello, Vincent	Immune complex disease
Johns Hopkins University	Moser, Hugo	Hunter's syndrome
<i>Other major studies</i>		
Rogovin Kidney Center	Saal, Stuart	Myasthenia gravis
Evanston Hospital (Ill.)	Dau, Peter	Myasthenia gravis, multiple sclerosis
Southwestern Medical School	Tindall, Richard	Myasthenia gravis
El Dorado Hospital	Giordano, Gerald	Multiple sclerosis
Froedtert Memorial Lutheran Hospital	Khatri, Bhupendra	Multiple sclerosis
Kingston General Hospital, Ontario	Giles, Alan	Rheumatoid arthritis
Toronto Western Hospital	Cardella, Carl	Renal transplant rejection
Froedtert Memorial Lutheran Hospital	Kaufman, H. Myron	Renal transplant rejection
Victoria Hospital, Ontario	Clark, William	Lupus nephritis
Hammersmith Hospital, London	Lockwood, Martin	Rapidly progressing glomerulonephritis
Canadian Red Cross (sponsor)	Rock, Gail	TTP, ITP, Rhesus Iso-immunization

SOURCE: National Institutes of Health, 1982

4

**Cost Effectiveness and
Reimbursement Policy:
Issues and Evidence**

Cost Effectiveness and Reimbursement Policy: Issues and Evidence

In addition to the issues of health status or other health outcome related effects (i.e., safety, efficacy, and effectiveness) of apheresis, efficiency issues must also be addressed. The cost of providing apheresis therapy is a matter of almost universal concern in the available literature. As spiraling health care costs continue to plague medical care delivery in this country and elsewhere, it is important to examine whether there is improvement in the quality of life and which therapies offer the greatest value for the resources invested.

Because of the broad and pervasive influence of third-party payment mechanisms on health care delivery, any discussion of economic effects of therapeutic apheresis must also be closely tied to an examination of funding and reimbursement policies of both private and government insurance programs. Reimbursement policies have profound effects on the adoption and use of medical technologies, as well as the innovation process itself of medical procedures such as therapeutic apheresis. Informed coverage decisions require information concerning medical technologies, that is at least as detailed as that needed for the regulatory decisions of the Food and Drug Administration (FDA) regarding device equipment. Whereas regulatory decisions tend to be of a “go”, “no go” nature, reimbursement decisions are, or at least could be, more related to *appropriate* use of technologies, a much finer distinction (104). Appropriate use decisions would support the provision of effective apheresis therapy and efficient

care. That is, only proven treatment alternatives would be considered for widespread clinical application and the lower cost treatment alternative would not only be available but used (102,104).

Until recently, apheresis was routinely reimbursed for by some third parties when prescribed by a physician. However, concerned about costs and estimates of expansion of use over the next 5 years, third-party payers are now attempting to tailor their policies according to the principle of appropriate use—i.e., to pay for apheresis where and when it is a proven and efficient therapeutic method (80,117). **Medical insurers are, however, far from a consensus on how, when, and if they should cover apheresis (34,49).**

The research and policy issues regarding the costs and benefits of apheresis therapy, including a discussion of third-party reimbursement, form the substance of this chapter. It is a discussion that initially examines the methods that can be used in assessing the economic effects of therapeutic apheresis. Currently, the most visible and potentially most useful of methods is cost-effectiveness analysis (CEA). As CEA is not simply an economic technique, but rather a blend of economic and clinical information, it will serve to conceptually integrate cost concerns with the assessment of safety and efficacy issues in chapter 3. An absence of reliable estimates of the efficacy and safety of apheresis treatment and of its costs and savings prohibits conclusive results, but gaps in present knowledge can be identified and directions for future research can be addressed.

COST EFFECTIVENESS

Two important methods used to assess the costs and benefits of therapeutic apheresis, and developing comparisons among effects, costs, and benefits are cost-benefit analysis (CBA) and cost-effective-

ness analysis (CEA). CEA implies a comparative analysis of the costs and health effects of alternative treatments. In a CEA, a common outcome is specified (e.g., functional status) and the costs

of providing alternative treatments are compared. Treatment costs are typically specified in monetary terms. CBA, on the other hand, requires that both cost and benefits be assigned monetary values. A CBA examines the ratio of resources used (cost) to resources saved (benefits) when particular treatments or even different treatment regimens **or** programs are employed (102, 104).

While CEA/CBA can be thought of as an aid to synthesis of both health effects and economic effects, the value of a CEA/CBA lies more in the process of performing the analysis than in any numerical results. There are a number of reasons for this, among the most important of which are CEA/CBA's inability to adequately address ethical issues and the uncertainty of specifying comprehensively the costs and benefits of alternative treatments. This is clearly the case with therapeutic apheresis because there are no reliable estimates of savings due to treatment benefits that are available or known. In addition, factors other than those qualified in a CEA/CBA (e.g., social, ethical, or value influences) should be considered in making a decision (12,98,102,104).

OTA, in its assessment of the methods of CEA/CBA (98) developed 10 principles to guide the conduct, use or evaluation of CEA/CBA studies (see table 6). The Principles most relevant to the assessment of therapeutic apheresis are that alternative means (technologies) to accomplish the stated objectives should be identified and subjected to analyses; all foreseeable benefits/effects should be defined and, if possible, measured, as should all expected costs; present value discounting should be performed; sensitivity analyses should be conducted to show a range of possible outcome val-

ues; and ethical issues (that have surfaced in significant ways in therapeutic apheresis) should be addressed. The rigorous specification of data sources for quantitative analyses was another important criterion for CBAS.

Potential costs and benefits can be assessed with varying degrees of comprehensiveness. Further, means for estimating them vary (102,104). Thus, in a CBA, the cost of a treatment procedure includes not only the direct costs of salaries of treatment providers and support staff, disposable, replacement fluids, drug therapies, administrative and overhead costs, but also indirect costs such as lost productivity due to patient's time missed in work. Additionally, it should be noted that uncritical use of market prices can lead to large gaps between cost estimates and true costs. Illustrative of this problem is the use of hospital charge data to reflect the costs of hospital care. A common practice, this form of "pricing" ignores the known idiosyncrasies of hospital accounting in which hospitals charge well above true marginal costs for certain services and **use** the profits to subsidize other services for which charges do not cover marginal costs. For example, hospital pharmacy charges can vary from 10 to 1,000 percent of the true cost of drugs depending on the frequency of their use, their level of cost, purpose, etc. (104). In the case of apheresis therapy, replacement fluids such as albumin, saline solutions, and fresh frozen plasma are particularly vulnerable to such pricing practices. For example, a recent survey by Levy (74) of Los Angeles hospitals showed almost all paid \$28 to \$29 for one unit of albumin. In turn, these hospitals charged the patient anywhere from a low price of \$90 to a high of \$175 per unit.

In conducting a CBA **or** CEA one must decide which benefits to measure and how to measure them, if measurement is at all possible. For example, it has been argued that substantial savings from reduced expenditures on drugs, surgery, and hospitalization accrue from therapeutic apheresis treatments, although this will vary depending on the differing lengths and intensity of the disease remission.

Unemployment and lost productivity could be reduced in the long-term as well. Limiting analyses

**Table 6.—Ten General Principles of Analysis
(for CEA/CBA Methodology)**

1. Define problem
2. State objectives
3. identify alternatives
4. Analyze benefits/effects
5. Analyze costs
6. Differentiate perspective of analysis
7. Perform discounting
8. Analyze uncertainties
9. Address ethical issues
10. Interpret results

SOURCE: Office of Technology Assessment, 1980.

to work-related measures, however, may have the effect of underestimating the potential benefits of apheresis therapy to a significant number of individuals not currently in the work force—e.g., the chronically ill, the retired elderly, students, full-time homemakers, etc. A further point is that the efficiency of apheresis may decline—as evidenced by frequent usage as a treatment of last resort—with severity of impairment. In addition, savings on such items as reduced expenditures for quack remedies need to be calculated. It is reported that rheumatoid arthritis patients, for example, spend over \$1 billion a year on purported remedies ranging from the “night shade diet,” which prohibits tomatoes, eggplant, and potatoes, to devices such as vibrators and drugs such as DMSO (dimethyl sulfoxide). Some arthritic sufferers even sit in uranium mines in their search for relief (34). Other benefits, such as the sense of well-being that apheresis reportedly generates in many patients (108), may be more difficult to quantify.

Despite problems, when it is done well, the use of CEA/CBA does aid the complete listing of expected costs and benefits as well as the explicit consideration of assumptions underlying them. Assuming such specification is possible, such analyses provide a better scientific basis to aid in making decisions. Given the current debate over the relative costs and benefits of apheresis, and the increasing debate over reimbursement policy, such information does indeed appear to be essential.

Estimating Costs

While no reliable estimates of savings due to treatment benefits are available or generally known (12), the present task of evaluating treatments can include the context of costs, for which there have been several general estimates. There has additionally been a more specific study concerning the costs of reimbursing for apheresis of rheumatoid arthritis patients under the Medicare program.

By almost any standard, the costs of providing this therapy are a concern. It is the issue of costs that has aroused the greatest controversy surrounding the technology and is the most obvious explanation for the increasing scrutiny of apher-

esis by a variety of health care professionals. The concerns over costs have focused not only on the price of a single treatment session, but also the dramatically rising use of apheresis for therapeutic purposes in recent years.

Calculations

There are two dimensions (124) to expenditure determination—price and quantity. Many technologies become expensive because of high cost even when applied to a small number of patients (e.g., end stage renal disease), while others generate large expenditures because the procedure is so extensively used even though the cost per patient is relatively low (e.g., routine in-hospital lab tests). Apheresis represents an interesting combination of a technology which is, on the one hand, extremely expensive per patient, but is simultaneously of potential benefit to great numbers of patients.

Simple cost projections for therapeutic apheresis can be said to depend on three variables: the price of each unit of service (cost per treatment), the quantity of services that would be used (treatments per patient), and the size of the population potentially benefiting from treatment (patient populations). By multiplying these variables together, an estimate of total expenditures can then be determined.

Cost per Treatment

Estimates of the costs of individual apheresis treatments are very much available, but vary widely according to individual author and analysis from \$400 to \$1,200. (A midpoint estimate, then, is \$800 per treatment.) An investment of \$19,000 to \$32,000 for a blood cell separator is the initial cost here, and disposable sets produced by manufacturers will vary between \$40 and \$90 per treatment. (Membrane disposable prices may be substantially higher—as much as \$400—at first.) Space (overhead expense), trained staff, and a physician-director are also essential (\$27 to \$300). Replacement fluids (at an average volume of 2.8 liters), such as albumin or fresh frozen plasma, make up the remainder of the costs, running \$125 to \$600 per treatment (the exception is cytoapheresis, which usually does not require re-

placement proteins because volume loss is small) (2,8,12,22,34,42,108,117,75,125) .

Treatments per Patient

Most studies estimate the number of treatments per patient as averaging about 10 per year, though a few estimate that number to be as low as and as high as 15 to 20 per year. As already discussed, apheresis protocols for various diseases will differ dramatically in number and frequency of treatments. Some applications will entail single treatments for emergencies, while it is likely that chronic diseases such as rheumatoid arthritis will generally require 15 to 20 treatments, although more than 30 will be used in some cases (2,34,73, 108,42,117).

Patient Populations

The potential patient population for apheresis can be appreciated in a number of different ways. If the potential patient population is defined as those persons with any of more than 75 diseases currently treated with apheresis, the potential population is significant. There are an estimated 5 million to 7 million people with rheumatoid arthritis, 400,000 to 500,000 persons with multiple sclerosis, 400,000 to 500,000 persons with systemic lupus erythematosus, 100,000 myasthenia gravis patients, and at least **50,000 to 60,000 others** with one of the other diseases. However, many patients in each disease category are presently being treated satisfactorily with drug therapy, and thus they may not now be considered candidates for apheresis (though in some diseases, such as multiple sclerosis and Goodpasture's syndrome, effective alternative therapy is very limited, so that virtually the entire patient population could eventually become candidates

for apheresis). If apheresis is used only on patients who have failed to respond to traditional forms of therapy, the potential total patient population is reduced to about 5 percent of its original size, and estimates place this population at from **325,000 to 427,000 (22,34,73,80,117,125)**. These must be considered conservative estimates because they limit the potential candidate population to those patients who have reached a severely debilitating or life-threatening state in these disease states. If apheresis therapy replaces other therapy modes in routine maintenance programs for various disorders, the patient population would be much higher (117).

Results

Having determined estimates for each of these several variables, and multiplying these variables together, total cost estimates for apheresis therapy per year can be projected to range from \$650 million to \$7.69 billion, with a midpoint estimate of \$3.01 billion (see table 7). Importantly, these **projections are simple cost calculations that carry with them a number of methodological caveats.**

Caveats

For one, there are no cost calculations of accompanying hospitalization, ancillary services or essential adjuvant therapies, such as immunosuppressive drugs, which would increase cost estimates. Secondly, there is no determination here of "adoption share," a yearly measure of market penetration, defined as the proportion of eligible candidates for which treatment was indicated and on which it would have actually been performed. Calculation of the adoption share requires fairly accurate procedural use data, as well as projecting what the diffusion rate for the procedure is

Table 7.—Estimating Costs of Apheresis Therapy

	High estimate	Midpoint	Low estimate
Costs per treatment	\$1,200	\$800	\$400
Treatments per year	15	10	5
Patient population	427,000	376,000	325,000
Total costs	\$7.69 billion	\$3.01 billion	\$650 million

SOURCE: Off Ice of Technology Assessment, 1983.

and will be. * Prediction of adoption share is one of the most difficult tasks, but one of the most important for predicting future costs. The **adoption share subsequently allows for the discounting back of future costs over a determined patient care time horizon, and the accumulation of a present value.**

Currently, apheresis is performed on only selected patients. Unfortunately, no accurate data exists on national figures, with estimates placing the number of procedures performed at from 80,000 to 200,000 per year (22,34,73,80,117). These estimates, if accurate, would mean that, using OTA treatment estimates (see table 7), current national expenditures on apheresis range from \$3.2 million to \$240 million. According to Schweitzer and Foxman (124), however, if one assumes availability of reimbursement for this therapy, then one must also assume expansion of availability of service, and utilization would increase over time to essentially the point where all who could derive benefit from treatment would do so. The importance of reimbursement policies covering apheresis becomes apparent, then, if such policies push the adoption share to 100 percent. Given present reimbursement policies (see section on “Third-Party Reimbursement”), this represents an extreme estimate but is useful for cost purposes here.

The economic and cost implications of a decision by a third-party payer to reimburse for apheresis is a last but crucial caveat to cost estimates. As Schweitzer and Foxman (124) **further point out, if medical services were not linked to one another, and criteria determining appropriateness or need for a service were unambiguous, the relationship between reimbursement**

● The classical pattern of diffusion has been the ascending logistic curve, which indicates that the proportion of adopters for a new technology rises with time according to an S-shaped pattern. This pattern is appropriate for technologies for which continued **ascendancy is likely** over the immediate horizon, and for which subsequent high utilization can be expected. For many applications of **apheresis**, however, the pattern is probably more complex. Warner (141) has proposed a three-stage “desperation-reaction” model of medical diffusion, in which initial enthusiasm is followed in the second stage by an adjustment, followed subsequently by informed decisions. The informed decisions could represent mature, high use (as in accepted innovation) or zero use (for an unacceptable innovation). Furthermore, disapproval of reimbursement could occur at any point in this process (19).

and expenditure would be a simple one. Under these conditions, one would simply identify the quantity and price of the service in question prior to a change in the reimbursement policy, and assume that these expenditures would be shifted to the new payer. However, both the demand for and the supply of medical care are price sensitive. A decision to reimburse, by lowering the net price to consumers and raising it to those who produce medical care—physicians and hospitals—will, therefore, have a tendency to increase the quantity of the service consumed. In addition, price effects will arise involving not only the service in question, but other services which are either substitutes for or complements to it. Failure to fully appreciate these quantity and price effects contributed to the serious underestimate of the End-Stage Renal Dialysis program in 1972 (113).

Cost Studies

Only one known study, prepared under contract to the National Center for Health Care Technology (NCHCT) in 1981, **has systematically examined the costs of apheresis. The study only estimated savings, if any, anticipated as a result of the disapproval of coverage for a medical procedure. The study was carried out following NCHCT’s recommendation to the Health Care Financing Administration (HCFA) not to reimburse for therapeutic apheresis in the treatment of rheumatoid arthritis. The cost projections, by most sensibilities, were considered startling. The study used a Wallace, et al. (140), estimate that as many as 700,000 Americans might be candidates for apheresis at a first-year cost of \$40,000 per patient and \$18,000 per patient each year thereafter. This implied a cost of up to \$28 billion in the first year. If 5 to 10 percent of the nearly 1 million Medicare-eligible patients with rheumatoid arthritis were to be given apheresis, it would cost between \$2 billion and \$4 billion (124). NCHCT noted that these were gross cost projections, and could be modified by projected savings from reduced expenditures for hospitalized bed rest, medication, and joint surgery. Maintenance of, or return to, a productive lifestyle would also have to be considered (as noted previously in this section) if apheresis were shown to be effective (107).**

The NCHCT study of potential costs, by comparison, casts OTA cost estimates as conservative, both from the standpoint of potential patient population and cost per treatment estimates. **The NCHCT study**, however, has been criticized for **usage** of “inflated” estimates pertaining to potential patient population. More widely accepted figures come from **Max** Hamburger, in concurrence with the American Society for Apheresis (49), who estimates the potential RA patient population at less than **70,000**, or about 10 percent of NCHCT estimates.

THIRD-PARTY REIMBURSEMENT

Reimbursement policies by third parties, like other aspects of therapeutic apheresis, has been the subject of some debate because of the competing factors of cost and therapeutic promise that this case study has variously discussed. The development of most of these policies has been recent, and there would appear to be the groundwork for an even more intensified period of evaluation, debate, and formulation of these policies in the near future. The following review elaborates on these developments and issues.

Federal Policies

The Federal Government has been substantially involved in the funding of apheresis through research support (see ch. 3); benefit programs such as Medicare, Medicaid, military, and Veterans' Administration hospitals; and employee insurance packages such as the Department of Defense's Civilian Health and Medical Program of the Uniformed Services (CHAMPUS) and the Federal Employee Health Benefit Plans.

Medicare*

Although the cost of apheresis has focused attention on reimbursement, cost information has not been explicitly or directly considered in

Regardless of which estimate is selected, the effect of reimbursement policy on potential direct expenditure estimates is clear from both studies. Furthermore, as alluded to earlier, the expenditure implications of a reimbursement decision are intertwined with the technology's diffusion, producing direct and indirect effects, some of which may be wide-reaching. The magnitude of the direct cost estimates alone suggests that the procedure's safety and efficacy should be closely scrutinized because of the potential cost of possibly premature diffusion.

Medicare coverage determinations. The legislatively mandated practice of paying usual and customary fees does not easily accommodate such analyses. Instead, Medicare coverage determinations have relied on safety and efficacy criteria in an effort to “sketch the boundaries of accepted good medical practice” (98).

Formal Federal policies for reimbursement of apheresis under its Medicare program have developed almost completely over just the past few years, probably reflecting the fact that HCFA procedures for making coverage decisions were highly informal until early 1980. The staff of the Office of Coverage Policy, often with assistance from the Health Standards and Quality Bureau, would review the issue, consult experts in the field with whom they were acquainted, and come to a decision (104). **Three or four regional office inquiries concerning coverage positions on apheresis surfaced during that period, but no national instructions were issued.**

Although a formal agreement between HCFA and the Public Health Service had existed since around 1966, a somewhat more formal, systematic, and credible assessment process involving a panel of physicians within HCFA and from NCHCT was established in early 1980. When

● On Apr. 20, 1983, Public Law 98-21 provided for extensive changes in Medicare reimbursement policies for hospital-based care. Under the statute, whose provisions will be phased in over 3 years, hospitals will receive a flat fee per patient, set prospectively, on the basis of patient diagnosis in one or more of 467 diagnosis-related groups (DRGs). It is unclear at this point how the DRG-based payment system will affect the adoption and use of apheresis. What is certain, however, is that information on the effectiveness of this treatment will be even more important as physicians and patients face increasingly scarce resources.

HCFA decided that a procedure involved a question of national importance, a request for a technology assessment was sent to NCHCT. Usually such a request asked NCHCT to determine the safety and efficacy of a particular technology and to recommend whether HCFA should reimburse (103,104). Because the number of questions about coverage of apheresis increased substantially beginning in 1979-80 (56), HCFA, on the advice of NCHCT, issued its first national instructions on apheresis in August 1981. **Effective September 15 of that year, HCFA announced the coverage of therapeutic apheresis for the following indications (52):**

1. plasma exchange for acquired myasthenia gravis;
2. leukapheresis in the treatment of leukemia; and
3. plasmapheresis in the treatment of primary macroglobulinemia (Waldenstrom) and hyperglobulinemias, including multiple myeloma.

The HCFA policy statement went on to say that apheresis should be denied for other indications, but that information on claims for what seems to be other nonexperimental uses should be provided to HCFA'S central office (53).

Even before the August policy release—in May of 1981—HCFA requested that NCHCT evaluate the safety and clinical effectiveness of apheresis for the treatment of (38):

1. Goodpasture's syndrome;
2. systemic lupus erythematosus;
3. membranous and proliferative glomerulonephritides;
4. multiple sclerosis;
5. potentially life-threatening complications of rheumatic diseases (rheumatoid arthritis, systemic lupus erythematosus, polymyositis/dermatomyositis, and progressive systemic sclerosis); and
6. thrombotic thrombocytopenic purpura (TTP).

NCHCT issued formal assessments on the indications of multiple sclerosis, rheumatoid arthritis, rheumatoid vasculitis, and TTP. Two other indications— Goodpasture's syndrome and mem-

branous proliferative glomerulonephritides—were evaluated in early 1983 by the Center's organizational successor, the Office of Health Technology Assessment (OHTA) (28). (NCHCT and OHTA assessments are discussed in ch. 3.) HCFA has yet to implement instructions on any of these six categories for national coverage policies.

Although Medicare's national coverage is relatively new, it is not unlikely that many hospital apheresis treatments for Medicare patients with covered and noncovered disease indications have been performed and reimbursed without official sanction of HCFA. Because Professional Standards Review Organizations do only a limited job of surveillance, because descriptions in the line item billings are very general, and because new procedures often do not have a procedure code number, the identity of Medicare reimbursements for apheresis therapies may have been concealed (104,117).

Medicare provides coverage for apheresis regardless of whether or not it is performed at a hospital (108). It has been reported, however, that independent, freestanding settings are less likely to receive reimbursement at this time, fueling speculation that HCFA hopes to control the use of apheresis by limiting reimbursement to hospital-based therapy (73). There is no known intention by HCFA to implement such a regulation at this time or in the near future.

Medicaid

Medicaid provides medical assistance to low-income individuals. Treatment costs are shared by the States and the Federal Government. Each participating State must provide certain basic health services, but the States have a great deal of leeway concerning specific coverage (102). Medi-Cal (California Medicaid), for example, will approve payment only for apheresis conducted in the treatment of certain diseases, including myasthenia gravis, lupus, and Goodpasture's syndrome. Treatment of such disorders as rheumatoid arthritis and multiple sclerosis, on the other hand, are at present considered investigational and are thus not covered (108). As of August 1982, Medi-Cal was in the midst of a review of all its apheresis coverage policies, and was ex-

pected to formulate a new policy statement concerning its coverage policies (58).

Veterans' Administration (VA) and Department of Defense (DOD)

The extent of VA and DOD involvement in the use of apheresis is reflected in a hospital and blood bank survey by Scoville Associates (108). That survey revealed that 30 VA and military hospitals performed therapeutic apheresis, on 260 patients, and a total number of 1,350 procedures. No breakdown of usage by disease, or whether use was for clinical or research purposes, is available.

Under DOD's CHAMPUS program, the use of apheresis in the treatment of any condition prior to August 1981 was considered investigational and not a CHAMPUS benefit. Since then, however, the CHAMPUS program has taken the basic Medicare policy and expanded it somewhat. CHAMPUS now extends coverage to use of the procedure as a "last resort treatment of certain medical conditions." The specified indications are (8):

1. myasthenia gravis during a life-threatening crisis;
2. anti-basement membrane antibody nephritis (i.e., as a result of Goodpasture's syndrome);
3. life-threatening immune complex vasculitis;
4. hyperviscosity of the blood associated with multiple myeloma, Waldenstrom's macroglobulinemia, and hypergammaglobulinemia purpura; and
5. TTP.

Private Sector Policies

Like their Federal counterparts, private insurers historically reimbursed on a routine basis for both apheresis procedures and replacement fluids, but have recently begun to examine apheresis procedures more closely and issue explicit policy statements concerning coverage. In March of 1981, **Blue Shield of California approved payment for therapeutic plasma exchange and lymph-apheresis** in the treatment of severe cases of rheumatoid arthritis if there are acute life-threatening complications or if conventional drug therapy has failed (80,117).

At present coverage under Blue Cross insurance programs varies greatly from State to State. For example, the Southern California, Texas, and South Carolina Blue Cross organizations generally follow the Medicare guidelines and will normally approve payment for apheresis. Illinois Blue Cross indicated that their reimbursement schedule depends on the disease being treated and what other therapies have been tried, but that in general, they will approve most requests. Massachusetts Blue Cross covers apheresis for 14 different disease indications. The Greater New York Blue Cross, on the other hand, does not cover apheresis therapy under any of their plans (61, 79,108).

The National Blue Cross/Blue Shield Association issued a policy statement in May 1982 as a guideline to local Blue Cross/Blue Shield plans. That policy recommends coverage—in hospital settings only—of nine disease categories including severe myasthenia gravis and leukemia (34). The National Blue Cross-Blue Shield Association policy does not necessarily mandate acceptance and implementation by individual plans, however, and is subject to a possible future review at an appropriate time (16).

Many private insurance companies, too, including Pacific Mutual and Prudential, provide coverage for apheresis regardless of whether or not it is performed at a hospital. As with Federal policies, uniform private third-party coverage is pivotal to the future development of the procedure, particularly in freestanding and commercial settings. The growth of commercial centers has been slowed in some States by the fact that some insurance organizations do not provide benefit payments for apheresis procedures performed outside the hospital. FDA has yet to establish licensing procedures for apheresis centers, and many private insurers have indicated a reluctance to provide reimbursement for therapy under uncontrolled conditions, which could lead to possible treatment overuse and abuse. There appears to be less overall concern, though, in the case of private payers, about future restrictions on reimbursement for apheresis treatment (108).

CONCLUSIONS

Acknowledgment of apheresis as a safe and effective treatment application, as an acute therapy in a small group of relatively uncommon diseases, is reflected in present Medicare reimbursement policy. Suggestive evidence of the safety and efficacy of apheresis in a host of other disorders has also forced a flurry of reimbursement policy reviews and formulations among both government and private party insurers.

Reimbursement policies to the present have revealed an increasingly cautious and explicit approach to coverage of apheresis for almost all disease indications, and understandably so. Apheresis is still not a proven cure for any disorder. It may need to be done repeatedly for certain disease conditions, at a cost of up to \$1,200 or more each time. Total cost estimates potentially run into the billions of dollars. Nevertheless, by treating certain disease complications, apheresis has reportedly lessened suffering and helped prolong lives. Reliable estimates of these benefits have yet to be determined and quantified. As a result, cost-benefit ratios and CEAS have not yet been conducted.

It should be reemphasized that the formation of cost-benefit ratios and CEAS should not be considered only economic tools. This point is not negated by the fact that CEA/CBA is described as an efficiency-based technique. Measurement of the efficiency of therapeutic apheresis will depend as much on output as on resources used to produce the output. One of the critical output or outcome measures that can be addressed by CEA/CBA is the effect of apheresis on health status or other health outcome related effects. Any CEA/CBA that attempts to analyze such outcomes for an evaluation of therapeutic apheresis will only be as comprehensive and valid as the data on the efficacy and safety of apheresis. Thus, health outcome related CEA/CBAs for apheresis are dependent on the existence of an adequate efficacy and safety information base. The status of such information for many disease indications for which therapeutic apheresis has been used, however, is inadequate. As a result, it may be exceedingly difficult to demonstrate therapeutic

apheresis a cost-effective technology for which third-party payment is justified.

Medical insurers are presently far from a consensus on which disease indications should be covered, probably stemming from a less than consistent scrutiny of the evidence on safety and efficacy. A widening of Medicare and private insurer coverage of therapeutic apheresis for specific life-threatening complications (e.g., rheumatoid vasculitis) is probable in the near future. But direct cost estimates and the potential cost of possibly premature diffusion alone make it unlikely and unwise that third-party payers will support any broad extension of benefits for apheresis treatment until more valid data is generated. Until evidence is available, therapeutic apheresis will largely be viewed as an experimental technique, not to be considered as a part of routine care. In light of such a situation, present research and clinical trials being carried out assume even greater importance. It will be several years, though, before all the results are in.

Lastly, a significant (but still speculative) factor amidst the cost and reimbursement policy debate is the potential cost reductions of new apheresis equipment and treatment modalities. The present trend towards plasma perfusion (more selective removal of undesirable plasma fractions) offers the possibility of eliminating the need for replacement fluids which could reduce the present cost per treatment by 20 to 50 percent. Staffing charges are presently based on a large proportion of acute treatments which are usually performed on an in-patient basis, often at the patient's bedside. Some observers predict the future growth in apheresis to involve increases in maintenance therapies which could be performed on an out-patient basis, with reduced involvement of hospital staff (74,108).

On the other hand, there seems to be a trend toward in-hospital use in areas such as Washington, D.C. In that region, after the Red Cross started doing therapeutic apheresis in March 1978, only one of the first 16 months' 106 procedures was done in a hospital. But from July 1980 to

April 1981, nearly five out of six were. Future decisions regarding treatment settings will no doubt depend on a number of factors such as hospital charges, regulation and standard setting ac-

tivities for freestanding, independent commercial clinics, reimbursement policies, and whether apheresis is administered largely for reasons of acute or maintenance therapy in specific disorders.

5 .

Implications for Policy

Implications for Policy

In summary, the confluence of technological advances in apheresis equipment and recent scientific research linking many chronic disease conditions to immunological dysfunction has served to expand dramatically the number of apheresis procedures in the past 10 years. Therapeutic apheresis has exhibited many of the classic features that have come to characterize the hopes, concerns, and fears about medical technologies over the last three decades.

Utilization and diffusion of therapeutic apheresis seems to have closely followed Warner's (141) "desperation-reaction" model. Initial rapid diffusion has occurred in the absence of safety and efficacy evidence. The rapid diffusion is due in part to a lack of a suitable alternative technology, in part to claims—some of them dramatic—of the technology's beneficial effects, and in part to desperation on the part of patients and of providers responsible for treatment. In chronic and life-threatening situations, apheresis has found its broadest and most frequent application.

Most recently, however, the lack of well-validated clinical evidence has influenced provider behavior. Ambiguous results have given rise to physician caution, while lack of evidence and high costs have provoked increased regulation by medical insurers, possibly slowing diffusion. Best estimates are that utilization and diffusion have plateaued, at least for the present. The future of therapeutic apheresis seems predictable in that increases or declines in use will be predicated on newly available evidence (35,95).

Several recurring issues in need of further study and resolution have run through the examination of therapeutic apheresis. One issue, given the current state of this technology and many unanswered questions about patient criteria for use, is what constitutes the appropriate timing of intervention in the course of a disease and whether the procedure to be followed in performing therapeutic apheresis is adequately standardized. Such questions are basic in the development of the tech-

nology, and research to address them is necessary, as it forms a foundation for the conduct of well-controlled testing and clinical trials. The Apheresis Panel of the American Medical Association's Council of Medical and Scientific Affairs has recently discussed the idea of a national apheresis registry that would track use and form a knowledge base for development of well-controlled studies (32). On a smaller scale, the American Red Cross has requested its regional blood services to register all apheresis patients at the onset of treatment and report treatment methods and results upon completion (1.21).

A second issue, which arises where conditions of use have been sufficiently standardized, is the lack of well-designed research studies and the need for such undertakings. There have been at least two obstacles preventing the accumulation of valid evidence of safety and efficacy: the ethics of providing sham apheresis or conventional therapy for control group patients, and the high costs of such trials. Long hours of sham apheresis procedures, while possibly inflicting on control group patients some of the same side effects of apheresis as treatment group patients, has led to questions of the ethical implications of such trials. Furthermore, in life-threatening or severely debilitating situations, doctors feel they cannot ethically deny apheresis therapy to control group patients.

The obstacle of costs of well-designed studies has been partially offset by a recent infusion of Government and foundation funding. Should costs continue to be a problem, one alternative might be to have third-party payers, including Medicare, selectively reimburse for therapeutic apheresis in return for clinical data. If implemented properly, this alternative could substantially increase the quality of information available for public and private reimbursement coverage decisions. Evidence of the technology's cost effectiveness could result in yielding substantial budgetary savings. Even if the results of such trials were disappointing, they could lead the way to unexpected advances in research (47).

Because of the promise of apheresis for certain disease complications, this technology would appear to be a particularly choice candidate for such a policy course. In such conditions as Goodpasture's syndrome, for example, effective alternative therapies are very limited and the disease is frequently fatal. Because apheresis has been claimed effective, selective reimbursement could be of great utility from both research and clinical standpoints.

There would be problems in implementing this alternative (see e.g., 104), primarily concerning the legal and ethical implications of selectively reimbursing for health care. It seems clear, however, that third-party payers could use this approach to encourage less costly and more effective forms of treatment. In the case of Medicare, too, elements of the Public Health Service could be involved in developing research protocols and in interpreting research evidence from the resulting experiments.

A recent precedent exists for third-party payer participation in clinical trial funding for apheresis. Five Midwestern State or local Blue Cross/Blue Shield groups and other third-party payers have agreed to reimburse five centers involved in a randomized clinical trial of apheresis for multiple sclerosis. Both the investigational procedure and a sham procedure are covered. Medicare and the State Medicaid groups, on the other hand, are not participating, but administrative and other research costs of the trial are being funded through a National Institutes of Health grant (97).

The Arthritis Foundation and the National Multiple Sclerosis Society are also sponsoring a meeting (to be held in July 1983) at which they hope to develop proposals for third-party payer participation in funding other clinical trials. Representatives of both private and public insurers will be participating (97).

A *third* issue is the possibly transitional nature of this technology. Some major new hardware developments are now undergoing clinical tests. These use adsorption columns and membranes that work like molecular sieves. When a specific fraction whose removal is desired can be identified, an adsorption column containing an antibody to that fraction can remove it from the plasma as

it passes through. Another method, resembling hemodialysis, passes the blood across a membrane with a specific antibody attached to it. A third technique uses a membrane filter to remove fractions of a specific molecular weight (80).

These advances in equipment may, in the course of the next decade, be reinforced or even overshadowed by advances in basic biomedical research or in emerging parallel developments such as biotechnology. The National Cancer Institute, and the National Heart, Lung, and Blood Institute, for example, are currently supporting strategies for the separation of complex blood proteins. Advanced separation technologies could make it possible to index most human proteins. Once proteins are displayed and distinguished from one another, investigators might then tease out individual functions and relate them to the DNA code. Other activities could include the detection of abnormal protein patterns in disease states (e.g., leukemia), and the corresponding production of preventive or neutralizing elements (e.g., monoclonal antibodies) to these noxious or damaging processes (53,60).

In the final analysis, such a state of scientific and technological flux has important policy implications. Therapeutic apheresis, as a medical intervention, falls into a category of medical technologies classically referred to as half-way *technologies* (133). These are generally treatments directed at correcting the effects of a disease or palliating them. It has been pointed out and illustrated repeatedly in the literature and research community that such measures are less satisfactory and more costly than so-called *definitive technologies*, which effectively prevent or control a disease or condition (e.g., poliomyelitis vaccine). As Robbins (116) and numerous others have asserted, "where alternatives exist, resources should be directed so as to encourage the development of definitive technologies as opposed to half-way measures." To the extent that such alternatives can be identified, considerable attention should be given to the possibility of devoting resources to their development. Indeed, one of the critical, ongoing policy issues in medicine is how to establish the most rational and productive balance between development and support of half-way technologies and that of basic research toward definitive technologies.

Appendixes

Appendix A.— Health Program Advisory Committee and Acknowledgments

HEALTH PROGRAM ADVISORY COMMITTEE

Sidney S. Lee, *Chair*
Michael Reese Hospital and Medical Center

Stuart H. Altman*
Florence Heller School
Brandeis University

Carroll L. Estes
Department of Social and Behavioral Sciences
School of Nursing
University of California, San Francisco

Rashi Fein
Department of Social Medicine and Health Policy
Harvard Medical School

Melvin A. Glasser
Health Security Action Council-
Committee for National Health Insurance

Patricia King
Georgetown Law Center

Joyce C. Lashof
School of Public Health
University of California, Berkeley

Margaret Mahoney
The Commonwealth Fund

Frederick Mosteller
Department of Health Policy and Management
School of Public Health
Harvard University

Mitchell Rabkin*
Beth Israel Hospital
Boston, Mass.

Dorothy P. Rice
Department of Social and Behavioral Sciences
School of Nursing
University of California, San Francisco

Richard K. Riegelman
George Washington University
School of Medicine

Walter L. Robb
Medical Systems Operations
General Electric
Milwaukee, Wis.

Frederick C. Robbins
Institute of Medicine

Rosemary Stevens
Department of History and Sociology Science
University of Pennsylvania

● Until April 1983.

ACKNOWLEDGMENTS

The development of this case study was greatly aided by the advice and review of a number of people in addition to the Advisory Panel for the assessment of *Medical Technology* and *Costs of the Medicare care Program* and the Health Program Advisory Panel. The case study director and OTA staff would like to express their appreciation especially to the following individuals:

Cheryl Anderson, Advocacy International, Ltd.
Jack M. Anthony, Travenol Laboratories, Inc.
Thomas Asher, Immunogenetics, Inc.
Robert Berenson, Washington, D.C.
Eugene Berkman, Tufts New England
Medical Center
Gary F. Brown, Seattle, Wash.
Meredith F. Buco, Blue Cross/Blue Shield
Association
Maria Charest, Arthur D. Little, Inc.,
Cambridge, Mass.
Arthur A. Ciarkowski, Food and
Drug Administration
Vincent Ciuryla, E. I. du Pont de Nemours & Co.,
Inc.
P. P. Clymer, Office of Technology Assessment
Robert M. Collins, Cobe Laboratories, Inc.
Dennis Cotter, Office of Health Technology
Assessment
W. Palmer Dearing, Blue Cross/Blue Shield
Association
Vincent T. DeVita, Jr., National Cancer Institute
Allen J. Douma, American Medical Association
Frances Edmondson, Travenol Laboratories, Inc.
Lenny Friedman, American Red Cross
W. Bradford Gary, Travenol Laboratories, Inc.
Murray Goldstein, National Institute of
Neurological and Communicative Disorders
and Stroke
Max I. Hamburger, State University of New York
at Stony Brook

Steven Heyse, National Institute of Arthritis,
Diabetes, and Digestive and Kidney Disease
Terry Hollis, Blue Cross/Blue Shield of
Massachusetts
Douglas W. Huestis, University of Arizona
John Verrier Jones, Dalhousie University,
Nova Scotia, Canada
Richard Landfield, Goodell, Landfield, Becker,
Green & Martingale, Washington, D.C.
Claude Lenfant, National Heart, Lung, and
Blood Institute
Joshua Levy, Immunogenetics, Inc.
L. M. Magner, E. I. du Pont de Nemours & Co.,
Inc.
Guy M. McKhann, Johns Hopkins Hospital
Donald Myers, RMR Health and Hospital
Consultants, Inc.
Terri Louise Nally, American Chemical Society
Nan Newell, Office of Technology Assessment
Robert K. Oldham, National Cancer Institute
Robert W. Reilly, American Blood Resources
Association
J. Gerald Sandier, American Red Cross
Phillips L. Scoville, Scoville Associates,
Greenville, S. C.
Ira D. Singer, Project Hope
Glenda Sweeney, American Red Cross
Garry Vibert, Parker-Hannifin Corp.
Donald Young, Health Care Financing
Administration

Appendix B.—Apheresis for Hemolytic-Uremic Syndrome

Prepared for OTA by: Paul M. Wortman, Ph. D.
Hillary Murt, M.H.S.A.
In collaboration with: Bruce Friedman, M.D.

The most prominent feature of hemolytic-uremic syndrome (HUS) is renal microangiopathy, which is characterized by endothelial damage in glomerular capillaries and renal arterioles. The event which initiates this endothelial damage is unknown although some authors have suggested that endotoxin is a prime candidate (71). The damaged endothelial cells become swollen, leading to renal ischemia and decay of kidney function and two secondary hematologic events—red cell destruction (hemolytic anemia) and a dramatically reduced level of circulating platelets (thrombocytopenia). The former results from mechanical damage to red cells passing through the damaged vessels. The reduced platelet count results not only from trauma but also localized intravascular coagulation (and platelet consumption) occurring in the damaged vessels.

An alternative and more recent hypothesis cites decreased formation of PGI₂ (prostacyclin) as the precipitating event leading to the full-blown clinical manifestation of the syndrome (instead of a toxic agent such as endotoxin). The finding of PGI₂ deficiency in adults and children with HUS supports this concept (11). In this case, the loss of PGI₂ causes localized platelet aggregation in renal vessels and vascular obstruction. Traumatic red cell destruction (hemolytic anemia) is a corollary of the development of the microthrombi which partly occlude the vascular lumens (84).

Finally, Seger, et al. (126), have suggested that HUS is a polyetiologic syndrome with neuraminidase being the culprit agent in some cases, particularly among children suspected of having pneumococcal infections, as this agent can produce lesions in all three cell systems (red blood cells, platelets, and endothelial cells).

The hemolytic-uremic syndrome shares a number of features, including vascular endothelial damage, with thrombotic thrombocytopenic purpura (TTP). In fact, HUS has been considered by some clinicians to be a variant of TTP, this being supported by similar overlapping clinical and pathologic characteristics and the possibility of similar precipitating events. There is no objective method at present to distinguish HUS from TTP, although in the case of the former, the kidney is typically the main and often only target organ,

children are primarily affected, and the prognosis is generally much better (71). These authors believe, however, that a clinical diagnosis of one or the other conditions must be made because the treatment differs and in HUS, depends on the management of the complications associated with renal failure.

Plasma exchange (PE) was first administered as a therapy for TTP in 1959 by Rubenstein and others (84). Rapid and sustained recovery was observed after two exchange transfusions with fresh whole blood to an n-year-old patient.

Taft and Baldwin (132) noted that centers which have experience with five or more patients diagnosed with TTP and treated with PE are reporting survival rates in the 60- to 80-percent range. Plasma exchange is now being advocated as a potential therapy for treating HUS because of the suspected etiological similarity between the syndrome and TTP. Apheresis is viewed as being potentially helpful in removing a toxic agent (e.g., endotoxin, neuraminidase) or replacing a missing factor, possibly a physiological inhibitor of platelet aggregation. In the latter case, Beattie, et al. (11), and Misiani, et al. (84), have both suggested that PE using normal plasma replaces a missing factor needed for stimulating PGI₂ production by vascular endothelium.

Specification of Treatment

Only eight reports (including two letters to the editor and one abstract) have been published in the English medical literature on the effectiveness of plasma exchange in the management of HUS. These eight communications account for 11 patients diagnosed with HUS ranging in ages from 1½ to 59 years who were treated as an ancillary therapy with corticosteroids, antiplatelet drugs, or heparin. * Moreover, in seven

● Beattie, et al. (11), report on a 3½-year-old boy diagnosed with HUS. The patient was initially treated with aspirin and dipyridamole (5 mg/kg/day) and his condition gradually improved. Plasma exchange was not initiated until 10 days later when the patient was readmitted to the hospital with recurrent symptoms of HUS. The authors do not indicate whether any drug therapy was administered during the second episode, so it is assumed that PE was the only therapy administered. The article by Taft and Baldwin (132) focuses primarily on the treatment of patients diagnosed with TTP. They only briefly mentioned two patients with HUS who were treated with apheresis and do not provide full case histories.

cases hemodialysis or peritoneal dialysis was performed concurrently with plasma exchange.

It appears that apheresis is not the sole treatment regimen of HUS and thus the particular impact on patient health may be hard to determine. Apheresis is commonly embedded within a more comprehensive treatment regimen including a variety of drugs, some form of dialysis, and blood or platelet transfusions. Several authors (84,132) have mentioned the difficulty in evaluating the efficacy of each treatment approach alone since different forms of therapy have typically been employed in combination. Misiani, et al. (84), for example, are concerned with separating the beneficial effects of PE from antihypertensive drugs in treating HUS, whereas Taft and Baldwin (132) emphasize the need to evaluate the relative contributions of ancillary therapies such as corticosteroids and antiplatelet drugs to the successful recovery of PE-treated patients.

Despite the fact that a sizable proportion of HUS patients are treated with some form of dialysis, none of the authors point out the possible confounding effects of hemodialysis and peritoneal dialysis performed concurrently with plasma exchange. It should be noted that dialysis may provide beneficial effects independent of apheresis. In the case of hemodialysis, all patients are heparinized during dialysis. Heparin, an anticoagulant drug, exerts an antithrombotic effect. Recall that thrombotic occlusions of capillaries and arterioles have been implicated in the pathogenesis of HUS. Thus, hemodialysis (which necessarily includes the administration of heparin) may be partly responsible for inhibiting the formation of microthrombi in the glomerular capillaries and thereby increasing renal blood flow.

Heparin was also administered to one HUS patient in the absence of hemodialysis, which suggests that clinicians recognize the potential efficacy of using heparin therapy alone for treating HUS. Parnes, et al. (106), report on two small series of HUS patients treated with only heparin; mortality rates of 9 and 50 percent were recorded. In each series, about 30 percent of the patients completely recovered; the remaining underwent chronic dialysis.

In the case of either hemodialysis or peritoneal dialysis, it may also be postulated that the removal of unspecified substances of low molecular weight may ameliorate the symptoms of HUS, if the substances that are removed are responsible for the development of the vascular lesions.

It is important to draw a distinction between plasma exchange and plasma infusion. In the former case, plasma is removed and replaced by a colloid solution, commonly albumin, fresh frozen plasma, or simple

donor plasma. Although the plasma replacement in early cases was initiated only for purposes of expansion of the intravascular volume, later authors suggested that the administration of fresh frozen plasma had an independent therapeutic effect. This led some investigators to administer it alone with apheresis; this is described in the literature as plasma infusion. The beneficial effects of PE may be confounded when plasma infusion is also administered as part of the treatment regimen. Obviously, both methods have the advantage of replacing the missing plasma factor, if, in fact, that is the underlying cause of HUS. However, PE may provide the additional advantage of removing other possible etiological agents, the products of damaged red blood cells, and other hypothetical platelet aggregating substances. In short, when these two forms of therapies are both administered during a relatively short period of time as in the case of two HUS patients described in the literature (84) it becomes difficult, if not impossible, to attribute any measure of success to one therapy or the other.

It is conceivable that some form of adjuvant drug therapy or dialysis is required in conjunction with apheresis to successfully treat patients with HUS. That is to say, clinicians may view PE as a necessary but not sufficient form of treatment to restore normal physiological functions. When other forms of therapy are used in addition to PE, particularly drug therapy, there still is the problem of operationalizing the treatment when the concomitant therapies vary widely across cases (e.g., the use of heparin with or without platelet inhibitors). When there is differential improvement by type of drug used, the integrity of the treatment is called into question. It may be the case that the synergistic effects of apheresis and drug therapy may vary according to the dosage and regimen of the particular drug used.

Plasma exchange therapy itself varies widely with respect to the number of exchanges performed and the volume of plasma removed at each exchange process. Table B-1 shows that the number of PEs performed for each episode of HUS ranges from one to eight exchanges for the 11 patients diagnosed with HUS. In two of the studies, the frequency of plasma exchange appears to be dictated by the platelet response (spontaneous increment v. lack of increment), and the level of serum LDH activity or creatinine levels. In one study, however, the frequency of plasma exchange in another study depended on the resolution of neurologic symptoms (sO). As best as can be determined from table B-1, the volume of plasma removed at each exchange is variable. However, the discrepancy in the volume of plasma removed at each exchange across patients may be due to the fact that 7 of the 11 pa-

Table B-1.—Apheresis Experience Among Patients Diagnosed With Hemolytic-Uremic Syndrome

Study reference number	Number of patients	Age range of patients	Range of plasma exchanges performed per episode	Range of plasma volume removed per exchange	Types of replacement fluids used
1	1	3½ yrs.	2	1,000 ml	Fresh frozen plasma
1	2	7 yrs.	3	Unknown	Whole blood
5	2	54-56 yrs.	1	3,000 ml	Fresh frozen plasma
6	1	21 yrs.	5	3,000 ml	Fresh frozen plasma and normal saline
7	2	19-22 mo.		1,500 ml-2,350 ml	Whole blood
8	1	8 yrs.	8	1,500 ml	Albumin, fresh frozen plasma
9	2	2-7 yrs.	1-6	27 ml/kg-89 ml/kg	Whole blood, fresh frozen plasma
10	1	37 yrs.	4	Unknown	Unknown

SOURCE: Office of Technology Assessment, 1983.

tients undergoing PE were children, who have smaller blood volumes. Table B-1 also shows that whole blood and fresh frozen plasma are the two most common replacement fluids used in the process of plasma exchange for patients with HUS. Human serum albumin was used as a replacement fluid in only one case and the authors noted that there was no improvement after three exchanges, suggesting that no circulating agent perpetuated the condition. Plasma exchange was then performed with fresh frozen plasma, which was followed by a prompt recovery in the platelet count (131).

The absence of explicit and detailed protocols for performing plasma exchange poses a major problem in the evaluation of the effectiveness of apheresis therapy. However, given the rare occurrence of HUS in the population, it comes as no surprise that not enough information has been accumulated to the use of plasma exchange to develop such protocols.

Misiani, et al. (84), suggest that at the present time it is impossible to define individual PE requirements since both the patient's and donor's plasma may differ with respect to the plasma factor (e.g., PGI) concentrations. Those authors recommend apheresing a full volume at the initial exchange, followed by one-half the initial amount daily until full hematologic remission is obtained. The literature on TTP, on the other hand, is considerably more extensive and consequently, a set of treatment guidelines or protocols has recently been proposed by Taft and Baldwin (132). They have developed a clinical scoring system (including necrologic evaluation) to evaluate the day-to-day severity of the disease, which maybe used to determine the frequency of PE. Relying on five clinical criteria (i.e., platelet count, serum LDH, total bilirubin, creatinine, and necrologic status) a score is calculated to determine whether therapy should be continued. Since several investigators have suggested that HUS is a variant of TTP, it is conceivable that

such a scoring system modified slightly to take account of the clinical manifestations specific to HUS could be used to determine the appropriate frequency and volume of PE.

Outcome Measures

A recurring critical issue in any attempt to analyze the effectiveness of a medical innovation is the selecting of appropriate endpoints for evaluating the success or failure of the innovation. In many instances, outcome measures are either lacking, not specified, or ill-defined in the written reports. For example, one study of HUS reports that the patient "showed improvement" after the PE was initiated, without defining precisely what improvement means (135).

It appears that on, the whole, nonspecification of outcome measures is less of a problem when evaluating the effectiveness of plasma exchange for patients with HUS. While it is noteworthy that none of the eight studies provide a discussion that specifically focuses on the kinds of outcome measures that should be used to evaluate apheresis for HUS, there does appear to be some consensus in the literature on the array of clinical indicators that are reported pre- and post-PE.

Table B-2 shows, for example, that all eight studies reported whether or not their patients underwent chronic dialysis and their mortality experience. However, the length of followup during which mortality data were collected varies across studies, which may limit the usefulness of directly comparing mortality rates. Furthermore, seven of the eight studies reported creatinine or BUN levels (i.e., indicators of renal insufficiency) and six studies indicated platelet counts. All six indicators displayed in table B-2 should be considered to be objective outcome measures. That is to say, none of these measures is likely to be influenced

Table B-2.—Variability in Effectiveness of Plasma Exchange Therapy for Hemolytic-Uremic Syndrome as Expressed in Selected Outcome Measures (all outcome measures relate to past plasma exchange period)

Study reference number	Number of patients	Outcome measures					Mortality
		Patients with increment in platelet count	Patients with eventual decline in serum LDH	Patients with remission of in neurologic signs	Patients with eventual decline in serum creatinine or BUN (renal improvement)	Patients for whom chronic dialysis was initiated or continued	
1	1	1/1	NA	NA	0/1	1/1	0/1
2	1	NA	NA	1/1	1/1	0/1	0/1
5	2	2/2	2/2	NA	1/2	1/2	1/2
6	1	1/1	NA	NA	1/1	0/1	0/1
7	2	NA	NA	NA	0/2	2/2	2/2
8	1	1/1	NA	NA	1/1	0/1	0/1
9	2	2/2	2/2	NA	2/2	0/2	0/2
10	1	1/1	NA	NA	1/1	0/1	0/0

NA-Not available.

SOURCE: Office of Technology Assessment, 1983.

by expectations of the physician or patient concerning the efficacy of treating HUS with apheresis.

These measures clearly represent endpoints that are evaluated at different times during a given episode of HUS. It may, in fact, be convenient to make a distinction between the more general measures of health status relating to HUS (e.g., chronic dialysis, mortality), which represent the sum total of many influences and the more sensitive and specific hematologic, biochemical, and clinical signs and symptoms (e.g., platelet count, creatinine, BUN, serum LDH levels, and neurological status) that often occur rapidly following plasma exchange. The former may be called "long-term" outcomes, whereas the latter may be termed "immediate" outcomes.

When an outcome measure such as mortality is used to evaluate the effectiveness of apheresis therapy for HUS, the benefits of apheresis may be substantially understated. Plasma exchange may, for instance, bring about a temporary improvement in the patient's clinical status, but other intervening factors may ultimately cause the patient's death. Most clinicians, however, would probably agree that the ultimate objective of apheresis therapy is to increase the likelihood of survival, which suggests that survival (or mortality) is an important outcome measure of the efficacy of apheresis and should not be disregarded.

The need for chronic dialysis, on the other hand, may be a more appropriate outcome measure for determining the ultimate success of plasma exchange in the treatment of HUS, since renal failure is a major element of the syndrome. Chronic dialysis was deemed necessary for 4 of the 11 patients listed in table B-2 (two of whom later died) which represents a 36-percent failure rate when dialysis is used as the sole measure of the effectiveness of PE therapy.

Finally, changes in hematologic and biochemical parameters such as platelet count, serum LDH, creatinine, and BUN levels may also be used to evaluate the effectiveness of apheresis therapy. The difficulty with using these measures, however, is that patients may show improvement in one or all of those parameters yet still require long-term dialysis (e.g., patients in studies 1 and 5). In short, the "immediate" outcome measures may be necessary but insufficient indicators of the efficacy of plasma exchange. Perhaps these measures and the end points of chronic dialysis and mortality could be combined in some way as co-measures. The problem of combining multiple evaluation criteria and assessing the significance of the results is a difficult one. For example, researchers may choose to assign different weights to each outcome measure which would lead to disagreement and perhaps a lack of consensus on the effectiveness of PE in treating HUS.

Patient Selection

In seven of the eight studies, PE therapy was initiated when patients diagnosed with HUS did not respond to either hemodialysis or peritoneal dialysis or other conventional therapies including corticosteroids, antiplatelet drugs, or heparin. In other words, apheresis was performed on these patients as a last resort therapy when there were no other effective alternative therapies and death was the likely outcome. Since only the "worst cases" of HUS appear to be selected for apheresis therapy, it is possible that the effectiveness of plasma therapy is underestimated, depending on which outcome measure is used. If PE is initiated in the later stages of the disease (i.e., when end-stage renal disease is inevitable), the beneficial effects of

apheresis maybe dramatically reduced if chronic dialysis is the end point used for evaluating the effectiveness of the treatment.

Evaluation of the Evidence

The eight communications that have appeared in the literature during the past 3 years describing the effectiveness of apheresis in treating patients with HUS present data on a total of 11 patients, but each case is described individually. Only one of the communications suggests that PE has limited effectiveness on the disease process (11). However, the authors in this article add that the clinical benefit may have been compromised because PE was performed during a recurrent phase of the illness which is recognized as being associated with poor prognosis. The remaining seven studies are almost uniformly favorable in suggesting that apheresis contributes to clinical improvement, although there is no explanation provided about which measures are used to gauge this improvement. Several authors add the caveat that PE be initiated during the early stages of the disease in order to realize its full benefit (132). Parries, et al. (106), caution that PE alone is associated with complications (e.g., hepatitis) and that these risks should be weighed against the potential benefits of apheresis.

What can be said about the “scientific soundness” of the data on which the conclusion that PE is efficacious is based? Scientific soundness is defined here

as the adequacy and the credibility of the available information for reaching a consensus. First, in the case of evaluating the use of PE therapy for treating HUS, it is quite clear that the newness of this particular application of the technique is associated with a small and incomplete research base. With only 11 patients, there is insufficient data on which to make a recommendation to endorse this procedure. Second, the credibility of the evidence is open to question because of the quality of research used in all eight studies; these case studies do not include any comparison groups. The major problem with the case-study approach (and other pretrial studies) is that they are subject to a variety of competing alternative explanations for the observed effects of the therapy. Interpreting the evidence becomes even more problematic when the potential affects of apheresis therapy are confounded by other therapies that are used concomitantly with plasma exchange. Apheresis was the single therapy used in only two case studies; one patient completely recovered and the other patient underwent chronic dialysis because of continued deterioration of renal function (11,106).

Finally, it is unclear as to which criteria (e.g., outcome measures) should be used in evaluating the effectiveness of the therapy. There are too few cases to determine whether there is high concordance between the “immediate” outcomes (e.g., platelet counts, LDH, creatinine, and BUN levels) and the “long-term” outcomes (e.g., chronic dialysis, mortality). If these measures turn out to be discordant, some method will have to be developed to combine these multiple evaluative criteria in order to arrive at the recommendation.

Appendix C.—Apheresis for Inhibitors to Factor VIII

Prepared for OTA by: Paul M. Wortman, Ph. D.
 Hillary Murt, M.H.S.A.
 In collaboration with: Bruce Friedman, M.D.

Factor VIII Antibodies

Apheresis, and more specifically, plasma exchange (PE), has been investigated as a potential therapy for patients with antibodies or inhibitors to Factor VIII during the past 10 years. Factor VIII is essential to achieve hemostasis (i.e., permit normal blood clotting and end bleeding). For that reason, patients with classic hemophilia have been particularly at risk from complications associated with the development of Factor VIII antibodies. It has been estimated that as many as 20 percent of such patients may develop this condition. Factor VIII inhibitors can also arise spontaneously in other patients. This so-called idiopathic or acquired inhibitor to Factor VIII can occur in women in their first year after childbirth, persons with rheumatoid arthritis, the elderly, and persons suffering a variety of other disorders.

The major concern in these situations has been to return Factor VIII to normal or effective levels. Treatment typically involved immediate and continued doses of human Factor VIII concentrate. This treatment often failed since it did not remove existing antibodies in the blood and frequently appeared to stimulate the production of more antibodies. To deal with these complications a variety of alternative treatments has been investigated. One of these has involved the use of apheresis with or without Factor VIII. The following sections summarize the available scientific research reporting on the use of PE in treating patients with antibodies to Factor VIII.

Literature Reviews

Twenty articles were located and retrieved from a MEDLARS search of the research literature. Four of these articles did not deal specifically with cases involving Factor VIII, five were in a foreign language (two in Russian, two in German, and one in Hungarian), one article was a duplicate copy of another, and one contained the same case information as another by the same authors. Of the foreign language articles, the two in Russian were excluded, the one in Hungarian also was published in English and that article was included in our review; the two German studies were read. One of the German articles did not deal with Factor VIII and the other presented a very brief case drawn from 210 patients and also was not included in this review.

There remained nine articles to review after the various exclusions were made. The articles were all case studies involving from one to six patients. Five studies reported treating a single patient; two had two patients; one had three, and another had six. Of the 18 patients in these nine studies, 10 had classic hemophilia, seven idiopathic Factor VIII antibodies, and one had von Willebrand's disease. The patients generally faced a life-threatening situation. Thirteen had severe bleeding and three required or were recovering from surgery. The patients ranged in age from 3 to 77 and generally had either low levels of Factor VIII or high levels of Factor VIII inhibitor reported prior to treatment.

Table C-1.—Apheresis Experience Among Patients Diagnosed With Inhibitor to Factor VIII

Study reference number	Number of patients	Range of PEs per episode	Range of plasma volume removed per exchange (in ml)	Replacement fluids used	Duration (days)
1	1	9	500-1,500	FFP ^a , saline	42
2	1	2	3,800-7,500	FFP	21
3	2	6-8	1,500-3,000	FFP, albumin	8-10
4	3	1-2	1,500-3,000	Gelatin, albumin, saline	2-50
5	1	3	17,100 total	FFP	1
6	1	3	1,400-6,000	FFP	7
7	1	3	600-1,000	FFP	18
8	2	3-15	4,000	FFP, saline	3-14
9	6	1-4	2,500-3,500	Gelatin, plasma protein	1-4

^aFFP = Fresh, frozen plasma.

SOURCE: Office of Technology Assessment, 1983.

Specification of Treatment

Although apheresis was employed in all of these studies, the actual definition or specification of treatment varies widely from one report to another (see table C-1). First, the number of PEs varies widely from just 1 (109,143) to 15 (129). The modal number of PEs was three (occurring in six of the 18 patients) with another four receiving two exchanges. The volume of plasma actually exchanged also differed widely from one study to the next, ranging from 500 to 6,000 ml per exchange. The replacement fluid also varied. Although in seven studies fresh frozen plasma was used, other fluids included albumin, gelatin, plasma protein, and saline (or plasma expander). It should be noted that in most patients who were severely compromised fresh frozen plasma was used. The treatment also varied in duration, lasting from 1 day to 6 weeks.

Perhaps most troublesome in determining the appropriate treatment regimen is the use of immunosuppressants such as azathioprine and cyclophosphamide in conjunction with apheresis. Five of the eight studies used one of them simultaneously with PE and two had tried it before using PE. Nevertheless, there is a great difference of opinion on the value of such therapy despite its confounding with apheresis. One study (129) claims that “immunosuppression has not been shown to be effective and may well interfere with wound healing and increase susceptibility to infection.” However, another study (111) concludes that “a combination of specific immune suppression and intensive . . . (apheresis) . . . may be the best form of treatment in patients with acquired idiopathic factor VIII inhibitors and life-threatening bleeding.” The resolution of these conflicting claims and the separation of the two treatments (PE and immunosuppression) poses some difficulties in so few studies.

The study by Pintado, et al. (111), contains the best discussion of possible alternative treatments. In that study one elderly patient with idiopathic or acquired

Factor VIII inhibitor was given six plasma exchanges over a 2-week period. These researchers reviewed the previous literature and concluded that “spontaneous remission of the immune response” (i.e., termination of production of Factor VIII antibodies) was “unlikely.” Instead, they feel that the remission was due to the combined use of immunosuppressants and “antigenic load” (i.e., human Factor VIII concentrate).

Treatment with Factor VIII concentrate poses an additional problem in determining the efficacy of apheresis. As noted in the introduction, Factor VIII supplementation is viewed as the primary treatment with apheresis an adjunct to improve its efficiency. The use of Factor VIII was, in fact, reported in all nine studies encompassing 16 of the 18 patients treated. However, in one study (37) involving two patients, this treatment was evidently discontinued just prior to apheresis because of a rise in inhibitor level in one patient and an adverse reaction (to a porcine derivative) in the other. Similarly, in the study by Piller, et al. (109), one of three patients was treated with Factor VIII concentrate just prior to apheresis. While the inhibitor level was reduced from 1.3 to 0.5, p/ml, the goal of this study was its complete neutralization and an increase in Factor VIII. In the remaining two patients (who were not in a life-threatening situation) apheresis using Factor VIII-free solutions was tried in an attempt to prevent the “rapid increase” in inhibitor activity. In both cases there was a “less rapid” return of inhibitor activity to its previous level (and, in one case, a “considerably higher” level). The authors conclude that inhibitor levels can be lowered through “repeated . . . (apheresis) . . . at intervals of about one month.”

The Piller, et al. (109), study did not employ immunosuppressants concurrently in conjunction with apheresis (although one patient received prior treatment with azathioprine and Factor VIII with cyclophosphamide “without success”). If the hypothesis of Pintado, et al. (111), is correct, then antibodies would continue to be produced requiring regular PE. As noted

Table C-2.—Effectiveness of Apheresis for Factor VIII Inhibitors

Study reference number	Immediate		Followup
	Hemostasis	Factor VIII inhibitor (μ/ml)	Factor VIII inhibitor (μ/ml)
1	—	1.2	0.8
2	yes	36	8
3	yes	1-8	0-1
4	—	0-4.8	0-1.7
5	yes	—	0
6	yes	—	0
7	yes	12	0
8	yes	—	—
9	yes	0-1	5-47

SOURCE: Office of Technology Assessment, 1983.

this is exactly the conclusion of Piller, et al. (109). Moreover, the two studies with the greatest number of PEs did not use immunosuppressants. In the study by Slocombe, et al. (129), noted above, one of the two patients received 15 PE exchanges along with varying doses of Factor VIII. Similarly, Cobcroft, et al. (23), performed nine apheresis treatments on a patient (who had previously had unsuccessful immunotherapy). One can only speculate on whether as many exchanges would have been required had immunosuppressants been employed concurrently. In both studies, however, there is little justification provided for additional exchanges beyond the first two.

In summary, the modal regimen in the research studies involved two or three apheresis treatments in conjunction with both immunosuppressants (typically cyclophosphamide) and Factor VIII concentrate (from humans). Two hypotheses seem tenable from these studies. First, immunosuppressants may stop the production of antibodies as Pintado, et al. (111), claim, with the apheresis quickly removing existing antibodies. And second, apheresis using Factor VIII-free solutions such as gelatin or saline may slow the return of the inhibitor activity as Piller, et al. (109), maintain. The two treatment therapies are clearly not independent and could be combined. At present there is a need for more systematic research on the most appropriate treatment for patients presenting with Factor VIII antibodies.

Results of Treatment

The results of the treatment just described in the nine studies reviewed are presented in table C-2. Both short-term or immediate results and long-term findings are indicated. For 16 of the 18 patients at risk due to severe bleeding or surgery the immediate clinical results were uniformly successful. In all cases hemostasis was achieved and the patient fully recovered from the acute episode. One should note, of course, that cases of clinical failures are much less likely to be submitted or accepted for publication.

The measures of Factor VIII inhibitor (in μ /ml) and Factor VIII (in percent normal) are not consistently reported in the text. Where possible this information was recorded or interpolated from tables and figures. These figures indicate a less than consistent pattern of results. In almost half the patients (i.e., 8 of 18) the inhibitor level falls below 2 μ /ml at followup; while in 9 of the patients reported, the inhibitor level is 8 μ /ml or greater. The inhibitor data for one patient (129) were not available, but were probably very low given the Factor VIII level of 75 percent.

Eight of the nine patients with poor long-term results are from just two studies (109,143). The Piller, et al., study differed from all the others in that its sole objective, as noted earlier, was the long-term reduction in the Factor VIII inhibitor level. This study did not employ Factor VIII therapy along with immunosuppressants in the two failed cases (although one had received them earlier). It should be noted that short-term control was achieved and the authors conclude that one could “treat severe hemorrhages immediately by only administering Factor VIII or by combining one . . . (apheresis) . . . run with replacement therapy.”

The other six patients, one-third of the total from all of the studies, with poor long-term or “secondary rise” in the inhibitor level, were treated by Wensley, et al. (143). In this case, apheresis combined with human Factor VIII concentrate produced an initial lowering of the inhibitor level to permit hemostasis and healing. The authors recommend this combined therapy as a better alternative to using “significant quantities” of Factor VIII alone.

As noted in the previous section, the impact of immunosuppressants should be considered. Neither of these two studies reported the concurrent administration of immunosuppressants to patients. On the other hand, five of the six patients treated with immunosuppressants had followup inhibitor levels of 1 μ /ml or less.

Evaluation of the Evidence

In conclusion, it is important to ask what one can infer from these nine studies. To do this, it is useful to consider the quality of the research evidence provided. A number of points should be considered in reaching an overall assessment.

First, the studies are all pretrial clinical reports generally of one patient (i.e., the five articles). There were no clinical trials comparing a number of patients systematically treated by a number of well-defined therapies. In fact, other than references to some prior treatment regimen there is no comparative information available.

Second, as an earlier section noted, there is no agreed upon treatment for patients with inhibitors to Factor VIII. While apheresis is used and endorsed in all nine studies, the treatment is more complex than that. Other concurrent therapies are described with varying results and the number of PEs also differed from study to study. While a number of possible hypotheses were examined, the evidence is far from con-

elusive on what is the best method to treat this condition.

Third, the goals of the studies also differed. Most involved acute, life-threatening situations, usually episodes of severe bleeding. In those cases, short-term resolution of the problem was sought and generally achieved. In a few other studies, longer term solutions to the anti-Factor VIII were attempted with varying results. Here too, there are possible treatment combinations that need to be further investigated.

Finally, with so few patients in so few studies one must consider the issue of sample bias. It would only take a few reports of a few patients with differing or negative results to alter one's notion of the efficacy of apheresis in this situation. For this reason the evidence can only be viewed as preliminary and provocative. It is far from persuasive.

Apheresis in combination with other therapy is only an emerging technology for treating patients with Factor VIII antibodies. There is a need for more careful study and specification of the treatment and its effects

—both of immediate and longer duration. There are a number of questions that need to be answered before its efficacy is established. If, as is likely, apheresis continues to be employed in life-threatening situations, then physicians should be encouraged to undertake more systematic study of the treatment. This could include a number of therapeutic alternatives systematically applied to a series of patients, perhaps in a controlled trial.

In conclusion, it should be noted that some experts believe all the treatment combinations described above are not effective. In particular, PE is viewed as a stopgap measure, at best, because (as the literature indicates) the antibody titer rapidly increases post exchange. For these reasons current interest has focused on bypassing the blockade of the Factor VIII inhibitor by administering new agents that contain a mixture of clotting factors, including activated Factor VIII. Given the availability of these new agents, such treatment may be the therapy of choice for patients with high titers of Factor VIII antibodies.

Appendix D.—Apheresis in Guillain-Barre Syndrome

Prepared for OTA by: Richard K. Riegelman, M. D., Ph. D.

Introduction

Guillain-Barré syndrome (GBS) (65,119,148) is an acute polyneuropathy. It begins in a restricted area of the body, most often distally, and then spreads or ascends to involve many muscle groups. The rate and extent of progression vary widely. Many patients recover spontaneously without life-threatening progression. Some become severely paralyzed within a few days while in others the disease worsens slowly and insidiously over a period of several days or even weeks. The extent of paralysis varies widely. Sensory and autonomic nervous system involvement can also occur. In the most severely involved individuals, control of blood pressure and breathing maybe affected requiring a respirator and intensive care management. Progression of weakness usually ceases less than 4 weeks after onset. Spontaneous recovery usually begins within 2 to 4 weeks after progression stops. Recovery is usually gradual, but abrupt spontaneous recovery has been documented.

With current intensive care management under the most ideal conditions the mortality can be reduced to 5 percent or less. Prognosis for complete recovery is good, with about 85 percent of patients restored to normal function. The remaining usually have only mild residual deficits.

The etiology of GBS remains unknown. Cases have been associated with injection of foreign protein, cat scratches, dog bites, transfusions, and immunizations, including rabies vaccine and the widely publicized association with the 1976 influenza vaccine program.

Rumpl, et al. (119), have summarized the evidence as of 1981 for an immunologic mechanism as follows:

Experimental allergic neuritis has shown striking similarity with the disease in humans. The immune pathogenesis of GBS was further supported by the finding of complement fixing antibodies, of precipitating antibodies against trypsinized white matter extracts and of myelinotoxin serum antibodies of the IgM class in patients with GBS. Cellular hypersensitization to peripheral nervous antigen presented by circulating immunoblasts and lymphocytes supported the role of cellular mechanisms in pathogenesis.

The rationale for the use of plasma exchange (PE) in GBS is based on the presence of serum antibodies which can be removed by PE.

Brettle, et al. (15), first reported the successful use of PE in acute GBS in 1978. An abrupt and dramatic improvement was seen in this case. This report was published shortly after Hughes, et al. (63), reported a poor response to steroids in a controlled clinical trial of acute GBS. With evidence against the use of steroids established in a controlled clinical trial and with evidence of a dramatic improvement with plasma exchange, many centers throughout the world began to experiment with and report their results of PE therapy.

The existing literature includes many case reports and small series of cases in which apheresis or more specifically PE was used in the treatment of acute GBS.

In reviewing this literature one must appreciate several factors repeatedly emphasized by the authors and critics.

1. As an experimental therapy initial use of the therapy was not standardized. The timing, quantity, duration, and type of PE varied considerably. In some patients the therapy was used concurrently with steroid treatment and in others after steroids had failed. Some patients were treated after extended respirator and intensive care therapy while others were treated in an effort to avoid the need for such care.
2. The measures of assessment of outcome also varied enormously. Some investigators reported obvious and at times dramatic clinical improvements while others reported changes in nerve conduction tests and immunological changes which preceded or were unassociated with a clinical response.
3. The reported studies are all case reports without any concurrent control groups, blinding, randomization, or other techniques used in controlled clinical trials.
4. The documentation of adverse effects was not systematic and may have been biased by the tendency to report successful uses of a new therapy.
5. The natural history of acute GBS with its tendency for spontaneous and occasionally abrupt improvement makes the interpretation of therapy related results more difficult.

Despite these difficulties much has been learned from the initial studies and reports on the use of PE in GBS. The following section summarizes the reported evidence on efficacy.

Efficacy

The reported individual cases repeatedly refer to striking or dramatic change which occur within minutes to hours after plasma exchange.

One report (134) stated: “the improvement after the exchanges was so abrupt and striking that it induced us to believe that the plasma exchanges were essentially responsible for this development. Particularly in our case with ventilator insufficiency and bulbar palsy, which worsened day by day, the course of the disease seemed to have been reversed by plasma exchange inducing an immediate amelioration. The response was quicker in those nerves which had deteriorated the latest, which is in accordance with clinical experience in cases of spontaneous recovery.”

Other cases of dramatic improvements after plasma exchange includes the following:

Littlewood and Bajada (77) report: “On day 8 of our patient’s illness respiratory vital capacity fell to 1.41 and was accomplished by complete ophthalmoplegia and iridoplegia. A dramatic improvement in vital capacity followed the first session and was subsequently maintained.” Similarly, Corachan, et al. (27), report a case of: “. . . dramatic improvement after . . . (apheresis) . . .” Levy, et al. (76), report that “clinical improvement was dramatic” in a patient with chronic relapsing disease.

Not all investigators have reported success. Cook, et al. (26), reported a series of five patients only one of whom had a “significant clinical improvement.” Maisey and Olczak (78) reported two patients who failed to respond to PE. Gross, et al. (45), have argued that Maisey’s use of 1.5 liters per day of plasma exchange was “small compared with those used by other operators for the same disease and in other disease processes.” They further argue that one would not expect all cases to respond. They write: “Cases of inflammatory polyneuropathy probably constitute a heterogeneous group and it would be surprising if every patient proved to benefit from plasma exchange.”

Several larger series have also been recently reported. Rumpl, et al. (119), reported eight cases of successful treatment with PE. They report: “Recovery was abrupt in all cases after the first PEs. Improvement was more marked, when . . . (apheresis) . . . was performed on three successive days with plasma exchanges of 2.0-3.0l each . . . Recovery seemed to be delayed in cases when plasma exchanges were reduced to 0.5-1.5l each and were spread over several days or weeks, even when the number of plasma exchanges was increased.”

Durward, et al. (33), reported their experience with six cases all of whom improved to some degree after

PE. They conclude “Our experience to date (11 incidents in six patients) is of recovery beginning or accelerating immediately after plasma exchange We started exchanges fairly early—usually about one week after onset—and exchanged more than 10—1 on each occasion (except in case 3).”

Dau, et al. (31), report on 13 patients with acute GBS who underwent 2 to 3 weeks of PE with 4 or 5 exchanges of 4 liters. Seven patients, all of whom were still progressing or stable “stopped progressing on the day of the first . . . (apheresis) . . . and had discernible clinical improvement within 48 hours.” Among the other patients two continued progressing, three were already slowly improving and apheresis “did not seem to accelerate recovery.” In these patients apheresis was started “relatively late after disease onset.” In the last patient there was progressive deterioration. The report concluded that factors associated with a good outcome were:

1. Institution of apheresis early in the course of the illness.
2. Normal evoked muscle action potential.
3. Little electromyographic evidence of denervation.
4. Age less than 50 years.

Schooneman, et al.’s (123), series of 10 patients with acute GBS is the only reported series in which no patients received steroids and in which a control group was attempted. In addition, the authors performed extensive neurological testing before and after each exchange. Respiratory impairment was assessed by clinical examination and blood gas determinations.

In 9 of their 10 cases patients showed improvement within 24 hours after the first exchange. The authors believe that “the progressive phase of the disease was halted.” They term their results “spectacular.” In comparing their 10 patients to 258 historical control patients with GBS they conclude that apheresis appeared to shorten the duration of paralysis, reduce the need for tracheotomy, and shorten the hospital course. They did not demonstrate reduced mortality since one patient died in each group. They also did not demonstrate or claim that these patients represented comparable study and control groups.

Safety

Plasma exchange carries inherent risks in all patients. Samtleben, et al. (120), reporting on 100 consecutive PE procedures, observed allergic reactions to albumen in 10 percent, hypocalcemic symptoms in 6 percent, and vasovagal reactions in 5 percent. Other side effects have included massive extracorporeal blood clotting, hypercoagulation states with vascular thrombosis, hemorrhagic tendencies, changes in serum lipid

fractions, cardiac arrhythmias, and pulmonary emboli (93).

Rumpl, et al. (119), reported that in their experience with plasma exchange for GBS, cardiovascular problems, coagulation difficulties, and allergic reactions made it necessary to interrupt PE and influenced the amount of exchanged plasma.

Patients with severe GBS may have an unstable autonomic nervous system predisposing them to problems with blood pressure control and cardiac arrhythmias. The need to perform the procedure on respirator dependent patients may further complicate PE.

In light of these considerations Mayr, et al. (81), who have successfully used PEs in GBS, conclude: "The considerable risks and high technical requirements may limit this therapy to the severe course of Guillain-Barré syndrome."

Need for Controlled Clinical Trials

A controlled trial is not a trial of a treatment. It is a trial of a specific means of administering a therapy; thus it requires agreement on the timing, extent, and duration of therapy.

The performance of a controlled clinical trial should be preceded by enough research to establish an agreed upon method for administering the therapy. In addition, before going to the expense of a well-performed controlled clinical trial, it is important that preliminary evidence exists of the effectiveness and additional benefit of the treatment. These two prerequisites to a controlled clinical trial have been adequately fulfilled by the existing literature.

Despite the controversy in the reported literature over the efficacy and safety of PE in GBS, both the advocates and the skeptics appear to agree on the need for controlled clinical trials. A sampling of their comments should demonstrate this point.

Irvine and Tibbles (64) in their report of an apparently successful treatment with exchange transfusions conclude: "In the future it will be important to document failures as well as success to place this treatment in its proper perspective. It is likely that the organization of a prospective controlled trial of this costly form of management will be necessary."

During 1981 a series of letters appeared in the *British Medical Journal* reporting dramatic improvement, evidence of subtle response, and cases without measurable improvement. All three reports agreed on the need for a controlled trial. The group (78) reporting no response wrote: "If anecdotal reports are relied on, publication bias ensures that apparently successful results dominate the literature." The group (62) reporting success

wrote: "... a controlled trial of plasma exchange is necessary in acute inflammatory polyradiculoneuropathy before its value can be assessed. Since patients with this condition begin to improve after a variable time after the onset of symptoms and usually recover completely, it is not surprising that each new treatment has been hailed with enthusiasm on the basis of anecdotal reports." The group (33) reporting subtle responses concurred, stating: "These data only re-emphasize the need for a controlled clinical trial, especially in the early phase, in order to delineate the role of plasma exchange in acute Guillain-Barré syndrome."

In their advocacy of their forthcoming controlled clinical trial Asbury, et al. (10), wrote in the October 1980 issue of *Neurology* that apheresis of "an acutely ill patient with respiratory depression and autonomic instability is not a benign procedure. Until this study is completed anecdotal reports of the efficacy of ... (apheresis) ... in the Guillain-Barre syndrome should be interpreted with caution. At present, it is not possible to state the therapeutic role that ... (apheresis) ... plays for this disease."

Controlled Clinical Trials in Progress

In December 1980, the National Institute of Neurological and Communicative Disorders and Stroke funded a 3-year multiple site cooperative study of apheresis treatment of acute GBS (87).

The primary study question is: Does apheresis effect a significant beneficial change in the early course of severely ill patients with GBS? Secondary study questions include the following:

1. Are there clinical, epidemiologic, laboratory, or electrodiagnostic factors associated with a good outcome of GBS? If so, how does apheresis interact with these factors?
2. Is there a subgroup of patients with GBS for whom apheresis can be expected to be of value and a subgroup for whom it cannot?
3. Can apheresis reduce the incidence of long-term complications (assessed at 6 months) in the 15 to 20 percent of GBS patients destined to have some lasting deficits?

The study uses generally accepted criteria for the diagnosis of GBS. Patients must be within 30 days of onset of definitive neuropathic symptoms. They must require a walker or support to walk 5 meters or be more severely affected. Steroid treatment is not given to study patients. The quantity and timing of the PE are consistent with that reported for successful uses of PE in GBS.

The study protocol provides standard methods for assuring randomization, informed consent, termination, monitoring of followup, and statistical analysis.

The study is designed to include about 240 patients. This number is adequate to provide an 80-percent chance of demonstrating a statistically significant improvement if apheresis actually provides a 50-percent improvement over conventional therapy. As of July 1, 1982, 102 patients had been enrolled in the study.

An interim analysis of the data is planned when approximately 120 patients have been entered into the study. The interim analysis is designed to determine whether the study should continue. This analysis will consider the following three possibilities:

1. The evidence is overwhelming that the apheresis patients are doing better, and if the study were to continue with little or no advantage to the exchange protocol over the second half of the study, a statistically significant difference would still exist.
2. the exchange protocol patients are doing worse or no better than the other patients and continuation of the study could not, even with an extreme reverse of results in the second half, demonstrate a beneficial effect of apheresis.
3. Neither extreme exists.

The endpoints considered in this analysis will be measures of clinical improvement 4 weeks after entry into the study as well as time spent on a respirator. If the interim report reaches conclusion 1 or 2, the study will be stopped and presumably the results released and reported. Otherwise the study will continue and the results presumably will not be released by the National Institutes of Health (NIH).

The NIH study appears to be adequately designed to answer the basic questions regarding efficacy of apheresis. The results should largely determine whether evidence exists for moving PE from an experimental status to that of a conventional therapy for acute GBS.

A second randomized controlled clinical trial is currently underway in Great Britain (87). This study also includes patients who require support to walk 5 meters or who are more severely affected. The findings on the first 19 randomized patients were reported in May 1982. A "decided trend in favor of plasma exchange was noted at 4 weeks after randomization which did not reach statistical significance."

NIH will not currently release preliminary results of the American study. The interim analysis should be completed by early 1983, but unless the results of the interim analysis clearly answer the efficacy question, a full report may not be available until 1984.

Conclusions

1. Case reports and small-scale, mostly uncontrolled trials provided suggestive evidence that plasma exchange may be efficacious for some patients with acute GBS.
2. Because of the low mortality and good prognosis for most patients with Guillain-Barré syndrome, the safety of the procedure and indications for its use should be delineated prior to nonexperimental use of plasma exchange in GBS.
3. The conditions for use of plasma exchange in acute Guillain-Barré syndrome have been sufficiently standardized to enable a controlled clinical trial of the procedure.
4. The potential cost saving and potential for shortened disability make well-designed controlled studies of this therapy important.
5. Controlled studies of the efficacy, safety, and indications for plasma exchange in acute GBS are currently in progress. These studies should be adequate to provide data which address the essential clinical questions. Until the results of these studies are available, the use of plasma exchange in GBS should be considered an experimental procedure.

Appendix E.—The Cause and Pathological Development of Autoimmune Diseases*

The cause and pathological development of autoimmune diseases are thought to be due to several mechanisms, each having varying importance in different diseases. These mechanisms are: inactivation reactions, cytotoxic reactions, immune complex deposition, anaphylaxis, and delayed hypersensitivity.

With inactivation reactions, autoimmune antibodies are directed against molecules that are receptors or mediators for important physiological functions. For example, people with myasthenia gravis have antibodies directed against neurotransmitter receptors on muscle membranes, and thus the conduction of electrical impulses between nerve and muscle is disturbed.

In diseases in which cytotoxic antibodies are thought to play a role, antibodies are directed against molecules on the surface of cells, and reactions between the antibodies and antigens result in the killing of the cells through complement mechanisms or clearance by lymphoid tissues. This can lead to depletion of sets of cells required for vital functions, such as platelet loss in idiopathic thrombocytopenic purpura.

In many diseases, deposition of immune complexes in tissues is thought to be the mechanism for the destructive lesions observed. These immune complexes may consist of antibodies and viral antigens, cancer

antigens or other antigens. In these diseases, the complexes are of such a nature or in such great amounts that they saturate the normal clearing system in lymphoid tissues (or these clearing systems are deficient secondary to the underlying disease). Deposition of the complexes in vessel walls, in structures of the kidney, and joint spaces leads to inflammation due to the activation of complement or cellular immune responses. Vasculitis, glomerulonephritis and arthritis, for example, can be the result.

Anaphylaxis refers to the release by antigen stimulation of immediately reacting inflammatory agents by tissue cells which have antibodies directly on their surfaces. Severe anaphylactic reactions are life threatening. Diseases that are manifested by anaphylactic reactions include food allergies, insect allergies, and asthma.

Finally, there are diseases transmitted by cellular immune mechanisms, referred to as delayed hypersensitivity reactions. In this case, specifically, sensitized lymphocytes infiltrate tissues and cause destruction. Often circulatory antibodies participate in the process as well. Examples of this disorder include viral hepatitis and graft rejection.

● This appendix is condensed from Frost & Sullivan, Inc., *in-Vivo Hemodetoxification and Hemoprocessing Markets in U. S.*, New York, June 1981.

Appendix F.—American Red Cross Bibliography

This appendix contains a Therapeutic Apheresis Bibliography that was compiled by the American Red Cross and is distributed to American Red Cross regional blood services to facilitate access to current information on therapeutic apheresis by specific disease categories.

The bibliography is divided into two sections. The first section contains 1,241 citations that comprised the apheresis literature as of May 1982. The second section is a supplement that adds 778 references through January 1983 to the original list.

References in both sections are listed by reverse chronological order and grouped by specific disease categories. Some articles may be cited in more than one category if their content warrants multiple listings. Texts, symposia, and review articles (sec. XVII) may also contain information pertinent to specific diseases, but some of these summary publications may not be listed by disease category.

AMERICAN RED CROSS BLOOD SERVICES
BIBLIOGRAPHY OF THERAPEUTIC PHERESIS* BY DISEASE CATEGORIES

- | | |
|---|--|
| <p>No. I: Neurological Disorders</p> <p>A. Myasthenia Gravis
Multiple Sclerosis</p> <p>: : Refsum's Disease</p> <p>D. Guillain-Barre Syndrome</p> <p>E. Miscellaneous: Polyneuropathy, Motor Neuron Disease, Amyotrophic Lateral Sclerosis</p> <p>No. II: Blood Diseases</p> <p>A. Hemophilia</p> <p>B. Autoimmune Hemolytic Anemia</p> <p>C. Aplastic Anemia</p> <p>D. Immune Thrombocytopenic Purpura</p> <p>E. Thrombotic Thrombocytopenic Purpura, Hemolytic Uremic Syndrome</p> <p>F. Sickle Cell Disease</p> <p>G. Leukemia, Myeloproliferative Syndrome, Sézary Syndrome</p> <p>H. Thrombocytosis</p> <p>L. Miscellaneous</p> <p>No. III: Malignant Paraproteinemias</p> <p>A. Hyperviscosity Syndrome “</p> <p>B. Macroglobulinemia</p> <p>C. Multiple Myeloma</p> <p>D. Cryoglobulinemia</p> <p>E. Miscellaneous</p> <p>No. IV: Renal Diseases</p> <p>A. GoodPasture's Syndrome</p> <p>B. Glomerulonephritis</p> <p>C. Miscellaneous</p> <p>No. V: Connective Tissue Disorders</p> <p>A. Systemic Lupus Erythematosus
Polyarteritis Nodosa - Wegener's Granuloma</p> <p>: : Rheumatoid Arthritis</p> <p>D. Raynaud's Syndrome</p> <p>E. Miscellaneous</p> <p>No. W: Transplantation</p> <p>A. Renal</p> <p>B. Bone Marrow</p> | <p>No. VU: Liver Disease</p> <p>A. Hepatitis, Hepatic Coma</p> <p>B. Miscellaneous</p> <p>No. VIII: Hemolytic Disease of the Newborn</p> <p>No. IX: Cancer</p> <p>No. X: Skin Diseases</p> <p>A. Pemphigus Vulgaris</p> <p>B. Erythrocyte Autosensitization</p> <p>C. Miscellaneous</p> <p>No. XI: Lipid Disorders (Hyperlipidemia)</p> <p>No. XII: Immunological Disorders</p> <p>A. Immunodeficiency</p> <p>B. Immune Complex Disease</p> <p>No. XIII: “Miscellaneous Diseases</p> <p>A. Thyroid Storm</p> <p>B. Pulmonary Edema, Adult Respiratory Distress Syndrome</p> <p>C. Hypertension</p> <p>D. Poisoning</p> <p>E. Asthma</p> <p>F. Crohn's Disease</p> <p>G. Miscellaneous</p> <p>No. XIV: Clinical Reactions, Complications</p> <p>No. XV: Technical Aspects</p> <p>No. XVI: Alternative Methodologies</p> <p>No. XVII: Texts, Symposia</p> |
|---|--|

*This Case Study has used the term "apheresis" throughout its contents for the purpose of consistency. However, the term "pheresis" is used by the American Red Cross with the same meaning.

A. Myasthenia Gravis

Anchie T: Plasm apheresis as a treatment for myasthenia gravis. *J Neurosurg Nurs* 13:23-27, 1981.

Dau PC: Response to plasmapheresis and immunosuppressive drug therapy in sixty myasthenia gravis patients. *Ann NY Acad Sci*, in press.

Dau PC, Denys EH: Plasmapheresis and immunosuppressive drug therapy in the Eaton-Lambert syndrome. *Ann Neurol*, in press.

Goulon M, et al: Treatment of myasthenia gravis by plasma exchange and immunosuppressors. *Rev Med Interne* 1:213-216, 1981 (English abstract).

Hawkey CJ, et al: Plasma exchange and immunosuppressive drug treatment in myasthenia gravis: No evidence for synergy. *J Neurol Neurosurg Psychiatry* 44:469-475, 1981.

Kornfeld P, Ambinder EP, Mittag MW, Bender AN, Papatostas AE, Genkins G: Plasmapheresis in myasthenia gravis. *Plasma Ther* 2:127-133, 1981.

Kornfeld P, et al: Plasmapheresis in refractory generalized myasthenia gravis. *Arch Neurol* 38:478-481, 1981.

Lang AE, et al: Plasma exchange therapy for severe penicillamine-induced myasthenia gravis. *J Rheumatol* 8:303-307, 1981.

Miller RG, et al: Antibody-negative acquired myasthenia gravis: Successful therapy with plasma exchange. *Muscle Nerve* 4:255, 1981.

Newsom-Davis J, Hawkey C, Vincent A: Plasma exchange in the treatment of myasthenia gravis. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 180-185.

Reuther P, Wiebecke D, Fateh-Moghadam A, Besinger U, Mertens HG: The role of plasma exchange in the treatment of myasthenia gravis. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 186-193.

Scadding GK, Havard CWH: Pathogenesis and treatment of myasthenia gravis. *Br Med J* 283:1008-1012, 1981.

Toyka KV, Besinger UA, Heiniger K, Samtleben W, Hein D, Fateh-Moghadam A, Gurland HJ, Grabensee B: Myasthenia gravis: The pathogenic role of antibodies to acetylcholine receptor and the effect of antibody depletion. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 172-179.

Wysenbeek AJ, Smith JW, Krakauer RS: Plasmapheresis 11: Review of clinical experience. *Plasma Ther* 2:61-71, 1981.

Campbell WW Jr, et al: Plasma exchange in myasthenia gravis: Electrophysiological studies. *Ann Neurol* 8:584-589, 1980.

Carter B, et al: Anti-acetylcholine receptor antibody titres in the sera of myasthenia patients treated with plasma exchange combined with immunosuppressive therapy. *J Neurol Neurosurg Psychiatry* 43:397-402, 1980.

Dau PC: Plasmapheresis therapy in myasthenia gravis. *Muscle Nerve* 3:468-482, 1980.

Gerlag K, et al: Successful treatment by plasmapheresis of respiratory insufficiency in myasthenia gravis. *Clin Neurol Neurosurg* 82:237-243, 1980.

Johns TR, Sanders D: Plasmapheresis in myasthenia gravis. Plasm apheresis Workshop sponsored by Muscular Dystrophy Association, New York University, April 1980.

Lisak RP, Abramowitz O, Khotland DL: Plasm apheresis in myasthenia gravis. Plasmapheresis Workshop sponsored by Muscular Dystrophy Association, New York University, April 1980.

Pollard 3D, Basten A, Hassall 3E, Kronenberg H, Cobcroft R, Dawkim R: Current trends in the management of myasthenia gravis: Plasmapheresis and immunosuppressive therapy. *Aust NZ J Physiol* 10:212-217, 1980.

Reuther P, Wiebecke D, Boske A, Mertens HG: Plasma exchange in myasthenia gravis and other neurological disease. Heidelberg: Springer, 1980 (in press).

Riley TL, Monagle WP: Antireceptor-antibody decline without improvement after plasm apheresis in myasthenia gravis. *Am Intern Med* 92:713, 1980.

Wntleben W, Besinger UA, Toyka KV, Fateh-Moghadam A, Brehm G, Gurland HJ: Plasma-separation in myasthenia gravis: A new method of rapid plasma exchange. *Klin Wochenschr* 58:47-49, 1980.

Sanders DB: Plasm apheresis in myasthenia gravis. Sixth International Conference on Diseases of the Eye Unit, Key Biscayne, Florida, June 1980.

Toyka KV, Augspach R, Besinger UA, Grabensee B: Treatment of myasthenia gravis and Guillain-Barre' syndrome with plasma exchange. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasma separation" Stuttgart: F. K. Schattauer Verlag, 1980, pp 289-296.

Behan PO, Shakir RA, Simpson 3A, Burnett AK, Allan TL, Haase G: Plasma-exchange combined with immunosuppressive therapy in myasthenia gravis. *Lancet* 2:438-440, 1979.

Blount M, Kinney AB, Stone M: Plasma exchange in the management of myasthenia gravis. *Nurs Clin North Am* 14:172-176, 1979.

Dau PC (cd): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979.

Dau PC, Lindstrom JM, Cassel CK, Clark EC: Plasmapheresis in myasthenia gravis and polymyositis. In Dau PC (cd): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979, pp 229-247.

Kornfeld P, Ambinder EP, Papatestas AE, Bender AN, Genkins G: Plasmapheresis in myasthenia gravis: Controlled study. *Lancet* 2:629, 1979.

Lisak RP, Abramsky O, Schotland DL: Plasmapheresis in the treatment of myasthenia gravis: Preliminary studies in 21 patients. In Dau PC (cd): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979, pp 209-215.

Newsom-Davis 3: Plasma exchange in myasthenia gravis. *Plasma Ther* 1:17-31, 1979.

Newsom-Davis J, Vincent A: Combined plasma exchange and immunosuppression in myasthenia gravis. *Lancet* 2:688, 1979.

Newsom-Davis J, Wilson SG, Vincent A, Ward CD: Long-term effects of repeated plasma exchange in myasthenia gravis. *Lancet* 1:464-468, 1979.

Pinching AJ, Peters DK, Newsom-Davis 3: Plasma exchange in the investigation and treatment of myasthenia gravis. *Plasma Ther* 1:29-32, 1979.

Plasmapheresis for myasthenia gravis. *Med Lett Drugs Ther* 21:64, 1979.

Reuther P, Wiebecke D, Hertel G, Böske A, Mertens HG: Treatment of myasthenia gravis with plasmapheresis. *Dtsch Med Wochenschr* 104:1806-1810, 1979.

Dau PC, Cassel CK, Denys EH, Shev EE, Spitler LE: Plasmapheresis for myasthenia gravis. *Lancet* 1:457, 1978.

Howard JF Jr, Sanders DB, Johns JR: The role of plasma exchange therapy in myasthenia gravis. *Haemonetics Research Advanced Component Seminar*, Boston, 1978.

Jacobs P, Dubovsky D, Ferguson A: Plasmapheresis and myasthenia gravis. *Br Med* 3 1:177, 1978.

Keesey 3: Caution on plasma apheresis for myasthenia gravis. *N Engl J Med* 298:1029, 1978.

Lisak RP, Schotland DL: Symposium on therapeutic controversies. Myasthenia gravis. Plasmapheresis in the treatment of myasthenia gravis. *Trans Am Neurol Assoc* 103:292-302, 1978.

Newsom-Davis 3, Pinching AJ, Vincent A, Wilson SG: Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange. *Neurology* 28:266-272, 1978.

Newsom-Davis J, Vincent A, Wilson SG, Ward CD, Pinching AJ, Hawkey C: Plasmapheresis for myasthenia gravis. *N Engl J Med* 298:456, 1978.

Dau PC, Lindstrom JM, Cassel CK, Denys EH, Shev EE, Spitler LE: Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis. *N Engl J Med* 297:1134-1140, 1977.

Finn R, Coates PM: Plasma exchange in myasthenia gravis. *Lancet* 1:190-191, 1977.

Havard CWH: Progress in myasthenia gravis. *Br Med* 3 2:1008-1011, 1977.

Pinching AJ, Peters DK, Newsom-Davis 3: Plasma exchange in myasthenia gravis. *Lancet* 1:428-429, 1977.

Pinching RJ, Peters DK, Newsom-Davis 3: Remission of myasthenia gravis following plasma exchange. *Lancet* 2:1373-1376, 1976.

B. Multiple Sclerosis

Masland W, Giordano GF: Lymphocytapheresis in multiple sclerosis. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Rosen AD, Hamburger MI: Plasmapheresis in multiple sclerosis: Effect on the visual evoked potential. *Plasma Ther* 2:239-242, 1981.

Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I: Plasma exchange in the management of selected neurological diseases. *Plasma Ther* 2:13-18, 1981.

Vukovich DM, Vaithianathan T, French A: Lymphocytapheresis in multiple sclerosis - a pilot study. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Dau PC, Petajan JH, Johnson KP, Panitch HS, Bernstein MB: Plasmapheresis in multiple sclerosis: Preliminary findings. *Neurology (NY)* 30:1023-1028, 1980.

Giordano GF, Wallace BA, Masland W, Ketchel S3, Tilmann K, Holland K: Lymphocytapheresis as a therapeutic modality in multiple sclerosis: A preliminary report. In "Second Annual Apheresis Symposium: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1980, pp 25-37.

Khatir Bo, McQuillen MP, Kiethe SM, Hussey C, Cook A: Plasmapheresis in multiple sclerosis: Correlation of clinical improvement with increased suppressor cell activity in peripheral blood. *Am Neurol* 8:14, 1980.

Plasmapheresis for multiple sclerosis. *Int Med Alert* 2:65-66, 1980.

Stefoski D, Schauf CL, Davis FA, et al: Plasmapheresis in multiple sclerosis: Clinical observations and effects on serum neuroelectric blocking factor. *Neurology* 30:362-363, 1980.

vanden Noort S, Waksman BH: Plasma exchange: Aid to therapy of multiple sclerosis. *Neurology* 30:1111, 1980.

Weiner HL, Dawson DM: **Plasmapheresis** in multiple sclerosis: Results of a preliminary study. *Neurology* 30:1029-1033, 1980.

Dau PC, Petajan JH, Johnson KP, Panitch HS, Bornstein MR: **Plasmapheresis** and immunosuppressive drug therapy in multiple sclerosis. *Neurology* 29:573, 1979.

Schauf CL, Stefoski DA, Davis FA, McLeod BC: The application of **plasmapheresis** to multiple sclerosis. *Plasma Ther* 1:33-42, 1979.

C. Refsum's Disease

Gibberd FB: Heredopathia atactica polyneuritiformis (Refsum's disease) and its management with plasma exchange. *Plasma Ther* 1:17-26, 1980.

Karnanabroo D, Harnest U, Feldman H, Assman G, van de Loo J: **Herodopathia atactica polyneuritiformis (Refsum's disease)** treated by diet and large-volume plasma exchange. In Sieberth HG (ed) "Plasma Exchange, **Plasmapheresis** - Plasma Separation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 297-299.

Moser HW, Braine H, Pyeritz RE, Unman D, Murray C, Asbury AK: Therapeutic trial of **plasmapheresis** in Refsum disease and in Fabry disease. *Birth Defects* 16:491-497, 1980.

Gibberd FB, Billimoria JD, Page NG, Retsas S: **Heredopathia atactica polyneuritiformis (Refsum's disease)** treated by diet and plasma-exchange. *Lancet* 1:575-578, 1979.

Penovich PE, Hollander J, Nusbacher SA, Griggs RC, McPherson I: Note on plasma exchange therapy in Refsum's disease. In Kark RAP, Rosenberg RN, Schut AJ (eds): "Advances in Neurology," Vol 21. New York: Raven Press, 1978, pp 151-153.

Lundberg A, Lilja LG, Lundberg PO, Try K: Heredopathia atactica polyneuritiformis (Refsum's disease). Experience of dietary treatment and **plasmapheresis**. *Eur Neurol* 8:309-324, 1972

D. Guillain-Barré Syndrome

Augsbach R, Tovka KV, Paulus W, Hein D, Grabensee B: Plasma exchange in chronic Guillain-Barré syndrome. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 208-209.

Durward WF, et al: Plasma exchange in Guillain-Barré syndrome. *Br Med J (Clin Res)* 283:794, 1981.

Gross MLP, Sweny P, Legg NJ: Successful **plasmapheresis** in Miller-Fisher syndrome. *Br Med J (Clin Res)* 282:1394, 1981.

Irvine AT, Tibbles J: Treatment of Fisher's variant of Guillain-Barré syndrome by exchange transfusion. *Can Sci Neurol* 8:49-50, 1981.

Littlewood R, Bajada S: Successful **plasmapheresis** in the Miller-Fisher syndrome. *Br Med J* 3 282:778, 1981.

Maisey DN, Olczak SA: Successful **plasmapheresis** in the Miller-Fisher syndrome. *Br Med J (Clin Res)* 282:1159, 1981.

Mayr U, Rumpl E, Hackl JM, Gerstenbrand F: Treatment of Guillain-Barré syndrome by plasma exchange. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 199-204.

Reuther P, Rauterberg EW, Hempel K, Mertens HG: Plasma exchange in relapsing Guillain-Barré syndrome. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 206-207.

Rumpl E, et al: Treatment of Guillain-Barré syndrome by plasma exchange. *Neurology* 225:207-217, 1981.

Schooneman F, Janet C, Streiff F, Gerard A, Dureux JB, Canton P, Roche G, Aubrun P: Plasma exchange in Guillain-Barré syndrome: Ten cases. *Plasma Ther* 2:117-121, 1981.

Successful **plasmapheresis** in the Miller-Fisher syndrome. *Br Med J (Clin Res)* 282:2055, 1981.

Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I: Plasma exchange in the management of selected neurological diseases. *Plasma Ther* 2:13-18, 1981.

Asbury A, Fisher R, McKhann GM, Mobley W, Server A: Guillain-Barré syndrome: Is there a role for **plasmapheresis**? *Neurology (NY)* 30:1112, 1980.

Corachan M, Talonu T, Oldfield E, Kaven 3, Flynn P: Treatment of acute severe Guillain-Barré syndrome by **plasmapheresis**. *Papua New Guinea Med J* 3 23:146-147, 1980.

Rail D, Stark R, Swash M, Newland A: Improvement in nerve condition after plasma exchange for Guillain-Barré syndrome. *Neurology Neurosurg Psychiatry* 43:1147, 1980.

Ropper AH, Shahani B, Huggins CE: Improvement in 4 patients with acute Guillain-Barré syndrome after plasma exchange. *Neurology* 30:361, 1980.

Tokya KV, Augspach R, Besinger UA, Grabensee B: Treatment of myasthenia gravis and Guillain-Barré syndrome with plasma exchange. In Sieberth HG (ed): "Plasma Exchange, **Plasmapheresis** - **Plasmaseparation**." Stuttgart: F.K. Schattauer Verlag, 1980, pp 289-296.

Valbonesi M, Mosconi L, Garelli S, Zerbi D, Celano I: Successful treatment by plasma exchange in Guillain-Barré syndrome with immune complexes. *Vox Sang* 38:181-184, 1980.

- Levy **RL**, Newkirk **R**, Ochoa **J**: Treatment of chronic **Guillain-Barré** syndrome by plasma exchange. **Lancet** **2**:741, 1979.
- Levy **RL**, Newkirk **R**, Ochoa **J**: Treating chronic relapsing **Guillain-Barré** syndrome by plasma exchange. **Lancet** **2**:259-260, 1979.

E. Miscellaneous: **Polyneuropathy**, Motor Neuron Disease,
Amyotrophic Lateral Sclerosis

- Dau **P**: Plasm **apheresis** in autoimmune necrologic diseases. In "Third Annual Symposium on **Apheresis**: Current Concepts and Future Trends." **Skokie, IL**: American Society for **Apheresis**, 1981 (abstract).
- Dau **PC**, Lindstrom **JM**, Denys **EH**: **Plasmapheresis** in necrologic disorders. In **Nemo GJ**, **Taswell H** (eds): "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and Cytapheresis. April 1979." **Washington, DC**: U.S. Department of Health and Human Services, 1981, pp 169-197.
- Dyck **PJ**: Controlled trial of **plasma** exchange on inflammatory **demyelinating neuropathy**: Preliminary report. In "Third Annual Symposium on **Apheresis**: Current Concepts and Future Trends." **Skokie, IL**: American Society for **Apheresis**, 1981 (abstract).
- Maas **AIR**, **Busch HFM**, van der Heuf **C**: Plasma infusion and plasma exchange in chronic idiopathic **polyneuropathy**. **N Engl J Med** **305**:344, 1981.
- Cook **JD**, **Tindall RAS**, Walker **J**, et al: Plasma exchange as a treatment of acute and chronic idiopathic **autoimmune polyneuropathy**: Limited success. **Neurology** **30**:361-362, 1980.
- Dechy **H**, et al: **Plasmapheresis** in the management of peripheral neuropathy in **dysglobulinemia** and collagen disease. **Rev Med Interne** **1**:219, 1980.
- Keleman **J**, **Hedlund H**, **Orlin JB**, **Berkman EM**, **Munsat TL**: Failure of partial plasma exchange (**PPE**) and immunosuppression to effect the course of lower motor neuron disease. **Transfusion** **20**:649, 1980.
- Mark **B**, **Hurwitz BJ**, **Olanow CW**, **Fay JW**: **Plasmapheresis** in idiopathic inflammatory **polyradiculoneuropathy**. **Neurology** **30**:361, 1980.
- Olarte MR**, **Schoenfeldt RS**, **McKiernan G**, **Rowland IP**: **Plasmapheresis** in amyotrophic lateral sclerosis. **Ann Neurol** **3**:644-645, 1980.
- Schauf CL**, **Antel SP**, **Arnason BG**, **Davis FA**, **Rooney MW**: **Neuroelectric blocking** activity and **plasmapheresis** in amyotrophic lateral sclerosis. **Neurology (NY)** **30**:1011-1013, 1980.
- Server **AC**, **Stein SA**, **Braine H**, et al: Experience with plasma exchange and **cyclophosphamide** in the treatment of chronic relapsing inflammatory **polyradiculoneuropathy**. **Neurology** **30**:362, 1980.

- Silani V**, **Scarlato G**, **VaUi G**, **Marconi M**: Plasma exchange ineffective in **amyotrophic lateral sclerosis**. **Arch Neurology** **37**:511-513, 1980.
- Tokya KV**, et al: Plasma exchange in **polyradiculoneuropathy**. **Ann Neurol** **8**:205-206, 1980.
- Fowler H**, **Volpe M**, **Marks G**, **Egolf C**, **Dau PC**: Recovery from chronic progressive **polyneuropathy** after treatment with plasma exchange and cyclophosphamide. **Lancet** **2**:1193, 1979.
- Monstad **I**, **Dale I**, **Petlund CR**, **Sjaastad O**: Plasma exchange in motor neuron disease. A controlled study. **J Neurol** **221**:59-66, 1979.
- Norris **FH Jr**, **Denys EH**, **Mielke CH**: **Plasmapheresis** in amyotrophic lateral sclerosis. In **Dau PC** (ed): "**Plasmapheresis** and the Immunobiology of **Myasthenia Gravis**." **Boston**: Houghton Mifflin, 1979, pp 258-264.
- Server **AC**, **Lefkowitz J**, **Braine H**, **McKhann GM**: Treatment of chronic relapsing inflammatory **polyradiculoneuropathy** by plasma exchange. **Ann Neurol** **6**:258-261, 1979.
- Vanderheyden **3E**, **Kennes B**, **Bain H**, **Hubert C**, **Neve P**: Plasma exchange in acute **polyneuropathy**. **Acta Clin Belg** **34**:246, 1979.
- Brettle RP**, **Gross M**, **Legg NJ**, **Lockwood MC**, **Pallis C**: Treatment of acute **polyneuropathy** by plasma exchange. **Lancet** **2**:1100, 1978.
- Elliott HL**, **McDougall AI**, **Hasse G**, **Curnming RLC**, **Gardiner RHE**, **Fell GS**: **Plasmapheresis** in the treatment of dialysis encephalopathy. **Lancet** **2**:940-941, 1978.
- Monstad I**, **Dale I**, **Dethund CF**, **Sjaastad O**: **Plasmapheresis** in motor neurone disease (**MND**): A controlled study. **Acta Neurol Scand** **57**: Suppl 67:270-271, 1978.
- Norris **FH Jr**, **Denys EH**, **Mielke CH**: **Plasmapheresis** in amyotrophic lateral sclerosis. **Muscle Nerve** **1**:342, 1978.
- Casper **JT**, **Varma RR**, **Lewis ID**, et al: Exchange **transfusion** in **Reye's** syndrome with saline-washed red **blood** cells. **Transfusion** **16**:130-134, 1976.
- Strauss **RA**, **Kling TF**, **Levinsohn MW**, et al: Facilitation of exchange transfusions with **Scribner** shunts in **Reye's** syndrome. **Am J Surg** **131**:772, 1976.

A. Hemophilia

Erskine JG, Burnett AK, Walker ID, Davidson JF: Plasma exchange in non-haemophilic patients with inhibitors to factor VIII. *Br Med J* 283:760, 1981.

Slocombe GW, Newland AC, Colvin MP, Colvin BT: The role of intensive plasma exchange in the prevention and management of hemorrhage in patients with inhibitors to Factor VIII. *Br J Haematol* 47:577-585, 1981.

Révész T, Mátyus 3, Goldschmidt B, Harsányi V: Combined plasmapheresis and immunosuppression in hemophilia in a patient with antibodies. *Orv Hetil* 121:1753-1754, 1980.

Révész T, Mátyus 3, Goldschmidt B, Harsányi V: Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a hemophilic with inhibitors. *Arch Dis Child* 55:641-643, 1980.

Schwerdtfeger R, Hinth G: Repeated intensive plasma exchange in a patient with high levels of factor VIII inhibitor. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 323-326.

Spero JA, Lewis JH, Hasiba U, Pierce JM: Plasma exchange in preparation of mild factor IX deficient hemophiliacs for surgical procedures. *Plasma Ther* 1:19-22, 1980.

Wensley RT, Stevens RF, Burn AM, Delamore IW: Plasma exchange and human factor VIII concentrate in managing hemophilia A with factor VIII inhibitors. *Br J Haematol* 3 281: 1388-1389, 1980.

Cobcroft R, Tamagnini G, Dormandy KM: Serial plasmapheresis in a hemophilic with antibodies in FVIII. *3 Clin Pathol* 30:763-765, 1977.

Mibashan RS: (Management of patients with inhibitors: Replacement therapy (including plasmapheresis). In "Workshop on Inhibitors of Factors VIII and IX." Vienna: Verlag, 1977, p 64.

Pineda AA, Brzica SM, Taswell HF: Continuous- and semicontinuous-flow blood centrifuge systems: Therapeutic applications with plasma-, platelet-, lympho-, and eosinapheresis. *Transfusion* 17:407-416, 1977.

Tilz GP, Teubl I, Kopplhuber CH, Vollmann H, Lanzer G: Therapeutische Plasmapheresis: Eineneue Form der symptomatischen Therapie. *MedKlin* 71:1952-1957, 1976.

Oon CJ, Hobbs JR: Clinical applications of the continuous flow blood separator machine. *Clin Exp Immunol* 20:1-16, 1975.

Stacher A, Höcker P, Pitterman E: Einsatzmöglichkeiten und Ergebnisse der Anwendung eines Zellseparators in der Hamatologie. *Wien Med Wochenschr* 125:35-44, 1975.

Pittermann E, Höcker P, Lechner K, Stacher A: Plasmaphereses with the continuous flow blood cell separator in the treatment of macroglobulinaemia, multiple myeloma, hemophilia and hyperlipidaemia. In Goldman JM, Lowenthal RM (eds): "Leukocytes: Separation Collection and Transfusion." London: Academic Press, 1974, pp 576-577.

Edson JR, McArthur JR, Branda RF, McCullough JJ, Chou SN: Successful management of a subdural hematoma in a hemophilic with an anti-factor VIII antibody. *Blood* 41:113-122, 1973.

Danilov IP, Ivanov EP, Margolin AZ: Effect of exchange plasmapheresis on the blood-coagulation mechanism in hemophilia. *Vestn Khir* 106:117-121, 1971.

Fischer M, Krenn 3, Lechner K, Steinbereithner K, Vonkylch E: The importance of plasma-pheresis during intensive postoperative care in hemophilia. *Anaesthesist* 17:72-76, 1968.

Abdullaev GM, Mailer AR, Kozhevnikov IN: On the use of plasma obtained by the plasmapheresis method in hemophilia A. *Probl Gematol Pereliv Krovi* 11:15-19, 1966.

Borucki DT, Peterson CA: Plasmapheresis in hemophilia utilizing angle head centrifugation, a new parameter in blood component therapy. *Proceedings 10th Congress International Society Blood Transfusion, Stockholm, 1965*, pp 1210-1213.

B. Autoimmune Hemolytic Anemia

Besa EC, Ray PK, Swami VK, Idiculla A, Rhoads JE, Bassett JG, Joseph RR, Cooper DR: Specific immunoadsorption of IgG antibody in a patient with chronic lymphocytic-leukemia and auto-immune hemolytic-anemia - a new form of therapy for the acute critical stage. *Am J Med* 71:1035-1040, 1981.

Bernstein ML, Schneider BK, Naiman 31: Plasma exchange in refractory acute autoimmune hemolytic anemia. *3 Pediatr* 98:774-775, 1981.

Garelli S, Mosconi L, Valbones M, Schieppa G, Navassa G: Plasma-exchange for a hemolytic crisis due to autoimmune hemolytic-anemia of the IgG Warm type. *Blut* 41:387-391, 1980.

Herrera A, Bernard 3F, Vroclans M, Dhermy D, Renoux M, Bolvin P: Intensive plasm apheresis and erythropoiesis, an emergency treatment of superacute auto-immune anemia. *Nouv Presse Med* 9:317, 1980.

Klein HG, Faltz LL, McIntosh CL, Appelbaum FR, Deisseroth AB, Holland PV: Surgical hypothermia in a patient with a cold agglutinin: Management by plasma exchange. *Transfusion* 20:354-357, 1980.

Orlitz JB, Berkman EM, Matloff DS, Kaplan MM: Primary biliary cirrhosis and cold autoimmune hemolytic anemia: Effect of partial plasma exchange. *Gastroenterology* 78:576-578, 1980.

Patten E, Reuter FP: Evans' syndrome: Possible benefit from plasma exchange. *Transfusion* 20:589-593, 1980.

Ruberto G, Gulinatti L, Pellegrino S, Ascari E: Plasmapheresis in the treatment of autoimmune hemolytic anaemias. *Haematologica* 64:759-763, 1979.

Gilcher RO: Plasma exchange in immune and autoimmune diseases. Haemonetics Research Institute, 1978.

Weleba K: The use of plasma exchange in AHA. Haemonetics Advanced Component Seminar, Boston, 1978.

Nieburg PI, Stockman JA III: Rapid correction of anemia with partial exchange transfusion. *Am J Dis Child* 131:60, 1977.

Patten E, Reuter FP, Castle R, Mercer C: Evan's syndrome: Benefit from plasma exchange. American Association of Blood Banks 30th Annual Meeting, 1977, Abstract S-34.

Taft EG, Propp RP, Sullivan SA: Plasma exchange for cold agglutinin hemolytic anemia. *Transfusion* 17:173-176, 1977.

C. Aplastic Anemia

Messner HA, Fauser AA, Curtis JE, Dotten D: Control of antibody-mediated pure red-cell aplasia by plasmapheresis. *N Engl J Med* 304:1334-1338, 1981.

Fitchen 3H, et al: Antibody-mediated aplastic anemia with recovery after exchange plasmapheresis. *Am J Med* (in press), 1980.

Fitchen JJ, Cline MJ, Saxon A, Golde DW: Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: Recovery after exchange plasm apheresis. *Am J Med* 66:537, 1979.

Messner HA, Fauser AA, Curtis JE, et al: Control of pure red cell aplasia by repeated plasm apheresis. *Blood* 54:71 A, 1979.

Marmont AM, Damasio EE, Bacigalupo A, Giordano D, Rose E, Reali G, Gay A, Dagna-Bricarelli F, Brema F, Carelloam Santini G: A to O bone marrow transplantation in severe aplastic anemia: Dynamics of blood group conversion and demonstration of early dyserythropoiesis in the engrafted marrow. *Br J Haematol* 36:511-518, 1977.

D. Immune Thrombocytopenic Purpura

Buskard NA, Grossman L, Shematek G: Plasma exchange for the treatment of immune thrombocytopenia. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 220-223.

LeRoux G, Pourriat 3L, Lapandry C, Aufevvre JP, LeFoch A, Baudalet 3, Lortholary P: Post-transfusion purpura. Report of a case: Treatment by plasma exchange and transfusion of P^{A1} negative platelets. *Rev Fr Transfus Immunohematol* 24:211-219, 1981.

Marder VJ, Nusbacher J, Anderson FW: One-year follow-up of plasma exchange therapy in 14 patients with idiopathic thrombocytopenic purpura. *Transfusion* 21:291-298, 1981.

Taft EG: Apheresis in platelet disorders. *Plasma Ther* 2:181-209, 1981.

Taft EG: Plateletpheresis in the treatment of thrombocytopenia. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 85-99.

Blum SF, Lessig MA: Plasmapheresis in quinidine purpura. *Plasma Ther* 1:65, 1980.

Weir AB, Peon M-C, McGowan EI: Plasma exchange in idiopathic thrombocytopenic purpura. *Arch Intern Med* 140:1101-1103, 1980.

Branda RF: Plasma exchange in the treatment of immune thrombocytopenia. *Plasma Ther* 1:43-48, 1979.

Buskard NA, Shematek G, Grossman L, et al: Failure of plasma exchange to improve immune thrombocytopenia. *Blood* 54:108a, 1979.

Novak R, Willimas 3: Plasmapheresis in catastrophic complications of idiopathic thrombocytopenic purpura. *J Pediatr* 92:434, 1979.

Nusbacher J, Marder VJ, Anderson FW: Long-term follow-up of 15 patients with idiopathic thrombocytopenic purpura (ITP) treated by plasma exchange. *Transfusion* 19:666-667, 1979.

Branda RE, Tate DY, McCullough JJ, Jacob HS: Plasma exchange in the treatment of fulminant idiopathic (autoimmune) thrombocytopenic purpura. *Lancet* 1:688-690, 1978.

Gandolfo GM, Afeltra A, Ferri GM: Plasmapheresis for thrombocytopenia. *Lancet* 1:1095, 1978.

Gilcher RO: Plasma exchange in immune and autoimmune diseases. Haemonetics Research Institute, 1978.

Larison S, Fattah MM: **Plateletpheresis** as a preventive measure to complications of asymptomatic cases of idiopathic **thrombocytopenia**. *J Med Assoc GA* 67:296-297, 1978.

Marder VJ, Nusbacher J, et al: Results of plasma exchange in six patients with idiopathic **thrombocytopenic purpura (ITP)**: A mixed bag. *Blood (suppl)* 52:167, 1978.

McLeod BC, Wu KK, Knospe WH: **Plasmapheresis** in **thrombocytopenia**. *Clin Res* 26:711A, 1978.

Novak R, Williams J: **Plasmapheresis** in catastrophic complications of idiopathic **thrombocytopenic purpura**. *Pediatr* 92:434-436, 1978.

Okuno T: **Plasmapheresis** for **thrombocytopenia**. *Lancet* 1:1095, 1978.

Patten E, Reuter FP, Castle R, Mercer C: Evans' syndrome: Benefit from plasma exchange. *Transfusion* 18:383, 1978.

Weir AB Jr, Peon MC, McGowan EI: Plasma exchange for idiopathic **thrombocytopenic purpura**. *Lancet* 2:689, 1978.

Gorodetskii VM, Pashkov W, Rogova EM: Replacement therapy in acute non-immune **thrombocytopenia**. *Ter Arkh* 48:127-130, 1976.

Howard JE, Glassberg AB, Perkins HA: Post-transfusion **thrombocytopenic purpura**: A case report. *Am J Hematol* 1:339-342, 1976.

Abramson N, Eisenberg PD, Aster RH: Posttransfusion **purpura**: Immunologic aspects and therapy. *N Engl J Med* 291:1163, 1974.

Cimo PL, Aster RH: Post-transfusion **purpura**: Successful treatment by plasma exchange. *N Engl J Med* 287:290-292, 1972.

Berglund G: Plasma **transfusion** of six children with idiopathic **thrombocytopenic purpura**. *Acta Paediatr* 51:523, 1962.

E. Thrombotic Thrombocytopenic Purpura, Hemolytic Uremic Syndrome

Beattie TJ, Murphy AV, Willoughby MLN, MaChin S3, Defreyn G: **Plasmapheresis** in the **haemolytic-uraemic** syndrome in children. *Br Med J* 3 282:1667-1668, 1981.

Byrnes JJ: Plasma infusion in the treatment of **thrombotic thrombocytopenic purpura**. *Semin Thromb Hemostas* 9:9-14, 1981.

Case DC Jr: Plasma therapy for **thrombotic thrombocytopenic purpura**. *Blood* 58:409, 1981.

Chen Y-C, McLeod B, Hall ER, Wu KK: Accelerated **prostacyclin** degradation in **thrombotic thrombocytopenic purpura**. *Lancet* 2:267-269, 1981.

Cooper MR, et al: Intensive plasma exchange in **thrombotic thrombocytopenic purpura (TTP)**. *NC Med J* 42:403-404, 1981.

Crain SM, Choudhury AM: **Thrombotic thrombocytopenic purpura**. *JAMA* 246:1243-1246, 1981.

Frankel AE, Rubenstein MD, Wall RT: **Thrombotic thrombocytopenic purpura**: Prolonged coma with recovery of neurologic function with intensive plasma exchange. *Am J Hematol* 10:387-390, 1981.

Gottschall JL, Pisciotta AV, Darin J, Hussey CV, Aster RH: **Thrombotic thrombocytopenic purpura**: Experience with whole blood exchange transfusion. *Semin Thromb Hemostas* 7:25-32, 1981.

Kohn D, et al: **Thrombotic thrombocytopenic purpura** with a subacute course: Remission after steroids and high-dose plasma exchange. *Isr J Med* 17:283-285, 1981.

Myers TJ: Treatment of **thrombotic thrombocytopenic purpura** with combined exchange **plasmapheresis** and anti-platelet agents. *Semin Thromb Hemostas* 7:37-42, 1981.

Sweny P, et al: **Plasmapheresis** in the **haemolytic-uraemic** syndrome in children. *Br Med J (Clin Res)* 282:2137, 1981.

Taft EG, Baldwin ST: Plasma exchange transfusion. *Semin Thromb Hemostas* 7:15-21, 1981.

Bukowski RM, Hewlett JS, Lucas F: **Plasmapheresis** in the treatment of **thrombotic thrombocytopenic purpura**. *Clin Res* 28:306A, 1980.

Harden LB, Gluck RS, Salcedo JR: Simultaneous **hemodialysis** and exchange transfusion in **hemolytic uremic** syndrome. *Clin Pediatr* 19:640-642, 1980.

MaChin SJ, Defreyn G, Chamone DAF, Vermeylen S: Plasma **6-keto-PGF₁** levels after plasma exchange in **thrombotic thrombocytopenic purpura**. *Lancet* 2:661, 1980.

McLeod BC, Wu KK, Knospe WH: **Plasmapheresis** in **thrombotic thrombocytopenic purpura**. *Arch Intern Med* 140:1059-1060, 1980.

Misiani R, Trevisan F, Marchesi D, Bertani T, Remuzzi G, Mecca G: **Plasmapheresis** and plasma infusion in the treatment of **hemolytic-uremic** syndrome. In Remuzzi G, Mecca G, de Gaetano G (eds): "Hemostasis, Prostaglandins and Renal Disease." New York: Raven, 1980, pp 423-431.

Myers TJ, Wakem CJ, Ball ED, Tremont SJ: **Thrombotic thrombocytopenic purpura**: Combined treatment with **plasmapheresis** and antiplatelet agents. *Ann Intern Med* 92:149-155, 1980.

Rossi EC, del Greco F, Kwaan HC, Lerman BB: **Hemodialysis-exchange** transfusion for treatment of **thrombotic thrombocytopenic purpura**. *JAMA* 244:1466-1468, 1980.

Sacher RA: **Plasmapheresis in TTP-clearance** of immune complexes. *Transfusion* 20:118-119, 1980.

Seger R, Joller P, Baerlocher K, Kenny A, Dulake C, Leumann E, Spierig M, Hitzig WH: **Hemolytic-uremic syndrome associated with neuraminidase-producing microorganisms: Treatment by plasma exchange.** *Helv Paediatr Acta* 35:359-367, 1980.

Vialtel P, Chenais F, Dechelette E, Elsener M, Bayle F, Cordonnier D: **Adult hemolytic uremic syndrome treated with plasma exchange.** *Plasma Ther* 1:51-54, 1980.

Walker BK, Ballas SK, Martinez J: **Plasma infusion for thrombotic thrombocytopenic purpura during pregnancy.** *Arch Intern Med* 140:981-983, 1980.

Yogore MG, Chawla MS, Kasprisin DO: **Plasma exchange in a case of thrombotic thrombocytopenic purpura and suspected acute systemic lupus erythematosus.** *Plasma Ther* 1:23-25, 1980.

Alloatti S, et al: **Use of hemofiltration in 'difficult' uremic patients.** *Minerva Nefrol* 26:365-372, 1979 (English abstract).

Bukowski RM, Hewlett 3S, Reimer RR, et al: **Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura (TTP).** *Blood* 54: Suppl 1, 235a, 1979.

Byrnes 33, Khurana M: **Treatment of thrombotic thrombocytopenic purpura with plasma.** *N Engl J Med* 297:1386-1389, 1979.

Okuno T, Kosova L: **Plasmapheresis for thrombotic thrombocytopenic purpura (TTP).** *Transfusion* 19:342-344, 1979.

Plasma exchange in thrombotic thrombocytopenic purpura. *Lancet* 1:1065-1066 (editorial), 1979.

Ryan PF, Cooper IA, Firkin BG: **Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura: A report of five cases.** *Med J Aust* 1:69-72, 1979.

Stern R, Cornell CJ Jr, Beck R, Smith RE: **Thrombotic thrombocytopenic purpura: Failure of plasma infusion and antiplatelet agents.** *Ann Intern Med* 90:989, 1979.

Taft EG: **Thrombotic thrombocytopenic purpura and dose of plasma exchange.** *Blood* 54:842-849, 1979.

Vialtel P, Chenais F, Dechelette E, Bayle F, Couderc P, Cordonnier D: **Adult hemolytic uremic syndrome successfully treated with plasma exchange.** *Kidney Int* 15:453, 1979.

Vialtel P, Chenais F, Dechelette E, Bayle F, Couderc P, Cordonnier D: **Hemolytic-uremic syndrome of adults successfully treated with massive plasmapheresis (proceedings).** *J Urol Nephrol (Paris)* 85:331-332, 1979.

Yang C, Nussbaum M, Park H: **Thrombotic thrombocytopenic purpura in early pregnancy: Remission after plasma exchange.** *Acta Haematol* 62:112-116, 1979.

Abramson N: **Treatment for thrombotic thrombocytopenic purpura: Plasma, vincristine, hemodialysis and exchange transfusions.** *N Engl J Med* 298:971-972, 1978.

Ansell 3, Beaser RS, Pechet L: **Thrombotic thrombocytopenic purpura fails to respond to fresh frozen plasma infusion.** *Ann Intern Med* 89:647-648, 1978.

Bukowski RM, Hewlett 3S, King 3: **Plasmapheresis in thrombotic thrombocytopenic purpura (TTP).** *Blood* 51:561, 1978.

Bymes 33, Khurana M: **Treatment for thrombotic thrombocytopenic purpura: Plasma, hemodialysis and exchange transfusions.** *N Engl J Med* 298:291, 1978.

Hanzlick RL, Shah NT, Senhauser DA: **Treatments for thrombotic thrombocytopenic purpura, plasma, vincristine, hemodialysis and exchange transfusions.** *N Engl J Med* 298:971, 1978.

Reiss R, Shah V, Kalter R, Panlilio A: **Plasmapheresis in thrombotic thrombocytopenic purpura (TTP).** *Blood* 51:560-561, 1978.

Rossi EC, del Greco F: **Treatment of thrombotic thrombocytopenic purpura with hemodialysis and exchange transfusion.** *N Engl J Med* 298:972, 1978.

Taylor HL, Gal K: **TTP treated with therapeutic pheresis.** *Transfusion* 18:599, 1978.

Bukowski RM, King JW, Hewlett 3S: **Plasmapheresis in the treatment of thrombotic thrombocytopenic purpura.** *Blood* 50:413-417, 1977.

Fisher WB: **Exchange transfusion in acute thrombotic thrombocytopenic purpura: Case report.** *Milit Med* 142:789-790, 1977.

Pisciotta AV, Garthwaite T, Darin I, Aster RH: **Treatment of thrombotic thrombocytopenic purpura by exchange transfusion.** *Am J Hematol* 3:73, 1977.

Bukowski RM, Hewlett 3S, Harris JW, Hoffman GC, Battle JD Jr, Silverblatt E, Yang I: **Exchange transfusions in the treatment of thrombotic thrombocytopenia purpura.** *Semin Hematol* 13:219-232, 1976.

Pisciotta AV, Garthwaite T, Darin J, et al: **Treatment of thrombotic thrombocytopenic purpura.** *Semin Hematol* 13:219-232, 1976.

Rubenstein MA, Kagan BM, MacGillviray MH, Reuben M, Sacks H: **Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions.** *Am Intern Med* 51:1409-1419, 1959.

F. Sickle Cell Disease

Fullerton MW, Philippart AI, Sarnaik S, Lusher JM: **Preoperative exchange transfusion in sickle cell anemia.** *J Pediatr Surg* 16:297-300, 1981.

Goldfinger D: Erythrocytapheresis in the management of sickle cell disease. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Haruda F, et al: Rapid resolution of organic mental syndrome in sickle cell anemia in response to exchange transfusion. *Neurology* 31:1015-1016, 1981.

Kleinman R, Thompson-Breton R, Breen D, Hurvitz C, Goldfinger G: Exchange red blood cell transfusion in a pediatric patient with severe complications of sickle cell anemia. *Transfusion* 21:443-446, 1981.

Nagey DA, Garcia J, Welt S: Isovolumetric partial exchange transfusion in the management of sickle cell disease in pregnancy. *Am J Obstet Gynecol* 141:403-407, 1981.

Rossof AH, McLeod BC, Holmes AW, Fried W: Intrahepatic sickling crisis in hemoglobin SC disease. Management by partial exchange transfusion. *Plasma Ther* 2:7-11, 1981.

Davis K, Thorp D, Taylor A, Dart G, Taylor A: Red cell exchange in sickle cell disease. *Plasma Ther* 1:27-32, 1980.

Key TC, Horger EP, Walker EM, Mitchum EN: Automated erythrocytapheresis for sickle cell anemia during pregnancy. *Am J Obstet Gynecol* 138:731, 1980.

Klein HG, Garner R3, Miller DM, Rosen SL, Statham NJ, Winslow RM: Automated partial exchange transfusion in sickle cell anemia. *Transfusion* 20:578-584, 1980.

Miller DM, Winslow RM, Klein HG, Wilson KC, Brown FL, Statham NJ: Improved exercise performance after exchange transfusion in subjects with sickle cell anemia. *Blood* 56:1127-1131, 1980.

Sheehy TW, Law DE, Wade BH: Exchange transfusion for sickle cell intrahepatic cholestasis. *Arch Intern Med* 140:1364-1366, 1980.

Keeling MM: Experiences with red blood cell exchange in sickle cell disorders in pregnancy. In "First Annual Apheresis Symposium: Current Concepts and Future Trends." Chicago: American Red Cross Blood Services, 1979, pp 97-102.

Kleinman S, Thompson-Breton R, Rifkind S, et al: Exchange red blood cell pheresis in the management of complications of sickle cell anemia. *Haemonetics Research institute Advance Component Seminar*, Boston, 1979.

Rifkind S, Waisman S, Thompson R, Goldfinger D: RBC exchange pheresis for priapism in sickle cell disease. *JAMA* 242:2317-2318, 1979.

Davey R3, Esposito DJ, Jacobsen R3, Corn M: Partial exchange transfusion as treatment for hemoglobin SC disease in pregnancy. *Arch Intern Med* 138:937, 1978.

Lanzowsky P, Shende A, Karayalcin G, Kim YJ, Abelli AM: Partial exchange transfusion in sickle cell anemia. *Am J Dis Child* 132:1206-1208, 1978.

Kernoff LM, Botha MC, Jacobs P: Exchange transfusion in sickle cell disease using a continuous-flow blood cell separator. *Transfusion* 17:269-271, 1977.

Morrison 3C, Wiser WL: The use of prophylactic partial exchange transfusion in pregnancies associated with sickle cell hemoglobinopathies. *Obstet Gynecol* 48:516-520, 1976.

Perkins RP: Partial exchange transfusion in a pregnant patient with sickle cell anemia. *Obstet Gynecol* 48:22-245, 1976.

Green M, Hall RJC, Huntsman RG, Lawson A, Pearson TC, Wheeler CG: Sickle cell crisis treated by exchange transfusion: Treatment of two patients with heterozygous sickle-cell syndrome. *AMA* 231:948-950, 1975.

Morrison JC, Whybrew WD, Bucovaz ET: Use of partial exchange transfusion preoperatively in patients with sickle cell hemoglobinopathies. *Am J Obstet Gynecol* 132:59-63, 1973.

Brody 31, Goldsmith MH, Park SK, Soltys HD: Symptomatic crises of sickle cell anemia treated by limited exchange transfusion. *Ann Intern Med* 72:327-330, 1970.

Buckle AER, Price TML, Whitmore DN: Exchange and simple transfusion in sickle cell diseases in pregnancy. *Postgrad Med J* 45:722-725, 1969.

Ricks P Jr: Further experience with exchange transfusion in sickle cell anemia and pregnancy. *Am J Obstet Gynecol* 100:1087-1091, 1968.

Anderson R, Cassell M, Mullinax GL, Chaplin H: Effect of normal cells on viscosity of sickle-cell blood: In vitro studies and report of six years' experience with a prophylactic program of "partial exchange transfusion." *Arch Intern Med* 111:286, 1963.

G. Leukemia, Myeloproliferative Syndrome, Sézary Syndrome

Bongiovanni MB, Katz RS, Tomaszewski JE, Ziselman EM, Goldwein MI, Wurzel HA: Cytapheresis in a patient with Sezary syndrome. *Transfusion* 21:332-334, 1981.

Cuttner J, Meyer R3, Ambinder EP, Greenberg ML, Button G, Holland 3F: Leukapheresis in acute myeloblastic leukemia. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 29-43.

Durkalec 3, et al: Repeated leukapheresis in a pregnant woman with myelocytic leukemia. *Pol Tyg Lek* 36:449-450, 1981 (English abstract).

Graubner M, et al: Discontinuous cell separation as depletion therapy in chronic leukemias. *Onkologie* 4:162-167, 1981 (English abstract).

Imamura N, Okada K, Karamoto A: Recommendation of leukapheresis as well as combination chemotherapy of adult T-cell leukemia. *Transfusion* 21:471, 1981.

- Karp DD, et al: Chronic **granulocyte** leukemia with respiratory distress. Efficacy of emergency **leukapheresis**. *Arch Intern Med* **141:1353-1354**, 1981.
- Klose HJ, et al: Initial treatment of acute childhood leukemia with extreme **leukocytosis** by blood exchange transfusion - theological aspects. *Klin Padiatr* **193:172-176**, 1981 (English abstract).
- Mód A, et al: **Plasmapheresis** in patients with **leukaemia**, multiple **myeloma** and **immune** complex diseases. *Haematologia (Budap)* **14:49-56**, 1981.
- Shende A, Festa R, Honigman, Lankowsky P: Exchange transfusion as a treatment for **hyperleukocytosis**, anemia, and metabolic abnormalities in patients with leukemia. *J Pediatr* **98:852**, 1981.
- Baidurin SA, Khoroshko ND, Polianskaia AM, Kalinin NN, Pashinin AN: use of **leukapheresis** in chronic **myeloleukemia**. *Sov Med* **10:55-58**, 1980.
- Cohen 3, et al: Plasma exchange in treatment of **leucocytoclastic vasculitis**. *3 R Soc Med* **73:457-460**, 1980.
- Goldfinger D, Capostagno V, Lowe C, Sacks HJ, Gatti RA: Use of long-term **leukapheresis** in the treatment of chronic **lymphocytic** leukemia. *Transfusion* **20:450-454**, 1980.
- Hamblin T, Gordon J, Stevenson F, Stevenson G: Reduction of blocking factor to immunotherapy by plasma exchange. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 387-391.
- Harrer S, Høcker P, Pittermann E: Rapid regression of **papilledema** under **leukapheresis** therapy in chronic **myelosis** (author's transl). *Klin Monatsbl Augenheilkd* **176:823-825**, 1980.
- Hester 3: **Cytopheresis** in the management of leukemia. In "Second Annual Apheresis Symposium: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1980, pp 111-116.
- Karnen BA, Summers CP, Pearson HA: Exchange transfusion as a treatment for **hyperleukocytosis** anemia, and metabolic abnormalities in a patient with leukemia. *3 Pediatr* **96:1045-1046**, 1980.
- Lane TA: Continuous-flow **leukapheresis** for rapid cytoreduction in leukemia. *Transfusion* **20:455-457**, 1980.
- Mód A, Füst G, Harsányi V, Natonek K, Poros A, Szabó J, Hollán SR: **Plasma**-**pheresis** in patients with **leukaemia**, multiple **myeloma** and immune complex diseases. *Acta Haematol Pol* **11:165-171**, 1980.
- Orlin JB, Berkman EM: Improvement of platelet function following **platelet**-**pheresis** in patients with **myeloproliferative** diseases. *Transfusion* **20:540-545**, 1980.
- Revuz J, Mannoni P, Touraine P: Long-term disease free, survival of **Sézary** syndrome obtained by **leukapheresis**. *3 Invest Dermatol* **74:448**, 1980.
- Winkelman RK, Pineda A: Leukapheresis for **Sézary** syndrome. In "Second Annual Apheresis Symposium: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1980, pp 83-89.
- Ballas SK, Kiesel JK: **Leukapheresis** for **hyperviscosity**. *Transfusion* **19:787**, 1979.
- Carpentieri U, Patten EV, Chamberlain PA, Young AD, Hitter ME. **Leukapheresis** in a 3-year-old child with **lymphoma** in leukemic transformation. *J Pediatr* **94:919-921**, 1979.
- Cooper IA, Ding JC, Adams PB, Quim MA, Brettell M: Intensive **leukapheresis** in the management of **cytopenias** in patients with chronic **lymphocytic leukaemia** (CLL) and **lymphocytic lymphoma**. *Am J Hematol* **6:387-398**, 1979.
- Cuttner J, Meyer RJ, Ambinder EP, Greenberg ML, Button G, Holland 3F: Therapeutic **leukapheresis** in acute **myelogenous leukemia**. In "First Annual Apheresis Symposium: Current Concepts and Future Trends." Chicago: American Red Cross Blood Services, 1979, pp 127-143.
- Fay JW, Moore JO, Logue GL, Huang AT: **Leukopheresis** therapy of leukemic **reticuloendotheliosis** (hairy cell leukemia). *Blood* **54:747-749**, 1979.
- Bell R, Sullivan JR, Hurley TH, D'Apice AJ, Kincaid-Smith P: Some uses of the **continuous** flow blood separator in the **myeloproliferative** syndrome. *Aust NZ J Med* **8:433-435**, 1978.
- Caplan SN, Coco FV, Berkman EM: Management of chronic **myelocytic** leukemia in pregnancy by cell **pheresis**. *Transfusion* **18:120-124**, 1978.
- Eisenstaedt RS, Berkman EM: Rapid **cytoreduction** in acute **leukemia**. Management of cerebral **leukostasis** by cell pheresis. *Transfusion* **18:113-115**, 1978.
- Goldfinger D, Capostagno V, et al: Long-term **leukapheresis** as therapy for chronic **lymphocytic** leukemia. *Transfusion* **18:625**, 1978.
- Greenberg ML, Ambinder EP, Grant S, Meyer R3, Paster J: A **cytokinetic** effect of **leukapheresis** in leukemic patients. *Cell Kinetics Society 2nd Annual Meeting*, 1978.
- Meyer RJ, Cuttner 3, Truog P, Ambinder EP, Holland 3F: Therapeutic **leuko**-**pheresis** of acute **myelo-monocytic** leukemia in pregnancy. *Med Pediatr Oncol* **4:77-83**, 1978.
- Taft EG, et al: **Leukapheresis** in the management of high count **leukemia**. *Transfusion* **18:625**, 1978.
- Capostagno V, Kurz L, Gatti RA, Goldfinger D: Effect of a three phase **leukapheresis** program for the management of chronic **lymphocytic** leukemia. *Blood* **50:216**, 1977.

- Glaser E: Separation and filtration of **granulocytes** and other substances which have qualities that contribute to the therapy of **leucosis**. *Blut Hematol Transfuz* 5:31-36, 1977.
- Kawashima K, Ueda R: **Leukapheresis** of patients with acute leukemia and chronic myelogenous leukemia. *Rinsho Ketsueki* 18:620-626, 1977.
- Kobayashi S: **Leukapheresis**. A. Treatment of chronic myelogenous leukemia. *Rinsho Ketsueki* 18:615-620, 1977.
- Lowenthal RM: Chronic leukaemias: Treatment by **leucapheresis**. *Exp Hematol* 5: Suppl 73-84, 1977.
- Meyer RJ, et al: Effect of **leukapheresis** on remission induction with chemotherapy in patients with acute myelocytic leukemia (AML). *Blood* 50 (Suppl 1):199, 1977.
- Stirling ML, Parker AC, Keller A3, Urbaniak SJ: **Leukapheresis** for papilloedema in chronic granulocytic leukaemia. *Br Med J* 2:676, 1977.
- Fortuny IE, Hadlock DC, Kennedy BJ, Theologies, McCullough J: The role of continuous flow centrifuge **leucapheresis** in the management of chronic lymphocytic leukemia. *Br J Haematol* 32:609-615, 1976.
- Huestis DW, Price MJ, White RF, et al: **Leukapheresis** of patients with chronic granulocytic leukemia (CGL), using the Haemonetics blood processor. *Transfusion* 16:255-260, 1976.
- Hadlock DC, Fortuny IE, McCullough J, Kennedy BJ: Continuous flow centrifuge **leucapheresis** in the management of chronic myelogenous leukaemia. *Br J Haematol* 29:443-453, 1975.
- Höcker P, Pittermann E, Gobets M, Pawlowsky J, Flegel U, Stacher A: The use of the cell separator in the treatment of leukemia. *Folia Haematol (Leipz)* 102:283-294, 1975.
- Höcker P, Pitterman E, Gobets M, Stacher A: Treatment of patients with chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) by **leukapheresis** with a continuous flow blood cell separator. In Goldman JM, Lowenthal RM (eds): "leukocyte= Separation Collection and Transfusion." London: Academic Press, 1975, pp 510-518.
- Huestis DW, Corrigan JJ Jr, Johnson HV: **Leukapheresis** of a five-year-old girl with chronic granulocytic leukemia. *Transfusion* 15:489-490, 1975.
- Lowenthal RM, Buskard NA, Goldman JM, Spiers AS, Bergier N, Graubner M, Galton DA: Intensive **leukapheresis** as initial therapy for chronic granulocytic leukemia. *Blood* 46:835-844, 1975.

- Edelson R, Facktor M, Andrews A, Lutzner M, Schein P: Successful management of the Sézary syndrome: **Mobilization** and removal of **extravascular neoplastic T cells** by **leukapheresis**. *N Engl J Med* 291:293-299, 1974.
- Höcker P, Pittermann E, Gobets M, Haist B, Gazda M, Stacher A: Therapeutic, functional and kinetic aspects of **leukopheresis** therapy in chronic lymphatic leukemia. *Blut* 28:396-410, 1974.
- Wheeler TG, McCredie KB, Freireich EJ, Daniels TV: **Increased** efficiency of leukocyte collection from patients with chronic myelocytic leukemia. *Transfusion* 14:253-256, 1974.
- Fortuny IE, Crandall L, McCullough J, et al: **Leukapheresis** in the management of chronic leukemia. *Minn Med* 56:674-676, 1973.
- Sakalova A, Gazova S, Hrubisko M, Ualikova J: Clinical utilization of **plasmapheresis** and **cyclophosphamide** in the treatment of malignant lymphoproliferative processes. *Neoplasma* 20:335-339, 1973.
- Vallejos CS, McCredie KB, Brittin GM, Freireich EJ: Biological effects of repeated **leukapheresis** of patients with chronic myelogenous leukemia. *Blood* 42:925-933, 1973.
- Curtis JE, Hersh EM, Freireich EJ: **Leukapheresis** therapy of chronic lymphocytic leukemia. *Blood* 39:163-174, 1972.
- Reich L, O'Hara K, Stoerlinger P, Clarkson B: Effect of massive **leukapheresis** on proliferation in AML. *Proc AACR* 12:25, 1971.
- Smálik S, Filová J: **Plasmapheresis** as an auxiliary method in the immunotherapy of chronic myelosis. *Cas Lek Cesk* 109:246-250, 1970.
- Buckner D, Graw RG Jr, Eisel RJ, Henderson ES, Perry S: **Leukapheresis** by continuous flow centrifugation (CFC) in patients with chronic myelocytic leukemia (CML). *Blood* 33:353-369, 1969.
- Morse EE, Carbonne PP, Freireich EJ, Bronson W, Kliman A: Repeated **leukapheresis** of patients with chronic myelocytic leukemia. *Transfusion* 6:175, 1966.
- Bierman HR, Marshall GJ, Kelly KH, Byron RL: **Leukapheresis** in **maf**. III. Hematologic observations in patients with leukemia and myeloid metaplasia. *Blood* 21:164, 1963.
- ### H. Thrombocytosis
- Belloni M, Fabris F, Ongaro G, Girolami A: Therapeutic **thrombocytapheresis** in a case of **thrombocytosis**. *Transfusion* 21:229-230, 1981.
- Taft EG: Apheresis in platelet disorders. *Plasma Ther* 2:181-209, 1981.

Taft EG: Plateletpheresis in the treatment of **thrombocytopenia**. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 85-99.

Beard MEJ, Blacklock HA, Varcoe AR: Control of **thrombocytosis** by plateletpheresis using a cell separator. *NZ Med J* 91:136-138, 1980.

Taft EG: Management of **thrombocytosis**. *Transfusion* 20:235-236, 1980.

Goldfinger D, Thompson R, Lowe C, Kurz L, Belkin G: Long-term plateletpheresis in the management of primary **thrombocytosis**. *Transfusion* 19:336-338, 1979.

Orlin JB, Berkman EM: **Plateletpheresis** improves platelet function in myeloproliferative disease. *Transfusion* 19:667, 1979.

Goldfinger D, Kurz L, Lowe C, Thompson R, Belkin G: Failure of long-term plateletpheresis to control primary **thrombocytosis**. *Transfusion* 18:384, 1978.

Younger J, Umlas J: Rapid reduction of platelet count in essential hemorrhagic **thrombocytopenia** by discontinuous flow **plateletpheresis**. *Am J Med* 64:659-661, 1978.

Goldfinger D, Kurz L, Lowe C, Thompson R, Belkin G: Failure of long-term plateletpheresis to control primary **thrombocytosis**. American Association of Blood Banks 30th Annual Meeting, 1977, Abstract S-39.

Taft EG, Babcock RB, Scharfman WB, Tartaglia AP: **Plateletpheresis** in the management of **thrombocytosis**. *Blood* 50:927-933, 1977.

Greenberg BR, Watson-Williams EJ: successful control of life-threatening **thrombocytosis** with a blood processor. *Transfusion* 15:620-622, 1975.

Miller DS, Rundles RW, Silver DC: Hemorrhagic **thrombocytopenia**: Rapid **plateletpheresis** by continuous flow blood cell separation. *Clin Res* 19:426A, 1971.

Colman RW, Sievers CA, Pugh RP: **Thrombocytopenia**: A rapid and effective approach to **thrombocytosis**. *J Lab Clin Med* 68:389-399, 1966.

L Miscellaneous

Bada HS, Korones SB, Fitch CW: Reversal of altered cerebral hemodynamics by plasma exchange transfusion in **polycythemia**. *Clin Res* 29:494A, 1981.

Chirnsi de A, et al: **Coagulation** abnormalities following intensive plasma exchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and antithrombin III. *Br J Haematol* 48:627-634, 1981.

Erskine 3G, Burnett AK, Walker ID, Davidson JF: Plasma exchange in **non-haemophilic** patients with inhibitors to factor VIII. *Br Med J* 283:760, 1981.

Gleich GJ, Pineda AA, Solley GO, Taswell HF: **Cytapheresis** for procurement of **eosinophils** and for the treatment of diseases associated with **eosinophilia**. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 73-79.

Quietzsch D, et al: Therapeutic **plasmapheresis** in the treatment of **plasmacytoma**. *Z Gesamte Inn Med* 36:308-310, 1981 (English abstract).

Schricker KT: Exchange transfusion and ABO erythroblastosis. *Crit Rev Clin Lab Sci* 14:21, 1981.

Anderson E, Skov F, Hippe E: A case of cold haemoglobinuria with later **sarcoidosis**. Treatment with **plasmapheresis** and **immunosuppression**. *Scand J Haematol* 24:47-50, 1980.

Ladisch S, Ho W, Hartman G: Treatment of familial **erythrophagocytic lymphohistiocytosis (FEL)** by repeated plasma exchange. *Clin Res* 28:105A, 1980.

Taft E, Becker H, Hammer C, Sullivan S, Baldwin S: Apheresis in platelet disease states. In Kasprisin DO, Vaithianathan T (eds): "Proceedings of the Second Annual Apheresis Symposium," Chicago, Mid-America Red Cross/Michael Reese Research Foundation/Rush Presbyterian-St. Luke's Medical Center, 1980, pp 138-153.

Blacklock HA, Cleland JR, Tan P, Pillai VM: The **hypereosinophilic** syndrome and **leukapheresis**. *Ann Intern Med* 91:650-651, 1979.

Gorodetskii VM, Buachidze LN, Paahkov W, Labetskaia IA, Fomina II: Blood components in the treatment of **myelotoxic agranulocytosis** and **thrombopenia**. *Ter Arkh* 51:3-89, 1979.

Panlilio AL, Reiss RF: Therapeutic **plateletpheresis** in **thrombocytopenia**. *Transfusion* 19:147-152, 1979.

Scharfman WB, Tillotson JR, Taft EG, Wright E: **Plasmapheresis** for meningococemia with disseminated intravascular coagulation. *N Engl J Med* 300:1277-1278, 1979.

Cundall JR, Moore WH, Jenkins DE: **Erythrocyte** exchange in paroxysmal nocturnal **hemoglobinuria** prior to cardiac surgery. *Transfusion* 18:626, 1978.

Landwehr DM, Evans PS, et al: Removal of **immune complexes** by **plasmapheresis** in patients with subacute bacterial endocarditis. *Proc Int Cong Nephrol*, Abstract D33, 1978.

Ellman L, Miller L, Rapoport 3: Leukapheresis therapy of a **hypereosinophilic** disorder. *JAMA* 230:1004-1005, 1974.

Vesely V: **Erythropheresis**—contribution to the treatment of **polycythemia**. *Vnitr Lek* 19:183-189, 1973.

Gutnik RB: **Plasmapheresis** in the treatment of erythremia. *Ter Arkh* 40:116-118, 1968.

Fullerton WT, Turner AG: Exchange transfusion in treatment of severe anaemia in pregnancy. *Lancet* 1:75, 1962.

AMERICAN RED CROSS BLOOD SERVICES

Therapeutic Pheresis Bibliography No. III: Malignant
Paraproteinemias

A. Hyperviscosity Syndrome

Ballas SK, Kiesel JK: Leukapheresis for hyperviscosity. *Transfusion* 19:787, 1979.

Buskard NA: Blood flow studies in the hyperviscosity syndrome before and after plasma exchange. In **Borberg H, Reuther P (eds):** "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 89-94.

Nusbacher S: Plasmapheresis in the treatment of hyperviscosity syndrome and paraproteinemia. In **Nemo G3, Taswell H (eds):** "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 105-118.

Isbister 3P, Biggs 3C, Penny R: Experience with large volume plasmapheresis in malignant paraproteinaemia and immune disorders. *Aust NZ J Med* 8:154-164, 1978.

Radovic M, Duric D, Trajkovi B, Radojicic B, Pekic B, Tomasevic R, Dujic A: Myeloma serum hyperviscosity syndrome treated with plasmapheresis. *Med Pregl* 30:471-476, 1977.

Loughrey JR, Meyer RL: Plasmapheresis in hyperviscosity syndrome—a better way? *3AMA* 229:1211, 1974.

B. Macroglobulinemia

Reynolds WA: Late report of the first case of plasmapheresis for Waldenström's macroglobulinemia. *JAMA* 245:606-607, 1981.

Waldenström JG: Plasmapheresis—bloodletting revived and refined. *Acta Med Scand* 208:1-4, 1980.

Barbolla L, Fernández MN: Plasmapheresis in the treatment of Waldenström's macroglobulinaemia. *Sangre (Bare)* 23:334-342, 1978.

Buskard NA, Galton DA, Goldman JM, Kohner EM, Grindle CF, Newman DL, Twinn KW, Lowenthal RM: Plasma exchange in the long-term management of Waldenström's macroglobulinemia. *Can Med Assoc* 3 117:135-137, 1977.

Plasmapheresis in macroglobulinaemia. *Lancet* 2:807-808 (editorial), 1977.

Russell 3A, Roy 3L, Powles RL: Plasma exchange in malignant paraproteinaemias. *Exp Haematol* 5:Suppl 1, 105-116, 1977.

Grindle C3F, Buskard NA, Newman D: Retinal blood flow changes following plasmapheresis in patients with Waldenström's macroglobulinaemia. Second, International Symposium on Leukocyte Separation and Transfusion. Abstract N7, 1976.

ARC Blood Services
Bibliography
TPB III-2

Sakalová A, G&a' S, Hrubisko M, Pokorná G, Mayer J: Follow up of certain immunological indicators in the treatment of plasmacytoma with cyclophosphamide in combination with plasmapheresis. *Neoplasma* 22:63-67, 1975.

Pittermann E, Höcker P, Lechner K, Stacher A: Plasmaphereses with the continuous flow blood cell separator in the treatment of macroglobulinaemia, multiple myeloma, hemophilia and hyperlipidaemia. In **Goldman JM, Lowenthal RM (eds):** "Leukocytes Separation Collection and Transfusion." London: Academic Press, 1974, pp 576-577.

Reich L, Feizi T, Winchester R, Wechsler B, Walzer P, Wright P: Effects of large scale plasmapheresis performed on patients with macroglobulinemia. *Proc Am Assoc Cancer Res* 14:68, 1973.

Powles R, Smith C, Kohn 3, Hamilton FG: Method of removing abnormal protein rapidly from patients with malignant paraproteinemias. *Br Med J* 3:664-667, 1971.

Mokeyeva RA, Zhuravlev VS: Effect of intensive plasmapheresis on the "syndrome of increased viscosity" and blood coagulation system in Waldenström's macroglobulinemia. *Probl Gematol Pereliv Krovi* 14:8-16, 1979.

Lawson NS, Nosanchuk 3S, Oberman HA, Meyers MC: Therapeutic plasmapheresis in treatment of patients with Waldenström's macroglobulinemia. *Transfusion* 8:174-178, 1968.

Moulinier 3, Servantie X, Mesnier F: Therapeutic effects of plasmapheresis in Waldenström's disease. *J Med Bord* 144:1295-1300, 1967.

Godal HC, Borchgrevink CF: The effect of plasmapheresis on the hemostatic function in patients with macroglobulinaemia Waldenström and multiple myeloma. *Scand J Lab Clin Invest* 17:Suppl 84, 133-137, 1965.

Mokeyeva RA, Rutberg RA, Chemyak VYa, et al: Use of plasmapheresis in macroglobulinemic reticulosis (Waldenström's disease). *Fed Proc (transl suppl)* 25:153-156, 1965.

Solomon A, Fahey JL: Plasmapheresis therapy in macroglobulinemia. *AM Intern Med* 58:789-800, 1963.

Skoog WA, Adams WS, Coburn JW: Metabolic balance study of plasmapheresis in a case of Waldenström's macroglobulinemia. *Blood* 19:425, 1962.

Schwab PJ, Fahey JL: Treatment of Waldenström's macroglobulinemia by plasmapheresis. *N Engl J Med* 263:574-579, 1960. **Schwab PJ, Okun E, Fahey JL:** Reversal of retinopathy in Waldenström's macroglobulinemia by plasmapheresis. A report of two cases. *Arch Ophthalmol* 64:515-518, 1960.

Schwab PJ, Okun E, Fahey JL: Reversal of retinopathy in Waldenström's macroglobulinemia by plasmapheresis. A report of two cases. *Arch Ophthalmol* 64:515-518, 1960.

Skoog WA, Adams WS: Plasmapheresis in a case of Waldenström's macroglobulinaemia. *Clin Res* 7:96, 1959.

C. Multiple Myeloma

Betourne C, Buge A, Dechy H, Dorra M, Dournon E, Rancurel G: The treatment of peripheral neuropathies in a case of **IgA myeloma** and one of mixed **cryoglobulinaemia**. Repeated **plasmapheresis**. *Nouv Presse Med* 9:1369-1371, 1980.

Blank HJ, Brinkmann OH, Junge-Hülsing G: **Plasmapheresis**: An effective procedure for paraproteinemia coma. *Dtsch Med Wochenschr* 105:1396, 1980.

Mod A, et al: **Plasmapheresis** in patients with **leukaemia**, multiple **myeloma** and immune complex diseases. *Haematologia (Budap)* 14:49-56, 1981.

Locatelli F, et al: Steroid pulses and **plasmapheresis** in the treatment of acute renal failure in multiple **myeloma**. *Proc Eur Dial Transplant Assoc* 17:690-694, 1980.

Locatelli F, Pozzi C, Pedrini L, et al: **Plasmapheresis** and methylprednisolone pulses in the treatment of acute renal failure in multiple **myeloma**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis** -Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 241-246.

Mód A, Füst G, Harsányi V, Natonek K, Poros A, Szabó Z, Hollán SR: **Plasmapheresis** in patients with **leukaemia**, multiple **myeloma** and immune complex diseases. *Acta Haematol Pol* 11:165-171, 1980.

Misiani R, Remuzzi G, Bertani T, Licini R, Levoni P, Crippa A, Mecca G: **Plasmapheresis** in the treatment of acute renal failure in multiple **myeloma**. *Am J Med* 66:684-688, 1979.

Sieberth HG, Glöckner W, Borberg H, Fohlmeister Z: Plasma separation in Goodpasture's syndrome and multiple **myeloma**. *Proc Eur Dialysis Transplant Assoc* 16:528, 1979.

Isbister JP, Biggs JC, Penny R: Experience with large volume **plasmapheresis** in malignant paraproteinaemia and immune disorders. *Aust NZ J Med* 8:154-164, 1978.

Russell SA, Fitzharris BM, Corringham R, Darcey DA, Powles RL: Plasma exchange v. peritoneal dialysis for removing Bence Jones protein. *Br Med J* 2:1397, 1978.

Fortuny IE, McCullough J: Plasma exchange by continuous flow centrifugation in the management of acute renal failure of multiple **myeloma**. *Minn Med* 60:25-26, 1977.

Radovic M, Duric D, Trajkovi B, Radojicic B, Pekic B, Tomasevic R, Duji A: **Myeloma** serum hyperviscosity syndrome treated with **plasmapheresis**. *Med Pregl* 30:471-4716, 1977.

Russell SA, Toy SI, Powles RL: Plasma exchange in malignant paraproteinaemias. *Exp Haematol* 5:Suppl 1, 105-116, 1977.

Feest TG, Burge PS, Cohen SI: Successful treatment of **myeloma** kidney by diuresis and **plasmapheresis**. *Br Med J* 1:503-504, 1976.

Hamblin TJ: Treatment of **myeloma** kidney. *Br Med J* 1:772, 1976.

Sakalová A, Gažová S, Hrubisko M, Pokorná G, Mayer J: Follow-up of certain immunologic indicators in the treatment of **plasmacytoma** with **cyclophosphamide** in combination with **plasmapheresis**. *Neoplasma* 22:63-67, 1975.

Virella G, Preto RV, Graca F: Polymerised monoclonal **IgA** in two patients with **myelomatosis** and **hyperviscosity syndrome**. *Br J Haematol* 30:479-487, 1975.

Loughrey JR, Meyer RL: **Plasmapheresis** in **hyperviscosity syndrome**—a better way? *JAMA* 229:1211, 1974.

Pittermann E, Höcker P, Lechner K, Stacher A: **Plasmaphereses** with the continuous flow blood cell separator in the treatment of **macroglobulinaemia**, multiple **myeloma**, **haemophilia** and **hyperlipidaemia**. In Goldman JM, Lowenthal RM (eds): "Leucocytes: Separation Collection and Transfusion." London: Academic Press, 1974, pp 561-567.

Tuddenham EGD, Whittaker JA, Bradley J, Lilleyman JS, James DR: **Hyperviscosity syndrome** in **IgA** multiple **myeloma**. *Br J Haematol* 27:65-76, 1974.

Revel L, Favre-Gilly J, Bryon PA, Guyon M, Fiere D: The treatment of **osseous** multiple **myelomas**; possible value of **plasmapheresis**. *Lyon Med* 227:901-903, 1972.

Benninger GW, Krepa S: **Aggregation** phenomenon in an **IgG** multiple **myeloma** resulting in the **hyperviscosity syndrome**. *Am J Med* 51:287-292, 1971.

Kopp WL, Bierne GJ, Burns RO: **Hyperviscosity syndrome** in multiple **myeloma**. *Am J Med* 43:141-146, 1967.

Tan BL, Cleton F3, Beusekom GT van, Veltkamp J3, Rood JJ van: **Plasmapheresis** treatment of hemorrhagic complications in a patient with multiple **myeloma**. *Folia Med Neerl* 10:174-179, 1977.

Godal HC, Borchgrevink CF: The effect of **plasmapheresis** on the hemostatic function in patients with **macroglobulinaemia Waldenström** and multiple **myeloma**. *Scand J Lab Clin Invest* 17:Suppl 84, 133-137, 1975.

D. Cryoglobulinemia

Bombardier S, Maggiore Q, L'Abbate A, Bartolomeo F, Terri C: Plasma exchange in essential mixed **cryoglobulinemia**. *Plasma Ther* 2:101-109, 1981.

Kater L, Schuurman HJ: **Immunobiology** and clinical aspects of **cryoglobulinemia**. *Plasma Ther* 2:83-99, 1981.

Berkman EM, Orlin JB: Use of **plasmapheresis** and partial **plasma** exchange in the management of patients with **cryoglobulinemia**. *Transfusion* 20:171-178, 1980.

A. GoodPasture's Syndrome

Betoume C, Buge A, Dechy H, Dorra M, Dournon E, Rancurel G: The treatment of *peripheral neuropathies* in a case of **IgA myeloma** and one of mixed **cryoglobulinaemia**. Repeated **plasmapheresis**. *Nouv Presse Med* **9**:1369-1371, 1980.

Cordonnier D, Vialtel P, Chenais F, Jeannoel P, et al: Plasma exchange in 3 cases of type **II IgM-IgG cryoglobulinaemia** with severe **membrano-proliferative glomerulonephritis**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 213-219.

Houwert DA, Hené RJ, Struyvenberg A, Kater L: Effect of **plasmapheresis**, **corticosteroids** and **cyclophosphamide** in essential mixed **polyclonal cryoglobulinemia** associated with **glomerulonephritis**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: FK Schattauer Verlag, 1980, p 179-184.

Maggiore Q, L'Abbate A, Bartolomeo F, Misefori V, Caccame A, Barbiano di Belgiojoso G, Tarantino A, Colasanti G: Cryopheresis in **cryoglobulinemia**. *Ric Clin Lab* **10**:67, 1980.

McLeod BC, Sasseti R3: **Plasmapheresis** with return of **cryoglobulin-depleted autologous plasma (cryoglobulinpheresis)** in **cryoglobulinemia**. *Blood* **55**:866-870, 1980.

Vandelli L, Gaiani G, Furci L, et al: Control of clinical symptoms in mixed essential **cryoglobulinaemia** with plasma exchange alone. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 221-223.

James MP, Kingston PJ: Essential monoclonal **cryoglobulinaemia**: The use of intermittent **plasmapheresis** to control cold induced symptoms. *Clin Exp Dermatol* **4**:209-213, 1979.

Kater L, Mul N3A, Smeur 1, et al: **Plasmapheresis** as an **adjuvant** therapy in systemic lupus **erythematosus** and in **vasculitis** associated with **cryoglobulinemia**. San Francisco, XIV International Congress on **Rheumatology**, 1977, p 98.

E. Miscellaneous

Haller P, Werry H, Wrabetz-Wölke A: **Plasmapheresis** and function of the optic nerve in **IgM-paraproteinemia**. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 95-100.

Russell JA: Treatment of paraproteinemias with plasma exchange. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 73-80.

Pussell BA, Lakwood CM, Bartolotti SR, Peters DK: Plasma exchange in **immune complex disease** and **Goodpasture's syndrome**. In Nemo GJ, Taswell H (eds): "Proceedings of the **Workshop** on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 147-160.

Wysebeek AJ, Smith JW, Krakauer RS: **Plasmapheresis** U: Review of clinical experience. *Plasma Ther* **2**:61-71, 1981.

Espinosa-Melendez E, Forbes RD, Hollomby D3, Ahuja 3, Katz MG: **Goodpasture's syndrome** treated with **plasmapheresis**. Report of a case. *Arch Intern Med* **140**:542-543, 1980.

Foidart JB, Pirard Y, Foidart JM, DuBois CH, Mahieu PR: Evidence for a **polyclonal stimulation** in **GoodPasture's syndrome**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 3-7.

Loew H, Lockwood M, Witting Ch: Successful treatment of **Goodpasture's syndrome** by **plasmapheresis**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 191-193.

Matloff DS, Kaplan MM: D-penicillin-induced **Goodpasture's-like syndrome** in primary **biliary cirrhosis** Successful **treatment** with **plasmapheresis** and **immunosuppressives**. *Gastroenterology* **78**:1046-1049, 1980.

Pozo-Rodrigues R, et al: Idiopathic pulmonary **haemosiderosis** treated by **plasmapheresis**. *Thorax* **35**:399-400, 1980.

Siegler RL, Bond RE, Morris AH: Treatment of **GoodPasture's syndrome** with plasma exchange and **immunosuppression**. *Clin Pediatr (Phila)* **19**:488-491, 1980.

Erickson SB, Kurtz SB, Donadio JV Jr, Honey KE, Wilson CB, Pineda AA: Use of combined **plasmapheresis** and **immunosuppression** in the treatment of **Goodpasture's syndrome**. *Mayo Clin Proc* **54**:714-720, 1979.

Finch RA, Rutsky EA, McGowan E, Wilson CB: Treatment of **Goodpasture's syndrome** with **immunosuppression** and **plasmapheresis**. *South Med J* **72**:1288-1290, 1979.

Lakwood CM, Peters DK: The treatment of **GoodPasture's syndrome** and **glomerulonephritis**. *Plasma Ther* **1**:19-27, 1979.

Munk ZM, Skamene E: **Goodpasture's syndrome-effects** of **plasmapheresis**. *Clin Exp Immunol* **36**:244-249, 1979.

Rosenblatt SG, Knight W, Bannayan GA, Wilson CB, Stein JH: Treatment of Goodpasture's syndrome with plasmapheresis. A case report and review of the literature. *Am J Med* 66:689-696, 1979.

Sieberth HG, Glöckner W, Borberg H, Fohlmeister J: Plasma separation in Goodpasture's syndrome and multiple myeloma. *Proc Eur Dialysis Transplant Assoc* 16:528, 1979.

Walker RG, d'Apice AJF, Becker GJ, et al: Plasmapheresis in Goodpasture's syndrome with renal failure. *Med J Aust* 1:875-879, 1979.

Cove-Smith JR, McLeod AA, Blarney RW, Knapp MS, Reeves WG, Wilson CB: Transplantation, immunosuppression and plasmapheresis in Goodpasture's syndrome. *Clin Nephrol* 9:126-128, 1978.

Johnson 3P, Whitman W, Briggs WA, Wilson CB: Plasmapheresis and immunosuppressive agents in antibasement membrane antibody-induced Goodpasture's syndrome. *Am J Med* 64:354-359, 1978.

McLeish KR, Maxwell DR, Luft FC: Failure of plasma exchange and immunosuppression to improve renal function in Goodpasture's syndrome. *Clin Nephrol* 10:71-73, 1978.

Misiani R, Bertani T, Licini R, Remuzzi G, Mecca G: Asphyxia in Goodpasture's syndrome. Early treatment by immunosuppression and plasma exchange. *Lancet* 1:552, 1978.

Swanson CP, Robson JS, Urbaniak SJ, Keller AJ, Kay AB: Treatment of Goodpasture's disease by plasma exchange and immunosuppression. *Clin Exp Immunol* 32:233-242, 1978.

Kamanabroo D, Intorp HW, Samizadeh H, Loew H: Successful treatment of Goodpasture's syndrome with plasmapheresis in combination with cyclophosphamide and glucocorticoids. *Verh Dtsch Ges Inn Med* 83:856-859, 1977.

Lang CH, Brown DC, Staley N, Johnson G, Ma KW, Border WA, Dalmaso AP: Goodpasture's syndrome treated with immunosuppression and plasma exchange. *Arch Intern Med* 137:1076-1078, 1977.

Walker RG, d'Apice AJF, Becker GJ, Kincaid-Smith P, Craswell PW: Plasmapheresis in Goodpasture's syndrome with renal failure. *Med J Aust* 1:875-879, 1977.

Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB: Immunosuppression and plasma exchange in the treatment of Goodpasture's syndrome. *Lancet* 1:711-715, 1976.

Rossen RD, Duff y J, McCredie KB, Reisberg MA, Sharp JT, Hersh EM, Eknoyan G, Suki WN: Treatment of Goodpasture's syndrome with cyclophosphamide, prednisone and plasma exchange transfusions. *Clin Exp Immunol* 24:218-222, 1976.

Depner TA, Chaffin ME, Wilson CB, Gulyassy PF: Plasmapheresis for severe Goodpasture's syndrome. *Kidney Int* 8:409, 1975.

Lockwood CM, Boulton-Jones 3M, Lowenthal RM, Simpson IJ, Peters DK: Recovery from Goodpasture's syndrome after immunosuppressive treatment and plasmapheresis. *Br Med J* 2:252-254, 1975.

& Glomerulonephritis

Clark WF, et al: Monthly plasmapheresis for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A pilot study. *Can Med Assoc J* 125:171-174, 1981.

Lockwood CM: Plasma exchange in glomerulonephritis. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart Georg Thieme Verlag, 1981, pp 155-160.

Nenov D, et al: Initial plasmapheresis treatment results in glomerulonephritis. *Vutr Boles* 20:105-108, 1981 (English abstract).

Praga M, et al: Rapidly progressive glomerular disease treated with plasmapheresis. *Med Clin (Bare)* 77:33-36, 1981 (English abstract).

Solomon LR, et al: Reduction of post-transplant proteinuria due to recurrent mesangial proliferative (IgM) glomerulonephritis following plasma exchange. *Clin Nephrol* 16:44-50, 1981.

Sommerlad KH, Leber HW, Rawer P, Scholz R, Graubner M, Schütterle G: Plasma exchange and immunosuppression in glomerulonephritis. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 161-167.

Warren SE, Mitas 3A 2d, Golbus SM, Swerdlin AR, Cohen IM, Cronin RE: Recovery from rapidly progressive glomerulonephritis. Improvement after plasmapheresis and immunosuppression. *Arch Intern Med* 141:175-180, 1981.

Asaba H, Bergström J, Bendz R, Löfquist B, et al: Plasma exchange with a membrane plasma filter for treatment of glomerulonephritis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 207-211.

Asaba H, et al: Clinical trial of plasma exchange with a membrane filter in treatment of crescentic glomerulonephritis. *Clin Nephrol* 14:60-65, 1980.

Botella J, Barbolla L, Sanz-Guajardo D, et al: Plasmapheresis treatment in diffuse extracapillary glomerulonephritis without immune complexes or linear deposits. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 195-199.

Cordonnier D, Vialtel P, Chenais F, Jeannoel P, et al: Plasma exchange in 3 cases of type II IgM-IgG cryoglobulinaemia with severe membranoproliferative glomerulonephritis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 213-219.

Freidman EA: Plasmapheresis for rapidly progressive glomerulonephritis: the mystique of dramatic intervention. *JAMA* 244:2446, 1980.

Houwert DA, Hené RJ, Struyvenberg A, Kater L: Effects of plasmapheresis (PP), corticosteroids and cyclophosphamide in essential mixed polyclonal cryoglobulinemia associated with glomerulonephritis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 179-183.

Lockwood CM, Peters DK: Plasma exchange in glomerulonephritis and related vasculitides. *Ann Rev Med* 31:167-179, 1980.

Lustenberger N, Neumann KH, Müller H-J, Ehrlich HH, Stolte H: In vitro characterization of plasma exchange membrane and in vivo application in rat immune complex glomerulopathy. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 225-230.

Rees AJ, Lockwood CM, Peters DK: Plasma exchange in the management of rapidly progressive nephritis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 161-167.

Riegger A3G, Liebau G, Steilner H, Roth W, Kochsiek K: Recovery of renal function in oligo-anuric patients with rapidly progressive glomerulonephritis (RPGN) after plasma exchange and immunosuppression. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 207-211.

Sanz Guajardo D, Barbolla ML, Fernández 3, Gallego 3L, Anaya A, Botella J: Plasmapheresis in the treatment of extracapillary glomerulonephritis. *Med Clin (Bare)* 74:337-341, 1980.

Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S: Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. *3AMA* 244:2423-2426, 1980.

Ahmad S, Young JH, Striker GE, et al: Plasma exchange in rapidly progressive glomerulonephritis (RPGN). *Clin Res* 27:91A, 1979.

Bruns FJ, Stachura 1, Adler S, et al: Effect of early plasmapheresis and immunosuppressive therapy on natural history of anti-glomerular basement membrane glomerulonephritis. *Arch Intern Med* 139:372-375, 1979.

d'Apice AJF, Kincaid-Smith P: Treatment of glomerulonephritis by plasma exchange. In Kincaid-Smith P, d'Apice AJF (eds): "Progress in Glomerulonephritis." New York: John Wiley & Sons, 1979.

Lockwood CM: Experience with plasmapheresis in glomerulonephritis and other allergic diseases. In Dau PC (ed): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979, pp 175-185.

Lockwood CM, Peters DK: The treatment of Goodpasture's syndrome and glomerulonephritis. *Plasma Ther* 1:19-27, 1979.

McKenzie PE, Taylor AE, Woodroffe A3, Seymour AE, Chan YL, Clarkson AR: Plasmapheresis in glomerulonephritis. *Clin Nephrol* 12:97-108, 1979.

Plasmapheresis and severe glomerulonephritis. *Br Med J* 1:434-435 (editorial), 1979.

Kincaid-Smith P, d'Apice AJF: Plasmapheresis in rapidly progressive glomerulonephritis. *Am J Med* 65:564-566, 1978.

Becker GJ, d'Apice AJF, Walker RG, Kincaid-Smith P: Plasmapheresis in the treatment of glomerulonephritis. *Med J Aust* 2:693-696, 1977.

Landwehr DM, Evans PS, Fisher LM, et al: Removal of immune complexes by plasmapheresis in glomerulonephritis with subacute bacterial endocarditis. *Clin Res* 25:507, 1977.

Lockwood CM, Rees AJ, Pussell B, Peters DK: Experience of the use of plasma exchange in the management of potentially fulminating glomerulonephritis and SLE. *Exp Haematol* 5:Suppl 1, 117-136, 1977.

Ravnskov U, Dahlback O, Messeter L: Treatment of glomerulonephritis with drainage of the thoracic duct and plasmapheresis. *Acta Med Scand* 202:489-494, 1977.

Bruns FJ, Stachura I, Adler S, Segel DP: Effect of early plasmapheresis and immunosuppressive therapy on natural history of anti-glomerular basement membrane glomerulonephritis: Report of a 22-month follow-up. *Arch Intern Med* 139:372-374, 1976.

C. Miscellaneous

Cohen PC: Plasma exchange in a group of selected patients with renal disease. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Cohen J: Plasmapheresis, infection, and renal disease. *JAMA* 246:1545, 1981.

Frasca G, et al: Plasmapheresis in the treatment of immunological nephropathies. *G Clin Med* 62:260-269, 1981 (English abstract).

Landini S, Coli U, Lucatello S, Bazzato G: Acute renal failure associated with liver impairment treated by plasma-exchange. Proceedings of Symposium on Acute Renal Failure. Tel Aviv, 1981, in press.

Lockwood CM: Plasma exchange in nephritis. *Plasma Ther* 2:227-234, 1981.

Lockwood M, Pusey C: Current status of plasma exchange in renal disease. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Morse EE, et al: Therapeutic plasmapheresis in patients with renal disease. *AM Clin Lab Sci* 11:361-366, 1981.

Valbonesi M, Garelli S, Mosconi L, Montani F, Camerone G: Plasma exchange and combined immunosuppressive therapy in the management of severe renal damage due to immune complex disease. *Plasma Ther* 2:139-142, 1981.

Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S: **Plasmapheresis, infection, and renal disease.** *JAMA* 246:1545, 1981.

Liebau G, Riegger AJG, Steilner H, Rath W, Kochsiek K: Plasma exchange in a patient with lupus nephritis and severe nephrotic syndrome. *Nieren und Hochdruck-Krankheiten* 9:145, 1980.

Neilson EG, Phillips SM, Agus Z: **Plasmapheresis in fulminating crescentic nephritis.** *Lancet* 1:264-265, 1980.

Swainson CP, Urbaniak SJ, Robson JS: Plasma exchange in the successful treatment of drug-induced renal disease. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 235-240.

Thyssel H, Bengtsson U, Lindholm T, Bygren P, et al: Plasma exchange and plasma filtration in renal disease. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 169-174.

Vangelista A, et al: Effects of plasmapheresis in the acute phase of immunocomplex nephropathy. *Minerva Nefrol* 27:567-570, 1980.

van den Berg CJ, Pineda AA: Plasma exchange in the treatment of acute renal failure due to low molecular-weight dextran. *Mayo Clin Proc* 55:387-389, 1980.

Harmer D, Fim R, Goldsmith HJ, et al: **Plasmapheresis in fulminating crescentic nephritis.** *Lancet* 1:679, 1979.

Lockwood CM, Worledge S, Nicholas A, Cotton C, Peters DK: Reversal of impaired splenic function in patients with nephritis or vasculitis (or both) by plasma exchange. *N Engl J Med* 300:524-530, 1979.

Reich LM, Turnbull AD: Combined renal and hepatic failure: The potential of serial hemodialysis and massive exchange plasmapheresis. *Curr Prob Cancer* 4:18-20, 1979.

Elliott HL, McDougall AI, Hasse G, Cumming RLC, Gardiner RHE, Fell GS: **Plasmapheresis in the treatment of dialysis encephalopathy.** *Lancet* 2:940-941, 1978.

Russell JA, Fitzharris BM, Corringham R, Darcey DA, Powles RL: Plasma exchange v. peritoneal dialysis for removing Bence Jones protein. *Br Med J* 2:1397, 1978.

Lockwood CM, Rees AJ, Pinching AJ, Pussell B, Sweny P, Uff J: Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. *Lancet* 1:63-67, 1977.

Peters OK, Rees AJ, Lockwood CM: Plasma exchange in glomerular and related auto-allergic diseases. *Proc Eur Dial Transplant Assoc* 14:409-422, 1977.

Plasma-exchange in nephritis. *Lancet* 1:83 (editorial), 1977.

Feest TG, Burge PS, Cohen SI: Successful treatment of myeloma kidney by diuresis and plasmapheresis. *Br Med J* 1:503-504, 1976.

Horisawa M, et al: Exchange transfusion in hepatorenal syndrome with liver disease. *Arch Intern Med* 136:1135, 1976.

Nose Y, Malchesky PS, Castino F, Koshino I, Scheucher K, Nokoff R: Improved hemoperfusion systems for renal/hepatic support. *Kidney Int* 10:5244, 1976.

Shafir E, Brenner T: Lipoprotein synthesis in hypoproteinemia of experimental nephrotic syndrome and plasmapheresis. In Bianchi R, et al (eds): "Plasma Protein Turnover." Baltimore: University Park Press, 1976, pp 343-355.

Buselmeier TJ, Merino GE, Rodrigo F, et al: Dialyzer-augmented whole blood and plasma exchange for patients with hepatic or hepatorenal failure. *Crit Care Med* 3:204, 1975.

AMERICAN RED CROSS BLOOD SERVICES

Therapeutic Pheresis Bibliography No. V: Connective Tissue Disorders

A. Systemic Lupus Erythematosus (SLE)

Abdou NI, Lindsley HB, Pollock A, Stechschulte DJ, Wood G: **Plasmapheresis** in active systemic lupus erythematosus: Effects on clinical serum, and cellular abnormalities. Case report. *Clin Immunol Immunopathol* 19:44-54, 1981.

Clark WF, et al: Chronic plasma exchange therapy in SLE nephritis. *Clin Nephrol* 16:20-23, 1981.

Clark WF, et al: Monthly **plasmapheresis** for systemic lupus erythematosus with diffuse proliferative glomerulonephritis: A pilot study. *Can Med Assoc J* 125:171-174, 1981.

Parr y HF, et al: Plasma exchange in systemic lupus erythematosus. *Am Rheum Dis* 40:224-228, 1981.

Rohkamm R, Przuntek H, Rockel A, Reuther P: Effect of plasma exchange in systemic lupus erythematosus with severe myopathy. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 197-198.

Schlansky R, DeHoratius R3, Pincus T, Tung Ks: **Plasmapheresis** in systemic lupus erythematosus: A cautionary note. *Arthritis Rheum* 24:49-53, 1981.

Verrier Jones J: **Plasmapheresis** in rheumatic disease - assessment of the impact on process and outcome. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Verrier Jones J: **Plasmapheresis** in the treatment of systemic lupus erythematosus. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 221-229.

Wysenbeek AJ, Smith JW, Krakauer RS: **Plasmapheresis** II: Review of clinical experience. *Plasma Ther* 2:61-71, 1981.

Hamblin I, Smith D: Plasma exchange as a long-term treatment of systemic lupus erythematosus. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis** - **Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 185-189.

Hamblin T, Smith D: Plasma exchange as a long term treatment of systemic lupus erythematosus. *Nieren und Hochdruck-Krankheiten* 9:142, 1980.

Hamblin TJ, Smith DS, Steven MM: Plasma exchange in SLE. *Lancet* 1:882, 1980.

Hamilton WA, Vergani D, Bevis L, Tee DE, Zülka KJ, Cotton LT: Plasma exchange in SLE. *Lancet* 1:1249, 1980.

ARC Blood Services
Bibliography
TPB V-2

Liebau G, Riegger AJG, Steilner H, Rath W, Kochsiek K: Plasma exchange in a patient with lupus nephritis and severe nephrotic syndrome. *Nieren und Hochdruck-Krankheiten* 9:145, 1980.

Meff ert H, Böhm F, Apostoloff E, Kramm H3: **Plasmapheresis** therapy in severe lupus erythematosus D.N.A. serum antibodies and erythrocyte sedimentation rate for therapy control. *Dermatol Monatsschr* 166:331-335, 1980.

Plasma exchange in SLE. *Lancet* 1:688-689 (editorial), 1980.

Schlansky R, DeHoratius RJ, Pincus T, et al: **Plasmapheresis** therapy in systemic lupus erythematosus (SLE). *Clin Res* 28:150A, 1980.

Yogore MG, Chawla MS, Kasprisin DO: Plasma exchange in a case of thrombotic thrombocytopenic purpura and suspected acute systemic lupus erythematosus. *Plasma Ther* 1:23-25, 1980.

Young DW, Thompson RA, Mackie PH: **Plasmapheresis** in hereditary angioneurotic edema and systemic lupus erythematosus. *Arch Intern Med* 140:127-128, 1980.

Fitch JJ, Cline M3, Saxon A, Golde DW: Serum inhibitors of hematopoiesis in a patient with aplastic anemia and systemic lupus erythematosus: Recovery after exchange **plasmapheresis**. *Am J Med* 66:537, 1979.

Hubbard HC, Portnoy B: Systemic lupus erythematosus in pregnancy treated with **plasmapheresis**. *Br J Dermatol* 101:87-89, 1979.

Lindsley HB, Pollock A, Stechshulte DJ, et al: **Plasmapheresis** (PL) in active systemic lupus erythematosus (SLE): Effects on serum and cellular abnormalities. *Clin Res* 27:645A, 1979.

Molodenkov MN, Lopukhin IuM, Evseev NG, Shurkalin BK, Ageev SL: **Plasmosorption** in the treatment of cold urticaria and systemic lupus erythematosus (a preliminary report). *Vestn Dermatol Venerol*, pp 58-60, 1979.

Schildermans F, Dequeker J, Van de Putte I: **Plasmapheresis** combined with corticosteroids and cyclophosphamide in uncontrolled active systemic lupus erythematosus. *J Rheumatol* 6:687-690, 1979.

Terman DS, Buff aloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ajus JC: **Extracorporeal immunoadsorption**: Initial experience in human systemic lupus erythematosus. *Lancet* 1:824-826, 1979.

Verrier Jones J, Cumming RH, Bacon PA, Evers J, Fraser ID, Bothamley J, Tribe CR, Davis P, Hughes GR: Evidence for a therapeutic effect of **plasmapheresis** in patients with systemic lupus erythematosus. *Q J Med* 48:555-576, 1979.

Verrier Jones J, Fraser ID, Bothamley J, et al: Acute systemic lupus erythematosus: A therapeutic role for **plasmapheresis**. *Plasma Ther* 1:33-41, 1979.

Wätzig V, Thiel W, Schreiber G: **Plasmapheresis** in the management of systemic lupus erythematosus. *Dermatol Monatsschr* 165:305-307, 1979.

Gilcher RO: Plasma exchange in immune and autoimmune diseases. Haemonetics Research Institute, 1978.

Houwert DA, Kater L, Struyvenberg A: **Plasmapheresis**, an aid in the treatment of patients with active systemic lupus erythematosus? *Ned Tijdschr Geneesk* 122:678-681, 1978.

Verrier Jones 3: **Plasmapheresis** in the management of systemic lupus erythematosus. *Muscle Nerve* 1:339-340, 1978.

Verrier Jones 1, Robinson MF, Layfer LF, et al: **Plasmapheresis** in SLE: Correlation of response with level of circulating immune complexes measured by Raji-cell assay. *Arthritis Rheum* 21:567, 1978.

Kater L, Mul NJA, Smeur I, et al: **Plasmapheresis** as an adjuvant therapy in systemic lupus erythematosus and in vasculitis associated with cryoglobulinemia. San Francisco, XIV International Congress on Rheumatology, 1977, p 98.

Lockwood CM, Rees A3, Pussell B, Peters DK: Experience of the use of plasma exchange in the management of potentially fulminating glomerulonephritis and SLE. *Exp Haematol* 5:Suppl 1, 117-136, 1977.

Moran CJ, Parry HF, Mowbray 3, Richards 3DM, Goldstone AH: **Plasmapheresis** in systemic lupus erythematosus. *Br Med J* 1:1573-1574, 1977.

Verrier Jones J, Fraser ID, Hughes G, et al: Therapeutic value of **plasmapheresis** in systemic lupus erythematosus. San Francisco, XIV International Congress on Rheumatology, 1977, p 98.

Verrier Jones J, Cumming RH, Bucknall RC, Asplin CM, Fraser ID, Bothamley F, Davis P, Hamblin TJ: **Plasmapheresis** in the management of acute systemic lupus erythematosus? *Lancet* 1:709-711, 1976.

B. Polyarteritis Nodosa - Wegener's Granuloma

Brubaker DB, Winkelstein A: Plasma exchange in rheumatoid vasculitis. *Vox Sang* 41:295-301, 1981.

Chalopin JM, Rife G, Turc JM, Cortet P, Severac M: Immunological findings during successful treatment of HBsAg-associated polyarteritis nodosa by plasmapheresis alone. *Br Med* 3 280:368, 1980.

Chenais F, Debru JL, Baret L, Faure 3, Chalopin JM, Rife G: Plasma exchange in the treatment of polyarteritis nodosa. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 285-288.

Suchy B-R, Nogai K, Schley R, Wehnelt I, et al: Plasma exchange in a case of Wegener's granulomatosis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 231-234.

Valbonesi M, et al: Plasma exchange in management of a patient with diffuse necrotizing cutaneous vasculitis. *Vox Sang* 39:241-245, 1980.

Hamblin TJ, Oscier D: **Polyarteritis** presenting with thrombocytosis and palliated by plasma exchange. *Postgrad Med J* 54:615-617, 1978.

C. Rheumatoid Arthritis

Apheresis helps some arthritics - not ready for all. *Med World News* 22:42-43, 1981.

Apheresis in the treatment of rheumatoid arthritis. Washington, DC: National Center for Health Care Technology Assessment Report Series, Volume 1, 1981.

Asanuma Y, Malchesky PS, Blumenstein M, Zawicki I, Smith JW, Kayashima K, Kyo A, Suzuki M, Shinagawa S, Krakauer RS, Calabrese L, Nosé Y: Continuous cryofiltration for rheumatoid arthritis. *Artif Organs* (accepted), 1981.

Bard H, et al: Rheumatoid polyarthritis and papular mucinosis with monoclonal paraprotein. Management with plasmapheresis. *Rev Rhum Mal Osteoartic* 48:359-365, 1981.

Brewer EJ, Nickeson RW Jr, Rossen RD, Person DA, Giannini EH, Milam 3A: Plasma exchange in selected patients with juvenile rheumatoid arthritis. *J Pediatr* 98:194-200, 1981.

Dubrovina NA, et al: **Lymphocytapheresis** in the treatment of rheumatoid arthritis. *Ter Arkh* 53:125-132, 1981 (English abstract).

Evaluation of therapeutic apheresis for rheumatoid arthritis 1981. Rockville, MD: National Center for Health Care Technology, 1981.

From the NCHCT: Evaluation of therapeutic apheresis for rheumatoid arthritis. *JAMA* 246:1053, 1981.

Goldfinger D, Wallace DJ, Klineberg JR: **Plasma-lymphocytapheresis** for the treatment of rheumatoid arthritis. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 215-219.

Hamburger M: A critical assessment of the value of therapeutic apheresis in rheumatoid arthritis. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Kanamono T, Iwata H, Yamanaka N, Ohta K, Maeda K: Plasma separation using various kinds of hemo-filters in rheumatoid arthritis. In "New Membranes in Medical Treatment." 2nd Tutzing Symposium on Chemical Engineering in Medicine, Munich, 1981.

Karsh J, Klippel JH, Plotz PH, Decker JL, Wright DG, Flye MW: Lymphapheresis in rheumatoid arthritis: A randomized trial. *Arthritis Rheum* 24:867-873, 1981.

Recommendations of the Arthritis Foundation and the American Rheumatism Association on **plasmapheresis** in rheumatic disease. Atlanta, GA: Arthritis Foundation, 1981.

Shiokawa Y, Yamagata J, Yuasa S, Shiozawa K: Plasma exchange for rheumatoid arthritis using a new bag system. In Shiokawa Y, Abe T, Yamauchi Y (eds): "New Horizons in Rheumatoid Arthritis." Amsterdam: **Excerpta Medica**, 1981.

Smith JW, Asanuma Y, Kayashima K, Suzuki M, Blumenstein M, Malchesky PS, Krakauer R, Calabrese L, Shinagawa S, Nose Y: Rheumatoid arthritis treated by membrane **plasmapheresis** with sequential plasma **cryofiltration for removal of macromolecules**. *Am Soc Artif Intern Organs* 10:74, 1981.

Bletry O, Bussel A, Aubert L, Cabane S, Herson S, Godeau P: The effect of plasma exchange on the treatment of adult Still's disease. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. **Schattauer Verlag**, 1980, pp 275-281.

Nickeson RW, Brewer EJ, Rossen RD, et al: **Plasma** exchange in juvenile rheumatoid arthritis. *Arthritis Rheum* 23:725, 1980.

Rothwell RS, Davis P, Gordon PA, Dasgupta MK, John KV, Russell AS, Percy 3S: A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. *Arthritis Rheum* 23:785-790, 1980.

Wallace D, Goldfinger D, Brachman M, et al: Therapeutic **pheresis** in the management of rheumatoid arthritis (RA). *Clin Res* 28:77A, 1980.

Wallace D3, Goldfinger D, Thompson-Breton R, Martin V, Lowe CM, Bluestone R, Klinenberg JR: Advances in the use of therapeutic pheresis for the management of rheumatic diseases. *Semin Arthritis Rheum* 10:81-91, 1980.

Chenais F, Arvieux S, Blanc D, Piton JL, Philip X: **Plasmapheresis** in the treatment of rheumatoid polyarthritis. *Nouv Presse Med* 8:2903, 1979.

Goldman 3A, Casey HL, McIlwain H, Kirby I, Wilson CH Jr, Miller SB: Limited **plasmapheresis** in rheumatoid arthritis with **vasculitis**. *Arthritis Rheum* 22:1146-1150, 1979.

Karsh 3, Wright DG, Klippel JH, Decker IL, Deisseroth AB, Flye MW: Lymphocyte depletion by continuous flow **centrifugation** in rheumatoid arthritis: Clinical effects. *Arthritis Rheum* 22:1055-1059, 1979.

Pheresis methods improve severe RA, but cost is a hurdle. *Med World News* 20(33):28, 1979.

Tennenbaum J, Urowitz MB, Keystone EC, Dwosh IL, Curtis 3E: **Leucapheresis** in severe rheumatoid arthritis. *Ann Rheum Dis* 38:40-44, 1979.

Wallace DJ, Goldfinger D, Gatti R, Lowe C, Fan P, Bluestone R, Klinenberg JR: **Plasmapheresis** and lymphoplasmapheresis in the management of rheumatoid arthritis. *Arthritis Rheum* 22:703-710, 1979.

Wright DG, Karsh 3, Fauci AS, et al: **Leukapheresis** to achieve lymphocyte **depletion and immunosuppression** in rheumatoid arthritis (RA). *Clin Res* 27:339A, 1979.

Tennenbaum J, Dwosh IL, Burowitz M, et al: Severe rheumatoid arthritis responsive therapy. San Francisco, XIV International Congress on **Rheumatology**, 1977, p 246.

Roja OG: **Blood transfusion** in rheumatoid arthritis. *Lancet* 2:1209-1210, 1975.

Jasin HE, LoSpalluto, Ziff M: Rheumatoid **hyperviscosity** syndrome. *Am J Med* 49:484-493, 1970.

Jaffe IA: Comparison of the effect of **plasmapheresis** and **penicillamine** on the level of circulating rheumatoid factor. *Ann Rheum Dis* 22:71-76, 1963.

D. Raynaud's Syndrome

Verrier Jones 3, Clough 3D, Klinenberg JR, Davis P: **The** role of therapeutic **plasmapheresis** in the rheumatic diseases. *3 Lab Clin Med* 97:589-598, 1981.

Hamilton WAP, Dodds A3, Hancock MEJ, Roberts VC, Vergani D, Cotton LT: Circulatory improvement in **Raynaud's** phenomenon following plasma exchange. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. **Schattauer Verlag**, 1980, pp 301-307.

Hamilton WAP, White JM, Cotton LT: Plasma exchange in **Raynaud's** phenomenon. *Lancet* 2:475, 1980.

McCune MA, Pineda AA, Winkelman RK, Osmundson PJ: Controlled study of the therapeutic effect of plasma exchange on **scleroderma** and **Reynaud's** phenomenon. *Transfusion* 20:649, 1980.

Zahavi J, Hamilton WAP, O'Reilly MJG, et al: **Plasma** exchange and platelet function in **Raynaud's** phenomenon. *Thromb Res* 19:85-93, 1980.

Dodds AJ, O'Reilly MJG, Yates CJP, Cotton LT, Flute PT, Dormandy 3A: **Haemorrhological** response to plasma exchange in **Raynaud's** syndrome. *Br Med J* 2:1186-1187, 1979.

O'Reilly M3, Talpos G, Roberts VC, White JM, Cotton LT: Controlled trial of plasma exchange in treatment of **Raynaud's** syndrome. *Br Med J* 1:1113-1115, 1979.

Zahavi J, Hamilton WAP, O'Reilly MJG, Dubiel M, Cotton LT, Kakkar VV: **Plasmapheresis** and platelet function in **Raynaud's** syndrome. *Thromb Haemost* 42:338, 1979.

Acheson ED: **Plasm apheresis** in **Raynaud's** disease. *Lancet* 1:672, 1978.

Cotton LT: **Plasm apheresis** in **Raynaud's** disease. *Lancet* 2:108, 1978.

Klinenberg JR, Wallace D: **Plasm apheresis** in **Raynaud's** disease. *Lancet* 1:1310-1311, 1978.

Talpos G, Cotton LT, White 3M: **Plasmapheresis in Raynaud's disease.** *Lancet* 1:672, 1978.

Talpos G, Horrocks M, White JM, Cotton LT: **Plasmapheresis in Raynaud's disease.** *Lancet* 1:416-417, 1978.

E. Miscellaneous

Anderson L, Ziter FA: **Plasmapheresis via central catheter in dermatomyositis: A new method for selected pediatric patients.** *JPediatr* 98:240, 1981.

Dau PC, Bennington 3: **Plasmapheresis in childhood dermatomyositis.** *JPediatr* 98:237-240, 1981.

Hertzman A, Cooke CL, Rodriguez GE, Sharp D: Treatment of childhood mixed connective disease with **plasmapheresis.** *Clin Immunol Newsletter* 2:142-144, 1981.

Verrier Jones 3, Clough JD, Klinenberg JR, et al: The role of therapeutic **plasmapheresis** in the rheumatic diseases. *J Lab Clin Med* 98:589-598, 1981.

Brewer EJ, Giannini EH, Rossen RD, et al: Plasma exchange therapy of a childhood onset **dermatomyositis** patient. *Arthritis Rheum* 23:509, 1980.

Dequeker 3, Geusens P, Wielands L: Short and longterm experience with **plasmapheresis** in connective tissue diseases. *Biomedicine* 32:189-194, 1980.

Kamanabroo D, Lonauer G, Knob J: **Plasmapheresis** in the treatment of mixed connective tissue disease. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation.**" Stuttgart: F. K. Schattauer Verlag, 1980, pp 283.

Liebau G, Riegger AJG, Steilner H, Roth W, Kochsiek K: Plasma exchange in a patient with lupus nephritis and severe **nephrotic syndrome.** *Nieren und Hockdruch-Krankheiten* 9:145, 1980.

Shiokawa Y, Yamagata J: **Plasmapheresis** in treatment of rheumatic fever. *Jpn Circ J* 44:797-800, 1980.

Verrier Jones 3: Therapeutic **plasmapheresis** in rheumatology. In "Second Annual Apheresis Symposium: Current Concepts and Future Trends." Skokie, IL: American Society for **Apheresis**, 1980, pp 11-14.

Wallace DJ, Goldfinger D, Thompson-Breton R, Martin V, Lowe CM, Bluestone R, Klinenberg JR: Advances in the use of therapeutic **pheresis for the** management of rheumatic diseases. *Semin Arthritis Rheum* 10:81, 1980.

Yamagata J, Shiozawa K, Shiokawa Y: Therapeutic plasma exchange for rheumatic diseases. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasma-separation.**" Stuttgart: F. K. Schattauer Verlag, 1980, pp 265-273.

Cardella C3: Plasma exchange-a new approach to **immune modulation** in rheumatic diseases. 3 *Rheumatol* 6:606-609, 1979.

Lockwood CM, Worledge S, Nicholas A, Cotton C, Peters DK: Plasma exchange reverses impaired **splenic function** in nephritis and **vasculitis.** *N Engl J Med* 300:524-530, 1979.

AMERICAN RED CROSS BLOOD SERVICES

Therapeutic Pheresis Bibliography No. VI: Transplantation

A. Renal

Adams MB, et al: **Plasmapheresis** in the treatment of refractory renal **allograft rejection**. *Transplant Proc* 13(1 Pt 1): 491-494, 1981.

Blume KG, Spruce WE: Bone marrow **transplantation** in acute leukemia. In Mielke CH Jr (ed): "Apheresis Development, Applications, and Collection Procedures." New York: Alan R. Liss, 1981, pp 69-80.

Pease E: **Plasmaleukapheresis** halts graft rejection. *3AMA* 246:1170, 1981.

Slapak M, et al: Renal transplant in a patient with major donor-recipient blood group incompatibility: Reversal of acute rejection by the use of modified **plasmapheresis**. *Transplantation* 31:4-7, 1981.

Allan TL, Briggs JD, Cumming RLC, et al: Plasma exchange in renal transplant rejection. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 247-250.

Cardella EJ, et al: A controlled trial evaluating intensive plasma exchange in renal transplant recipients. *Proc Eur Dial Transplant Assoc* 17:429-434, 1980.

Cardella CJ, Uldall PR, Sutton DMC, et al: Effect and complications of intensive plasma exchange in renal **transplant recipients**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 251-255.

Kurland S, Franklin S, Goldfinger D: Treatment of renal **allograft rejection** by exchange **plasma-lymphocytapheresis**. *Transfusion* 20:337-340, 1980.

Lynngaard F, Ladefoged J, Jans H: Intensive **plasma exchange prior** to renal transplantation to prevent rejection. *Plasma Ther* 1:55-57, 1980.

Ota K, Toma H, Takahashi K, et al: Plasma exchange for treatment of renal **allograft rejection**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 257-261.

Adams MB, Kauffman HM Jr, Hebert LA, Hussey CV, Duquesnoy RI, Tomasulo PA: **Plasmapheresis** in the treatment of renal **allograft rejection**. *Proc Clin Dial Transplant Forum* 9:252-255, 1979.

Cardella CJ, Sutton DM, Uldall PR, et al: Renal **allograft rejection** and intensive plasma exchange. *Haemonetics Research Institute Advanced Component Seminar, Boston*, 1979.

Naik RB, Ashlin R, Wilson C, Smith DS, Lee HA, Slapak M: The role of **plasmapheresis** in renal transplantation. *Clin Nephrol* 2:245-250, 1979.

ARC Blood Services
Bibliography
TPB VI-2

Rifle G, Chalopin JM, Turc JM, Guigner F, Vialtel P, Dechelette E, Chenais F, Cordonnier D: **Plasmapheresis** in the treatment of renal **allograft rejections**. *Transplant Proc* 11:20-26, 1979.

Terman DS, Garcia-Rinaldi R, McCalmon R, Mattioli C, Cook G, Poser R: **Modification** of hyperacute renal xenograft rejection after **extracorporeal immunoadsorption of hetero-specific antibody**. *Int J Artif Organs* 2:35-41, 1979.

Cardella CJ, Sutton DM, Falk JA, Katz A, Uldall PR, deVeber GA: Effect of intensive **plasma exchange** on renal transplant rejection and serum **cytotoxic antibody**. *Transplant Proc* 10:617-619, 1978.

Vialtel P, Chenaie F, Dechelette E, Bayle F, Cordonnier D, Seigneurin JM: Massive **plasmapheresis** in the treatment of acute graft rejection resistant to usual treatment. *Nouv Presse Med* 7:2663, 1978.

Cardella CJ, Sutton DM, Falk JA, Katz A, Uldall PR, deVeber GA: Intensive plasma exchange, complement dependent **microcytotoxicity**, and renal transplant rejection. *Proc Eur Dial Transplant Assoc* 14:328, 1977.

Cardella CJ, Sutton D, Uldall PR, deVeber GA: Intensive **plasma exchange** and renal-transplant rejection. *Lancet* 1:264, 1977.

Yoshioka H, McCalmon R, Putman C, Terman DS: Attenuation of **hyperacute xenograft rejection** in unmodified host by **extracorporeal plasma perfusion**. *Transplantation* 23:72-76, 1977.

& Bone Marrow

Buckner CD, Williams B: **Pheresis techniques** in marrow **transplantation**. In Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Liss, 1981, pp 81-89.

Buckner CD: **Pheresis techniques** in marrow transplantation. In "First Annual Apheresis Symposium: Current Concepts and Future Trends." Chicago: American Red Cross Blood Services, 1979, pp 147-154.

Berkman EM, Caplan S, Kim CS: **ABO-incompatible bone marrow transplantation**: Preparation by plasma exchange and in vitro antibody absorption. *Transfusion* 18:504-508, 1978.

Merkel FK, Bier M, Beavers CD, Merriman WG, Wilson C, Starzl TE: **Modification** of xenograft response by selective **plasmapheresis**. *Transplant Proc* 3:534-537, 1971.

Bier M, Beavers CD, Merriman WG, Merkel FK, Eiseman B, Starzl TZ: Selective **plasmapheresis** in dogs for delay of **heterograft response**. *Trans Am Soc Artif Intern Organs* 16:325-333, 1970.

A. Hepatitis, Hepatic Coma

- Lösgen H, Brunner G, Schmidt FW: Removal of toxic metabolites by plasma exchange in patients with hepatic failure. In "New Membranes in Medical Treatment." 2nd Tutzing Symposium on Chemical Engineering in Medicine, Munich, 1981.
- Lepore MJ, McKenna PJ, Martinez BD, et al: Fulminant hepatitis with coma successfully treated by plasmapheresis and hyperimmune Australia-antibody-rich plasma. *Plasma Ther* 1:49-56, 1979.
- Gelfand MC, Winchester 3F, Kneppshield JH, Cohan S1, Schreiner GE: Reversal of hepatic coma by charcoal perfusion: Clinical and biochemical observations. *3 Am Soc Artif Intern Organs* 1:37-43, 1978.
- Kvasnicka J, Svejda 3, Rennerova 3, Rezac 3, Zalud P: Exchange plasmapheresis and heparin in treatment of coma in viral hepatitis. *Unitrni Lek* 24:440-444, 1978.
- Boland J, Broux R, Bury J, Pirotte 3: La plasmapherese dans le traitement de l'hepatite fulminante avec corm Rapport de 6 cas. *Acta Clin Belg* 31:173-187, 1976.
- Gelfand MC, Kneppshield JH, Cohan SL, et al: Treatment of hepatic coma with hemoperfusion through polyacrylamide hydrogel-coated charcoal. *Kidney Int* 10:5239, 1976.
- Jesipowicz M, Jakubowska M, Karski 3, Osterowa K: Exchange transfusion with plasmapheresis in the management of hepatic coma. *Polish Med Sci History Bull* 15:207-211, 1976.
- Sanjo K, Fujimori Y, Yamazaki Z, et al: The effect of liver support system (plasma perfusion detoxication) providing removal of plasma amino acids in patients with fulminant hepatitis. *Artif Organs (Jpn) Suppl* 5:231-234, 1976.
- Buselmeier TJ, Merino GE, Rodrigo F, et al: Dialyzer-augmented whole blood and plasma exchange for patients with hepatic or hepatorenal failure. *Crit Care Med* 3:204, 1975.
- Gazzard BG, Portmann BA, Weston MJ, Langley PG, Murray-Lyon IM, et al: Charcoal haemoperfusion in the treatment of fulminant hepatic failure. *Lancet* 1:1301, 1974.
- Gazzard BD, Weston MJ, Murray-Lyon IM, et al: Charcoal haemoperfusion in the treatment of fulminant hepatic failure. *Lancet* 1:1301, 1974.
- Buckner CD, Clift RA, Volwiler W, Donohue DM, Burnell JM, Saunders FC, Thomas ED: Plasma exchange in patients with fulminant hepatic failure. *Arch Intern Med* 132:487-492, 1973.
- Redeker AG, Yamahiro HS: Controlled trial of exchange transfusion therapy in fulminant hepatitis. *Lancet* 1:3-6, 1973.
- Lepore MJ, McKenna PJ, Martinez DB, Stutman LJ, Bonanno CA, Conklin EF, Robilotti JG: Fulminant hepatitis with coma successfully treated by plasmapheresis and hyperimmune Australia-antibody-rich plasma. *Am J Gastroenterol* 58:381-389, 1972.
- Lepore MJ, Stutman LJ, Bonanno CA, Conklin EF, Robilotti JG, McKenna PJ: Plasmapheresis with plasma exchange in hepatic coma. *Arch Intern Med* 120:900-907, 1972.
- Reynolds JDH, Wilber RD: Treatment of hepatic coma. *J Kans Med Soc* 72:54-57, 1971.
- Rivera RA: Current status of exchange transfusion in fulminant hepatitis. *Med AM District of Columbia* 41:277-280, 1972.
- Abouna GM, Amemiya H, Fisher LMcA, Still WJ, Porter KA, Costa G, Hume DM: Hepatic support therapy by intermittent liver perfusion and exchange blood transfusions. *Transplant Proc* 3:1589-1596, 1971.
- Graw RG Jr, Buckner CD, Eisel R: Plasma exchange transfusion for hepatic coma: New technique. *Transfusion* 10:26-32, 1970.
- Lepore MJ, Martel AJ: Plasmapheresis with plasma exchange in hepatic coma: Methods and results in five patients with acute hepatic necrosis. *Ann Intern Med* 72:165-174, 1970.
- Rivera RA, Seaighter RL, Boyce HW: Exchange transfusion in the treatment of patients with acute hepatitis in coma. *Dig Dis* 15:589-601, 1970.
- Davidson CS, McDermott WV Jr, Trey C: Sustaining life during fulminant hepatic failure. *Ann Intern Med* 71:415-416, 1969.
- Demeulenaere L, Barbier F, Vermeire P: Plasmapheresis in hepatic coma. *Lancet* 2:152-153, 1969.
- Reynolds TB: Exchange transfusion in fulminant hepatic failure. *Gastroenterology* 56:170, 1969.
- Cree IC, Berger SA: Plasmapheresis and positive-pressure ventilation in hepatic coma with respiratory arrest. *Lancet* 2:976-977, 1968.
- Exchange transfusion in fulminant hepatitis. *Br Med J* 1:270 (editorial), 1968.
- Lederman RJ, Davis FB, Davis P3: Exchange transfusion as treatment of acute hepatic failure due to antituberculosis drugs. *Ann Intern [Meal* 68:830-838, 1968.
- Sabin S, [Merritt JA: Treatment of hepatic coma in cirrhosis by plasmapheresis and plasma infusion (plasma exchange). *Am Intern [Meal* 68:1-7, 1968.
- Burnell JM, Dawborn 3K, Epstein RB, Butman RA, Leinbach MD, Thomas ED, Volwiler W: Acute hepatic coma treated by cross-circulation or exchange transfusion. *N Engl J Med* 276:935-943, 1967.

Gelfand ML, Sussman L, Caimol BC, Florita C, Joson F: Successful treatment of hepatic coma by exchange transfusions. *JAMA* 201:630-633, 1967.

Jones EA, Clain D, Clink HM, et al: Hepatic coma due to acute hepatic necrosis treated by exchange blood transfusion. *Lancet* 2:169-172, 1967.

Lepore MJ, Martel AJ: Plasmapheresis in hepatic coma. *Lancet* 2:771-772, 1967.

Krebs R, Flynn M: Treatment of hepatic coma with exchange transfusion and peritoneal dialysis. *JAMA* 199:430, 1967.

Berger RL, Liversage RM Jr, Chalmers TC, Graham JH, McGoldrick DM, Stohlman F Jr: Exchange transfusion in the treatment of fulminating hepatitis. *N Engl J Med* 247:497-499, 1966.

Berger RL, Stohlman F Jr: Evaluation of blood exchange in the treatment of hepatic coma. *Amer J Surg* 112:412-418, 1966.

Eckhardt RD: Exchange transfusions for hepatic coma. *N Engl J Med* 274:1444, 1966.

Grey C, Burns DG, Saunders SJ: Treatment of hepatic coma by exchange blood transfusion. *N Engl J Med* 274:473-481, 1966.

Trey C, Burns DG, Saunders SJ: Treatment of hepatic coma by exchange blood transfusions. *N Engl J Med* 274:473-481, 1966.

Lee C, Tink A: Exchange transfusion in hepatic coma: Report of a case. *Med* 3 Aust 1:40-42, 1958.

B. Miscellaneous

Hughes RD, Williams R: Removal of protein-bound metabolites in fulminant hepatic failure. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 113-119.

Landini S, Coli U, Lucatello S, Bazzato G: Acute renal failure associated with liver impairment treated by plasma-exchange. Proceedings of Symposium on Acute Renal Failure. Tel Aviv, 1981, in press.

Lauterburg BH, Taswell HF, Pineda AA, Dickson ER, Bergstaler EA, Carlson GL: Charcoal affinity column plasma perfusion for the treatment of intractable pruritus of cholestasis. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytopheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 269-276.

Levy VG, et al: Treatment of cholestasis by plasmapheresis. *Nouv Presse Med* 10:2588, 1981.

Lösgen H, Brunner G, Schmidt FW: Removal of toxic metabolites by plasma exchange in patients with hepatic failure. In "New Membranes in Medical Treatment." 2nd Tutzing Symposium on Chemical Engineering in Medicine, Munich, 1981.

Asanuma Y, et al: Clinical hepatic support by on-line plasma treatment with multiple absorbents - evaluation of system performance. *Trans Am Soc Artif Intern Organs* 26:400-405, 1980.

Bazzat G, Coli U, Landini S, Lucatello S: Plasma exchange and peritoneal dialysis: Combined treatment in the management of severe leptospirosis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 347-351.

Brunner G, Lösgen H, Schmidt FW: Plasmapheresis treatment for support of the failing liver and other forms of liver disease. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 329-333.

Carey WD, Nosé Y, Ferguson DR, Asanuma Y, Smith 3W, Hermann RE, Malchesky PS: Plasma perfusion in liver disease: Phase 1 study. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F.K. Schattauer Verlag, 1980, pp 335-339.

Eriksson S, Lindgren S: Plasma exchange in primary biliary cirrhosis. *N Engl J Med* 302:809, 1980.

Horiuchi T, Otsubo O, Takahashi I, Yamada Y, Yamauchi 3, Inou T: Study of plasma cross circulation in experimental hepatic failure. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 341-345.

Matloff DS, Kaplan MM: D-penicillin-induced GoodPasture's-like syndrome in primary biliary cirrhosis: Successful treatment with plasmapheresis and immunosuppressives. *Gastroenterology* 78:1046-1049, 1980.

Milich DR, et al: Plasmapheresis of hepatitis B surface antigen carriers. *Acta Haematol Pol* 11:73-78, 1980.

Nosé Y, Malchesky PS, Asanuma Y, Zawicki I: Plasma filtration detoxification on hepatic patients: Its optimal operating conditions. In Gurland HJ, Heinze V, Lee HA (eds): "Plasmapheresis." Berlin: Springer Verlag, 1980 (in press).

Okamura 3, Kuroda H, Horikawa S, Shibata N, Monden M, Gotoh M, Sikujara O, Kosaki G, Sakurai M: Experiences on plasma exchange for treatment of intrahepatic cholestasis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag 1980, pp 353-357.

Orlin 3B, Berkman EM, Matloff DS, Kaplan MM: Primary biliary cirrhosis and cold autoimmune hemolytic anemia: Effect of partial plasma exchange. *Gastroenterology* 78:576-578, 1980.

Sheehy TW, Law DE, Wade BH: Exchange transfusion for sickle cell intrahepatic cholestasis. *Arch Intern Med* 140:1364-1366, 1980.

Milich DR, Vyas GN, Holland PV, et al: Preliminary observations on **plasmapheresis** of chronic carriers of hepatitis B surface antigen. *Blood* **54:127a**, 1979.

Pineda AA, Lauterburg BH, Taswell HF, Burgstaler EA, Carlson GA, Dickson ER: Charcoal affinity column plasma **perfusion** for the treatment of intractable pruritus of **cholestasis**. *Transfusion* **19:666**, 1979.

Lauterburg BH, Pineda AA, Dickson ER, Baldas WP, Taswell HF: **Plasmapheresis** for the treatment of intractable pruritus of **cholestasis**. *Mayo Clin Proc* **53:403-407**, 1978.

Horisawa M, et al: Exchange transfusion in **hepatorenal** syndrome with liver disease. *Arch Intern Med* **136:1135**, 1976.

Silva YJ, Parameswaran PG, James P: Exchange **transfusion** and major surgery in acute **hepatic** failure. *Surgery* **80:343-349**, 1976.

Buckner CD, Clift RA, Volwiler W, et al: **Plasma exchange** in patients with **fulminant hepatic** failure. *Arch Intern Med* **132:487-492**, 1973.

Redeker AG, Yamahiro HS: Controlled trial of exchange-transfusion **therapy** in **fulminant** hepatitis. *Lancet* **1:3-6**, 1973.

Turnberg LA, Mahoney MP, Gleeson MH, Freeman CB, Gowenlock AH: **Plasmapheresis** and plasma exchange in the treatment of **hyperlipaemia** and **xanthomatous neuropathy** in patients with primary **biliary** cirrhosis. *Gut* **13:976-981**, 1972.

Marin GA, Montoya CA, Sierra JL, et al: Evaluation of **corticosteroid** and exchange-transfusion treatment of acute yellow-phosphorus **intoxication**. *N Engl J Med* **284:125-128**, 1971.

Therapeutic **Pheresis** Bibliography No. VIII: **Hemolytic** Disease of the Newborn

Fraser ID, Bennett MO, Bothamley JE: **Antenatal** plasma **exchange** in the management of mothers with Rh antibodies. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 224-226.

Graham-Pole J, Willoughby M: Plasma exchange for severe rhesus (Rh) disease. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 203-215.

Hauth JC, Brekken AL, Pollack W: **Plasmapheresis** as an adjunct to management of Rh isoimmunization. *Obstet Gynecol* **57:132-135**, 1981.

Robinson EAE: Unsuccessful use of absorbed **autologous** plasma in Rh-incompatible pregnancy. *N Engl J Med* **305:1346**, 1981.

Rock G: Plasma exchange in Rh disease: Past, present and future. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Rock GA: Plasma exchange in the treatment of rhesus **hemolytic** disease. *Plasma Ther* **2:211-225**, 1981.

Rock G, Lafreniere I, Chan L, McCombie N: Plasma exchange in the treatment of **hemolytic** disease of the newborn. *Transfusion* **21:546-551**, 1981.

Schwerdtfeger R, Malchus R, Hoffbauer H: **Plasmapheresis** and intrauterine transfusions in Rh incompatible pregnancies. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 227-228.

Angela E, et al: Intensive plasma **exchange** in the management of severe Rh disease. *Br J Haematol* **45:621-631**, 1980.

Barclay GR, Greiss MA, Urbaniak SJ: Adverse effect of plasma exchange on anti-D production in rhesus immunisation owing to removal of inhibitory factors. *Br Med J* **1:1569-1571**, 1980.

Harbord MG, et al: **Antenatal** plasma exchange therapy. *Med J Aust* **1:647-648**, 1980.

Robinson EAE, Tovey LAD: Intensive plasma exchange in the management of severe Rh disease. *Br J Haematol* **45:621-631**, 1980.

Teixeira DM, Abrash MP, Smith CL, Sheets JL, Kateley JR, Maldonado WE: Treatment of severe rhesus disease by intensive **plasmapheresis**: A case report and review of the literature. *Plasma Ther* **1:39-49**, 1980.

Urbaniak SJ, Barclay GR, Greiss MA: Adverse **effect** of plasma exchange on maternal anti-D levels in HDN due to the removal of plasma **inhibitory** factors.

Joint Meeting 18th Congress International Society of Hematology and 16th Congress International Society of Blood Transfusion, August 1980, Montreal, Canada (Abstract 1413).

Asanuma Y, Smith JW, Malchesky PS, Hermann RE, Carey WD, Ferguson DR, Nose Y: **Preclinical** evaluation of membrane **plasmapheresis** with on-line bilirubin removal. *Artif Organs* **3:279**, 1979.

James V, Weston J, Scott IV, et al: Intensive **plasma** exchange in rhesus **isoimmunization**. *Vox Sang* **37:290-295**, 1979.

Sussmann LN, Barias M, Colli W: Intensive **plasmapheresis** during pregnancy and spurious amniotic **fluid bilirubin**. *Am J Obstet Gynecol* **135:156-157**, 1979.

Timoshenko LI, Timoshenko LV, Minchenko ZhN, Vovchenko VP: Use of **plasmapheresis** for reduction of iso sensitization level in **Rh-incompatible** pregnancy. *Vopr Okhr Materin Det* **24:61-64**, 1979.

Weston JV, Scott IV, Doughty R, Tomlinson J, Whitfield M: Intensive plasma exchange in Rhesus **isoimmunization**. *Vox Sang* **37:290**, 1979.

Woyton J, Baranowski H, Kwoczyńska K, Partyka T, Dzierżkowska W: Results of treatment of Rh blood group incompatibility with **plasmapheresis**. *Ginekol Pol Suppl*:**62-64**, 1979.

Fraser ID, Bothamley JE, Bennet MO: **Alteration** of amniotic fluid pigment values and anti-D levels during **plasmapheresis** in severe rhesus **haemolytic** disease. *Br J Haematol* **39:173**, 1978.

Herve P, Coffe C, Lapprand L, Peters A, Selva J, Gillet JY: Severe anti-D all-immunization Failure of repeated **antenatal plasmapheresis** (a case report). *Nouv Presse Med* **7:1956-1957**, 1978.

McBride JA, O'Hoski P, Blajchman MA, et al: Rhesus alloimmunization following intensive plasmapheresis. *Transfusion* **18:626-627**, 1978.

Pepperell RT, Cooper IA: Intensive **antenatal plasmapheresis** in severe rhesus **isoimmunization**. *Aust NZ J Obstet Gynaecol* **18:121**, 1978.

Woyton J, Partyka T, Gajewska E, Kwoczyńska K, et al: The use of **plasmapheresis** in pregnancy with antenatal prediction of a serious **hemolytic** disease due to Rh immunization. *Arch Immunol Ther Exp (Warsz)* **26:1139**, 1978.

Fraser IB, Bennett MO, Bothamley JE, et al: Intensive **antenatal plasmapheresis** in severe rhesus isoimmunisation. *Lancet* **1:6**, 1977.

Graham-Pole J, Barr W, Willoughby MLN: Continuous-flow **plasmapheresis** in management of severe rhesus disease. *Br Med J* **1:1185-1188**, 1977.

Iglesias J: **Plasmapheresis** in series in pregnant women severely sensitized to Rh factor. *Rev Chil Obstet Ginecol* **42:1-12**, 1977.

Isbister SP, Ling A, Seeto KM: Development of **Rh-specific maternal auto-antibodies** following intensive **plasmapheresis** for Rh immunization during pregnancy. *Vox Sang* **33:353-358**, 1977.

McGuinness EPJ, Reen DJ: Plasma exchange in severe rhesus disease. *Br Med J* **1:1269**, 1977.

Tilz GP, Weiss PA, Teubl I, Lanzer G, Vollmann H: Successful plasma exchange in rhesus incompatibility. *Lancet* **2:203**, 1977.

Bowman JM: Intensive **antenatal plasmapheresis** in severe rhesus **iso-immunisation**. *Lancet* **1:421-422**, 1976.

Fraser ID, Bothamley JE, Bennett MO, Airth GR: Intensive **antenatal plasmapheresis** in severe rhesus isoimmunisation. *Lancet* **1:6-8**, 1976.

Walker W: Management of Rh **isoimmunisation**. *Lancet* **1:256-257**, 1976.

Graham-Pole JR: **Proceedings: Plasmapheresis** in rhesus disease. *Scott Med J* **20:168-169**, 1975.

Graham-Pole JR, Barr W, Willoughby MLN: Continuous-flow **exchange-plasmapheresis** in severe rhesus isoimmunisation. *Lancet* **1:1051**, 1974.

Graham-Pole JR, Donald I, Barr W, Willoughby MLN: **Plasmapheresis** in rhesus **iso-immunisation**. *Lancet* **2:1459**, 1974.

Pole JR, Barr W, Willoughby ML: Continuous-flow **exchange-plasmapheresis** in severe rhesus **isoimmunisation**. *Lancet* **1:1051**, 1974.

Pole JR, Donald I, Barr W, Willoughby ML: **Plasmapheresis** in rhesus **isoimmunisation**. *Lancet* **2:1459**, 1974.

Fias I, Dombi E, Wenhardt E, Horvath I: **Plasmapheresis** in Rh isoimmunisation. *Lancet* **1:1519-1520**, 1973.

Kovacs L, Kesztői TL, Imre G: **Plasmapheresis** in Rh isoimmunisation. *Lancet* **1:1253**, 1973.

Vasileva ZF, Kuznechikova VV, Anichkova S1, Laevskaia SA, Susloparov LA: Plasmapheresis as a method of lowering the degree of **Rh-sensitivity** in pregnant women. *Akush Ginekol* **49:62-64**, 1973.

Crespo Cortina M, Arroyo A, Olivares Tinajero G, Manuel Septien J: Use of **plasmapheresis** to control **anti-Rh** antibodies in **isoimmunized** mothers. *Ginecol Obstet Mex* **31:485-490**, 1972.

Maynier M, Cregut R, Maignet P, Poulain M: Development of **anti-Rh** antibody titers after labor of **immunized** women. Application to the immune plasma sample by **plasmapheresis**. *J Gynecol Obstet Biol Reprod (Paris)* **1:205-207**, 1972.

Nublat M, Melis C, Boissieu G, Gaujoux J, Serment H: Repeated **plasmapheresis** in severe rhesus **isoimmunization**. *J Gynecol Obstet Biol Reprod (Paris)* **5: Suppl 2, 205-207**, 1972.

Clarke CA, Elson CJ, Bradley J, Donohoe WTA, Lehane D, Hughes-Jones NC: Intensive **plasmapheresis** as a therapeutic measure in **rhesus-immunised** women. *Lancet* 1:793-798, 1970.

Ivanov LV, Shuvaeva BA: Effect of **plasmapheresis** on rhesus-antibody titer. *Probl Gematol Pereliv Krovi* 15:61-62, 1970.

Bowman JM, Peddle LJ, Anderson C: **Plasmapheresis** in severe Rh iso-immunization. *Vox Sang* 15:272-277, 1968.

Powell LC Jr: Intensive **plasmapheresis** in the pregnant Rh-sensitized woman. *Am J Obstet Gynecol* 101:153-170, 1968.

Bansal SC, Bansal BR, Sjogren HO, Husberg B, Lindstrom C, Nylander G, Mark R: Use of biological immunoabsorbents in the treatment of tumor host. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 281-299.

Edelson RL, Berger CL, Armstrong RB: **Lymphapheresis** in the treatment of the leukemic phase of cutaneous T-cell **lymphoma** and pemphigus **vulgaris**. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 55-66.

Graf 3, Carpenter N, Medenica R, Miescher PA: **Plasmapheresis** in cancer patients. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 229-232.

Harada T, et al: Regional arterial infusion of an anticancer drug combined with direct **hemoperfusion**. *Tohoku J Exp Med* 133:423-429, 1981.

Hellström KE, Hellström I: Does perfusion with treated plasma cure cancer? *N Engl J Med* 308:1215-1216, 1981.

Israël L, Edelstein R, Samak R: Repeated plasma exchange in patients with **metastatic** cancer. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 238-243.

Israël L, Edelstein R, Samak R, et al: Clinical results of multiple **plasmaphereses** in patients with advanced cancer. In Rosenfeld and Serrou (eds): *Human Cancer Immunology*, vol. 2, North-Holland (in press).

Smit Sibinga CT: **Haematological supportive** therapy for cancer-chemotherapy, and therapeutic **plasmapheresis** in a **community** blood bank by a **cell** separator unit. In "Third Annual Symposium on **Apheresis**: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Terman DS: ExtraCorporeal **immunoabsorbents** for therapy of **autoimmune** and **neoplastic** disease. In Nemo GJ, Taswell F (eds): Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 301-328.

Terman DS, Young JB, Shearer WT, Ayus C, Lehane D, et al: Preliminary observations of the effects on breast **adenocarcinoma** of plasma perfused over immobilized protein A. *N Engl J Med* 305:1195-1200, 1981.

Beyer JH, et al: First clinical experience with large volume plasma exchange in **malignant tumor** patients. *Schweiz Med Wochenschr* 110:1147-1149, 1980 (English abstract).

Beyer 3-H, Klee M, Bartsch HH, Borghardt 3, et al: First experiences with **plasmapheresis** in patients with **neoplastic** diseases. German Cancer Congress, Munich, March 1980.

Israël L, Edelstein R, Mannoni P, et al: **Plasmapheresis** in patients with **disseminated** cancer. *Plasma Ther* 1:57-68, 1980.

Israël L, Sarnak R, Edelstein R: Multiple plasma exchange therapy for metastatic cancer. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasma-separation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 381-385.

Iwamoto H, Nakagawa S, Matsui N, Yoshiyama N, Shinoda T, Shibamoto T, Takeucki J: An experience of plasma exchange by membrane separator for **IgA myeloma**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasma-separation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 377-380.

Samak R, Israël L, Edelstein R: Influence of tumor burden, tumor removal, immune stimulation, **plasmapheresis** on monocyte mobilization in cancer patients. In Escobar R, et al (eds): "Macrophages and Lymphocytes," part B. New York: Plenum publishing Co., 1980, pp 411-423.

Shaw D, Trotter 3M, Colman KC: Plasma exchange to control sweats and pruritus in malignant disease. *Br Med* 3 281:1459, 1980.

Zander AR, et al: **Plasmapheresis** as immunotherapeutic modality in the treatment of the canine venereal tumor. *Exp Hematol* 8:1123-1128, 1980.

Israël L, Edelstein R: In vivo and in vitro studies on non-specific blocking factors of host origin in cancer patients: Role of plasma exchange as an immunotherapeutic modality. *Isr J Med Sci* 14:105-130, 1978.

Israël L, Edelstein R, McDonald 3, Weiss 3, Schein P: Immunological and plasma protein changes in cancer patients following a single **plasmapheresis**. *Biomedicine* 28:292-297, 1978.

Zhukov 01, Pleshakov VT, Singaevskii SB: Hemodynamics in double **plasmapheresis** in lung cancer. *Vestn Khir* 121:96-99, 1978.

Edelson RL: Efficacy of **leukapheresis** procedures in the management of cutaneous T-cell **lymphoma-leukemic** phase. Proceedings of the 4th Advanced Blood Components Seminar 4:1-7, 1977.

Hobbs JR, Byrom N, Elliott P, et al: Cell separators in cancer immunotherapy. *Exp Haematol* 5:Suppl 95-103, 1977.

Israël L, Edelstein R, Mannoni P, Radot E, Greenspan EM: **Plasmapheresis** in patients with disseminated cancer: Clinical results and correlation with change in serum proteins. *Cancer* 40:3146-3154, 1977.

Browne O, Bell 3, Holland PDJ, Thorne PD: **Plasmapheresis** and immunostimulation. *Lancet* 2:96, 1976.

Hersey P, Isbister 3, Edwards A, Murray E, Adams E, Briggs J, Milton GW: Antibody-dependent cell-mediated **cytotoxicity** against melanoma cells induced by **plasmapheresis**. *Lancet* 1:825-828, 1976.

Israël L, Edelstein R, Mannoni P, Radot E: **Plasmapheresis** and immunological control of cancer. *Lancet* 2:642-643, 1976.

Israël L, Mannoni P, Radot E, Greenspan E: Immune and tumor reactions to plasma exchange in advanced cancers. *Nouv Presse Med* 5:433, 1976.

Laroye GJ: On the potential usefulness of exchange **plasmapheresis** in the immunotherapy of cancer and of some chronic persistent infections. *Med Hypotheses* 2:214-218, 1976.

Whitehead RH, Teasdale C, Hughes LE: **Plasmapheresis** and immunological control of cancer. *Lancet* 2:748, 1976.

Buckner CC, Clift RA, Thomas ED: Plasma exchange with the continuous flow centrifuge. In Goldman 3M, Lowenthal RM (ed): "Leukocytes: Separation Collection and Transfusion." London: Academic Press, 1975, pp 578-580.

Langved E, Hyden H, Wolf H, Kroeigaard N: **Extracorporeal immunoabsorption** of circulating specific serum factors in cancer patients. *Br J Cancer* 32:680-692, 1975.

Waldman SR, Roth 3A, Kern DH, Pilch YH: Effects on cancer patients of **leukapheresis** with the continuous-flow blood cell separator. II. Immunologic parameters in vitro. *J Lab Clin Med* 86:950-961, 1975.

Waldman SR, Roth 3A, Silverstein M, Veltman LL, Pilch yH: **Effects on cancer** patients of leukapheresis with the continuous-flow blood cell separator. I. Hematologic and immunologic parameters in vivo. *J Lab Clin* 86:938-949, 1975.

A. Pemphigus Vulgaris

Edelson RL, Berger CL, Armstrong RB: **Lymphapheresis** in the treatment of the leukemic phase of cutaneous T-cell lymphoma and pemphigus vulgaris. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytopheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 55-66.

Velte H, W Rabetz-Wolke A, Eckert G, Marghescu S, Deicher H, Stangel W, Peter H, Schedel I: Plasma exchange in the treatment of pemphigus vulgaris. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 210-214.

Swanson DL, et al: Pemphigus vulgaris and plasma exchange: Clinical and serologic studies. *J Am Acad Dermatol* 4:325-328, 1981.

Neppert J, Meissner K, Voigt H, Meigel W: Trials with therapeutic plasmapheresis in pemphigus vulgaris. *Z Hautkr* 55:783-789, 1980.

Roujeau JC, Revuz J, Fabre M, Andre C, Akerman C, Mannoni P, Touraine R: Plasma exchanges in pemphigus vulgaris. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 315-319.

Auerbach R, Bystryn JC: Plasmapheresis and immunosuppressive therapy. Effect on levels of intercellular antibodies in pemphigus vulgaris. *Arch Dermatol* 115:728-730, 1979.

Meurer M, Braun-Falco O: Plasma exchange in the treatment of pemphigus vulgaris. *Br J Dermatol* 100:231-232, 1979.

Cotterill JA, Barker DJ, Millard LG: Plasma exchange in the treatment of pemphigus vulgaris. *Br J Dermatol* 98:243, 1978.

Ruocco V, Rossi A, Argenziano G, Aatarita C, Alviggi L, Farzati B, Papaleo G: Pathogenicity of the intercellular antibodies of pemphigus and their periodic removal from the circulation by plasmapheresis. *Br J Dermatol* 98:237-241, 1978.

B. Erythrocyte Autosensitization

Hamblin TJ, Hart S, Mufti GJ: Plasmapheresis and a placebo procedure in autoerythrocyte sensitization. *Br Med J* 283:1575-1576, 1981.

Lockwood CM, Pearson T: Use of plasma exchange in treatment of allergic disease. Proceeding of Advanced Component Seminar. Haemonetics Research Institute, Wayland, MA, 1977.

C. Miscellaneous

Anderson L, Ziter FA: Plasmapheresis via central catheter in dermatomyositis: A new method for selected pediatric patients. *3 Pediatr* 98:240, 1981.

Bennington JL, et al: Patients with polymyositis and dermatomyositis who undergo plasmapheresis therapy. Pathologic findings. *Arch Neurol* 38:553-560, 1981.

Maeda K, Shinzato T, Usuda M, Sezaki R, et al: Psoriasis treatment with hemofiltration and plasma exchange. In "New Membranes in Medical Treatment." 2nd Tutzing Symposium on Chemical Engineering in Medicine, Munich, 1981.

Brewer EJ Jr, Giannini EH, Rossen ED, et al: Plasma exchange therapy of a childhood onset dermatomyositis patient. *Arthritis Rheum* 23:509-513, 1980.

Moser HW, Braine H, Pyeritz RE, Unman D, Murray C, Asbury AK: Therapeutic trial of plasmapheresis in Refsum disease and in Fabry disease. *Birth Defects* 16:491-497, 1980.

Neumann E, Skalisz H, Bowszyc Z: Plasmapheresis in the treatment of bullous skin diseases. *Przegl Dermatol* 67:487-492, 1980.

Pyeritz RE, Ullman MD, Moser AB, Braine HG, Moser HW: Plasma exchange removes glycosphingolipid in Fabry disease. *Am J Med Genet* 7:301-307, 1980.

Young DW, Thompson RA, Mackie PH: Plasmapheresis in hereditary angioneurotic edema and systemic lupus erythematosus. *Arch Intern Med* 140:127-128, 1980.

Biaszyk M, Chorzeliski T, Daszynski J, Klenowska Z, Beutner EH, Jablonska S: Plasmapheresis in the treatment of bullous skin diseases. *Przegl Dermatol* 66:399-404, 1979.

Dandona P, Marshall NJ, Bidey SP, et al: Successful treatment of exophthalmos and pretibial myxoedema with plasmapheresis. *Br Med J* 1:374-376, 1979.

Dav PS: Resolution of psoriasis during plasmapheresis. *Arch Dermatol* 115:1171, 1979.

Howert DA, Kater L, de la Faille HB: Some applications of plasmapheresis notably in a patient with necrotizing ulcers. *Br J Dermatol* 101:233-234, 1979.

Lewis RA, Slater N, Croft DN: Exophthalmos and pretibial myxoedema not responding to plasmapheresis. *Br Med J* 1:390-391, 1979.

Therapeutic Pheresis Bibliography No. X1: Lipid Disorders (Hyperlipidemia)

- Barr S1, et al: Plasma lipid and apoprotein levels following **plasmapheresis** in a subject **homozygous** for familial **hypercholesterolemia**. *Experientia* **37**:114-115, 1981.
- Borberg H, Greve V, Sawatski C, Oette K, Stoffel W**: Specific continuous flow immunoabsorption ex vivo in patients with familial **hypercholesterinaemia**. In "New Membranes in Medical Treatment." 2nd Tutzing Symposium on Chemical Engineering in Medicine, Munich, 1981.
- Kottke BA, Burgstaler EA, Taswell HF, Ellefson RD, Witte LD, Pineda AA**: Hypercholesterolemia treatment by **heparin-agarose** affinity column. In **Nemo GJ, Taswell H (eds)**: "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 341-346.
- Schriewer H, **Assman G**: Aspects of familial **hypercholesterolemia** with regard to plasma exchange. In **Borberg H, Reuther P (eds)**: "Plasma Exchange Therapy." Stuttgart: **Georg Thieme Verlag**, 1981, pp 104-109.
- Stein EA, et al: Repetitive intermittent flow plasma exchange in patients with severe **hypercholesterolemia**. *Atherosclerosis* **38**:149-164, 1981.
- Stoffel W, Borberg H, Greve V**: Application of specific extracorporeal removal of low density lipoprotein in familial **hypercholesterolaemia**. *Lancet* **2**:1005-1007, 1981.
- Thompson GR: Long-term plasma exchange in severe familial **hypercholesterolemia**. In **Nemo GJ, Taswell H (eds)**: "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 235-246.
- Thompson GR: Plasma exchange for **hypercholesterolaemia**. *Lancet* **1**:1246-1248, 1981.
- Graisely B, Cloaree M, Salmon S, Polonovski S, et al**: Extracorporeal plasma therapy for **homozygous** familial **hypercholesterolaemia**. *Lancet* **2**:1147, 1980.
- King ME, Breslow G, Lees RS**: Plasma-exchange therapy of **homozygous** familial **hypercholesterolemia**. *N Engl J Med* **302**:1457-1459, 1980.
- Stoffel W, Demant Th, Sieberth HG, Borberg H, Glöckner WM**: Selective removal of Apo B containing serum lipoproteins from blood plasma. In **Sieberth HG (ed)**: "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 127-132.
- Thompson GR: Plasma exchange for **hypercholesterolemia**: A therapeutic mode and investigative tool. *Plasma Ther* **1**:5-15, 1980.
- Thompson GR, **Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE**: Assessment of long-term plasma exchange for familial **hypercholesterolaemia**. *Br Heart J* **43**:668-680, 1980.
- Witztum IL, Williams JC, Ostlund R, Sherman L, Siccardi G, Schonfeld G**: Successful **plasmapheresis** in a 4-year-old child with **homozygous** familial **hypercholesterolemia**. *J Pediatr* **97**:615-618, 1980.
- Soutar AK, Myant MB, Thompson GR**: Metabolism of **apolipoprotein-B-containing lipoproteins** in familial **hypercholesterolaemia**. Effects of plasma exchange. *Atherosclerosis* **32**:315-325, 1979.
- Apstein CS, **Zilvermit DB, Lees RS, George PK**: Effect of intensive **plasmapheresis** on the plasma cholesterol concentration with familial **hypercholesterolemia**. *Atherosclerosis* **31**:105-115, 1978.
- Berger GMB, Miller JL, Bonnici F, Jaffe HS, Dubovsky DW**: Continuous flow plasma exchange in the treatment of **homozygous** familial **hypercholesterolemia**. *Am J Med* **65**:243-251, 1978.
- Berger GMB, Miller JL, Bonnici F, Jaffe HS, Dubovsky DW**: Plasma exchange in the treatment of **homozygous** familial **hypercholesterolaemia**: Criteria for patient selection. *S Afr Med J* **53**:194, 1978.
- Betteridge DJ, Bakowski M, Taylor KG, Reckless JPD, de Silva SR, Galton DJ**: Treatment of severe **dialytic hypertriglyceridaemia** by plasma exchange. *Lancet* **1**:1368, 1978.
- Simons LA, Gibson JC, Isbister SP, Biggs JC**: The effects of plasma exchange on cholesterol metabolism. *Atherosclerosis* **31**:195-204, 1978.
- Thompson GR, **Kilpatrick D, Oakley C, Steiner R, Myant N**: Reversal of cholesterol accumulation in familial **hypercholesterolemia** by long-term plasma exchange. *Circulation Suppl* **2**:171, 1978.
- Thompson GR, **Kilpatrick D, Raphael M, Oakley C, Myant NB**: Use of plasma exchange to induce regression of atheroma in familial **hypercholesterolaemia**. *Eur J Clin Invest* **7**:233, 1977.
- Berger GMB, Miller JL, Bonnici F, Jaffe HS, Dubovsky DW**: Continuous flow plasma exchange in treatment of **homozygous** familial **hypercholesterolemia**. *Am J Med* **65**:243-251, 1976.
- Lupien PJ, Moorjari S, Arrad J**: A new approach to the management of familial **hypercholesterolaemia**. *Lancet* **1**:1261-1263, 1976.
- Thompson GR, **Myant NB**: Low density lipoprotein turnover in familial **hypercholesterolaemia** after plasma exchange. *Atherosclerosis* **23**:371-377, 1976.

Thompson GR, Lowenthal R, Myant NB: Plasma exchange in the management of homozygous familial hypercholesterolaemia. *Lancet* 1:1208-1211, 1975.

Apstein CS, George PK, Zilversmit DB, Feldman HA, Lees RS: Cholesterol reduction with intensive plasmapheresis. *Clin Res* 22:459A, 1974.

Pittermann E, Höcker P, Lechner K, Stacher A: Plasmaphereses with the continuous flow blood cell separator in the treatment of macroglobulinaemia, multiple myeloma, hemophilia and hyperlipidaemia. In Goldman JM, Lowenthal RM (eds): "Leucocytes: Separation Collection and Transfusion." London: Academic Press, 1974, pp 561-567.

Turnberg LA, Mahoney MP, Gleeson MH, Freeman CB, Gowenlock AH: Plasmapheresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. *Gut* 13:976-981, 1972.

Gennes JL de, Touraine R, Maunand B, Truffert J, Laudat P: Homozygous cutaneous forms of hypercholesteremic xanthomatosis in an exemplary familial case. Trial of plasmapheresis and heroic treatment. *Bull Mem Soc Med Hop (Paris)* 118:1377-1402, 1977.

A. Immunodeficiency

Branda RF, McCullough JJ: Plasmapheresis in the treatment of immune disease. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 125-133.

Wegmüller E: The therapeutic significance of plasmapheresis in immunologic disease. *Schweiz Med Wochenscher* 111:443-449, 1981.

Calabrese LH, Clough JD, Krakauer RS, Hoeltge GA: Plasmapheresis therapy of immunologic disease. Report of nine cases and review of the literature. *Cleve Clin Q* 47:53-72, 1980.

Samtleben W, et al: Membrane plasma separation for treatment of immunologically mediated diseases. *Trans Am Soc Artif Intern Organs* 26:12-16, 1980.

Birdsall HH, Brewer EJ, Rossen RD, Moake JL: Clinical improvement associated with hypocomplementemia following plasmapheresis. In Dau PC (ed): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979, pp 191-198.

Glassman AB: Immune responses: The rationale for plasmapheresis. *Plasma Ther* 1:13-18, 1979.

Lockwood CM, Worledge S, Nicholas A, Cotton LC, Peters DK: Reversal of impaired splenic function by plasma exchange. *N Engl J Med* 300:524-530, 1979.

Pinching AJ: Recent advances in immunological therapy: Plasm-exchange and immunosuppression. *Br J Anaesth* 51:21-28, 1979.

Winkelstein A, Volkin RL, Starz TW, et al: The effects of plasma exchange on immunologic factors. *Clin Res* 27:691A, 1979.

Gilcher RO: Plasma exchange in immune and autoimmune diseases. Haemonetics Research Institute, 1978.

Isbister SP, Biggs JC, Penny R: Experience with large volume plasmapheresis in malignant paraproteinaemia and immune disorders. *Aust NZ J Med* 8:154-164, 1978.

Keller AJ, Urbaniak SJ: Intensive plasma exchange on the cell separator: Effects on serum immunoglobulins and complement components. *Br J Haematol* 38:531-540, 1978.

Lockwood CM, Rees AJ, Pinching AJ, Pussell B, Sweeny P, Uff J, Peters DK: Plasma exchange and immunosuppression in the treatment of fulminating immune complex crescentic nephritis. *Lancet* 1:63-67, 1977.

Rossen RD, Hersh EM, Sharp JT, et al: Effect of plasma exchange on circulating immune complexes and antibody formation in patients treated with cyclophosphamide and prednisone. *Am J Med* 63:674-682, 1977.

Browne O, Bell J, Holland PDJ, Themes RD: Plasmapheresis and immunostimulation. *Lancet* 2:96, 1976.

Plasmapheresis and immunosuppression. *Lancet* 1:1113-1114, 1976.

Brands RF, Moldow CF, McCullough JJ, Jacob HS: Plasma exchange in the treatment of immune disease. *Transfusion* 15:570-576, 1975.

Friedman BA, Schork MA, Mocaia JL, et al: Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. *Transfusion* 15:467-472, 1975.

Branda R, Moldow C, McCullough J, Jacob H: Plasma exchange in the treatment of immune disease. *Clin Res* 21:831, 1973.

Bystryn JC, et al: Regulation of antibody formation by serum antibody. II. Removal of specific antibody by means of exchange transfusion. *J Exp Med* 132:1279, 1970.

Bach J-F: The immunological treatment of autoimmune and immune complex diseases: An overview. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 17-19.

B. Immune Complex Diseases

Clough JD, Calabrese LH: Theoretical aspects of immune complex removal by plasmapheresis. *Plasma Ther* 2:73-81, 1981.

Mód A, et al: Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. *Haematologia (Budap)* 14:49-56, 1981.

Pussell BA, Lockwood CM, Bartolotti SR, Peters DK: Plasma exchange in immune complex disease and GoodPasture's syndrome. In Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytophoresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 147-160.

Valbonesi M, Garelli S, Mosconi L, Montani F, Camerone G: Plasma exchange and combined immunosuppressive therapy in management of severe renal damage due to immune complex disease. *Plasma Ther* 2:139-142, 1981.

Bach J-F: The immunological treatment of autoimmune and immune complex diseases: An overview. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 17-19.

Calabrese LH, Sauder DN, Verbic MA, et al: Plasma exchange in immune complex mediated disease. *Clin Res* 28:138A, 1980.

Clough JD, Calabrese LH, Verbic MA, Mansfield LR, Frank SA, Getzy D: Effect of plasmapheresis on circulating immune complex (IC) levels in patients with IC diseases. *Fed Proc* 39:681, 1980.

Lustenberger N, Neumann KH, Müller H-3, Ehrlich HH, Stolte H: In vitro characterization of plasma exchange membrane and in vivo application in rat immune complex glomerulopathy. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 225-230.

Mód A, Füst G, Harsányi V, Natonek K, Paos A, Szabo Z, Hollan SR: Plasmapheresis in patients with leukaemia, multiple myeloma and immune complex diseases. *Acta Haematol Pol* 11:165-171, 1980.

Simon TL, Goldman R, Tung TSK: Relationship between circulating immune complexes and plasmapheresis. *Transfusion* 19:667, 1979.

Gilcher RO: Plasma exchange in immune and autoimmune diseases. Haemonetics Research Institute, 1978.

Immune complexes in health and disease. *Lancet* 1:580 (editorial), 1977.

Hamblin TJ: Proceedings: The therapeutic use of plasmapheresis in an immune complex disease. *J Clin Pathol* 29:83, 1976.

AMERICAN RED CROSS BLOOD SERVICES

Therapeutic Pheresis Bibliography No. XIII: Miscellaneous Diseases

ARC Blood Services
Bibliography
TPB XIII-2

A. Thyroid Storm

Brehm G: Plasma exchange in **thyreotoxicosis**. In **Borberg H, Reuther P (eds):** "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 121-125.

Haire W, Newcomer J, Hartman C: **Plasmapheresis** in the management thyroid storm. *Plasma Ther* 2:3-5, 1981.

Dandona P, Nathan AW, Marshall NJ, Bidey S, Havard CWH: **Plasmapheresis as treatment for acute fulminant endocrine exophthalmos.** In **Sieberth HG (ed):** "Plasma Exchange. **Plasmapheresis - Plasmaseparation.**" Stuttgart: F. K. Schattauer Verlag, 1980, pp 321.

Siegenbeck van Heukelom LH, der Kinderen PJ, Vingerhods ACM: **Plasmapheresis** in L-thyroxine intoxication. *Plasma Ther* 1:33-37, 1980.

van **Heukelom LHS, der Kinderen PJ, Vingerhods ACM:** **Plasmapheresis** in L-thyroxine intoxication. *Plasma Ther* 1:33-37, 1980.

Herrmann J, Rudorff KH, Gockenjan G, et al: Charcoal **haemoperfusion** in thyroid storm. *Lancet* 1:248, 1977.

Horn K, Brehm G, Habermann J, Pickardt CR, Scriba PC: Successful treatment of thyroid storm by continuous **plasmapheresis** with a blood-cell separator. *Klin Wochenschr* 54:983-986, 1976.

Tsirsch LS, Drews J, Liedtke R, Schemmel K: Treatment of thyroid storm with **plasmapheresis**. *Med Klin* 70:807-811, 1975.

Herrmann J, Hüger P, Rusche HJ, Kruskemper HL: **Plasmapheresis** in the treatment of **thyrotoxic crisis**. *Dtsch Med Wochenschr* 99:888-892, 1974.

Ashkar FS, Katims RB, Smoak WM, Gilson AJ: Thyroid storm: Treatment with blood exchange and **plasmapheresis**. *3AMA* 214:1275-1279, 1970.

B. Pulmonary Edema

Lucian S, Nicolae M: **Plasmapheresis** in acute pulmonary edema. *N Engl J Med* 283:1289-1290, 1970.

C. Hypertension

Kris M, Whit DA: Treatment of **eclampsia** by plasma exchange. *Plasma Ther* 2:143-147, 1981.

d'Apice AJF, et al: Treatment of severe **pre-eclampsia** by plasma exchange. *Aust NZ J Obstet Gynaecol* 20:231-235, 1980.

Whitworth JA, d'Apice AJF, Kincaid-Smith P, Shulkes AA, Skinner SL: Antihypertensive effect of plasma exchange. *Lancet* 1:1205, 1978.

D. Poisoning

Gelfand MC, Winchester JF: **Hemoperfusion** and toxin adsorption in the treatment of poisonings. In **Nemo GJ, Taswell H (eds):** "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and Cytapheresis, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 249-263.

Stevens DC, Kleiman MB, Lietman PS, Schreiner RL: Exchange transfusion in acute **chloramphenicol** toxicity. *J Pediatr* 99:651-653, 1981.

Davison AM, Mascie-Taylor BH, Robinson A, Barnard DL: The use of plasma exchange, transfusion and **haemodialysis** in the management of sodium chlorate intoxication. In **Sieberth HG (ed):** "Plasma Exchange. **Plasmapheresis - Plasmaseparation.**" Stuttgart: F. K. Schattauer Verlag, 1980, pp 373-374.

Arsac Ph, Barret L, Chenais F, Debru JL, Faure J: **Digitoxin** intoxication treated by plasma exchange. In **Sieberth HG (ed):** "Plasma Exchange. **Plasmapheresis - Plasmaseparation.**" Stuttgart: F. K. Schattauer Verlag, 1980, pp 369-371.

Kessler DL, Smith AL, Woodrum DE: **Chloramphenicol** toxicity in a neonate treated with exchange transfusion. *J Pediatr* 96:140, 1980.

Rommes JH, Imhof JW, Kreek P: Successful plasma exchange in **thyrotoxic crisis**. In **Sieberth HG (ed):** "Plasma Exchange. **Plasmapheresis - Plasmaseparation.**" Stuttgart: F. K. Schattauer Verlag, 1980, pp 361-363.

Ariani G, Ciccarelli P, Ghergo GF, Reverberi R: Therapeutic treatment of 3 cases of acute **Amanita phalloides** poisoning. *Minerva Anestesiol* 45:335-344, 1979.

Mastrangelo F, et al: **Hemodialysis** and **hemoperfusion** in the treatment of paraquat or diquat poisoning. *Minerva Hefrol* 26:399-403, 1979 (English abstract).

Berlyne GM: **Plasmapheresis**, aluminum, and dialysis **dementia**. *Lancet* 2:1155-1156, 1978.

Elliott HL, MacDougall AI, Fell GS, Gardiner PHE: **Plasmapheresis**, aluminum, and dialysis **dementia**. *Lancet* 2:1255, 1978.

Dearnley DP, Lindstrom MFR: **Plasmapheresis** for paraquat poisoning. *Lancet* 1:162, 1978.

Elliott HL, MacDougall AI, Fell GS, Gardiner PHE: **Plasmapheresis** in the treatment of dialysis **encephalopathy**. *Lancet* 2:940-941, 1978.

Miller J, Sanders E, Webb D: **Plasmapheresis** for paraquat poisoning. *Lancet* 1:875-876, 1978.

Lembeck F, Beubler E, Lepuschutz HT, Stolze A: **Plasmapheresis** for elimination of toxic substances with marked plasma protein binding properties. *Wien Klin Wochenschr* 89:257-260, 1977.

Luzhnikov EA, Yaroslavsky AA, Molodenkov MN, Shurkalin BK, Enseer NG, Barsukov VF: Plasma perfusion through charcoal in methylparathion poisoning. *Lancet* 1:38-39, 1977.

Mercurial F, Sircchia G: Plasma exchange for mushroom poisoning. *Transfusion* 17:644-646, 1977.

Winchester JF, Gelfand MC, Kneppshield 3H, et al: Dialysis and hemoperfusion of poisons and drugs - update. *Trans Am Soc Artif Intern Organs* 23:762-842, 1977.

Mercurial F, Sircchia G: Plasma exchange for mushroom poisoning. In Proceedings of Advanced Component Seminar, Vol. 4. Haemonetics Research Institute, Wayland, MA, 1976.

Okonek S: **Haemoperfusion** with coated activated charcoal for treating acute poisoning by remedies, plant poisons, and fungi. *Wochenschr Klin Prax* 71:112, 1976.

Lopukhin IM, Kmoarov BD, Luzhnikov EA, Shimanko U, Molodenkov MN: Treatment of acute barbiturate poisoning by the method of hemisorption. *Sov Med* 11:3, 1975.

Vale 3A, Rees AJ, Widdop B, Goulding R: Use of charcoal **haemoperfusion** in the management of severely poisoned patients. *Br Med* 3 1:3, 1975.

Winchester IF, Edwards RO, Tilstone W3, Woodcock BG: Activated charcoal **hemoperfusion** and experimental acetaminophen poisoning. *Toxicol Appl Pharmacol* 31:120, 1975.

E. Asthma

Gartmann 3: **Plasmapheresis** in severe asthma. *Lancet* 1:903-904, 1978.

Gartmann 3, Grob P, Frey M: **Plasmapheresis** in severe asthma. *Lancet* 2:40, 1978.

Muers MF, Dawkins KD: **Plasmapheresis** in severe asthma. *Lancet* 2:260, 1978.

F. Crohn's Disease

Hamblin T, Holdstock G, Fisher A, Loehry C: Plasma exchange in **Crohn's disease**. In Sieberth HG (ed): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 309-313.

Holdstock GE, Fisher 3A, Hamblin TJ, Loehry C: **Plasmapheresis** in **Crohn's disease**. *Digestion* 19:197-201, 1979.

Holdstock G, Fisher A, Loehry C, Hamblin TJ: Trial of **plasmapheresis** in patients with **Crohn's disease**. *Gut* 19:974-975, 1978.

G. Miscellaneous

Simon TL: Therapeutic **plasma** exchange: A request for information. *Plasma Q* 4:8, 1982.

Yarrish RL, Janas 3 S, Nosanchuk JS, Steigbigel RT, Nusbacher J: **Transfusion-acquired falciparum malaria**: Treatment with exchange transfusion following delayed diagnosis. *Arch Intern Med* 142:187-188, 1982.

Blumberg N, Katz AJ: Therapeutic **plasmapheresis** and **cytapheresis**. A review. *Corn Med* 45:85-90, 1981.

Bulova S: **Plasmapheresis** as a therapeutic modality. In "Apheresis: Application, Collection, and Research Procedures Seminar." Bethesda, MD: National Naval Medical Center and Haemonetics Research Institute, December 1981.

Cahill KM, Benach JL, Reich LH, Bilmes E, Zins 3H, Siegel FP, Hochweis S: Red cell exchange: Treatment of **babesiosis** in a **splenectomized** patient. *Transfusion* 21:193-198, 1981.

Créguet R: Theoretical model of **epuration** by plasma exchange. *Rev Fr Transfus Immunohematol* 23:365-371, 1981.

Dau PC: **Plasmapheresis** in idiopathic inflammatory myopathy. Experience with 35 patients. *Arch Neurol* 38:544-552, 1981.

Del Taverio A, et al: Clinical use of **plasmapheresis**. *Clin Ter* 96:93-99, 1981.

Freireich EJ: Future trends in **apheresis**. In Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Liss, 1981, pp 155-162.

Handley SL, Vogel RA: Therapeutic **apheresis**. New York: L.F. Rothschild, Unterberg, Towbin, 1981 (status report).

Hill N: Therapeutic studies on **leukapheresis** and **plasmapheresis**. In Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Liss, 1981, pp 147-154.

Kellogg RM, Hester 3P: Plasma exchange by continuous flow Centrifugation. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 5-10.

Klein H: Clinical **erythrocytapheresis**. In "Apheresis: Application, Collection, and Research procedures Seminar." Bethesda, MD: National Naval Medical Center and Haemonetics Research Institute, December 1981.

Klein HG: Therapeutic **cytapheresis**. In "Third Annual Symposium on Apheresis: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).

Kris M, Whit DA: Treatment of **eclampsia** by plasma exchange. *Plasma Ther* 2:143-147, 1981.

Landini S, Coli U, Lucatello S, Bazzato G: Plasma exchange in severe **leptospirosis**. *Lancet* 2:1119-1120, 1981.

Lundsgaard-Hansen P, Riedwyl H, Deubelbeiss K: Computer simulation of therapeutic plasma exchange. In Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981, pp 53-59.

McGillough J, Chopek M: Therapeutic plasma exchange. *Lab Med* 12:745-753, 1981.

Mielke CH Jr, Mielke MR: Technical and therapeutic applications of plasma exchange. In Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Liss, 1981, pp 123-145.

New blood washing therapy: Catching on big despite lack of controlled studies. *Med World News* 22:47, 1981.

Nusbacher J: Therapeutic **cytapheresis** and **plasma** exchange. In Petz LD, Swisher SM (cd) *The Clinical Practice of Blood Transfusion*. New York: Churchill Livingstone, 1981, pp 719-734.

Perveev V: Direct exchange **blood** transfusions and therapeutic **plasmapheresis** in the overall treatment of severely burned patients. *Vism Khir* 126:124-128, 1981.

Pineda AA, Taswell HF, Moore SB: Therapeutic **plasmapheresis** and **cytapheresis**. In Nemo G3, Taswell H (eds): "Proceedings of the Workshop on Therapeutic **Plasmapheresis** and **Cytapheresis**, April 1979." Washington, DC: U.S. Department of Health and Human Services, 1981, pp 1-23.

Plasmapheresis: Turning old techniques into new therapy. Washington, DC: GWU Medical Center 4:1, 1981.

Rock G: A forum for information: Plasma therapy. *Plasma Ther* 2:51-52, 1981.

Samet JM, Simon TL: Idiopathic pulmonary **fibrosis** treated with plasma exchange. *Plasma Ther* 2:135-137, 1981.

Schmidt PJ: Therapeutic plasma exchange. *Arch Intern Med* 141: 1661-1662, 1981.

Shapiro M: Medical-legal considerations of **apheresis**. In "Apheresis: Application, Collection, and Research Procedures Seminar." Bethesda, MD: National Naval Medical Center and Haemonetics Research Institute, December 1981.

Singsen BH: **Plasmapheresis**: A pediatric perspective. *J Pediatr* 98:232-235, 1981.

Solomon JM: Apheresis and health care: Current policies and long term consequences. In "Apheresis: Application, Collection and Research Procedures Seminar." Bethesda, MD: National Naval Medical Center and Haemonetics Research Institute, December 1981.

Taft EG, Baldwin ST: Plasma exchange transfusion. *Semin Thromb Hemostas* 7:15-21, 1981.

Verrier Jones J: **Plasmapheresis**: Current research and success. *Heart Lung* 9:671-674, 1981.

Wenz B, Barland P: Therapeutic intensive **plasmapheresis**. *Semin Hematol* 18:147-162, 1981.

Wright DG, et al: Lymphocytapheresis. *Prog Clin Biol Res* 58:217-224, 1981.

Wright DG, et al: Lymphocyte depletion and immunosuppression with repeated **leukapheresis** by continuous flow **centrifugation**. *Blood* 48:451-458, 1981.

Wysenbeek AJ, Smith JW, Krakauer RS: **Plasmapheresis** II: Review of clinical experience. *Plasma Ther* 2:61-71, 1981.

Blumberg N, Katz AJ: **Partial** plasma exchange: Diseases in which it is of reported efficacy. In Berkman EM, Umlas J (eds): "Therapeutic **Hemapheresis**." Washington, DC: American Association of Blood Banks, 1980, pp 79-95.

d'Apice AJF, et al: Treatment of severe **pre-eclampsia** by plasma exchange. *Aust NZ J Obstet Gynaecol* 20:231-235, 1980.

Das PC: **Plasma** exchange program for patient in a regional blood transfusion service. In Smit Sibinga CT, Das PC (eds): "Symposium on Donor Management and seminar of **Pheresis** Programmed." Proceedings of 4th Annual Symposium and Seminar on Blood Transfusion. Groningen: Drukkerij H. Schut, 1980, pp 137-146.

Gilcher RO: Therapeutic **plasmapheresis** and plasma exchange. In Sherwood WC, Cohen A (eds): *transfusion Therapy. The Fetus, Infant, and Child.* New York: Masson Publishing USA, Inc., 1980, pp 201-209.

Gratwohl A, et al: Experience with intensive plasma exchange. *Schweiz Med Wochenschr* 110:1449-1451, 1980 (English abstract).

Guidelines for therapeutic **apheresis**. Braintree, MA: Haemonetics Research Institute, 1980.

Hughes GR: Plasma exchange (**plasmapheresis**). *Agents Actions (Suppl)* 7:62-65, 1980.

Hughes GRV, Ryan PFI: Plasma exchange conference report. *AM Rheum Dis* 39:95-96, 1980.

Pinching AJ: Recent advances in immunological therapy: Plasma-exchange and immunosuppression. *Br J Anaesth* 1:21-28, 1980.

Plasma exchange. *Lancet* 2:241-242 (editorial), 1980.

Schmitt E, Falkenhagen D, Preussner S, Tessenow W, Holtz M, Klinkmann H: Plasma separation (PS) and **plasmapheresis** (PP) - a comparative study. In Sieberth HG (cd): "Plasma Exchange. **Plasmapheresis** - **Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 99-103.

ARC Blood Services
Bibliography
TPB XIV-2

ARC Blood Services
Bibliography
TPB XIV-3

Aufevvre 3P, Morin-Hertel F, Cohen-Solal M, Lefloch A, Baudelot 3: Hazards of plasma exchange. A nation-wide study of 3431 exchanges in 592 patients. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 149-157.

Beyer 3-H, Klees M, Köstering H, Nagel GA: Coagulation studies before, during and after repeated plasma exchanges with a 5% human albumin/saline solution in normal donors. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 87-92.

Chopek M, McCullough 3: Protein and biochemical changes during plasma exchange. In Berkman EM, Umlas J (eds): "Therapeutic Hemapheresis." Washington, DC: American Association of Blood Banks, 1980, pp 13-52.

Evans RT, MacDonald R, Robinson A: Suxamethonium apnoea associated with plasmapheresis. *Anesthesia* 35:198-201, 1980.

Fabre M, Andreu G, Mannoni P: Sane biological modifications and clinical hazards observed during plasma exchanges. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 143-148.

Gelabert A, Ruig L, Maragall S, Monteagudo 3, Castillo R: Coagulative alterations during massive plasmapheresis. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 71-75.

Lumley J: Prolongation of suxamethonium following plasma exchange. *Br J Anaesth* 52:1149-1150, 1980.

Malchesky PS, et al: Complement removal by sorbents in membrane plasmapheresis with on-line plasma treatment. *Trans Am Soc Artif Intern Organs* 26:541-545, 1980.

Milich DR, et al: Plasmapheresis of hepatitis B surface antigen carriers. *Acta Haematol Pol* 11:73-78, 1980.

Morse EE, Hohnadel DC, Genco P, et al: Decreased ionized calcium during therapeutic plasma exchange, pheresis and plateletpheresis. *Johns Hopkins Med J* 146:260-263, 1980.

Orlin JB, et al: Partial plasma exchange using albumin replacement: Removal and recovery of normal plasma constituents. *Blood* 56:1055-1059, 1980.

Peters U, Risler T, Grabensee B: Digitoxin elimination by plasma exchange. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 365-368.

Schooneman F, Janet C, Streiff F: Hemolysis following cytophoresis. 2 cases. *Nouv Presse Med* 9:540, 1980.

Urbaniak S3, Barclay GR, Greiss MA: Adverse effect of plasma exchange on maternal anti-D levels in HDN due to the removal of plasma inhibitory factors. Joint Meeting 18th Congress International Society of Hematology and 16th Congress International Society of Blood Transfusion, August 1980, Montreal, Canada (Abstract 1413).

Watson DK, Penny AF, Marshall RW, et al: Citrate induced hypocalcemia during cell separation. *Br J Haematol* 44:503-507, 1980.

Flaurin MA, Cuneo RA, Appelbaum FR, Deisseroth AB, Engel WK, Gralnick HR: The hemostatic imbalance of plasma-exchange transfusion. *Blood* 54:694-702, 1979.

Keller AJ, Chirside A, Urbaniak S3: Coagulation abnormalities produced by plasma exchange on the cell separator with special reference to fibrinogen and platelet levels. *Br J Haematol* 42:593-603, 1979.

Kilpatrick D, Fleming 3, Clyne C, Thompson CR: Reduction of blood viscosity following plasma exchange. *Atherosclerosis* 32:301-306, 1979.

Paterson 3L, Walsh ES, Hall GM: Progressive depletion of plasma cholinesterase during daily plasma exchange. *Br Med J* 2:580, 1979.

Shafir E, Brenner T: Lipoprotein lipid and protein synthesis in experimental nephrosis and plasmapheresis. I: Studies in rate in vivo. *Lipids* 14:695-702, 1979.

Simon TL: Changes in hemostasis during plasma exchange. *Blood* 54:129a, 1979.

Sultan Y, Bussel A, Maisonneuve P, Poupenev M, Sitty X, Gajdos P: Potential danger of thrombosis after plasma exchange in the treatment of patients with immune disease. *Transfusion* 19:588-593, 1979.

Winkelstein A, Volkin RL, Starz TW, et al: The effects of plasma exchange on immunologic factors. *Clin Res* 27:691A, 1979.

Avanzi G: The apheresis: plasmapheresis, plateletpheresis, leukapheresis. *Physiopathology of the donor. Pathologic* 70:467-480, 1978.

Drescher WP, Shih N, Hess K, et al: Massive extracorporeal blood clotting during discontinuous flow leukapheresis. *Transfusion* 18:89-90, 1978.

Gorodetskii VM: Reactions observed in blood donors and patients during cytophoresis on the blood cell separator. *Ter Arkh* 50:129-131, 1978.

Keller A3, Urbaniak S3: Intensive plasma exchange on the cell separator: Effects on serum immunoglobulins and complement components. *Br J Haematol* 38:531-540, 1978.

Mose JR: Influence of plasmapheresis on total and T-lymphocyte count. *Blut* 36:175-178, 1978.

Wood GJ, Hall GM: Plasmapheresis and plasma cholinesterase. *Br J Anaesth* 50:945-949, 1978.

Isbister JP, Ling A, Seeto KM: Development of Rh-specific maternal auto-antibodies following intensive plasmapheresis for Rh immunization during pregnancy. *Vox Sang* 33:353-358, 1977.

Lundsgaard-Hansen P: Intensive plasmapheresis as a risk factor for arterio-sclerotic cardiovascular disease? *Vox Sang* 33:1-4, 1977.

Pinching AJ, Rees AJ: Plasmapheresis and plasmacholinesterase. *Lancet* 2:134-135, 1977.

Wood GJ: Plasmapheresis and plasma-cholinesterase. *Lancet* 1:1305-1306, 1977.

Browne O, Bell J, Holland PO, Thornes RD: Plasmapheresis and immunostimulation. *Lancet* 2:96, 1976.

Buskard NA, Varghese Z, Wills MR: Correction of hypocalcaemic symptoms during plasma exchange. *Lancet* 2:344-345, 1976.

Hersey P, Isbister J, Edwards A, Murray E, Adams E, Biggs J, Milton GW: Antibody-dependent, cell-mediated cytotoxicity against melanoma cells induced by plasmapheresis. *Lancet* 1:825-827, 1976.

Howard JE, Perkins HA: Lysis of donor RBC during plateletpheresis with a blood processor. *JAMA* 236:289-290, 1976.

Isbister JR, Biggs JC: Reactions to rapid infusion of stable plasma protein solution during large volume plasma exchange. *Anaesth Intensive Care* 4:103, 1976.

Plasmapheresis and immunosuppression. *Lancet* 1:1113-1114 (editorial), 1976.

Strauss RA, Kling TF, Levinsohn MW, et al: Facilitation of exchange transfusions with Scribner shunts in Reye's syndrome. *Am J Surg* 131:772, 1976.

White JM, White YS, Buskard N, Gillies IDS: Increasing whole blood oxygen affinity during rapid exchange transfusion: A potential hazard. *Transfusion* 16:232, 1976.

Bayer WL, Farrales FB, Summers T, Belcher C: Coagulation studies after plasma exchange with plasma protein fraction and lactated Ringer's solution. In Goldman JM, Lowenthal RM (eds): "Leucocytes: Separation, Collection and Transfusion." London: Academic Press, 1975, pp 551-560.

Friedman BA, Schork MA, Mocniak JL, et al: Short-term and long-term effects of plasmapheresis on serum proteins and immunoglobulins. *Transfusion* 15:467-472, 1975.

Oon CJ, Hobbs 3R: Medical problems in donors on treatment using the continuous flow blood separator. In Goldman JM, Lowenthal RM (eds): "Leucocytes: Separation, Collection and Transfusion." London: Academic Press: 1975, pp 576-577.

Shanbrom E, Lundak R, Walford RL: Long-term plasmapheresis: Effects on specific plasmaproteins. *Transfusion* 12:162-167, 1972.

Salvaggio 3, Arquembourg P, Bickers 3, Bice D: The effect of prolonged plasmapheresis on immunoglobulins, other serum proteins, delayed hypersensitivity and phytohemagglutinin-induced lymphocyte transformation. *Int Arch Allergy Appl Immunol* 41:883-894, 1971.

Murphy GP, Williams PD, Brede HD, Mirand EA, Groenewald 3H, Weber HW, Grace JT Jr: The effect of lymphocyte depletion by continuous flow centrifugation in canine renal allotransplants. *Surg Oncol* 2:257-270, 1970.

Arcadio F, Loire R, Roche L: Quick death from myocardial infarct during plasmapheresis: Clinical and anatomic study. *Med Leg Domm Corpor (Paris)* 2:278-281, 1969.

Pacitti C: Metabolic effects caused by blood protein restoration after plasmapheresis. *Arch Fisiol* 67:215-223, 1969.

Pacitti C, Mondino M: Nitrogen balance in rats exposed to plasmapheresis. *Arch Fisiol* 67:205-214, 1969.

Gutnik RB, Zinevich AK: The electrolyte content of donor blood in frequently repeated plasmapheresis. *Vrach Delo* 2:150-151, 1968.

Schurek HG, von de Heyde C, Velte H, Deicher H, Marghescu S, Stolte H: Different applications of plasma exchange and optimal adaption of exchange procedure. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasma-separation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 93-98.

Shiokawa Y, et al: Plasmapheresis in treatment of rheumatic fever. *3pn Circ* 3 44:797-800, 1980.

van de Wiel A, et al: Plasma exchange in herpes gestationis. *Br Med J* 281:1041-1042, 1980.

Waldenström JG: Plasmapheresis - bloodletting revived and refined. *Acta Med Scand* 208:1-4, 1980.

Amemiya Y, Baba M, Itoh T, Nunokawa H, Kohzu H, Shindo T, Morita K, Amaki I: Therapeutic pheresis. *Rinsho Ketsueki* 20:1191-1197, 1979.

Isbister 3P: Plasma exchange: a selective form of blood-letting. *Med J Aust* 2:167-173, 1979.

James MP, Kingston PJ: Plasmapheresis slows destructive bodies (news): *Am Fam Physician* 20:191-192, 1979.

Katz AJ, Blumberg N, King C: Meeting therapeutic pheresis needs in the region. In "First Annual Apheresis Symposium: Current Concepts and Future Trends." Published Proceedings. Chicago: American Red Cross Blood Services, 1979.

Lewis RA, Slater N, Croft DN: Exophthalmos and pretibial myxoedema not responding to plasmapheresis. *Br Med J* 3:390-391, 1979.

Lockwood CM: Plasma-exchange: An overview. *Plasma Ther* 1:1-12, 1979.

Lockwood CM, Worledge S, Nicholas A, Cotton LC, Peters OK: Reversal of impaired splenic function by plasma exchange. *N Engl J Med* 300:524-530, 1979.

Lundsgaard-Hansen P, Deubelbeiss K: Computer simulation studies of therapeutic plasmapheresis. *ISBT Symposium*, Warsaw, 1979, Book of Abstracts, p 23.

Muggeo M, Flier JS, Abrams RA, Harrison LC, Deisseroth AB, Kahn CR: Treatment by plasma exchange of a patient with autoantibodies to the insulin receptor. *N Engl J Med* 300:477-480, 1979.

Newsom-Davis 3, Ward CD, Wilson SG, Pinching AJ, Vincent A: Plasmapheresis: Short- and long-term benefits. In Dau PC (ed): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979, pp 199-208.

Nosé Y, Malchesky PS: Therapeutic application of plasmapheresis. *Plasma Q* 1:102-103, 1979.

Pineda AA, Taswell HF, Moore SB: Therapeutic plasma and cytoapheresis. *Transfusion* 19:666, 1979.

Raich PC, Traver MI: Therapeutic plasmapheresis. *Wis Med J* 78:37, 1979.

Roncoroni A3, Martino OH: Therapeutic use of exchange transfusion in malaria. *Am J Trop Med Hyg* 28:440, 1979.

Rossi PL: Therapeutic value of the cell separator. Review and case reports. *Minerva Med* 70:1289-1298, 1979.

Betteridge DJ, Bakowski M, Taylor KG, Reckless JP, de Silva SR, Galton DJ: Treatment of severe diabetic hypertriglyceridaemia by plasma exchange. *Lancet* 1:1368, 1978.

Obeid D, Cotton P: Plasmapheresis. *Br Med J* 1:1486-1487, 1978.

Pinching AJ: Plasma exchange. *Br J Haematol* 20:552-558, 1978.

Plasmapheresis. *Br Med J* 1:1011-1012, 1978.

Laningham JET: Partial plasma exchange, an adjunct in therapy to complex clinical problems. *Transfusion* 17:547-554, 1977.

Pineda AA, Brzica SM Jr, Taswell HF: Continuous- and semicontinuous-flow blood centrifugation systems: Therapeutic applications, with plasma-, platelet-, lympho-, and eosinapheresis. *Transfusion* 17:407-416, 1977. -

Verrier Jones J: Plasmapheresis: Great economy in the use of horses. *N Engl J Med* 297:1173-1175, 1977.

Buskard NA, Varghese Z, Wills MR: Correction of hypocalcaemic symptoms during plasma exchange. *Lancet* 2:344-345, 1976.

Tülz GP, Teubl I, Kopplhuber CH, Vollman H, Lanzer G: Therapeutische Plasmaphese: Eineneue Form der symptomatischen Therapie. *Med Klin* 71:1952-1957, 1976.

Lagrec G, Sprovieri L: Plasmapheresis on children of less than twenty kilograms. *Haemonetics Proceedings of the Advanced Component Seminar, Natick, IMA*, 1975.

Lockwood M, Pearson T: Use of plasma exchange in treatment of allergic diseases. *Haemonetics Research Institute*, 1975, pp 1-8.

McCullough J: Therapeutic plasma exchange. *Advanced Pheresis Seminar*. Boston: Haemonetics Research Institute, 1975.

Oon CJ, Hobbs JR: Clinical application of the continuous flow blood separator machine. *Clin Exp Immunol* 20:1-16, 1975.

McCullough J, Fortuny IE, Kennedy BJ, Edson JR, Branda RF, Jacob HS: Rapid pi-a exchange with the continuous flow centrifuge. *Transfusion* 13:94-99, 1973.

Agolini G, Giunta L, Nicolini R: Plasmapheresis as a basis for new therapeutic possibilities in transfusion. *Fracastoro* 61:647-652, 1968.

Speiser P: **Plasmapheresis**. Wien *Klin Wochenschr* **79:689-692**, 1967.

Abel 33, Rowntree LG, Turner BB: Plasma removal with return of corpuscles (Plasmapheresis). *J Pharmacol Exp Ther* **5:625-641**, 1914.

Appelgate R, et al: Removal of **tobramycin** during plasma exchange therapy. *Ann Intern Med* **94:820-821**, 1981.

Chirnside A, Urbaniak SJ, Prowse CV, Keller AJ: Coagulation abnormalities following plasma ● xchange on the cell separator. II. Effects on factors I, II, V, VII, VIII, IX, X and **antithrombin III**. *Br J Haematol* **48:627-634**, 1981.

Gutnik RB, Iaralova PV, Muravova LP, Kovalkina LA, Khazan LD: State of the cardiovascular system in donors **undergoing** multiple, frequently repeated **plasmapheresis**. *Probl Gematol Pereliv Krovi* **26:27-29**, 1981.

Hester 3P, Kellogg RM, McCredie KB, Freireich EJ: Cross cellular contamination in **plateletpheresis**, **leukapheresis** and plasma exchange. In Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Lisa, 1981, pp 109-121.

Levy J: Safety and standards for therapeutic **apheresis**. In "Third Annual Symposium on **Apheresis: Current Concepts and Future Trends**." Skokie, IL: Am Soc **Apheresis**, 1981 (abstract).

McLeod BC, Viemes A, Sasseti FJ: Complement activation **during** membrane plasmapheresis. *Blood* **58 (Suppl 1):183a**, 1981.

Monaghan WP: Reactions, monitoring and **complications**. In "Apheresis: Application, Collection, and Research **Procedures Seminar**." Bethesda, MD: National Naval Medical Center and **Haemonetics Research Institute**, December 1981.

Seiler FR, Karges H, Geursen R, Sedlacek HH: Possibilities, problems and hazards with blood plasma **substitution** therapy. In Borberg H, Reuther P (eds): "Plasma Exchange **Therapy**." Stuttgart: Georg Thieme Verlag, 1981, pp 37-52.

Shapiro M: Medical-legal **considerations** of **apheresis**. In "Apheresis: Application, Collection, and Research **Procedures Seminar**." Bethesda, MD: National Naval Medical Center and **Haemonetics Research Institute**, December 1981.

Sharp DE: Drug kinetics following plasmapheresis. In "Apheresis: Application, Collection and Research **Procedures Seminar**." Bethesda, MD: **National Naval Medical Center and Haemonetics Research Institute**, December 1981.

Sutton DMC, Cardella CJ, Uldall PR, deVeber GA: **Complications** of intensive plasma ● xchange. *Plasma Ther* **2:19-23**, 1981.

Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S: **Plasmapheresis**, infection and renal disease. *JAMA* **246:1545**, 1981.

Wright DG, et al: Lymphocyte **depletion** and **immunosuppression** with repeated **leukapheresis** by continuous flow **centrifugation**. *Blood* **48:451-458**, 1981.

AMERICAN RED CROSS BLOOD SERVICES

Therapeutic Pheresis Bibliography No. XV: Technical Aspects

ARC Blood Services
Bibliography
TPB XV-2

- Ah J, Adjizian JC, Droulle Ch, Toupance O, Le Roux G, et al: Cryoprecipitate-depleted plasma as a replacement fluid. *Plasma Ther* 2:243-246, 1981.
- Anderson L, Ziter FA: Plasmapheresis via central catheter in dermatomyositis: A new method for selected pediatric patients. *J Pediatr* 98:240, 1981.
- Cohen PG: Circulatory access for extracorporeal blood modification. *Plasma Ther* 2:235-238, 1981.
- Green TP: Gentamicin elimination during exchange transfusion. *J Pediatr* 98:507-508, 1981.
- Kalinin NN: Principles and methods of using apparatus for plasmocytapheresis with donors and patients. *Probl Gematol Pereliv Krovi* 26:11-16, 1981.
- Lyday JG: Formulas to simplify partial red cell exchange. *Plasma Therapy* 2:111-115, 1981.
- Mielke CH Jr, Mielke MR: Technical and therapeutic applications of plasma exchange. In Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Liss, 1981, pp 123-145.
- Nosé Y: Technical aspects of therapeutic separation of plasma macromolecules by membrane filtration and cryogelation. In "Third Annual Pheresis Symposium: Current Concepts and Future Trends." Skokie, IL: American Society of Apheresis, 1981 (abstract).
- Passlick J, et al: Puncture of the internal jugular vein as an access for extracorporeal circulation in hemodialysis, hemoperfusion and plasma separation. *Med Welt* 32:1143-1145, 1981 (In German).
- Prince AS, Kliegman R, Phaneuf D, Neu HC: The effect of exchange transfusion on the blood levels of ampicillin and gentamicin in neonates. *Infection* 9:1-5, 1981.
- Stellon AJ, et al: Polygeline compared with plasma protein fraction as the sole replacement fluid in plasma exchange. *Br Med J (Clin Res)* 282:696-697, 1981.
- Taft EG: Choice of replacement solutions for plasma exchange. In "Third Annual Apheresis Symposium: Current Concepts and Future Trends." Skokie, IL: American Society for Apheresis, 1981 (abstract).
- Blacklock HA, et al: Therapeutic plasmapheresis by continuous flow centrifugation. *NZ Med J* 92:145-148, 1980.
- Chimel H: Technologische Aspekte zur Membranplasmapherese. *Bialyse-Arztwerkshop*, Bernried, 1980.
- Goudemand M, Toussain-Breyan B, Juyet 3P: Utilisation de l'albumine diluée lors des plasmaphereses therapeutiques. Communication au symposium sur les plasmaphereses therapeutiques, Cologne, 1980.
- Kliegman RM, Bertino JS, Fanarof AA, Gavan TL, Speck WT: Pharmacokinetics of gentamicin during exchange transfusions in neonates. *J Pediatr* 96:927, 1980.
- Lundsgaard-Hansen P, et al: Computer simulation studies of therapeutic plasmapheresis. *Acta Haematol Pol* 11:117-120, 1980.
- McLeod BC: Automated plasmapheresis through a single central vein. *Plasma Ther* 1:45-49, 1980.
- Orlin JB, Berkman EM: Partial plasma exchange using albumin replacement: Removal and recovery of normal plasma constituents. *Blood* 56:1055-1059, 1980.
- Chopek M, McCullough 33: Some hematologic and biochemical effects of plasma exchange. *Transfusion* 19:631, 1979.
- Epstein M, Puguay D, Smith A: Effect of exchange transfusion on serum aminoglycoside concentrations. *Pediatr Res* 13:368, 1979.
- McLeod BC: Technical aspects of therapeutic plasmapheresis. *Plasma Ther* 1:43-51, 1979*
- Menke AM, Dau PC: Technical notes on plasmapheresis. In Dau PC (ed): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979, pp 351-358.
- Taft EG, Sullivan SA, Becker HA, Hammer CE: Plasma exchange transfusion: Kinetics, dose and markers. *Transfusion* 19:651, 1979.
- Ward WJ: A relative value unit for pheresis products. *Transfusion* 19:622, 1979.
- Zitko M, Reuter H, Borberg H, Mishler JM: The utilisation of a new strength citrate anticoagulant during centrifugal plateletpheresis. III. Assessment of in vitro platelet metabolism. *Vox Sang* 36:347-352, 1979.
- Menke A, Dau PC: Technical aspects of plasmapheresis. *Muscle Nerve* 1:342, 1978.
- Moulinier 3, Vegon G, Conte PH, Fizez D, Lauroua P: Applications therapeutiques des echanges plasmatiques a l'aide de separateurs a flux discontinue. XVII Congress of Inter Soc Hematol, 1978, p 330.
- Rosegger H, Zach M, Gleispach H, Beitzke A: Digoxin elimination by exchange transfusion. *Eur J Pediatr* 127:217-222, 1978.
- Strauss RA, Kling TF, Levinsohn MW, et al: Facilitation of exchange transfusions with Scribner shunts in Reye's syndrome. *Am J Surg* 131:772, 1978.
- Winchester IF: Haemostatic changes induced by adsorbent haemoperfusion. In Kenedi RM, Courtney JM, Gaylor JDS, Gilchrist T (eds): "Artificial Organs." London: Macmillan, 1977, pp 280-290.

Szymanski LO, Patti K, **Kilman** A: Efficacy of Latham blood processor to perform **plateletpheresis**. *Transfusion* **13:405**, 1973.

Colart DJ, Watson D, Howard MR: Effect of exchange transfusion in plasma **digoxin** levels. *Arch Dis Child* **47:814-815**, 1972.

Marsaglia G, Thomas ED: Mathematical consideration of cross circulation and **exchange** transfusion. *Transfusion* **11:216**, 1971.

Cohen MA, Oberman HA: Safety and long term effects of **plasmapheresis**. *Transfusion* **10:58-66**, 1970.

Smalik S: Therapeutic effect of plasma obtained by long-term massive **plasma-pheresis** (preliminary report). *Vnitř Lek* **16:1022-1029**, 1970.

Anderson L, Ziter FA: **Plasmapheresis** via central catheter in dermatomyositis: A new method for selected pediatric patients. *J Pediatr* **98:240**, 1981.

Asanuma Y, **Malchesky** PS, **Blumenstein** M, **Zawicki** I, Smith 3W, **Kayashima** K, Kyo A, Suzuki M, **Shinagawa** S, Krakauer RS, **Calabrese** L, Nose Y: Continuous **cryofiltration** for rheumatoid **arthritis**. *Artif Organs* (accepted), 1981.

Besa EC, Ray PK, Swami VK, **Idiculla** A, Rhoads **JE** Jr, Bassett **JG**, Joseph RR, **Cooper** DR: Specific **immunoabsorption** of IgG antibody in a patient with chronic **lymphocytic** leukemia and autoimmune **hemolytic anemia**: A new form of therapy for the acute critical stage. *Am J Med* **71:1035-1040**, 1981.

Buff aloe GW, Dau P: Development and clinical evaluation of a parallel plate membrane **plasma** exchange system. In "Third Annual **Apheresis** Symposium: Current Concepts and Future Trends." **Skokie**, IL: American Society of Apheresis, 1981 (abstract).

Castino F, Friedman 11, Wiltbank TB, **Daniels** JR, Grapka B, Solomon in BA: Plasma separation by membrane filtration. In **Borberg** H, Reuther P (eds): "**Plasma** Exchange Therapy." **Stuttgart**: Georg Thieme Verlag, 1981, pp 11-19.

Gurland H3, **Samtleben** W, Schmidt B: **Plasmaperfusion**. In **Borberg** H, Reuther P (eds): "**Plasma** Exchange Therapy." **Stuttgart**: Georg Thieme Verlag, 1981, pp 26-29.

Hellström KE, **Hellström** k Does **perfusion** with **treated** plasma cure cancer? *N Engl J Med* **308:1215-1216**, 1981.

Kanamono T, **Iwata** H, Yarnanaka N, Ohta K, Maeda K: Plasma separation using various kinds of **hemo-filters** in rheumatoid arthritis. In "New Membranes in Medical **Treatment**." 2nd Tutzing Symposium on Chemical Engineering in Medicine, Munich, 1981.

Lösgen H, **Brunner** G, Schmidt FW: Removal of toxic metabolizes by plasma exchange in patients with hepatic failure. In "New Membranes in Medical Treatment," 2nd TutZing Symposium on Chemical Engineering in Medicine, **Munich**, 1981.

McLeod BC, Viernes A, **Sassetti** FJ: Complement activation during membrane plasrapheresis. *Blood* **58 (Suppl 1):183a**, 1981.

Maeda K, **Shinzato** T, **Usuda** M, **Sezaki** R, et al: Psoriasis treatment with **hemofiltration** and plasma exchange. In "New Membranes in Medical Treatment." 2nd Tutzing **Symposium** on Chemical Engineering in Medicine, **Munich**, 1981.

Passlick 3, et al: Puncture of the internal jugular vein as an access for extracorporeal circulation in **hemodialysis**, **hemoperfusion** and plasma separation. *Med Welt* **32:1143-1145**, 1981 (in German).

Sieberth HG, Glöckner WM: Separation of cells from plasma in man using hollow-fiber membranes of large pore size. In **Borberg H, Reuther P (eds):** "Plasma Exchange Therapy." Stuttgart: **Georg Thieme Verlag**, 1981, pp 20-25.

Stoffel W, Borberg H, Greve V: Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. **Lancet** 2:1005-1007, 1981.

Terman DS, Young JB, Shearer WT, Ayus C, Lehane D, et al: Preliminary observations of the effects on breast adenocarcinoma of plasma perfused over immobilized protein A. **N Engl J Med** 305:1195-1200, 1981.

Agishi T, et al: Double filtration plasmapheresis. **Trans Am Soc Artif Intern Organs** 26:406-411, 1980.

Asaba H, Bergström B, Bendz R, Löfquist B, et al: Plasma exchange with a membrane plasma filter for treatment of glomerulonephritis. In **Sieberth HG (ed):** "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: **F.K. Schattauer Verlag**, 1980, pp 207-211.

Asaba H, et al: Clinical trial of plasma exchange with a membrane filter in treatment of crescentic glomerulonephritis. **Clin Nephrol** 14:60-65, 1980.

Asanuma Y, et al: Clinical hepatic support by on-line plasma treatment with multiple absorbents - evaluation of system performance. **Trans Am Soc Artif Intern Organa** 26:400-405, 1980.

Das PC, Smit Sibinga CT: Replacement fluid in plasma exchange. **Lancet** 2:644, 1980.

Grob PJ, Gmür B, von Telten A, Frey-Wettstein M, Hartmann S, Gartmann S: Plasma exchange and non-specific immune parameters. Comparison of two methods. In **Sieberth HG (ed):** "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: **F. K. Schattauer Verlag**, 1980, pp 113-119.

Horiuchi T, Otsubo O, Takahashi I, Yamada Y, Yamauchi J, Inou T: Study of plasma cross circulation in experimental hepatic failure. In **Sieberth HG (ed):** "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: **F. K. Schattauer Verlag**, 1980, pp 341-345.

Malchesky PS, Asanuma Y, Smith J, Zawicki I, Ncae Y: Membrane plasmapheresis with on-line plasma treatment. In **Sideman S, Chang TMS (eds):** "Hemoperfusion, Kidney and Liver Supports and Detoxification." Washington, DC: Hemisphere Publishing Corporation, 1980 (in press).

Malchesky PS, et al: Complement removal by sorbents in membrane plasmapheresis with on-line plasma treatment. **Trans Am Soc Artif Intern Organs** 26:541-545, 1980.

Otsubo O, et al: Handy type haemofiltration - plasma exchange apparatus. **Proc Eur Dial Transplant Assoc** 17:357-361, 1980.

Samtleben W, et al: Membrane plasma separation for treatment of immunologically mediated diseases. **Trans Am Soc Artif Intern Organs** 26:12-16, 1980.

Inoue N, Yamazaki Z, Sakai T, Kanai K, et al: A new method for plasmapheresis using cellulose acetate hollow fibers as a plasma separator. **Artif Organs** 3:18, 1979.

Lauterburg BH, Dickson ER, Pineda AA, Carlson GL, Taswell HF: Removal of bile acids and bilirubin by plasmapheresis of USP charcoal-coated glass beads. **3 Lab Clin Med** 94:585, 1979.

Sieberth HG, Glöckner W, Hirsch HH, Borberg H, Mahieu P: Plasmaseparation by membranes in man. **ISAIO**, 1979, in press.

Terman DS, Buff aloe G, Mattioli C, Cook G, Tillquist R, Sullivan M, Ajus JC: Extracorporeal immunoadsorption: Initial experience in human systemic lupus erythematosus. **Lancet** 1:824-826, 1979.

Gelfand MC: Charcoal hemoperfusion: Georgetown University Hospital experience." In **Chang TMS (ed):** "Artificial Kidney, Artificial Liver, and Artificial Cells." New York: Plenum Press, 1978, pp 117-123.

Glöckner WM, Sieberth HG: Plasmafiltration, a new method of plasma exchange. **Proceedings of the European Society for Artificial Organs**, Vol. 5, 1978, p 214.

Solomon BA, Castino F, Lysaght M3, Colton CK, Friedman LI: Continuous flow membrane filtration of plasma from whole blood. **Trans Am Soc Artif Intern Organs** 24:21, 1978.

Gelfand MC, Winchester JF, Kneppshield 3H, Hartson KM, Cohan SL, Strauch BS, Geoly KL, Kennedy AC, Schreiner GE: Treatment of severe drug overdose with charcoal hemoperfusion. **Trans Am Soc Artif Intern Organs** 25:599, 1977.

Hill JB, Palaia FL, Hores CR: The design of a charcoal hemoperfusion system. In **Kenedi R, Courtney JM, Gaylor JDS, Gilchrist T (eds):** "Artificial Organs." London: Macmillan, 1977, pp 123-132.

Winchester 3F, Apiliga MT, Kennedy AC: Short term evaluation of charcoal hemoperfusion combined with dialysis in uremia patients. **Kidney Int** 10: 5315, 1977.

Gazzard BG, Weston MJ, Murray-Lyon IM, et al: Experience at King's College Hospital with charcoal haemoperfusion: Overall results in 37 patients. In **Williams R, Murray-Lyon IM (eds):** "Artificial Liver Support." London: Pitman, 1976, p 234.

Gelfand MC, Kneppshield JH, Cohan SL, et al: Treatment of hepatic coma with hemoperfusion through polyacrylamide hydrogel-coated charcoal. **Kidney Int** 10: 5239, 1976.

Nosé Y, Malchesky PS, Castino F, Koshino I, Scheucher K, Nokoff R: Improved hemoperfusion systems for renal/hepatic support. **Kidney Int** 10:5244, 1976.

Rosenbaum JL, Kramer MS, Raja R: Resin hemoperfusion for acute drug intoxication. *Arch Intern Med* 136:263, 1976.

Sanjo K, Fujimori Y, Yamazaki Z, et al: The effect of liver support system (plasma perfusion detoxication) providing removal of plasma amino acids in patients with fulminant hepatitis. *Artif Organs (Jpn) Suppl* 5:231-234, 1976.

Thyssel H, Linkholm T, Heinegard D, Henrikson H, Johnson E, Nylén U, Svensson T, Bergkvist G, Gullberg CA: A haemoperfusion column using cellophane coated charcoal. *Proc Eur Soc Artif Organs* 2:231, 1976.

Gazzard BG, Portmann BA, Weston M3, Langley PG, Murray-Lyon IM, et al: Charcoal haemoperfusion in the treatment of fulminant hepatic failure. *Lancet* 1:1301, 1974.

Gazzard BD, Weston MJ, Murray-Lyon IM, et al: Charcoal haemoperfusion in the treatment of fulminant hepatic failure. *Lancet* 1:1301, 1974.

Medd RK, Widdop B, Braithwaite RA, Rees AJ, Goulding R: Comparison of haemoperfusion and haemodialysis on the therapy of b= biturate intoxication in drugs. *Arch Toxicol* 31:163, 1973.

Rosenbaum JL, Winsten S, Kramer MS, Moms 3, Raja R: Resin hemoperfusion in the treatment of drug intoxication. *Trans Am Soc Artif Intern Organs* 16:134, 1970.

Hagstam KE, Larsson LE, Thyssel H: Experimental studies on charcoal hemoperfusion in phenobarbital intoxication and uremia. *Acta Med Scand* 180:593, 1966.

Yatzidis H: A convenient haemoperfusion micro-apparatus over charcoal for the treatment of endogenous and exogenous intoxications. Its use as an artificial kidney. *Proc Eur Dial Transplant Assoc* 1:83, 1964.

Nusbacher 3: Therapeutic hemapheresis. *Clin Lab Med* 2(1), March 1982.

"Apheresis: Application, Collection and Research Procedures seminar." Co-sponsored by National Naval Medical Center and Haemonetics Research Institute, Bethesda, MD, December 1981.

Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Stuttgart: Georg Thieme Verlag, 1981.

Hennesen W (ed): "Albumin, Plasma Substitutes and Plasmapheresis." Basel: Karger, 1981.

Hennesen W (ed): "International Symposium on Standardization of Albumin, Plasma Substitutes and Plasmapheresis." Basel: S. Karger, 1981.

Mielke CH Jr (ed): "Apheresis: Development, Applications, and Collection Procedures." New York: Alan R. Liss, Inc, 1981.

Nemo GJ, Taswell H (eds): "Proceedings of the Workshop on Therapeutic Plasmapheresis and Cytapheresis, April 1979." Bethesda, MD: U.S. Department of Health and Human Services, 1981 (NIH Publication No. 82-1665).

Rubin AL, Stenzel KH, Sullivan 3S (eds): "Clinical and Experimental Dialysis and Apheresis." New York: Marcel Dekker, Inc, 1981.

"Third Annual Apheresis Symposium: Current Concepts and Future Trends." Published abstracts. Skokie, IL: American Society of Apheresis, 1981.

Berkman EM, Umlas J (eds): Therapeutic Hemapheresis. A Technical Workshop." Washington, DC: American Association of Blood Banks, 1980.

Borberg H, Reuther P (eds): "Plasma Exchange Therapy." Proceedings of International Society on Plasma Exchange Therapy, Wiesbaden, 1980. New York: Thieme-Stratton, Inc, 1980.

Hamblin TJ: "Plasmapheresis and Plasma Exchange." St. Albans, VT: Eden Medical Research, Inc, 1980.

"Second Annual Apheresis Symposium: Current Concepts and Future Trends." Published Proceedings. Skokie, IL: American Society for Apheresis, 1980.

Sherwood WC, Cohen A (eds): "Transfusion Therapy. The Fetus, Infant, and Child." New York: Masson Publishing USA, Inc., 1980.

Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F.K. Schattauer Verlag, 1980.

Dau PC (ed): "Plasmapheresis and the Immunobiology of Myasthenia Gravis." Boston: Houghton Mifflin, 1979.

ARC Blood Services
Bibliography
TPB XVII-2

"First Annual **Apheresis** Symposium: Current Concepts and Future **Trends**."
Published Proceedings. **Chicago**: American Red Cross Blood Services, 1979.

"**Leukapheresis** and Donor Safety **Workshop**." June 4, 1979. Bethesda, MD: Bureau
of **Biologics**.

"**Pheresis** A Vital Blood Service." Workshop **for** American Red Cross **Pheresis**
Staff. Washington, DC: American Red Cross Blood Services, 1979.

Goldman JM, Lowenthal RM (eds): 'Leukocytes Separation Collection and
Transfusion.' **London**: Academic Press, 1975.

AMERICAN RED CROSS
BLOOD SERVICES

Therapeutic **Pheresis** Bibliography

Supplement No. 2

January 1983

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. 1: Neurological Disorders

A. Myasthenia Gravis

- Another antibody in **myasthenia gravis sera**? JAMA **247:1237**, 1982 (editorial)
- Jacobsen H, Thorlaci S, Aarli SA: **Plasmapheresis in myasthenia gravis** - clinical results and changes in serum-proteins. Acta Neurol Scand **65:128-129**, 1982
- Lenzhofer B, Mamoli B, Graninger W, Zeitlhofer S: Reduction of **anti-acetylcholine receptor antibodies** by **plasmapheresis in myasthenia gravis**. In "International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques**." Cleveland: Int Soc Artif Organs, 1982, p 21
- Mizuno Y, Humphrey S, Dosch HM, Gelfand EW: **Carbamylcholine** modulation of E-rosette formation - effect of **plasmapheresis** in myasthenia-gravis. Clin Exp Immunol **49:209-216**, 1982
- Nielsen VK, et al: Rapid improvement of **myasthenia gravis** after plasma exchange. Ann Neurol **11:160-169**, 1982
- Pascuzzi RM, Coslett HE, Johns TR: Treatment of **myasthenia gravis**: Extension of data on **prednisone** and **adjunctive** thyrnectomy, **antimetabolites**, and **plasmapheresis**. AM Neurol **12:109**, 1982
- Valbonesi M, Garelli S, Zerbi D, Forlani G, Cornelio F, Pelucchetti D: Plasma exchange combined with **cytotoxic drugs** and **lymphocytopheresis** for **myasthenia gravis**. Vox Sang **143:142-146**, 1982
- Vincent A: Role of plasma exchange in **myasthenia gravis** and the **Eaton-Lambert syndrome**. Boston: **Haemonetics Advanced Component Seminar**, Boston: 1982 (abstract)
- Arahata K, Sato T, Narabayashi H: Evaluation of plasma exchange in management of **myasthenia gravis**. Rinsho Shinkeigaku **21:597-606**, 1981 (English abstract)
- Dau PC: Response to **plasmapheresis** and **immunosuppressive** drug therapy in sixty **myasthenia** patients. Ann NY Acad Sci **377:700-708**, 1981
- Gajdos P, et al: Plasma exchange in **myasthenia gravis** and **polyradiculonephritis**. Rev Fr Transfus Immunohematol **24:657-659**, 1981 (In French)
- Keesey J, et al: Plasma exchange alone as therapy for **myasthenia gravis**. Ann NY Acad Sci **377:729-743**, 1981
- Miller RG: **Plasmapheresis in myasthenia gravis**. Ann Neurol **10:396-397**, 1981
- ARC Blood Services
Bibliography Supplement 2
TPB I-2
- Motomura S, Konishi T, Tsukie T, Ohta M, Matsubara F, Nishitani H, Yasuda M, Kotani R: Treatment of **myasthenia gravis** with intermittent **plasmapheresis** and on the new double filtration method of **plasmapheresis**. In Oda T (ed): "**Therapeutic Plasmapheresis**." Stuttgart: F. K. Schattauer Verlag, 1981, pp 215-219
- Nishitani H, et al: Plasma exchange in the treatment of **myasthenia gravis**. Nippon Rinsho **39:3302-3309**, 1981 (In Japanese)
- Olarte MR, et al: **Effect of plasmapheresis in myasthenia gravis** 1978-1980. Ann NY Acad Sci **377:725-728**, 1981
- Pasternak JF, Hageman S, Adams MA, Philip AGS, Gardner TH: Exchange transfusion in neonatal **myasthenia**. J Pediatr **99:644-646**, 1981
- Perlo VP, et al: **Effect of plasmapheresis in myasthenia gravis**. Ann NY Acad Sci **377:709-724**, 1981
- Reuther P, Wiebecke D, Böske A, Martens HG: Die **Plasmaaustausch-Behandlung bei Myasthenia gravis und anderen neuropsychiatrischen Erkrankungen**. In Gurland HJ, Heinze V, Lee HA (eds): **therapeutic Plasma Exchange**." New York: Springer Verlag, 1981, pp 55-73 (In German)
- Riley TL, Monaghan WP: **Plasmapheresis in myasthenia gravis**: Decline in **antireceptor antibody** without clinical improvement. Case report. Milit Med **146:724-725**, 1981
- Rodnitzky RL, Bosch EP: **Plasmapheresis as a guide for azathioprine therapy in prednisone-resistant myasthenia gravis**. Muscle Nerve **4:529-530**, 1981
- Sato T, Arahata K, Nishimiya H, Morimoto K, Anno M, Narabayashi H, Yuasa S: Treatment of **myasthenia gravis** by plasma exchange and **corticosteroids**: Levels of antibody to **acetylcholine** receptor and clinical states. In Oda T (ed): "**Therapeutic Plasmapheresis**." Stuttgart: F. K. Schattauer Verlag, 1981, pp 221-225
- Dau PC, Poole M: **Plasmapheresis in myasthenia gravis**. NHK **9:139**, 1980
- Goulon M, et al: Determination of **anti-acetylcholine** receptor antibodies in **myasthenia gravis** and its treatment by plasma exchange and **immunosuppressants**. C R Soc Biol (Paris) **174:467**, 1980 (In French)
- Lisak RP, Schotland DL: **Plasmapheresis in the treatment of myasthenia gravis**. Trans Am Neurol Assoc **103:292**, 1980
- Bender AN, Jenkins G: **Plasmapheresis in myasthenia gravis: Controlled study**. Lancet **2:629**, 1979
- Arahata K, Imai H, Yokoi Y, Ishi H, Yuasa S, Marabayashi H: Plasma exchange in **myasthenia gravis**. Shinkei Naika **9:477**, 1978 (In Japanese)
- Arrigo A, Ascari E, Ippoliti G, Piccolo G, Pinelli P, Rubert G: The effect of **plasmapheresis on myasthenic** blocking of neuromuscular transmission: A follow-up **electromyographic** investigation. Muscle Nerve **1:341**, 1978
- Dau PC, Lindstrom JM, Cassel CK, Clark EC: **Plasmapheresis in myasthenia gravis and polymyositis**. Muscle Nerve **1:341**, 1978

Denys EH, Dau PC, Lindstrom JM: Neuromuscular transmission before and after plasmapheresis in myasthenia gravis and the myasthenia syndrome. *Muscle Nerve* 1:341, 1978

Lisak RP, Abramsky O, Schotland SL: Plasmapheresis in the treatment of myasthenia gravis: Preliminary studies in 21 patients. *Muscle Nerve* 1:341, 1978

Pinching A3, Peters DK, Newsom-Davis 3: Plasma exchange in the investigation and treatment of myasthenia gravis. Boston: Haemonetics Advanced Component Seminar, 1977

B. Multiple Sclerosis

Hauser S: Plasmapheresis, lymphocytapheresis and immunosuppressive therapy in multiple sclerosis. Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

Hauser SL, Dawson D, Beal MF, Lehigh JR, Keyv SV, Propper RD, Mills 3A: Controlled randomized trial of high-dose cyclophosphamide, plasmapheresis, and ACTH in progressive multiple-sclerosis. *Neurology* 32:78, 1982

Höcker P, Summer K: Plasma exchange and lymphocytapheresis in multiple sclerosis. Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

Khatrri BO, McQuille MP: Plasmapheresis (PP) in chronic progressive multiple-sclerosis (CPMS) - a pilot study. *Neurology* 32:148, 1982

Plasmapheresis with immunosuppressives may help MS patient. *Intern Med News* 15:14, 1982

Stefoski D, Schauf CL, McLeod BC, Haywood CP, Davis FA: Plasmapheresis decreases neuroelectric blocking activity in multiple sclerosis. *Neurology* 32:904-907, 1982

Tindall RSA, Walker JE, Ehle AL, Near L, Rollins J, Becker D: Plasmapheresis in multiple sclerosis - prospective trial of pheresis and immunosuppression versus immunosuppression alone. *Neurology* 32:739-743, 1982

Uchida A, Maida EM, Lenzhofe R, Micksche M: Natural killer cell-activity in patients with multiple sclerosis - interferon and plasmapheresis. *Immunobiology* 160: 392-402, 1982.

Valbonesi M, Garelli S, Mosconi L, Zerbi D, Forlani G: Plasma exchange in the management of patients with multiple sclerosis: Preliminary observations. *Vox Sang* 41:68-73, 1981

C. Refsum's Disease

Braine HG, Pyeritz RE, Folstein MF, Moser HB, Ullman MD: A prospective double-blind study of plasma exchange therapy for the acroparesthesia of Fabry's disease. *Transfusion* 21:686-689, 1981

Blauhut B, Lenz H, Bergman H: Plasma exchange in Refsum's disease. In Rainer H (cd): "Cell Separation and Cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 332

D. Guillain-Barré Syndrome

Fiorini G, Bigi G, Paracchini ML, Marinig C, Gibelli A: Immunological monitoring of a patient with Guillain Barré syndrome successfully treated with plasma exchange. *Vox Sang* 42:304-307, 1982

Osterman PO, Fagius 3, Safwenbe 3, Danersun A, Wallin BG, Nordesjo LO: Treatment of the Guillain-Barré syndrome by plasmapheresis. *Arch Neurol* 39:148-154, 1982

Brettler RP: Successful plasmapheresis in the Miller Fisher syndrome. *Br Med* 3 282:1627, 1981

de Lager AE, et al: Plasma exchange in five patients with acute Guillain-Barré syndrome. *Int J Artif Organs* 4:230-233, 1981

de Jager AE, The TH, Sibinga CThS, Dau PC: Plasma exchange in Guillain-Barré syndrome. *Br Med* J 282:794, 1981

Hughes RA: Plasma exchange of acute polyradiculoneuritis (Guillain-Barré syndrome). *Int J Artif Organs* 4:275-276, 1981

Squara P, et al: Recurrence of Guillain-Barré syndrome treated by plasma exchange. Parallel courses of clinical symptoms and circulating immune complexes. *Nouv Presse Med* 10:3854-3855, 1981 (In French)

Thomas L, et al: Plasma exchange treatment of Guillain-Barré syndrome. The need for a controlled study. *Nouv Resse Med* 10:2911, 1981

Valbonesi M, Garelli S, Mosconi L, Zerbi D, Celano I: Plasma exchange as a therapy for Guillain-Barré syndrome with immune complexes. *Vox Sang* 41:74-78, 1981

Zerbi D, et al: Plasmapheresis in the treatment of four cases of Guillain-Barré syndrome (acute form). *Ital J Neurol Sci* 2:331-336, 1981

Dureux JB, Gerard A, Roche G, Lehey B, Canton Ph, Schoneman F, Jannot C, Streiff F: Treatment of Guillain-Barré syndrome by plasma exchange. *Nouv Presse Med* 9:3696, 1980

Garelli S: Confirmation of the utility of plasma-exchange in the treatment of severe Guillain-Barré syndrome. *Riv Emoter Immunoematol* 27:187-194, 1910

E. Miscellaneous: Polyneuropathy, Motor Neuron Disease, Amyotrophic Lateral Sclerosis

Connor RK, Ziter FA, Anstall HB: Childhood chronic relapsing polyneuropathy: Dramatic improvement following plasmapheresis. *3 Clin Apheresis* 1:46-49, 1982

Dau PC, et al: Experience with plasmapheresis in 153 necrologic patients. *Int J Artif Organs* 5:37-46, 1982

Supplement 2

Therapeutic Pheresis Bibliography No. II: Blood Diseases

A. Hemophilia

Lin 3, Rowe V, Abdou NI: Effect of plasmapheresis on specific and nonspecific immune parameters in chronic inflammatory polyradiculoneuropathy. *Neurology* **32:154-155A**, 1982

Lovaste MG, Boninsegi C, Girardi P, Ferrari G: Plasmapheresis in acute idiopathic polyradiculoneuritis - report of 3 cases. *Ital J Neurol Sci* **3:129-132**, 1982

Norris FH, Denys EH, Mielke CH: Plasmapheresis (plasma-exchange) in necrologic disorders. *Clin Neuropharmacol* **5:93-114**, 1982

Poplard A, Emile 3, Bernat Ch, Alcalay D, Vincent F: Plasma exchange in Parkinson's disease: A new therapeutic approach with successful results. **Boston: Haemofonetics** Advanced Component Seminar, 1982 (abstract)

van Nunen SA, Gateby PA, Pollard JD, Deacon M, Clancy RL: Specificity of plasmapheresis in the treatment of chronic relapsing polyneuropathy. *Aust NZ J Med* **12:81-84**, 1982

Gross MLP, Thomas PK: The treatment of chronic relapsing and chronic progressive idiopathic inflammatory polyneuropathy by plasma exchange. *3 Neuro Sci* **52:69-78**, 1981

Mass AI, Busch HP, van der Heul C: Plasma infusion and plasma exchange in chronic idiopathic polyneuropathy. *N Engl J Med* **395:344**, 1981

Newton R: Plasma exchange in acute post-infectious demyelination. *Dev Med Child Neurol* **23:538-543**, 1981

Lawyer C, Aitchison 3, Sutton J, Beunett w: Treatment of theophylline neurotoxicity with resin hemoperfusion. *Ann Intern Med* **88:516-517**, 1978

Norris FH Jr, Denys EH, Mielke CH: Plasmapheresis in amyotrophic lateral sclerosis. *Muscle Nerve* **1:342**, 1978

Erskine JG: Plasma exchange in patients with inhibitors to factor VIIIc. *Plasma Ther Transfus Technol* **3:123-130**, 1982

Francesco M, Korniger C, Thaler E, Niessner H, Hocker P, Lechner K: Plasmapheresis - its value in the management of patients with antibodies to Factor VIII. *Haemostasis* **11:79-86**, 1982

Salmassi S, Ilangovan S, Kasprisin DO: Treatment of hemophilia A with factor VIII inhibitor by plasma exchange transfusion. *Plasma Ther Transfus Technol* **3:131-136**, 1982

Erskine JG, Burnett AK, Walker ID, Davidson JF: Plasma exchange in nonhaemophilic patients with inhibitors to factor VIIIc. *Br Med J* **282:758-759**, 1981

Kawagoe H, et al: Plasma exchange in Weber-Christian disease and a case with anti-factor VIII antibody. *Rinsho Ketsueki* **22:1616-1620**, 1981 (In Japanese)

Kawagoe H, Matsubuchi T, Shinohara Y: Plasma exchange therapy for Weber-Christian disease and anti-factor VIII antibody disease. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 113-118

Mugishima H, et al: HB virus induced fulminant hepatitis in hemophilia B: successful management with plasmapheresis and hemoperfusion. *Rinsho Ketsueki* **22:1628-1631**, 1981 (In Japanese)

Slocombe GW, Newland AC, Colvin MP, Colvin BT: The role of intensive plasma exchange in the prevention and management of haemorrhage in patients with inhibitors to factor VIII. *Br J Haematol* **47:577-585**, 1981

Fridrich L, Piller G, Niessner H, Hocker P, Rainer H, Lechner K: Plasma exchange in hemophiliacs with antibodies to factor VIII. In Rainer H (ed): "Cell-separation and cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 174

Piller G, Hocker H, Ludwig E, Niessner H: Plasmapheresis. Its role in the management of inhibitor patients. Workshop in Inhibitors of Factor VIII and IX. *Wien Facultas-Verlag*, 1977, p 57

B. Autoimmune Hemolytic Anemia

Krakauer R, Smith J, W ysenbeek A, Malchesky P, Nose Y: New technologies for plasma exchange in autoimmune disease. In "International Symposium on Plasma-

pheresis: Therapeutic Applications and New Techniques." Cleveland: *Int Soc Artif Organs*, 1982, p 17

Lawe JE: Successful exchange transfusion of an infant for AIHA developing late in mother's pregnancy. *Transfusion* 22:66-68, 1982

Monch H, Lynen R, Beyer J-H, Mueller-Eckhardt C: Plasma exchange in a case of autoimmune hemolytic anemia with temporary Evan's syndrome. In Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in immunology and Oncology." Basel: S. Karger, 1982, pp 232-237

Lopukhin IuM, Chuchalin AC, Shurkalin BK, Evseev NG, Gorchakov VD: Hemisorption in the therapy of autoimmune diseases. *Sov Med* 10:49-53, 1981 (English abstract)

Ofuji T, Kurata N: Plasma exchange and thoracic duct drainage in autoimmune diseases. *Nippon Rinsho* 39:1841-1846, 1981 (In Japanese)

C. Aplastic Anemia

Mangan KF, Shaddock RK, Winkelstein A: Plasmapheresis and anti-thyocyte globulin treatment of chronic refractory pure red-cell aplasia - correlation of clinical results with in vitro erythroid culture studies. *Clin Rea* 31:323A, 1982

Isbister 3P, Ralston M, Hayes JM, Wright R: Fulminant lupus pneumonitis with acute renal failure and RBC aplasia. Successful management with plasmapheresis and immunosuppression. *Arch Intern Med* 141:1081-1083, 1981

Marinone G, et al: Bone marrow erythroblastic recovery after plasmapheresis in acquired pure red cell anemia. Case report. *Haematologica (Pavia)* 66:796-802, 1981

Messner HA, Fauser AA, Curtis 3E, Dotten D: Control of antibody-mediated pure red cell aplasia by plasmapheresis. *N Engl J Med* 304:1334-1338, 1981

Sakalova A, Gazova S, Hrubisko M, Pokorna G, Mayer J: Follow-up of certain immunologic indicators in the treatment of plasmacytoma with cyclophosphamide in combination with plasmapheresis. *Neoplasma* 22:63-67, 1975

D. Immune Thrombocytopenic Purpura

Blanchette V, Hogan V, Rock G: Plasma exchange in immune thrombocytopenic purpura (ITP). In 'International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques.' Cleveland: *Int Soc Artif Organs*, 1982, p 5

International Medical Service: Plasmapheresis improves outcome in thrombocytopenic purpura. (Summary of ACP No. California Regional Meeting report by Dr. David Cooney). *Intern Med News* 15:9, 1982

Kelton JG, McBride 3, Wilson W, Gaudie J: The pretreatment identification of those patients with idiopathic thrombocytopenic purpura who respond to plasmapheresis. *Clin Res* 30:320A, 1982

Beyer J-H, Schuff-Werner P, Mönch H, Klee M, Kaboth U, Küstering H, Nagel GA: Plasma exchange in 3 patients with idiopathic thrombocytopenic purpura (ITP). In Nydegger UE (cd): "Immunohemotherapy. A Guide to Immunoglobulin Prophylaxis and Therapy.*" London: Academic Press, 1981, pp 405-408

Buskard NA: Plasma exchange for the treatment of immune thrombocytopenia. In Nydegger UE (cd): "Immunohemotherapy. A Guide to Immunoglobulin Prophylaxis and Therapy.*" London: Academic Press, 1981, pp 395-404

Saigo K, et al: Plasma exchange in idiopathic thrombocytopenic purpura. *Rinsho Ketsueki* 22:1624-1627, 1981 (In Japanese)

Buskard NA: Plasma exchange for the treatment of immune thrombocytopenia. Proceedings of International Society of Hematology, Abstract 138, 1980

Branda RF, Tate DY, McCullough 33, et al: Plasma exchange in the treatment of fulminant idiopathic (autoimmune) thrombocytopenic purpura (ITP). *Blood* 50A:235, 1977

Zittoun R, Bergeret S, Thierry S, Pillier C, Radeau-Coquin E, Bussel A, Bilski-Pasquier G: Value of plasma exchange in the management of acute immunologic thrombocytopenic purpura. *Nouv Reue Med* 10483-688, 1981 (English abstract)

E. Thrombotic Thrombocytopenic Purpura, Hemolytic Uremic Syndrome

Bambauer R, Jutzler GA, Hartmann H, Stolz D, Schmengler K, Kohler M, Wahlen W: Hemolytic uremic syndrome, successfully treated by plasma exchange. In 'International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques.' Cleveland: *Int Soc Artif Organs*, 1982, p 2

Breckenridge RL Jr, Solberg LA, Pineda AA, Pettit RM, Dharker DD: Treatment of thrombotic thrombocytopenic purpura with plasma exchange, antiplatelet agents, corticosteroid, and plasma infusion: Mayo Clinic experience. *J Clin Apheresis* 1:6-13, 1982

Feldoff CM: Plasmapheresis in recurrent hemolytic uremic syndrome in a child. *Int J Pediatr Nurs* 3:118, 1982

Kalmin ND, Himot ED: Plasmapheresis in a child with the hemolytic-uremic syndrome. *Transfusion*, 1982 (accepted)

Kwaan HC: Thrombotic thrombocytopenic purpura. *JAMA* 247:3119-3120, 1982

Liu E, Rebenstein M: Phenytoin removal by plasmapheresis in thrombotic thrombocytopenic purpura. *Clin Pharmacol* 31:762-765, 1982

Parries B, Dube VE, Simon NM, Miller HJ: Adult hemolytic uremic syndrome successfully treated with plasma exchange. *Plasma Ther Transfus Technol* 3:57-61, 1982

Pini M, et al: Normal protacyclinlike activity and response to plasma exchange in thrombotic thrombocytopenic purpura: Report of 2 cases. *Acta Haematol (Basel)* 67:198-205, 1982

Rothberg H, Pachter I, Kosmin M, Stevens DB: Thrombotic thrombocytopenic purpura: Recovery after plasmapheresis, corticosteroids, splenectomy, and anti-platelet agents. *Am J Hematol* 12:281-287, 1982

Spencer CD, Crane FM, Kumar JR, Alving BM: Treatment of postpartum hemolytic uremic syndrome with plasma exchange. *JAMA* 247:2808-2809, 1982

Beattie TJ, Murphy AV, Willoughby ML, MaChin SJ, Defreyn G: Plasmapheresis in the haemolytic-uraemic syndrome in children. *Br Med J* 282:1667-1668, 1981

Berkessy S, et al: Successful treatment of thrombotic thrombocytopenic purpura with plasma transfusion. *Orv Hetil* 122:1387-1390, 1981 (In Hungarian)

Pedersen RS, et al: Hemolytic uremic syndrome. Treatment by plasma exchange. *Ugeskr Laeger* 143:2800-2802, 1981 (English abstract)

Rossi EC, del Greco F: The adaption of hemodialysis to facilitate rapid exchange transfusion in patients with thrombotic thrombocytopenic purpura (TTP). *Semin Thromb Hemostas* 7:22-24, 1981

Shinoda A, Kitada H, Suzuki S, Kurihara S, Saito Y, Yuri T, Ishikawa I: Accessible plasma exchange using membrane filter - a successfully treated case of TTP with repeated plasma exchanges. *Artif Organs* 5:248-253, 1981

F. Sickle Cell Disease

Legout J, Aubeuvre 3P, Casteran R, Cupa M, Morin-Hertel F, Baudelot T: Sickle cell anemia and surgery. Value of the cell separator in preparation for the operation. *Rev Fr Transfus Immunohematol* 24:229-232, 1981 (In French)

Kleinman S, Thompson-Breton R, Rifkind S, Goldfinger D: Exchange red blood cell pheresis in the management of complications of sickle cell anemia. *Plasma Ther Transfus Technol* 1:27, 1980

Morrison 3C, Whybrew WD, Bucovaz ET: Use of partial exchange transfusion preoperatively in patients with sickle cell hemoglobinopathies. *Am J Obstet Gynecol* 132:59-63, 1978

G. Leukemia, Myeloproliferative Syndrome, Sézary Syndrome

Ford 3 M, Cullen MH, Roberts MM, Brown LM, Oliver RTD, Lister TA: Prophylactic granulocyte transfusions. Results of a randomized controlled trial in patients with acute myelogenous leukemia. *Transfusion* 22:311-316, 1982

Hester J P, McCredie KB, Freireich EJ: Response to chronic leukapheresis procedures and survival of chronic myelogenous leukemia patients. *Transfusion* 22:305-307, 1982

Mielke CH, Dobbs CE, Winkler DF, Yam LT: Therapeutic leukapheresis in hairy cell leukemia. *Arch Intern Med* 142:700-702, 1982

Worsley A, Cuttner 3, Gordon R, Reilly M, Ambinder EP, Conjalca M: Therapeutic leukapheresis in a patient with hairy cell leukemia presenting with a white cell count greater than 500,000/. *Transfusion* 22:308-310, 1982

Imamura N, et al: Cytapheresis therapy of adult T-cell leukemia: 'A case report. *Rinsho Ketsueki* 22:885-890, 1981 (English abstract)

Quaglino D, De Pasquale A, Montagnani G: Unusual response to leukapheresis in a case of myelofibrosis with elevated peripheral cell count. *Haematologica* 66:327-334, 1981

Pineda M, Winkelman RK: Leukapheresis in the treatment of Sézary syndrome. *J Am Acad Dermatol* 5:544-549, 1981

Polianskaia AM, Khorashko ND, Baidurin SA, Kalinin NN, Kasatkina VV: Mechanisms of the therapeutic action of leukapheresis in leukemias. *Probl Gematol Pereliv Krovi* 26:6-10, 1981 (In Russian)

Semen G: Ultrastructural study of B-bodies in leukapheresed cells of patients with acute leukemia. *Oncology* 38:20&209, 1981

Cuttner 3, Holland 3F, Ambinder E, et al: Randomized study of leukapheresis (L) in acute myelocytic leukemia. *Proc Am Soc Clin Oncol* 21:443, 1980

Eisenstaedt RS, Berkman EM: Rapid cytoreduction in acute leukemia: Management of cerebral leukostasis by cell pheresis. *Transfusion* 18:113-115, 1978

H. Thrombocytosis

Gonzales L, Cargella F, Ancochea L, Casals F, Villalta J, Ingelmo M, Gorina AB: Blue toe syndrome in a patient with essential thrombocythemia: Favorable response to plateletpheresis. *Med Clin* 79:133-136, 1982 (In Spanish)

Wiebecke D, Gunzer U, Kondler R, Pfrang C, Wilke HJ: Cytapheresis in combination with azathioprine for the management of thrombocytosis in myeloproliferative diseases. *Blut* 45:188, 1982

Fabris F, et al: Improvement of platelet aggregation abnormalities in thrombocytosis after thrombocytapheresis. *Folia Haematol (Leipz)* 108:853-862, 1981

Puig L, et al: Indication for **plateletpheresis** in the treatment of essential thrombocythemia. *Sangre (Bare)* **26:517-518**, 1981 (In Spanish)

L Miscellaneous

Blumenstein M, Samtleben W, Randerson DH, Habersetzer R, Gurland H3: Membrane plasma filtration for treatment of plasma cell disease. In "International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques.**" Cleveland: *Int Soc Artif Organs*, 1982, p 6

Deubelbeiss KA: **Therapeutische Zytapherese** aus der Sicht des **Hamatologen** und **Onkologen.** *Therapeutische Umschau/Revue Therapeutique* **39:512-514**, 1982 (English abstract)

Dialer P, Day R, Burman N, Blekkenh G, Eales L: Treatment of **hemodialysis-related porphyria cutanea-tarda** with plasma-exchange. *Am J Med* **72:989-993**, 1982

Pimstone NR, Gandhi SN, Mukerji SK: Effect of **plasmapheresis** on porphyrin kinetics in an atypical case of congenital **erythropoietic porphyria (CEP)**. *Clin Res* **30: A327**, 1982

Szymanski IO, Snyder LM: Treatment of life-threatening anemia with **plasmapheresis** in a patient with paroxysmal nocturnal **hemoglobinuria**. *Plasma Ther Transfus Technol* **3:51-56**, 1982

Wenz B, et al: Partial **immunologic** reconstitution of a patient with acquired **agammaglobulinemia: A transient phenomenon accompanying therapeutic plasmapheresis.** *Blood* **59:233-235**, 1982

Yoshida Y, Yoshida H, Ohkubo T, Kamamoto T, Sawada H, Hiraoka A, Yamagishi M, Urchino H: **Plasmapheresis** in the treatment of **hemopoietic** diseases. *ICU & CCU* **6:21**, 1982 (In Japanese)

Anderson E, Skw F, Hippe E: A case of cold **haemoglobinuria** with later **sarcoidosis: Treatment with plasmapheresis** and immunosuppression. *Scand J Haematol* **24:47-50**, 1981

Erskine JG, Burnett AK, Walker ID, Davidson IF: Plasma exchange in **nonhaemophilias** with inhibitors to factor **VIIIc.** *Br Med J* **282:758-759**, 1981

Isbister J P, Ralston M, Hayes J M, Wright R: **Fulminant lupus pneumonitis with acute renal failure and RBC aplasia.** Successful management with **plasmapheresis** and **immunosuppression.** *Arch Intern Med* **141:1081-1083**, 1981

Kawagoe H, et al: Plasma exchange in Weber-Christian disease and a case with anti-factor VIII antibody. *Rinsho Ketsueki* **22:1616-1620**, 1981 (In Japanese)

Pillar G, Hückler H, Ludwig E, Niessner H: **Plasmapheresis.** Its role in the management of inhibitor patients. Workshop in Inhibitors of Factor VIII and IX. Wien *Facultas-Verlag*, 1977, p 57

Therapeutic **Pheresis** Bibliography No. 111: Malignant Paraproteinemias

A. Hyperviscosity Syndrome

Beck JR, Quinn BM, Meier FA, Rawnsley HM: **Hyperviscosity** syndrome in **paraproteinemia.** Managed by plasma exchange; monitored by serum tests. *Transfusion* **22:51-53**, 1982

Fazzini G, Albanese B, Manescal P, Lombardi C, Pasquini G, Bartoli V: Biochemical and **haemoreological** findings during treatment of plasma-cell **dyscrasias** by **plasmapheresis** or plasma exchange. *Clin Hemorh* **1:565-573**, 1981

Isbister J P: Plasma exchange in the management of **hyperviscosity** syndrome. *Bibl Haematologica* **47:228-241**, 1981

Somer T, et al: Clinical and theological studies in a patient with **hyperviscosity** syndrome due to **Waldenström's macroglobulinemia.** *Bibl Haematologica* **47:242-246**, 1981

Blaha M, et al: Case report of **hyperviscosity** syndrome **treatment** with plasma exchange using the "Aminco" separator. *Vnitř Lek* **26:786-791**, 1980 (In Czechoslovakian)

Anamiya Y, Baba M, Hisamitsu S, Ito T, Amaki T: Application of an apparatus for **plasmapheresis (Haemonetics Model 30)** in **hyperviscosity** syndrome. *Rinsho Ketsueki* **19:1436**, 1978 (In Japanese)

B. Macroglobulinemia

Euler H-H, Beress R, Gülzow K, Kleine L, Laessing C, Burck HC, Löffler H: Clinical evaluation of different **plasmapheresis** techniques in **IgM-paraproteinemias.** In "International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques.**" Cleveland: *Int Soc Artif Organs*, 1982, p 10

Kawai T, Yamagishi Y, Narita Y, Yuda M, Chiba A: Some pertinent factors involving blood **viscometry.** In Oda T (ed): "Therapeutic **Plasmapheresis.**" Stuttgart: F. K. *Schattauer Verlag*, 1981, pp 41-46

Somer T, et al: Clinical and theological studies in a patient with **hyperviscosity** syndrome due to **Waldenström's macroglobulinemia.** *Bibl Haematologica* **47:242-246**, 1981

Brehm G, Dorn W, Fateh-Moghadam A, Lydtin H: **Plasmapherese** beim **Waldenström** mit dem **IBM-Blutzell** separator. *Congr Dtsch Oster Ges Hamatologie*, 1975 (In German)

C. Multiple Myeloma

Pourrat J P, Dueymes J M, Conte 33, Pourrat O, Alcalay D, Touchard G, Patte D: Plasma exchange in **myeloma** renal failure. In "International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques.**" Cleveland: **Int Soc Artif Organs**, 1982, pp 32-33

Iwamoto H, Nakagawa S, Matsui N, Yoshiyama N, Shinoda T, Shibamoto T, Takeuchi J: An experience of plasma exchange by membrane separator for **IgA myeloma**. In **Sieberth H G (ed): 'Plasma Exchange. Plasmapheresis - Plasmaseparation.'** Stuttgart: F. K. **Schattauer Verlag**, 1980, pp 377-380

Ray PK, Idiculla A, Rhoads J E Jr, Besa E, Bassett J G, Cooper DR: Immuno-adsorption of **IgG** molecules from the plasma of multiple **myeloma** and **autoimmune hemolytic anemia** patients. **Plasma Ther Transfus Technol** 1:11, 1980

D. Cryoglobulinemia

Viguer E, Quaranta J F, Ortonne J P, Cassuto J P, Duplay H, Dujardin P: Effect of plasma exchange in the course of **cryoglobulinemias:** Study of 6 cases. In "International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques.**" Cleveland: **Int Soc Artif Organs**, 1982, p 47

Geltner D, Kohn R W, Gorevic P, Franklin E C: The effect of combination therapy (**steroids, immunosuppressive and plasmapheresis**) on 5 mixed **cryoglobulinemia** patients with renal, necrologic and **vascular** involvement. **Arthritis Rheum** 24:1121-1127, 1981

McKenzie R G, et al: **Glomerulonephritis** secondary to mixed **polyclonal cryoglobulinemia:** Response to **immunosuppression** and **plasmapheresis**. **Aust NZ J Med** 11:529-533, 1981

Reik L Jr, Kern J H: **Cryoglobulinemia** with **encephalopathy:** Successful treatment by plasma exchange. **Ann Neurol** 10:488-490, 1981

Houwert D A, et al: Effect of **plasmapheresis (PP), corticosteroids** and **cyclophosphamide** in essential mixed **polyclonal cryoglobulinemia** associated with **glomerulonephritis**. **Proc Eur Dial Transplant Assoc** 17:650, 1980

L'Abbate A L, Paciucci A, Bartolomeo F, Misefari V, Mobile F, Cerrai T, Maggiori Q: Selective removal of **plasma cryoglobulins** in **cryoglobulinemia**. **Proc Eur Dial Transplant Assoc** 14:486, 1977

E. Miscellaneous

Valbonesi M, Garelli S, Montaini F, Cefis M, Rossi U: Management of **immune-mediated** and **paraproteinemias** diseases by membrane plasma separation and **cascade** filtration. **Vox Sang** 43:91-101, 1982

Iwamoto H, Matsui N, Nakagawa S, Takeuchi J: An experience of plasma exchange in malignant paraproteinemia. In Oda T (ed): "Therapeutic **Plasmapheresis.**" Stuttgart: F. K. **Schattauer Verlag**, 1981, pp 107-112

Blank H J, Brinkmann O H, 3 unge-Hulsing G: **Plasmapheresis:** An effective procedure for paraproteinemia coma. **Dtsch Med Wschr** 105:1396, 1980 (In German)

Camerone G, et al: Use of **plasma** exchange in treating kidney failure from paraproteinemic diseases. **Riv Emoter Immunoematol** 27:168-174, 1980 (In Italian)

Jako J, Schopper 3: Plasma exchange in **paraproteinemia**. In Rainer H (ed): "Cell-separation and Cryobiology." Stuttgart: F. K. **Schattauer Verlag**, 1978, p 148

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. IV: Renal Diseases

A. Goodpasture's Syndrome

Euler H-H, Kleine L, GutSchmidt HJ, Herrlinger 3 D: Effect of early plasmapheresis and high-dose cyclophosphamide therapy in Goodpasture's syndrome. In Beyer H-J, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology." Basel: S. Karger, 1982, pp 238-246

Euler H-H, Kleine L, Gutschmidt HJ, Herrlinger 3 D: Goodpasture's syndrome: Rapid remission after early plasmapheresis and high-dose cyclophosphamide therapy. *Klin Wochenschr* 60:635-636, 1982 (English summary)

Arnold P, Dicker P: Experiences in often repeated plasma separation by membrane in a case of Goodpasture's syndrome. *Nieren-u. Hochdruckkrankht* 9:136, 1980

Goudable C, Segonds A, Eschapsse Y, Ton That H, Durand D, Gassia 3P, Suc JM: Plasma separation in a Goodpasture's syndrome associated with angeitis. *Nieren-u. Hochdruckkrankht* 9:142, 1980

Kamanabroo D, Intorp H W, Loew H, Müller K: Plasma exchange in combination with cytotoxic drugs and corticosteroids in the treatment of Goodpasture's syndrome. *Nieren-u. Hochdruckkrankht* 9:144, 1980

Oldenbroek C, Bakker P, Krediet RT, Arisz L: Plasma filtration in the treatment of Goodpasture's disease. *Nieren-u. Hochdruckkrankht* 9:147, 1980

Glöckner WM, Kindler 3, Vlaho M, Maerker-Alzer G, Mahieu P, Sieberth HG: Antikörper-Eliminierung mittels Plasmafiltration über Hohlfasermembranen am Beispiel des Goodpasture-Syndroms. *Verh Dtsch Ges Inn Med* 85:971, 1979 (In German)

Hensel A, Herrath DV, Schaefer K, Schroter-Lankowsky R: Goodpasture-Syndrom: erfolgreiche Behandlung durch Plasmapherese Kombiniert mit immunosuppressiver Therapie. *Diagnostik Intensivtherapie* 4:136, 1979 (In German)

Pussell BA: Plasma exchange in immune complex diseases and Goodpasture's syndrome. *Workshop on Therapeutic Plasma and Cytapheresis*, Mayo Clinic, April 1979

Erickson St. B, Kurtz SB, Donadio JV Jr, Honey KE, Velosa J, Wilson CB, Pineda AA: Treatment of Goodpasture's syndrome by plasmapheresis and immunosuppression. *Kidney Int* 11:640, 1978

Glöckner WM, Sieberth HG: Plasmafiltration in der Behandlung des Goodpasture-Syndroms. *Z ImmunForsch* 18:155, 1978 (In German)

ARC Blood Services
Bibliography Supplement 2
TPB IV-2

Kamanabroo D, Intorp H W, Müller K, Loew H: Plasma exchange in the treatment of Goodpasture's syndrome. In Rainer H (ad): "Cell Separation and cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 114

Lockwood CM, Rees AI, Russell B, Wilson CB, Peters DK: Plasmapheresis, cytotoxic drugs, and corticosteroids in the management of Goodpasture's syndrome. *Muscle Nerve* 1:339, 1978

Sieberth HG, Borberg H, Kinder J, Mahieu P, Seeling J: Plasmapheresebehandlung des Goodpasture-syndrom. In Watschinger B (cd): "Second Donau-Symposium für Nephrologie, Budapest, 1977

B. Glomerulonephritis

Bonomini V, et al: Effect of plasma exchange and thoracic duct drainage on immunological status in glomerulonephritis. *Proc Eur Dial Transplant Assoc* 18:736-742, 1981

Glöckner WM, Dienst C, Kinder J, Sieberth HG: Plasma exchange in rapidly progressive glomerulonephritis. *Dtsch Med Wochenschr* 106:1616-1620, 1981 (English abstract)

Kauffmann RH, et al: Plasmapheresis in rapidly progressive Henoch-Schoenlein glomerulonephritis and the effect on circulating IgA immune complexes. *Clin Nephrol* 16:155-160, 1981

Kupari M, et al: Plasma exchanges in the treatment of rapidly progressive glomerulonephritis associated with chronic dental infection. *Acta Med Scand* 21 OZ511-514, 1981

McKenzie RG, et al: Glomerulonephritis secondary to mixed polyclonal cryoglobulinemia: Response to immunosuppression and plasmapheresis. *Aust NZ J Med* 11:529-533, 1981

Peters DK, Lockwood CM: Plasma exchange in anti-GBM disease. In Gurland HJ, Heinze V, Lee HA (eds): *Therapeutic Plasma Exchange*. New York: Springer Verlag, 1981, pp 139-147

Rifle G, et al: Treatment of idiopathic acute crescentic glomerulonephritis by immunosuppression and plasma exchanges. A prospective randomized study. *Proc Eur Dial Transplant Assoc* 18:493-502, 1981

Sieberth HG, Glöckner WM, Borberg H, Kinder J, Vlaho M, Dienst C, Mitrenga D, Vaith P: Plasmaseparation in der Behandlung von rapid progressive Glomerulonephritiden. In Gurland HG, Heinze V, Lee HA (eds): *Therapeutic Plasma Exchange*. New York: Springer Verlag, 1981, pp 149-164 (In German)

Houwert DA, et al: Effect of plasmapheresis (PP), corticosteroids and cyclophosphamide in essential mixed polyclonal cryoglobulinemia associated with glomerulonephritis. *Proc Eur Dial Transplant Assoc* 17:650, 1980

Lockwood CM, Rees AJ, Pussell B, Peters DK: Experience in the use of **plasma exchange in the management of potentially fulminating glomerulonephritis**. In Rainer H (ed): "Cell Separation and Cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 134

McKenzie EE, Clarkson AR, Taylor H, Seymour AE, Woodroffe AJ, Chan YL: Plasma exchange therapy in **glomerular** diseases. Aust NZ J Med **8:223**, 1978

C. Miscellaneous

Banks RA, May S, Wellington T: Acute renal-failure in dense deposit disease: Recovery after **plasmapheresis**. Br Med J **284:187**, 1982

Clark WF, Williams W, Cattran DC, Chodirker WB, Koval J, Lindsay RM, Linton AL: Controlled trial of chronic plasma exchange therapy in SLE nephritis. Boston: **Haemoneutics Advanced Component Seminar, 1982 (abstract)**

Hene RJ, Valenti RM, Kater L: **Plasmapheresis** in nephritis of the **Henoch-Schonlein** purpura and primary **IgA** nephropathy. Eur J Clin Invest **12:16**, 1982

Iwanaga T, et al: Plasma exchange in intractable **nephrotic** syndrome and active systemic **erythematosus**. Rinsho Ketsueki **22:1620-1623**, 1982 (In 3 **apanese**)

Lopot F, et al: **Haemofiltration** - a new method of treatment for chronic renal failure. Cas Lek Cesk **121:210-213**, 1982 (English abstract)

Montoliu J, Bergada E, Arrizaba P, Revert L: Acute renal-failure in dense deposit disease - recovery after **plasmapheresis**. Br Med J **294:940**, 1982

Pourrat 3P, Dueymes J M, Conte 13, Pourrat O, Alcalay D, Touchard G, Patte D: Plasma ● xchange in **myeloma** renal failure. In "International Symposium on **Plasmapheresis**: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, pp 32-33

Sharon Z, Roberts J L, Fennell J S, Schwartz M M, Lewis E J: **Plasmapheresis** in lupus nephritis. Plasma Ther **Transfus Technol 3:163-169**, 1982

Bazzato G, et al: **Plasmapheresis** in the treatment of chronic secondary **nephropathy** of various etiologies. Minerva Nefrol **28:235-241**, 1981 (English abstract)

Itoh K, Narumi F, Ono M, Kawaguchi H: **Plasmapheresis** in the treatment of severe renal diseases in children. In Oda T (ed): "Therapeutic **Plasmapheresis**." Stuttgart: F. K. Schattauer Verlag, 1981, pp 201-206

Kuroda M, Akiyama T, Miyazaki R, Tofuku Y, Takeda R: Plasma exchange in the treatment of various renal diseases. In Oda T (ed): "Therapeutic **Plasmapheresis**." Stuttgart: F. K. Schattauer Verlag, 1981, pp 191-200

Landini S, Coli U, Lucatello S, Racasso A, Morachiello P, Toffoleto P, Bazzato G: Plasma-exchange and dialysis. Combined treatment in acute renal insufficiency secondary to severe hepatopathies. Minerva Nefrol **28:179-186**, 1981 (English abstract)

Morse EE, Pisciotto PT: Therapeutic **plasmapheresis** in patients with **renal** disease. Ann Clin Lab Sci **11:361-366**, 1981

Siciński A: Plasma ● xchange in kidney disease. Pol Arch Med Wewn **65:67-77**, 1981 (In Polish)

Stefoni S, et al: **Combined hemodialysis-hemoperfusion** treatment reduces the time of substitutive therapy in chronic **uremia**. Int J Artif Organs **4:186-191**, 1981

Camerone G, et al: Use of plasma exchange in treating kidney failure from **paraproteinemic** diseases. Riv Emoter Immunoematol **27:168-174**, 1980 (In Italian)

Swainson CP, Urbaniak SJ, Robson IS: Plasma exchange in the successful treatment of drug-induced renal failure. Nieren-u. Hochdruckkrankht **9:150**, 1980

Vilches AR, et al: **Plasmapheresis** and its use in nephritis. Medicine (B Aires) **40:196-202**, 1980

Apostoloff E, Blauarmel O, Kramm H J, Meffert H: **Therapieeffekt und** Antikörper **verhalten** nach **Plasmaphorese** bei Lupus erythematoses **visceralis mit** Lupus-Nephritis. Dtsch Gesundh Wesen **34:64**, 1979 (In German)

Clark WF, Lindsay RM, Chodirker WB, Cattran DC, Linton AL: Elective **plasmapheresis** in SLE nephritis: Pilot for a controlled prospective study. Am Soc Nephrol, 1979, p 928

Lockwood CM, Pussell B, Wilson CB: Plasma exchange in nephritis. Adv Nephrol **8:383**, 1979

Pinching AJ, et al: Plasma exchange in nephritis. J R Soc Med **72:97-108**, 1979

Uldall RP, Dyck RF, Woods F, Merchant N, Martin GS, Cardella Q, Sutton D, de Veber GA: **Subclavian cannula** for temporary vascular access for **haemodialysis** or **plasmapheresis**. Dial Transplant **9:963**, 1979

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. V: Connective Tissue Disorders

A. Systemic Lupus Erythematosus

Clark WF, Williams W, Cattran DC, Chodirker WB, Koval XI, Lindsay RM, Linton AL: Controlled trial of chronic plasma exchange therapy in SLE nephritis. Boston: *Haemonetics Advanced Component Seminar, 1982* (abstract)

Eden C, Herrlitz H, Lindholm L, Mulec H, Westberg G: Plasmapheresis in systemic lupus erythematosus. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: *Int Soc Artif Organs, 1982*, p 9

Gunby P: Plasmapheresis to be tried in systemic lupus. *JAMA* 247:1688, 1982

Hamblin TJ, et al: Severe deafness in systemic lupus erythematosus: Its immediate relief by plasma exchange. *Br Med J [n Res]* 284:1374, 1982

Iwanaga T, et al: Plasma exchange in intractable nephrotic syndrome and active systemic erythematosus. *Rinsho Ketsueki* 22:1620-1623, 1982 (In Japanese)

Lewis EJ: Plasmapheresis for the treatment of severe lupus nephritis. - uncontrolled observations. *Am J Kidney* 2:182-187, 1982

Plasmapheresis to be tried in systemic lupus. *JAMA* 247:1688, 1982 (editorial)

Sharon Z, Roberts JL, Fennel JS, Schwartz MM, Lewis EJ: Plasmapheresis in lupus nephritis. *Plasma Ther Transfus Technol* 3:163-169, 1982

Tsokos GC, Balow JE, Huston DP, Wei N, Decker J L: Effect of plasmapheresis on lymphocyte-T and lymphocyte-B functions in patients with systemic lupus erythematosus - a double-blind study. *Clin Exp Immunol* 48:449-457, 1982

Wallace DJ, Goldfinger D, Bluestone R, Klinenberg JR: Plasmapheresis in lupus nephritis with nephrotic syndrome: A long-term followup. *J Clin Apheresis* 1:42-45, 1982

Amano I, Inagaki U, Tsuzuki K, Yamamoto T, Sugiyama T, Ide M, Kanoh H: Experiences with plasma exchange for treatment of paraquat intoxication, SLE, and acute liver failure. *Artif Organs* 10:563, 1981

Evans DT, Giles M, Home DJ, d'Apice AJ, Riglar A, Toh BH: Cerebral lupus erythematosus responding to plasmapheresis. *Postgrad Med J* 57:247-251, 1981

Hamburger MI, Gerardi EN, Fields TR, Bennett RS: Reticuloendothelial system Fc receptor function and plasmapheresis in systemic lupus erythematosus: A preliminary report. *Artif Organs* 5:264-268, 1981

ARC Blood Services
Bibliography Supplement 2
TPB V-2

Kater L, et al: Effect of plasmapheresis in active systemic lupus erythematosus. *Neth J Med* 24:209-216, 1981

Matsumoto Y, Masaoka A, Kotoh Y: plasma-exchange-regimes in the treatment of autoimmune disorders: Systemic lupus erythematosus and pemphigus. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 209-214

Millman RP, et al: Systemic lupus erythematosus complicated by acute pulmonary hemorrhage: Recovery following plasmapheresis and cytotoxic therapy. *J Rheumatol* 8:1021-1023, 1981

Nasonova VA, et al: Hemoperfusion through activated charcoal in the complex treatment of systemic lupus erythematosus. *Ter Arkh* 53:107-112, 1981 (In Russian)

Verrier Jones J, Robinson MF, Parciany RK, Layfer LF, McLeod B: Therapeutic plasmapheresis in systemic lupus erythematosus. Effect on immune complexes and antibodies. *Arthritis Rheum* 24:1113-1120, 1981

Apolstoioff E, Blauarmel O, Kramm HJ, Meffert H: Therapieeffekt und Antikörperverhalten nach Plasmaphorese bei Lupus erythematoses visceralis mit Lupus Nephritis. *Dtsch Gesundh Wesen* 34:64, 1979 (In German)

Clark WF, Lindsay RM, Chodirker WB, Cattran DC, Linton AL: Elective plasmapheresis in SLE nephritis: Pilot for a controlled prospective study. *Am Soc Nephrol*, 1979, p 928

Verrier Jones J, Cumming RH, Bucknall RC, Asplin CM, Fraser ID, Bothamley J, Davis P, Hamblin TJ: A therapeutic role for plasmapheresis in the management of acute systemic lupus erythematosus. Boston: *Haemonetics Advanced Component Seminar*, 1976

B. Polyarteritis Nodosa - Wegener's Granuloma

Suchy B-R, Schley R, Nogai K, Bennhold J, Pribilla W: Plasma exchange in a case of Wegener's granulomatosis. In Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology." Basel: S. Karger, 1982, pp 247-250

C. Rheumatoid Arthritis

Cooling, then culling blood complexes combats arthritis. *JAMA* 248:632, 1982

Hamburger MI: A critical review of therapeutic apheresis in the treatment of severe rheumatoid arthritis. Boston: *Haemonetics Advanced Component Seminar*, 1982, abstract

Heyse SP, Renault PR, Perry S: National Center for Health Care Technology assessment of therapeutic apheresis for rheumatoid arthritis, 1981. *J Clin Apheresis* 1:50-54, 1982

Krakauer RS, Aa anuma Y, Zawicki I, Calabrese L, Malchesky PS, Nosé Y: Circulating immune complexes in rheumatoid arthritis: Selective removal by cryogelation with membrane filtration. *Arch Intern Med* 142:395-397, 1982

van Wanghe P, Dequeker J: Effect of intravenous cyclophosphamide as an adjuvant to therapeutic plasma exchange in rheumatoid arthritis. *Plasma Ther Transfus Technol* 3:171-176, 1982

Wallace DJ, Goldfinger D, Brachman M, Klinenberg J: A double-blind controlled study of lymphoplasmaferesis (LP) in rheumatoid arthritis (RA). Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

Wallace D, Goldfinger D, Lowe C, Nichols S, Weiner J, Brachman M, Klinenberg JR: A double-blind, controlled study of lymphoplasmaferesis versus sham apheresis in rheumatoid arthritis. *N Engl J Med* 306:1406-1410, 1982

Asada H, Kobayashi S, Niwa T, Sezaki R, Kano K, Kawanishi A, Yokoyama M, Kishi T, Kawaguchi S, Maeda K: Plasma exchange in the treatment of psoriasis pustulosa and malignant rheumatoid arthritis. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 145-151

Azuma N, Nobuto T, Suzuki M, Asanuma Y, Malchesky PS, Shimo K, Takahashi M, Suzuta T, Nosé Y: Clinical effect of plasmapheresis with continuous cryofiltration for three cases of rheumatoid arthritis. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 159-163

Denman AM: Removal of lymphocytes in rheumatoid arthritis. *Br Med J* 3:283:1492, 1981

Dequeker J, Naessens M, Martens J, Pieters R: The effect of plasma exchange on synovitis in rheumatoid arthritis. *Scand J Rheumatol* 10:273-279, 1981

Dequeker J, Walravens M, Leys A, Pieters R: Arteritis associated with hyper-viscosity-like syndrome in rheumatoid arthritis, treated by intermittent plasma-exchange for 2.5 years. *Rheumatol Rehabil* 20:203-207, 1981

Hamburger MI, Gerardi EH, Fields TS, Bernstein ML, Bennett RS: Lymphoplasmaferesis and reticuloendothelial system (RES) Fc receptor function in rheumatoid arthritis (RA). *Arthritis Rheum* 24: S98, 1981

Karsh J: Plasmapheresis or lymphapheresis in rheumatoid arthritis. In Gurland HJ, Heinze V, Lee HA (eds): "Therapeutic Plasma Exchange." New York: Springer Verlag, 1981, pp 111-123

Russell AS, Davis P, Percy JS: Plasma exchange in rheumatoid arthritis? *J Rheumatol* 8:364-366, 1981

Scott DG, Bacon PA, Bothamley JE, Allen C, Elson CJ, Wellington TB: Plasma exchange in rheumatoid vasculitis. *J Rheumatol* 8:433-439, 1981

Shimo K, Suzuta T, Suzuki M, Noae Y: Basic and clinical studies on continuous cryofiltration: A new treatment for rheumatoid arthritis. *Rheumachi* 21:61, 1981

Shiozawa K, Yamagata J, Shiokawa Y, Yuasa S, Hashimoto H: Plasma exchange for rheumatoid arthritis. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 166-168

Takahashi K, Ogita T, Miyamoto Y, Takaishi T, Saito K, Yoshizawa H, Horiuchi Y: Effect of plasmapheresis as a new therapy for rheumatoid arthritis. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 169-173

Wallace DJ, Goldfinger D, Klinenberg JR: Current status of therapeutic pheresis in rheumatoid arthritis. *Artif Organs* 5:297-298, 1981

Yano T, Naiki K, Kato R, Kazui H, Terasawa T, Tsuchioka H: Plasma exchange in a case of malignant rheumatoid arthritis with ulcers of legs and feet. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 153-157

Karsh J, Wright DC, Klippel JH, Deisseroth AB, Decker JL: Lymphocyte removal by continuous flow cell separation in rheumatoid arthritis. *Arthritis Rheum* 22:626, 1979

Wallace DJ, Gatti R, Goldfinger D, Klinenberg JR: Promising results reported in trial of plasmapheresis in rheumatoid arthritis treatment. *Rheum News Int*, vol 7, 1979

D. Raynaud's Syndrome

O'Reilly M: Raynaud-Syndrom-Ulzera heilen nach Plasmapherese. *Medical Tribune Kongressbericht*, May 1978 (In German)

E. Miscellaneous

Bjelle A, et al: Plasma exchange in two patients with rheumatoid vasculitis. *Scand J Rheumatol* 11:58-62, 1982

Camerone G, et al: Plasma exchange treatment in a patient with severe Schoenlein-Henoch purpura. *Minerva Med* 73:1185-1187, 1982 (English abstract)

Cecere FA, Spiva DA, Langley JW: Plasmapheresis/lymphocytapheresis for the treatment of dermatomyositis and polymyositis. Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

Gipstein RM, Adams DA, Gracie MT, Peter J B: Response of lupus nephritis to plasmapheresis without demonstration of circulating immune-complexes. *Am J Med Sci* 283:37-41, 1982

Hamblin T, Clark CI: Plasma exchange in polymyositis and Sjogren's syndrome. Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

A. Renal

Mandel D, Calabrese L, Clough J: Plasma exchange therapy of **immune** complex mediated **vasculitis**. In "International Symposium on **Plasmapheresis**: Therapeutic Applications and New **Techniques**." Cleveland: **Int Soc Artif Organs**, 1982, p 28

Wysenbeek A3, **Calabrese LH, Mandel DR, Clough 3 D**: Limited **plasmapheresis** in **fulminant leukocytoclastic vasculitis**. **J Rheumatol** **9**:315-318, 1982

Bennington 3 L, **Dau PC**: Patients with **polymyositis** and **derrnatomyositis** who **undergo plasmapheresis** therapy. Pathologic findings. **Arch Neurol** **38**:553-560, 1981

Brubaker DB, Winkelstein A: Plasma exchange in rheumatoid **vasculitis**. **Vox Sang** **41**:295-301, 1981

Dau PC, Kahleh MB, Sagebiel RW: **Plasmapheresis** and **immunosuppressive** drug therapy in **scleroderma**. **Arthritis Rheum** **24**:1128-1136, 1981

Dmitriev AA, et al: Experience using **hemosorption** therapy in allergic cutaneous **vasculitis**. **Vestn Dermatol Venerol** **9**:19-22, 1981 (English abstract)

Eliasson S, Florence 3, Reppun T: Idiopathic inflammatory myopathy and **plasmapheresis**. **Muscle Nerve** **4**:446-447, 1981

Kawagoe H, et al: Plasma exchange in **Weber-Christian** disease and a case with anti-factor VIII antibody. **Rinsho Ketsueki** **22**:1616-1620, 1981 (In la-)

Pieters R, Dequeker J: Infectious complications with plasma-exchange in connective tissue diseases. Abstract 643, 15th International Congress of Rheumatology, Paris, **June** 1981

Scott DGI, Bacon PA, Bothamley JE, Allen C, Elson CJ, Wellington TB: Plasma exchange in rheumatoid **vasculitis**. **J Rheumatol** **8**:433-439, 1981

Cohen J, Lockwood CM, Calnan CD: **Plasma-exchange** in treatment of **leucocytoclastic vasculitis**. **3 R Soc Med** **73**:457-460, 1980

Valbonesi M, Garelli S, Mosconi L, Camerone G, Bedarida G, Di Guardo G: Plasma exchange in the management of a patient with diffuse **necrotizing** cutaneous **vasculitis**. **Vox Sang** **39**:241-245, 1980

Jaffe IA: Comparison of the effect of **plasmapheresis** and **penicillamine** on the level of circulating rheumatoid factor. **Am Rheum Dis** **22**:71-76, 1963

Allen N, Dyer P, Harris K, Smith 3, Lee HA, Slapak M: Effects of plasma exchange on immunoglobulins, complement, and immune complexes in renal transplant recipients. **Plasma Ther Transfus Technol** **3**:157-162, 1982

Cardella a: Does plasma exchange have a role in renal transplant rejection? **Plasma Ther Transfus Technol** **3**:153-156, 1982

Joeekes AM, Amir-Ansari B: **Plasmapheresis** in transplant rejections. In "International Symposium on Therapeutic **Plasmapheresis**: Therapeutic Applications and New Techniques." Cleveland: **Int Soc Artif Organs**, 1982, p 15

Kleinman S, Nichols M, Strauss F, Goldfinger D: Use of **lymphoplasmapheresis** or **plasmapheresis** in the management of acute renal **allograft** rejection. **J Clin Apheresis** **1**:14-17, 1982

McCurdy PR, Darr FW: *Treatment* of steroid resistant **renal allograft rejection** with **plasmalymphapheresis**. Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

McCurdy PR, Darr F W, Helfrich GB, Philips T, Pechan BW, Alijani M, Papadopolous ZL, Gelfand M: Treatment of steroid resistant renal **allograft** rejection with **plasmalymphapheresis**. In "International Symposium on **Plasmapheresis**: Therapeutic Applications and New Techniques." Cleveland: **Int Soc Artif Organs**, 1982, pp 29-30

Slapak M, Naik RB, Lee HA: The effect of plasma exchange on crossing the major blood group barrier in renal transplantation: Clinical and experimental observations. Boston: **Haemonetics** Advanced Component Seminar, 1982 (abstract)

Allen NH, Slapak M, Lee HA: Plasma exchange in renal **allograft** rejection. In **Gurland I-U, Heinze V, Lee HA (eds)**: "Therapeutic Plasma Exchange." New York: Springer Verlag, 1981, pp 175-190

Cardella CJ, Sutton DMC, Katz A, Uidall PR, Harding M, Cook CT, deVeber GA: Plasma exchange in renal transplantation. In **Zurukzoglu W, Papadimitriou M, Pyrapasopoulos M, Sion M, Zamboulis C (eds)**: "Proceedings, 8th International Congress of Nephrology." Stuttgart: **S. Karger**, University Studio, 1981, pp 681-685

Kirubakaran MC, Disney APS, Norman I, Pugsley 03, Mathew TH: A controlled trial of **plasmapheresis** in the treatment of renal **allograft** rejection. **Transplantation** **32**:164-165, 1981

A. Hepatitis, **Hepatic** Coma

Lundgren G, Asaba H, Bergstrom J, **Groth** CG, **Magnusson** G, **Moller** E, **Strindberg** J, **Wehle** B: Fulminating anti-A **autoimmune hemolysis** with anuria in a renal transplant recipient: A therapeutic role of plasma exchange. **Clin Nephrol** 16:211-214, 1981

Power D, Nicholls A, Muirhead N, **MacLeod** AM, Engeset J, Catto GRD, Edward N: Plasma exchange in acute renal **allograft** rejection: Is controlled trial really necessary? **Transplantation** 32:162-163, 1981

Burrows L, **Schanzer** H, **Haimov** M, **Jhaver** K, **Deutsch** V, Ambinder E: Reversal of rejection and subsidence of **immunoglobulinuria** by intensive plasmapheresis. **Proc Eur Dial Transplant Assoc** 17:491-495, 1980

Disney A, Taylor H, Norman J, **Fazzalari** R, **Pubsley** D, Mathew T: **Plasmapheresis** in renal transplantation. **Aust Soc Nephrol** 8:227, 1978

Merkel FK, Bier M, Beavers CD, **Merriman** WG, **Starzl** TE: Delay of the **heterograft** reaction by selective **plasmapheresis**. **Surg Forum** 21:261-263, 1970

B. Bone Marrow

Bensinger W: Plasma exchange and **immunoabsorption** for removal of antibodies prior to ABO incompatible bone marrow transplant. **Artif Organa** 5:254-258, 1981

Buckner CD, et al: **Pheresis techniques** in marrow transplantation. **Prog Clin Biol Rea** 65:81-89, 1981

Gonzalez Lopez MA, **Montoro** JA, **Martinez** J, Sanz MA, Perez **Castellanos** T, **Soler** MA, Marty ML: Massive **plasmapheresis** in the conditioning for **ABO-incompatible bone-marrow** transplant. **Sangre (Bare)** 26:497-503, 1981 (English abstract)

Harada M, et al: **Plasmapheresis** in familial **hypercholesterolemia** and **bone marrow transplantation** from an ABO incompatible donor. **Rinsho Ketsueki** 22:1632-1635, 1981 (English abstract)

Higby DJ, et al: Reversal of possible marrow graft rejection with plasma exchange therapy. **J Med** 12:455-461, 1981

Clift RA, **Sanders** JE, Thomas ED, Williams B, **Buckner** CD: **Granulocyte** transfusions for the prevention of infection in patients receiving bone marrow transplants. **N Engl J Med** 298:1052-1057, 1978

Landini S, **Coli** U, **Lucatello** S, **Fracasso** A, **Morachiello** P, **Righetto** F, **Bazzato** G: The effect of plasma-exchange (**PE**) on **hepatic** coma in **leptospirosis** and **fulminant** hepatitis. In "International Symposium on **Plasmapheresis: Therapeutic Applications** and New Techniques." Cleveland: **Int Soc Artif Organs**, 1982, p 18

Inoue N: Treatment of **fulminant** hepatitis - **prevention of complications** and plasma exchange therapy. **Kango Gijutsu** 27:25-33, 1981 (In Japanese)

Kono Y, **Tsuhishashi** N, **Shimizu** C: Management and nursing of a patient with **fulminant** hepatitis receiving plasma exchange. **Kango Gijutsu** 27:51-56, 1981 (In Japanese)

Mugishima H, et al: HB virus induced **fulminant** hepatitis in hemophilia B: Successful management with **plasmapheresis** and **hemoperfusion**. **Rinsho Ketsueki** 22:1628-1631, 1981 (In Japanese)

Ueda T, **Masaoka** T, **Shibata** H, **Kubota** Y, **Saigo** K, **Takubo** T, Nakamura H, **Yoshitake** J, **Ishigami** S: Hepatic coma treated by plasma exchange during treatment for **hematological** malignancies. In Oda T (ed): **therapeutic Plasmapheresis**." Stuttgart: **F.K. Schattauer Verlag**, 1981, pp 93-97

Yamamoto H, Endo A, Yamamoto Y, **Matsunaga** S, **Noguchi** H, Nagasaki Y, Nishioka S, Yataka I, Abe T: A case of severe hepatitis A with renal **failure** treated by plasma exchange, **hemodialysis** and **glucagon-insulin** therapy. in **Oda** T (ed): **therapeutic Plasmapheresis**." Stuttgart: **F. K. Schattauer Verlag**, 1981, pp 99-103

Sakamoto H, Shimizu M, Harada H, Ohtake H, Tanaka S, **Ohbayashi** A: Evaluation of plasma exchange as a liver **support** therapy for **fulminant** hepatitis. **Liver** 21:723, 1980

Valbonesi M: The cell separator in the therapy of hepatic coma: Preliminary experience in cases of viral hepatitis. **Riv Emoter Immunoematol** 27:51-56, 1980

Boland J, et al: Fulminating hepatitis treated by plasmapheresis. **Acta Gastro-Enterol Belg** 38:207-217, 1975

Jesipowicz M, et al: **Termination** of hepatic coma complicating viral hepatitis by means of exchange transfusion with **plasmapheresis**. **Pol Tyg Lek** 30:1265-1266, 1975

Jesipowicz M, **Jakubowska** M, Karski J, Osterowa K: **Plasmapheresis** and exchange transfusion in the treatment of **hepatic** coma. **Pol Tyg Lek** 30:707, 1975

Klebanoff G: A preliminary assessment of the efficacy of **asanguineous-hypothermic total body perfusion** in the management of stage IV **hepatic coma**. *Am J Gastroenterol* **60:103-113**, 1973

Chang TMS: Hemoperfusion over **microencapsulated adsorbent** in a patient with **hepatic coma**. *Lancet* **2:1371-1372**, 1972

Haapanen E, Tiula E: **Plasmapheresis** with albumin as main substitute in acute **hepatic coma**. *Scand J Gastroenterol* **7:75-83**, 1972

Hautfova D, et al: Plasmapheresis in the treatment of **hepatic coma** (preliminary report). *Vnitř Lek* **18:319-327**, 1972

Sandu L, et al: **Plasmapheresis** with plasma replacement in the treatment of **hepatic coma**. *Anesth Analg (Paris)* **28:1101-1107**, 1971 (In French)

Graw RG, Buckner CD, Eisel R: Plasma exchange transfusion for **hepatic coma**. New technique. *Transfusion* **10:26**, 1970

Durden WD, Siemsen AW, Briggs WA: Exchange transfusions in the treatment of **fulminant hepatitis and coma**. *Am J Gastroenterol* **51:129-137**, 1969

Szwed 33, Mendenhall CL, Grisell TW: Exchange transfusions for intractable **hepatic coma**. *Arch Intern Med* **123:441-444**, 1969

B. Miscellaneous

Balentin L, Lin J, Greenberg N, Abdou NI: Efficacy of **plasmapheresis (PL)** in primary **biliary-cirrhosis (PBC)** - dissociation between correction of immune parameters and clinical improvement. *Clin Res* **30: A279**, 1982

Landini S, Coli U, Lucatello S, Fracasso A, Morachiello P, Righetto F, Bazzato G: Plasma-exchange: Prevention and treatment of toxic acute hepato renal failure. In International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques**. Cleveland: *Int Soc Artif Organs*, 1982, p 19

Landini S, Coli U, Lucatello S, Fracasso A, Morachiello P, Righetto F, Bazzato G: Plasma-exchange in severe **leptospirosis**. In 'International Symposium on **Plasmapheresis: Therapeutic Applications and New Techniques**.' Cleveland: *Int Soc Artif Organs*, 1982, p 20

Le Pogamp C, et al: **Cholestasis** of pregnancy. A new indication for plasma exchange. *Now Presse Med* **11:457**, 1982 (In French)

Amano I, Inagaki U, Tsuzuki K, Yamamoto T, Sugiyama T, Ide M, Kanoh H: Experiences with plasma exchange for treatment of **paraquat** intoxication, SLE, and acute liver failure. *Artif Organs* **10:563**, 1981

Asanuma Y, et al: Chronic ambulatory liver support by membrane **plasmapheresis** with on-line detoxification. *Trans Am Soc Artif Intern Organs* **27:416-422**, 1981

Horak W, Polterauer P, Renner F, Silberbauer K, Funovics 3, Muhlbacher F, Rauhs R: **Plasmapheresis** in **fulminant hepatic failure**. In Rainer H (ed): "Cell Separation and Cryobiology." Stuttgart: F. K. **Schattauer Verlag**, 1981, p 101

Inoue N, Yamazaki Z, Yoshiba M, Ichikawa K, Sakai T, Oda T, Sanjo T, Wada T, Inoue 3, Saoshiro T, Horiuchi T, Ide K, Fujisaki Y: **Plasma** exchange using membrane **plasmapheresis** in the treatment of acute **hepatic failure**. *Artif Organs* **10:557**, 1981

Inoue N, Yamazaki Z, Yoshiba M, Okada Y, Sanjo K, Oda T, Wada T: **Membrane plasmapheresis with plasma** exchange in the treatment of acute liver failure. In **Oda T (ed): "Therapeutic Plasmapheresis."** Stuttgart: F. K. **Schattauer Verlag**, 1981, pp 57-63

Keeling PW, Bull J, Kingston P, Thompson RP: Plasma exchange in primary **biliary cirrhosis**. *Postgrad Med J* **57:433-435**, 1981

Landini S, et al: Plasma exchange in severe **leptospirosis**. *Lancet* **2:1119-1120**, 1981

Mizokami M, Kano H, Amano I: Experience with plasma exchange in **hepatic failure** of hyperbilirubinemia and hyperalpha-fetoprotein (**AFP**) of **hepatoma**. In **Oda T (ed): "Therapeutic Plasmapheresis."** Stuttgart: F. K. **Schattauer Verlag**, 1981, pp 89-92

Okamura 3, Horikawa S, Fujiyama T, Kambayashi J, Gotoh M, Sikujara O, Monden M, Kosaki G, Sakurai M: Indication and effect of plasma exchange on **hepatic failure**. In **Oda T (ed): "Therapeutic Plasmapheresis."** Stuttgart: F. K. **Schattauer Verlag**, 1981, pp 71-75

Shimizu H, Yoshida S, Hosoya R, Eiraku K, Nishimura K: **Clinical trial of plasmapheresis** in **hepatic failure**. In **Oda T (ed): Therapeutic Plasmapheresis."** Stuttgart: F. K. **Schattauer Verlag**, 1981, pp 83-88

Takayama M, Tomita Y, Okumura H, Katsuta Y, Satomura K, Aramaki T, Henmi H, Murakami M, Koseki K: A case of **fulminant hepatic failure** treated with plasma exchange: Problems and effectiveness. In **Oda T (ed): Therapeutic Plasmapheresis."** Stuttgart: F. K. **Schattauer Verlag**, 1981, pp 77-82

Ueda K, et al: Effectiveness of plasma exchange in liver diseases and studies of dose of plasma exchange. *Rinsho Ketsueki* **22:1636-1638**, 1981 (In Japanese)

Maini R: A detoxification scheme for liver assist utilizing **plasmapheresis, biocompatible sorbents** and dialysis. *Artif Organs* **3:153-155**, 1979

Geerdink P, Snel P, Van Berge Henegouwen GP, Huybregts A, Tangerman A, Kunst VAJ M, Van Tongeren JHM: Treatment of intractable pruritus in patients with **cholestatic jaundice** by plasma exchange and plasma perfusion. *Neth J Med* **21:239**, 1978

Geerdink P, Van Berge Henegouwen GP, Hectors M, Huybregts A, Kunst VAJ M, Van't Laar A, Snel P, Tangerman A, Van Tongeren JHM: Treatment of intractable pruritus in patients with **cholestatic jaundice** by plasma exchange and plasma perfusion. In **Rainer H (ed): "Cell Separation and Cryobiology."** Stuttgart: F. K. **Schattauer Verlag**, 1978, p 111

Baltzer G, et al: Exchange transfusion in acute liver failure. *Dtsch Med Wochenschr* **96:1329-1333**, 1971

de **Estable Puig RF**, Eatable **Puig JF**: Acute yellow atrophy in pregnancy: A case treated by **plasmapheresis** and studied with the electron **microscope**. *L'Union Med du Canada* **99:1083-1093**, 1970

Konstantinov VN: Effect of **plasmapheresis** on the protein-synthetic function of the liver and several immunologic indices of reactivity of the donor **organism**. *Probl Gematol Pereliv Krovi* **15:50-51**, 1970 (In Russian)

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic **Pheresis** Bibliography No. **VIII: Hemolytic** Disease of the Newborn

Robinson EA: Potential for plasma exchange in **children**. *Arch Dis Child* **57:300-308**, 1982

Rock-C, **Laferriere I**, Chan L, McCombie N: Plasma exchange in the treatment of **hemolytic** disease of the newborn. In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: Int Soc Artif Organs, **1982**, p 38

Rubinstein P: Repeated small **volume plasmapheresis** in the management of **hemolytic** disease of the newborn. In **Frigoletto FD Jr, Jewett JF, Konugres AA (eds): "Rh Hemolytic Disease. New Strategy for Eradication."** Boston: G. K. Hall Medical Publishers, **1982**, pp 211-220

Krislo V, et al: **Plasmapheresis** in the treatment of Rh **isoimmunizations** during **gravidity**. *cas. Gynecol* **46:174-177**, 1981 (English abstract)

Macchia A, et al: Bleed chemical **parameters** in newborn infants with fatal **erythroblastosis** during exchange transfusion. *Minerva Ginecol* **33:548-553**, **1981**

Olowe SA, et al: Exchange transfusion using G-6-PC deficient **Hgb-AS** blood in **icteric** neonates. *J Natl Med Assoc* **79:811-819**, **1981**

Sagi E, et al: Exchange transfusion in newborns via a peripheral **artery** and **vein**. *Eur J Pediatr* **137:283-284**, 1981

Simonovits I, Vedrodi K, Jokuti I, Forgacs J, Gy S: **Plasmapheresis** in Rh immunized pregnant **women**. *Acta Haematol* **12:65-67**, **1981**

Yoshida Y, Yoshida H, Tatsumi K, Asoh T, Nishimura T, Uchino G: A new method of selective antibody elimination for the treatment of **severe** M-incompatible pregnancy. In **Oda T (ed): "Therapeutic Plasmapheresis."** Stuttgart: F. K. Schattauer Verlag, 1981, pp 235-239

Takahashi H, et al: Plasma exchange in the pregnant **Rh-sensitized** woman. *Rinsho Ketsueki* **22:1644-1647**, 1981 (In Japanese)

Cregut R, et al: Theoretical model of **epuration** by plasma **exchange**. Application to anti-(D) immunization. *Rev Fr Transfus* **23:365-371**, 1980

Heyns AduP, Odendaad HJ, Siabber CR, Karshagen WF, Du Plessis HH3, Potgieter GM: Severe **Rh-isoimmunization** and intensive plasma exchange during pregnancy. *S Afr Med J* **58:884**, 1980

Newland AC, Colvin BT, Dodd BE: Plasma exchange in severe **rhesus haemolytic** disease. *Br Med J* **2:452**, 1980

Tovey D, Robinson EAE: Effect of plasma exchange in *rhesus* immunization. *Br Med J* 2:387, 1980

Wensley RT, Lee D, Fletcher S: Adverse effect of plasma exchange on anti-D production. *Br Med J* 2:619, 1980

Brossart Y: Incidents et accidents observés après 200 échanges plasmatiques chez 12 femmes enceintes, severement RH immunisees. Les échanges plasmatiques: Pratique, résultats et perspectives. Bois Guillaume, March 1979

Graham-Poole 3: Exchange plasmapheresis for severe rhesus disease. Minneapolis: Workshop on Therapeutic Plasma and Cytapheresis, April 1979, Mayo Clinic

Brossard Y, Bussel A, Cregut R, Benbunan M, Gerota I, Roberts JF: Massive plasma exchange during pregnancy using the CFC blood cell separator in cases of Rh-immunization. In Rainer H (ed): "Cell Separation and Cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 124

Tilz GP, Weiss P, Teuble I, Lanzer G, Wollman H: Successful plasma exchange in rhesus incompatibility and other clinical conditions. In Rainer H (ed): "Cell Separation and Cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 121

Correa N, et al Immunologic aspects of plasmapheresis in series of Rh negative pregnant women. *Rev Chil Obstet Ginecol* 41:237-258, 1976

Fraser ID, et al Proceedings: Anti-natal plasmapheresis in severe rhesus iso-immunisation. *Br J Haematol* 23:147, 1974

Beyer J-H, Klee M, Kaboth U, Kehl A, Köstering H, Krieger G, Nagel GA: Problems of plasma+ xchange solutions, gamma-globulin substitution, and tumor enhancement in plasmapheresis of tumor patients. In **Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology."** Basel: S. Karger, 1982, pp 204-217

Borghardt J, Beyer J-H, Nagel GA: Monitoring the course of CEA concentration in tumor patients receiving plasmapheresis. In **Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and oncology."** Basel: S. Karger, 1982, pp 260-266

Israel L, Edelstein R, Samak R: Repeated plasma exchanges in patients with metastatic cancer. In **Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology."** Basal: S. Karger, 1982, pp 196-203

Klee M, Beyer J-H, Schuff-Werner P, Nagel GA: The treatment of malignant lymphomas with plasma exchange. In **Bayer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology."** Basel: S. Karger, 1982, pp 251-259

Köstering H, Beyer J-H, Klee M, Kasten U, Schuff-Werner P, Nagel GA: Blood coagulation changes induced by repeated plasmapheresis in 12 normal donors and 15 patients with malignomas. In **Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology."** Basel: S. Karger, 1982, pp 218-231

Micksche M, Colot M, Kokoecek EM, Moser K, Rainer H: Plasmapheresis in patients with advanced malignant disease - a pilot study. *Oncology* 39:146-151, 1982

Schuff-Werner P, Brattig N, Beyer J-H, Bartel J, Berg PA, Nagel GA: Bio-assays as a tool for the demonstration of immune alteration in cancer patients Suppression of mitogen-induced lymphocyte proliferation by patients' sera during plasma exchange. Preliminary results in four patients. In **Beyer J+1, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology."** Basel: S. Karger, 1982, pp 178-193

Beyer 3 -H, Schuff-Werner P, Kaboth U, Klee M, Kostering H, Krieger G, Nagel GA: Combined plasmapheresis, chemotherapy and gammaglobulin-substitution in patients with drug resistant malignant disease: Preliminary clinical results. In **Nydegger UE (ed): "Immunoheatherapy. A Guide to Immunoglobulin Prophylaxis and Therapy."** London: Academic Press, 1981, pp 347-350

Beyer J-H, Schuff-Werner P, Kaboth U, Klee M, Köstering W, Nagel GA: Plasmapherese: erste Klinische Ergebnisse bei malignen tumoren. *Schweiz Med Wochenschr* 111:1522-1524, 1981

Cupissol D, Gauci L, Serrou B: Evaluation of a simplified plasma exchange therapy in the treatment of advanced cancer - effects on the immune response. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Cancer Patients." New York: Elsevier/North Holland Biomedical Press, 1981, p 329

Dimitrov NV, Rapaon C, McNutt R: Clinical results of multiple plasmapheresis in patients with advanced cancer. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Cancer Patients." New York: Elsevier/North Holland Biomedical Press, 1981, p 293

Glassman AB: Gammopathies - clinical considerations related to plasmapheresis. In **Serrou B, Rosenfeld C** (eds): "Immune complexes and Plasma Exchanges in Cancer Patients." New York: Elsevier/North Holland Biomedical Press, 1981, p 277

Israel L, Edelstein R: Repeated plasma exchange in patients with metastatic cancer. *Immunol Parasite Immunol* 97:75, 1981

Israel L, Edelstein R, Samak R, Baudelot J, Breau 3L, Mannoni P, Radot E: Clinical results of multiple plasmapheresis in patients with advanced cancer. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Cancer Patients." Amsterdam: Elsevier/North Holland, 1981, pp 309-327

MacDonald 3S, Phillips TM, Smith FP, Lewis M, Israel L: The effect of aggressive plasma exchange on immune complex levels in plasma of patients with metastatic cancer. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Patients with Cancer." New York: Elsevier/North Holland Biomedical Press, 1981, p 243

Rainer H, Kokoschka EM, Micksche M, Moser K, Colot M: Plasmapheresis for therapy in patients with metastasizing solid tumors. In **Gurland HJ, Heinze V, Lee HA** (ads): "Therapeutic Plasma Exchange." New York: Springer Verlag, 1981, pp 75-87

Retas S, Thomas CR, Chambers J D, Newton KA, Hobbs JR: The effect of plasmapheresis on the clinical and immune status of patients with renal adenocarcinoma. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Patients with Cancer." New York: Elsevier/North Holland Biomedical Press, 1981, p 271

Salinas FA, Silver HKB, Grossman L, Thomas J W: Plasmapheresis - a new approach in the management of advanced malignant melanoma. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Patients with Cancer." New York: Elsevier/North Holland Biomedical Press, 1981, p 253

Samak R, Edelstein R, Israel L, Bogucki D, Samak M: Repeated plasma exchange in patients with advanced cancer - biological and immunological findings. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Patients with Cancer." New York: Elsevier/North Holland Biomedical Press, 1981, p 22

Trotter J M, Shaw D, Carlyle E, Shephard 3, Calman KC: Nutritional aspects of plasma exchange in cancer patients. In **Serrou B, Rosenfeld C** (eds): "Immune Complexes and Plasma Exchanges in Cancer Patients." New York: Elsevier/North Holland Biomedical Press, 1981, p 209

Ueda T, Masaoka T, Shibata H, Kubota Y, Saigo K, Takubo T, Nakamura H, Yoshitake J, Ishigami S: Hepatic coma treated by plasma exchange during treatment for hematological malignancies. In **Ode T** (cd): "Therapeutic Plasmapheresis." Stuttgart: F.K. Schattauer Verlag, 1981, pp 93-97

Pedersen F, et al: Treatment of metastasizing renal adenocarcinoma with specific plasma transfusion. A controlled trial of the effects on metastasis and survival time. *Ugeskr Laeger* 142:3167, 1980

Rainer H, Kokoschka EM, Moser K: Plasmapherese als therapeutische Massnahme bei Patienten mit metastasierendem soliden tumor. *Verh Dtsch Ges Inn Med* 85:1303, 1979

Bottino J C, Rossen RD, Hersh EM, Rios A, Hester J P, McBride CM: Response of malignant melanoma to plasma exchange, surgical debulking and corynebacteria parvum. *Int J Artif Organs* 1:53, 1978

Davidson WD, Isacoff WH, Block J B: Methotrexate "escape" using charcoal hemoperfusion: An alternative to citrovorum "rescue." *Trans Am Soc Artif Intern Organs* 6:16, 1977

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. X: Skin Diseases

A. Pemphigus Vulgaris

Roujeau J C, Andre C, Revuz S, Touraine R: Effects of various immunosuppressive regimens on the 'rebound phenomenon' induced by plasma exchange in pemphigus. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 39

Roujeau J C, Joneau-Fabre M, Revuz S, Touraine R: Plasma exchange in the management of pemphigus. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 40

Roujeau J C, et al: Plasma exchange in corticosteroid-resistant pemphigus. *Br J Dermatol* 106:103-104, 1982

Hunziker T, Schwarzenbach HR, Krebs A, Nydegger UE, Camponovo F, Hess M: Plasma exchange in pemphigus vulgaris. *Schweiz Med Wochenschr* 111:1637-1642, 1981 (English abstract)

Matsumoto Y, Masaoka A, Kotoh Y: Plasma-exchange-regimes in the treatment of autoimmune disorders: Systemic lupus erythematosus and pemphigus. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 209-214

Takada M, et al: Case of pemphigus vulgaris with development of factor VIII inhibitor: Successful treatment with plasma exchange. *Rinsho Ketsueki* 22:1605-1610, 1981 (In Japanese)

Takamori K, et al: Plasma exchange in skin diseases, with special reference to pemphigus vulgaris. *Rinsho Ketsueki* 22:1611-1615, 1981 (In Japanese)

Török L, Borka I, Reszler M, Toth E: Adjuvant therapy of pemphigus with plasmapheresis. *Orv Hetil* 122:2349-2351, 1981 (In Hungarian)

Amblard P, Raymond 3L, Beani S C, Chenais F, Arvieux J: Bullous pemphigoid. Therapeutic efficacy and limitations of plasmapheresis. *Nouv Presse Med* 9:1446, 1980

Rifle G, Chalopin J, Tanter Y: Treatment of bullous pemphigoid by plasma exchange - two cases. *Nouv Presse Med* 9:1445-1446, 1980

Roujeau J C, Revuz J, Fabre M, Mannoni P, Touraine R: Plasma exchanges in pemphigus vulgaris. *NHK* 9:148, 1980

ARC Blood Services
Bibliography Supplement 2
TPB X-2

Roujeau J C, Revuz S, Touraine R, Joneau-Fabre M, Mannoni P: Pemphigoïde bulleuse cortico-résistance: Succès des plasmaphéreses. *Nouv Presse Med* 8:3362, 1979

C. Miscellaneous

Andersen E, Andersen R, Clemmens OJ: Treatment of psoriasis with plasmapheresis. *Arch Dermatol* 118:74, 1982

Halevy S, Ideses C, Shohat B, Feuerman EJ: Plasmapheresis for psoriasis. *Arch Dermatol* 118:292, 1982

Rebora A, et al: Plasma exchange in psoriatic erythroderma. *Br J Dermatol* 106:119-120, 1982

Steck WD, et al: Hemofiltration treatment of psoriasis. *J Am Acad Dermatol* 6:346-349, 1982

Valbonesi M, Garelli S, Montani F, Levi L, Lampertico M, Ferrari A: Short-term effects of plasma exchange treatment of psoriasis: Preliminary clinical and immunochemical investigations. *Plasma Ther Transfus Technol* 3:177-181, 1982

Valsecchi R, Bellavitz P, Cavagneri A, Cainelli T: Psoriasis improvement with plasmapheresis. *Int J Artif Organs* 5:278, 1982

Wexler D, et al: Plasma exchange and dermatitis herpetiformis. *Arch Dermatol* 119:141-142, 1982

Asada H, Kobayashi S, Niwa T, Sezaki R, Kano K, Kawanishi A, Yokoyama M, Kishi T, Kawaguchi S, Maeda K: Plasma exchange in the treatment of psoriasis pustulosa and malignant rheumatoid arthritis. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 145-151

Kawagoe H, Matsubuchi T, Shinohara Y: Plasma exchange therapy for Weber-Christian's disease and anti-factor VIII antibody disease. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 113-118

Korotkii NG, et al: Hepatocyte state in psoriasis patients treated by hemosorption. *Vestn Dermatol Venerol* 7:16-19, 1981 (English abstract)

Maeda K, Shinzato T, Usuda M, Sezaki R, Niwa T, Asada H, Kawaguchi S, Saito A, Yamanaka N, Ohta K: Psoriasis treatment with hemofiltration and plasma exchange. *Int J Artif Organs* 4:253, 1981

Maeda K, Saito A, Kawaguchi S, Niwa T, Sezaki R, Kobayashi K, Asada H, Yamamoto Y, Ohta K: Psoriasis treatment with direct hemoperfusion. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification," Part L Washington: Hemisphere Publishing Corporation, 1980, pp 349-354

Takamori K, et al: Plasma exchange in skin diseases, with special reference to pemphigus vulgaris. *Rinsho Ketsueki* 22:1611-1615, 1981 (In Japanese)

Wallach D, Cottenot F, Busnel A, Palangie A, Pennec J: Plasma exchange therapy in Lucio's phenomenon. Arch Dermatol 116:1101, 1980

Maeda K: Psoriasis hemodiafiltration and hernoperfusion. Int Soc Artif Organs, New York, 1979

Wallach D, et al: Plasma exchange in the treatment of lepromatous leprosy. Acta Leprol (Grieve) 76-77:285-290, 1979

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. XI: Lipid Disorders (Hyperlipidemia)

Dabels J, Preussner S, Brauer P, Wilmbuss H: 1st results of plasmapheresis in type-2A homozygotic familial hypercholesterolemia. Endokrinologie 80:73, 1982 (In German)

Gerard A, Schooneman F, Guine JM, Roche G, Canton P, Dureux JB, Jannot C, Streiff F: Treatment by plasma exchange of a patient with hyperlipidemia and diabetic keto-acidosis with lesional pulmonary edema and acute pancreatitis. Vox Sang 43:147-150, 1982

Jan F, et al: Type II familial hyperlipoproteinaemia: Value of plasma exchange treatment. Am Med Interne (Paris) 133:110-113, 1982 (English abstract)

Postiglione A, et al: Increased blood flow to lower limbs after plasma exchange in two patients with familial hypercholesterolemia. Arteriosclerosis 41:421-423, 1982

Harada M, et al: Plasmapheresis in familial hypercholesterolemia and bone marrow transplantation from an ABO incompatible donor. Rinsho Ketsueki 22:1632-1635, 1981 (English abstract)

Kikawa T, Kishino B, Fushimi H, Nishikawa M, Yamamoto A: Plasma exchange therapy for homozygous familial hypercholesterolemia. In Oda T (ed): therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 127-130

Leonard JV, Clarke M, McCartney FJ, Slack J: Progression of atheroma in homozygous familial hypercholesterolaemia during regular plasma exchange. Lancet 2:811, 1981

Levy VG, Julien PE, Oppenheimer M, Denis S, Opolon P: Treatment of cholestasis by plasmapheresis. Nouv Presse Med 10:2588, 1981 (In French)

van de Wiel A, et al: Effects of plasma exchange on serum cholesterol levels in heterozygous familial hypercholesterolemia. Acta Med Scand 210:61-65, 1981

Moser H W, et al: Therapeutic trial of plasmapheresis in Refsum's disease and in Fabry disease. Birth Defects 16:491-497, 1980

Pyeritz RE, et al: Plasma exchange removes glycosphingolipid in Fabry disease. Am J Med Genet 7:301-307, 1980

Thompson GR: Long-term plasma exchange in severe familial hypercholesterolaemia. Works Imp on Therapeutic Plasma and Cytapheresis, Mayo Clinic, April 1979

Thompson GR: Therapeutic use of plasma exchange in familial hypercholesterolaemia. In Crepaldi B, Lefebvre PJ, Alberti KGMM (eds): "Diabetes, Obesity and Hyperlipidemias." London: Academic Press, 1978, p 351

Shafir E, et al: Lipoprotein synthesis in hypoproteinemia of experimental nephrotic syndrome and plasmapheresis. In **Bianchi R, et al (eds): "Plasma Protein Turnover."** Baltimore: University Park Press, 1974, pp 343-3.

A. Immunodeficiency

Plasmapheresis techniques advance in treatment of immunologically-mediated diseases. *Immunol Trib* 4:3-6, 1982

Yamagata J, Shiozawa K, Tsuda H, Katayama S, Hashimoto H, Shiokawa Y: Plasma exchange for immune disorders. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 48

B. Immune Complex Disease

Chuchalin AG, et al: Lung involvement in immune complex diseases and let clinical use of hemoaorption. *Ter Arkh* 53:15-18, 1981 (English abstract)

Schur PH: Immune complexes. *Clin Immunol Newsletter* 3:75-80, 1982

Valbonesi M, Garelli S, Montani F, Manca F, Cantarella S: Plasma exchange and immune complex diseases: The predictability of immune complexes removal to clinical response. *Vox Sang* 42:27-32, 1982

Geltner D: The place of plasmapheresis in immune complex disease. *Harefuah* 101:77-78, 1981 (in Hebrew)

Steven MM, et al: The effect of plasma exchange on the in vitro monocyte function of patients with immune complex diseases. *Clin Exp Immunol* 45:240-245, 1981

Valbonesi M, et al: Patients with high titers of circulating immune complexes are most likely to benefit from plasmapheresis treatment. *Int J Artif Organs* 4:234-237, 1981

Fassbinder W, Platzer E, Ernst W, Baldamus CA, Kock KM: Immune complex elimination by plasma separation with membrane filtration. In **Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasmaseparation."** Stuttgart: F. K. Schattauer Verlag, 1980, pp 107-112

Menini C, et al: Plasma exchange using a cell separator for immune complex disease. *Riv Emoter Immunematol* 27:38-50, 1980 (In Italian)

Pussell BA: The plasma exchange in immune complex diseases and Goodpasture's syndrome. Workshop on Therapeutic Plasma and Cytapheresis, Mayo Clinic, April 1979

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. XIII: Miscellaneous Diseases

A. Thyroid Storm

Brehm G: **Plasmapherese bei thyreotoxischer Krise.** In Gurland HG, Heinze V, Lee HA (eds): "Therapeutic Plasma Exchange." New York: Springer Verlag, 1981, pp 99-103 (In German)

Glinder D, Gaham N, Sand G, Libert J, Grivegne A, Badjou R, Ermans AM: Use of **plasmapheresis** in a case of Graves-disease with malignant **ophthalmopathy.** Ann Endocrinol (Paris) 42:545-546, 1981 (In French)

van Heukelom LHS, et al: **Plasmapheresis** in L-thyroxine intoxication. Vet Hum Toxicol 21:7, 1979

Wysk J, Stangel W, Korle J, Papastavrou S, Just S, Hesch RD: Treatment of thyroid storm by continuous **plasmapheresis.** In Rainer H (ed): "Cell Separation and Cryobiology." Stuttgart: F. K. Schattauer Verlag, 1978, p 151

Suematsu H, Matsuda K, Shizume K, Nakao K: Effect of **plasmapheresis** on thyroid hormone secretion. Endocrinology 86:1281, 1970

C. Hypertension

d'Apice AJF, Shuikes AA, Skinner SL, Whitworth 3A, Kincaid-Smith P: Plasma exchange: An antihypertensive procedure. Aust Soc Nephrol 8:227, 1979

D. Poisoning

Berlinger WG, Spector R, Flanigan MJ, Johnson GF, Groh MR: **Hemoperfusion** for phenylbutazone poisoning. Ann Intern Med 96:334-335, 1982

Cherskov M: **Extracorporeal detoxification: Still debatable.** JAMA 247:3047 - 3048, 1982

Amano I, Inagaki U, Tsuzuki K, Yamamoto T, Sugiyama T, Me M, Kanoh H: Experiences with plasma exchange for treatment of **paraquat** intoxication, SLE, and acute liver failure. Artif Organs 10:563, 1981

Glöckner WM, Sieberth HG: **Plasmaaustausch bei Digitalis-Intoxikation.** In Gurland HJ, Heinze V, Lee HA (eds): "Therapeutic Plasma Exchange." New York: Springer Verlag, 1981, pp 105-110 (In German)

ARC Blood Services
Bibliography Supplement 2
TPB XIII-2

Sabto JK, Pierce RM, West RH, Gurr FW: **Hemodialysis**, peritoneal dialysis, **plasmapheresis** and forced **diuresis** for the treatment of quinine overdose. Clin Nephrol 16:264-268, 1981

Arsac Ph, Credoz D, Barret L, Faure J: Digitalis poisoning treated by plasma exchange. Nouv Presse Med 9:41, 1980

Marin GA, Montoya CA, Sierra JL, Senior JR: Evaluation of **corticosteroid** and exchange transfusion treatment of acute yellow-phosphorus intoxication. N Engl J Med 284:125-128, 1971

Kuzmin DS, et al: **Plasmapheresis** in acute **atropine** poisoning (research experiment). Probl Gematol Pereliv Krovi 12:51-54, 1966

G. Miscellaneous

Berkman E: Issues in therapeutic **apheresis.** N Engl J Med 306:1418-1420, 1982

Boral H, Waid ME, Watson MJ, Muller VH: A mobile therapeutic **apheresis** program at a regional blood center. Plasma Ther Transfus Technol 3:217-221, 1982

Feng CS: Therapeutic **plasmapheresis** - bloodletting makes a return. Postgrad Med 72:251-255, 1982

Garinger G: Legal issues for **apheresis** operators. Technical Forum. Plasma Ther Transfus Technol 3:65-70, 1982

Ginder PA, et al: **Plasmapheresis:** A therapeutic option for treatment of selected patients. J Kans Med Soc 83:140-142, 1982

Kambic H, Nose Y: "Plasmapheresis: Historical perspective, therapeutic applications and new frontiers." Cleveland: International Center for Artificial Organs and Transplantation, 1982

Kelly WF, Wensley RT: An evaluation of plasma exchange treatment of Graves **ophthalmopathy.** Boston: Haemonetics Advanced Component Seminar, 1982 (abstract)

Le Pogamp C, Le Pogamp P, Brissot P, Le Berre C: Intensive plasma exchange: A new treatment for **cholestasis** of pregnancy. In 'International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques.' Cleveland: Int Soc Artif Organs, 1982, p 23

Marner B, Molenaar J, Nerup J, Ludvigss J, Lernmark A: Reliability of the indirect immunofluorescence test for islet cell antibodies and an evaluation of the effects of **plasmapheresis on antibody-titers in type-1 (insulin dependent) diabetes.** Diabetologia 23:185-186, 1982

Marner B, Moelnaar J, Nerup J, Ludvigss J, Lernmark A: Reliability of the indirect immunofluorescence test for islet cell antibodies and an evaluation of the effects of **plasmapheresis** on antibody-titers. Acta Endocrinol 100:44, 1982

Reuther P, Rohkamm R, Wiebeck D, Mertens HG: Plasma exchange in idiopathic inflammatory myopathy. In "International Symposium on **Plasmapheresis**: Therapeutic Applications and New Techniques." Cleveland: **Int Soc Artif Organs**, 1982, p 35

Samtleben W, Blumenstein M, Haberset R, Gurland HJ: Indications for the application of **plasmapheresis**. **Mün Med Wochenschr** 124:641-645, 1982 (In German)

Takahashi I, Inoue T: **Plasmapheresis**: Present and perspective. **ICU and CCU** 6:1, 1982 (In Japanese)

Apheresis: Development, applications, and collection procedures. **Rog Clin Biol Res** 65:1-66, 1981

Cattaneo A, et al: Plasma exchange. **Ann Med Interne (Paris)** 132:89-92, 1981 (In French)

Cona 3A: Establishing a therapeutic pheresis program. **Artif Organs** 5:229-233, 1981

Cunio 3E: Plasma exchange therapy. **Nephrol Nurse** 3:35-38, 1981

Eliasson S, et al: Idiopathic inflammatory myopathy and **plasmapheresis**. **Muscle Nerve** 4:446-447, 1981

Freireich EJ: Future trends in **apheresis**. **Prog Clin Biol Res** 65:155-162, 1981

Gratwohl A, Comu P, Nissen C, Ruggero D, Ostervalder B, Speck B: Experience with intensive plasma exchange. **Schweiz Med Wochenschr** 110:1449-1451, 1981 (English abstract)

Hill N: Therapeutic studies on **leukapheresis** and **plasmapheresis**. **Prog Clin Biol Res** 65:147-154, 1981

Holderman C, Schlesinger RG: Modified plasma therapy using the **Haemonetics** 30 blood processor. **Plasma Ther Transfus Technol** 2:31-33, 1981

Horiuchi T, Otsubo O, Uchima T, Kusaba R, Sugimoto H, Yanagisawa T, Inou T, Nagata S, Tanaka S: Development of high performance membrane and optimum design of plasma separator. **Artif Organs** 10:304, 1981 (In Japanese)

Isbister 3P, et al: **Fulminant** lupus pneumonitis with acute renal failure and RBC **aplasia**. Successful management with **plasmapheresis** and immunosuppression. **Arch Intern Med** 141:1081-1083, 1981

Kalinin NN: Principles and methods of using apparatus for plasmacytapheresis with donors and patients. **Probl Gematol Pereliv Krov** 26:11-16, 1981 (In Russian)

Kater L: **Indications and limitations of therapeutic plasmapheresis**. **Neth J Med** 24:206-208, 1981

Kuroda M, et al: Successful treatment of fulminating complications associated with extensive **rhabdomyolysis** by **plasma** exchange. **Artif Organs** 5:372-378, 1981

Levy 3: The anatomy of the therapeutic plasma exchange. In Werner WL (cd): "Plasma Forum IV, **February 11-13, 1981**." American Blood Resources Association, 1981, pp 81-85

Marconi M, et al: Approaching plasma-exchange mathematically. **Int J Artif Organs** 4:295-299, 1981

Naito R: The **beginning of plasmapheresis** in Japan. In Oda T (cd): "Therapeutic **Plasmapheresis**." Stuttgart: F. K. Schattauer Verlag, 1981, pp 29-34

Olanow CW, Roses AD, Fay JW: The **effect of plasmapheresis** on post-thy mectomy ocular dysfunction. **Can J Neurol Sci** 8:169-172, 1981

Ota K: Present status and future prospect of **plasmapheresis**. In Oda T (cd): "therapeutic **Plasmapheresis**." Stuttgart: F. K. Schattauer Verlag, 1981, pp 15-25

Pekker S: **Immunohematology: Plasmapheresis**. Therapeutic possibilities. **ZFA (Stuttgart)** 57:187-189, 1981 (In German)

Perveev VI: **Plasmapheresis** in severely burned patients. **Sov Med** 12:17-21, 1981 (English abstract)

Plasma exchange. **W Presse Med** 10:1493-1498, 1981 (In French)

Strauer BE, et al: Use of **plasmapheresis** and immunosuppressive therapy in coronary **microangiopathies**. **Bibl Haematologica** 47:213-227, 1981

Symposium on plasma substitutes, volume replacement and **hemodilution**. **Ann Clin Rea** 13 Suppl 33:1-88, 1981

Terekhov NT, et al: Hemosorption and transfusion therapy in diffuse peritonitis. **Vesm Khir** 127:62-65, 1981 (English abstract)

van de Wiel A, Imhof JW, Rommes JH: **Plasmapheresis** as a component of treatment. **Ned Tijdschr Geneesk** 125:1714-1718, 1981 (In Dutch)

Yamagata J, et al: Therapeutic plasma exchange. **Ryumachi** 21:424-429, 1981 (In Japanese)

Clark WF: Plasma exchange: A popular form of therapy. **Dimens Health Serv** 57:26-28, 1980

Frohlich CH, Schneider W: **Plasmapherese**: Therapeutische **Möglichkeiten**. **Diagnostik und Intensivtherapie** 5:89, 1980 (In German)

Hylland RG: Further evidence for **plasmapheresis**. **Arthritis Rheum** 23:129, 1980

Isbister JP: Blood letting reborn: Plasma exchange. **Med J Aust** 3:633, 1980

Koepke 3A: Plasma exchange at the University of Iowa hospitals and clinics. **J Iowa Med Soc** 70:510-512, 1980

Krebs JH: **Plasmapheresis**: A review. **MMW** 122:1755, 1980 (In German)

Verrier Jones J: Therapeutic **plasmapheresis**: An update. In Warner WL (cd): 'Plasma Forum II, February 25-27, 1980.' American Blood Resources Association, 1980, pp 173-174

Wallach D, Cottenot F, Bussel A, Palangie A, Pennec 3: Plasma exchange therapy in Lucio's phenomenon. Arch Dermatol 116:1101, 1980

Crispin JF: Medical ethics and the morality of **plasmapheresis**. In Crouch RL (cd): 'Plasma Forum.' McNally & Loftin, West: 1979, pp 39-51

Kriss 3P: Treatment of **ophthalmos** and **pretibial myxoedema** with **plasmapheresis**. Br Med J 1:1149, 1979

Neppert 3: Possibilities of therapeutic **plasmapheresis**. Beitr Infusionther Klin Ernahr 3:53-65, 1979 (In German)

Nosé Y, Malchesky PS: Therapeutic applications of **plasmapheresis**. In Warner WL (ed): 'Plasma Forum. A Public Exchange of Views Regarding **Plasmapheresis**.' American Blood Resources Association, 1979, pp 47-60

Pineda AA: Therapeutic plasma and **cytapheresis** (abstracts). Mayo Clinic Workshop on Therapeutic **Plasma** and **Cytapheresis**, April 1979

Schareman WB, Tillotson JR, Taft EF, Wright E: **Plasmapheresis** for **meningococemia** with disseminated intravascular **coagulation**. N Engl J Med 300:1277, 1979

Smaller device **under trial** may widen **plasmapheresis** application. Hospital Practice, 1979, pp 29-33

Sussman LN, et al: Intensive **plasmapheresis** during **pregnancy** and spurious amniotic fluid **bilirubin**. Am J Obstet Gynecol 135:156-157, 1979

Swisher SN: **Plasmapheresis**: A medical viewpoint. In Crouch RL (cd): 'Plasma Forum.' McNally & Loftin, West: 1979, pp 67-72

Warner WL (ad): 'Plasma Forum. A Public Exchange of Views Regarding **Plasmapheresis**.' American Blood Resources Association, 1979

Buskard NA: Plasma exchange and **plasmapheresis**. CMA 119:681, 1978

Sebahoun G, Lefevre P, Carcassonne Y, Battaglini P: Attempted clearance by massive **plasmapheresis** of an **anti-HLA** antibody in a patient who had received multiple transfusions. Nouv Presse Med 7:28, 1978

Bedry J, et al: Anti-tetanus **immunoglobulins** and **plasmapheresis**. Rev Fr Transfus Immunohematol 20:131, 1977

Thompson RN: Therapeutic **pheresis**. Boston: **Haemonetics** Advanced Component seminar, 1977

Borberg H, Muller T, Lauterjung KL: Experimentelle und Klinische Erfahrungen zur **Plasmapheresis** mit **Blutzellseparatoren**. Verh Dtsh Ges Inn Med 82:1582, 1976 (In German)

Baldassarre G, et al: **Plasmapheresis**: Method and value in extensive burns. Ann Med Nav (Roma) 76:111, 1971.

Sandu L, Nustalea N: Therapeutical **plasmapheresis** in resuscitation. Chirurgia 20:843, 1971 (In Russian)

Bystryń JC, Graf MW, Uhr JW: Regulation of antibody formation by serum antibody. IL Removal of specific antibody by means of **exchange transfusion**. J Exp Med 132:1278-1287, 1970

Mathes M: **Plasmapheresis** for the isolation of **coagulating** plasma fractions. Folia Haematol 93:327-333, 1970 (In German)

Dukic M, et al: **Plasmapheresis** in **puerperal** woman. Srps Arh Celok Lek 97:75-79, 1969

Shikunova LG, et al: **Plasmapheresis** and **erythrocyte** reinfusion during the restoration period following prolonged clinical death. Probl Gematol Pereliv Krovi 11:47-51, 1966 (In Russian)

AMERICAN RED CROSS BLOOD SERVICES

supplement 2

Therapeutic Pheresis Bibliography No. XIV: Clinical Reactions, Complications

Aufeuve 3P, Mortin-Hertel F, Cohen-Solal M, Lefloch A, Baudelot 3: Clinical tolerance and hazards of plasma exchanges: A study of 6200 plasma exchanges in 1033-patients. In Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology." Basel: S. Karger, 1982, pp 65-77

Beyer J-H, Klee M, Kaboth U, Kehl A, Kosterling H, Krieger G, Nagel GA: Problems of plasma-exchange solutions, gamma-globulin substitution, and tumor enhancement in plasmapheresis of tumor patients. In Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology." Basel: S. Karger, 1982, pp 204-217

Castelli D: Risiken and Komplikationen der therapeutischen Plasmapherese. Therapeutische Umschau/Revue Therapeutique 39:555-557, 1982 (English abstract)

Connell JM, et al: Self-poisoning with sustained-release aminophylline: Secondary rise in serum theophylline concentration after charcoal haemoperfusion. Br Med J 284:943, 1982

Huston DP, White M: Assessment of immunoglobulin-G metabolism during plasmapheresis. Clin Res 30:A471, 1982

Keller F, Hauff A, Schultze G, Offermann G: Effect of repeated plasma exchange on steady state kinetics of digoxin and digitoxin. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 16

Kiprov DD, Dau PC: The effect of plasmapheresis and immunosuppressive drug therapy on T cell subsets as defined by monoclonal antibodies. Boston: Haemoneutics Advanced Component Seminar, 1982 (abstract)

Levy 3: Safety and standards in therapeutic apheresis. Plasma Ther Transfus Technol 3:195-216, 1982

Rao AK, et al: The hemostatic system in children undergoing intensive plasma exchange. J Pediatr 100:69-75, 1982

Roberts WH, Kennedy MS, Doreen RE, Wanger GP: Acute copper deficiency in patients undergoing plasma exchange. In "International Symposium on Plasmapheresis; Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 36

Roujeau JC, Andre C, Revuz J, Touraine R: Effects of various immunosuppressive regimens on the "rebound phenomenon" induced by plasma exchange in pemphigus. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 39

ARC Blood Services
Bibliography Supplement 2
TPB XIV-2

Samtleben W, Blumensstein M, Habersetzer R, Gurland HJ: Indikationen zum Einsatz der Plasmapherese. MUn Med Wochenschr 124:641-645, 1982 (English abstract)

Schuff-Werner P, Brattig N, Beyer J-H, Bartel J, Berg PA, Nagel GA: Bio-assays as a tool for the demonstration of immune alteration in cancer patients: Suppression of mitogen-induced lymphocyte proliferation by patients' sera during plasma exchange. Preliminary results in four patients. In Beyer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and oncology." Basel: S. Karger, 1982, pp 178-193

Senhauser DA, Westphal RG, Bohman JE, Neff JC: Immune system changes in cytapheresis donors. Transfusion 22:302-304, 1982

Simon TL: Coagulation disorders with plasma exchange. Plasma Ther Transfus Technol 3:147-152, 1982

Spiva DA, Robinson CW Jr, Langley JW: Acute changes in antithrombin III levels during apheresis procedures. Plasma Ther Transfus Technol 3:137-145, 1982

Tsokos CC, Balow JE, Huston DP, Wei N, Decker JL: Effect of plasmapheresis on lymphocyte-T and lymphocyte-B functions in patients with systemic lupus-erythematosus - a double-blind study. Clin Exp Immunol 48:449-457, 1982

Urbaniak SJ: Intensive plasma exchange - effects on haemostasis. In Collins 3A, Shafer AW, Murawski K (eds): "Massive Transfusion in Surgery and Trauma." New York: Alan R. Liss, Inc., 1982, pp 191-212

Volkin RL, Starz TW, Winkelstein A, Shaddock RK, Lewis JH, Hasiba U, Spero 3A: Changes in coagulation factors, complement, immunoglobulins, and immune complex concentrations with plasma exchange. Transfusion 22:54-58, 1982

Baudelot J, Aufeuve JP, Cohen-Solal M, Estewes A: Technical aspects of repeated plasmapheresis and plasma exchanges, and some of their clinical and biological consequences. In Serrou B, Rosenfeld C (eds): "Immune Complexes and Plasma Exchanges in Cancer patients." New York: Elsevier/North Holland Biomedical Press, 1981, p 169-195

Borberg H: Problems of plasma exchange therapy. In Gurland HJ, Heinze V, Lee HA (eds): "therapeutic Plasma Exchange." New York: Springer-Verlag, 1981, pp 191-202

Brossard Y, et al: Severe complications of plasma exchange. Proposals for attitudes to take in their prevention. Rev Fr Transfus Immunohematol 24:701-708, 1981 (In French)

Dwyer J, Wade MJ, Katz AJ: Removal of thymic-derived lymphocytes during pheresis procedures. Vox Sang 41:287-294, 1981

Fiala J: Problems in plasmapheresis (transfusions and clinical aspects). Vnitr Lek 27:1131-1136, 1981 (English abstract)

Hester JP, et al: Cross cellular contamination in plateletpheresis, leukapheresis and plasma exchange. Rog Clin Biol Res 65:109-121, 1981

Jaffe P, Mosher DF: Plasma **antithrombin III** and **plasminogen levels** in chronic **plasmapheresis**. *N Engl J Med* 304:789, 1981

Jasso-Gutiérrez L, Rizohera A, Delarosa L: Effects of ● xchange transfusion on platelet counts. *Arch Invest Med (Mex)* 12:297-306, 1981

Kater L: Indications and limitations of therapeutic **plasmapheresis**. *Neth J Med* 24:206-208, 1981

Koepke 3A, Parks WM, Goeken 3A, Klee GG, Strauss RG: The safety of weekly **plateletpheresis**: Effect on the donor's lymphocyte population. *Transfusion* 21:59-63, 1981

Kuroda M, et al: Successful treatment of fulminating complications associated with extensive **rhabdomyolysis** by plasma exchange. *Artif Organs* 5:372-378, 1981

Lasky LC, Lin AT, McCullough 33: Platelet counts before and after apheresis. *Transfusion* 21:760-761, 1981

Pachl J, et al: **Hemoperfusion** and its pitfalls with children. *Cesk Pediatr* 36:511-513, 1981 (English abstract)

Pieters R, Dequeker J: Infectious complications with plasma-exchange in connective tissue diseases. Abstract 643, 15th International Congress of Rheumatology, Paris, June 1981

Seiler F, Karges H, Geursen R, Sedlacek H: Possibilities, problems and hazards with blood plasma substitution therapy, plasma exchange therapy. Proceedings International Symposium, Wiesbaden. Georg-Thieme-Verlag, 1981, pp 37-52

Sunder-Plassmann L: Hemodynamic changes during acutely induced **hemodilution**. *Ann Clin Res* 13 Suppl 33:37, 1981

Talbert RL, et al: **Propranolol** plasma **concentrations** and **plasmapheresis**. *Drug Intell Clin Pharm* 15:993-996, 1981

Vasileva D: Effect of **leukopheresis** in donor **hemopoiesis**. *Eksp Med Morfol* 20:225-231, 1981 (English abstract)

Wright DG, Karsh 3, Fauci AS, Klippel 3H, Decker JL, O'Donnell JF, Deisseroth AB: Lymphocyte depletion and immunosuppression with repeated **leukapheresis** by continuous flow **centrifugation**. *Blood* 58:451-458, 1981

Garelli S, et al: Studies on some coagulation parameters and platelet function in **leuko-** and **platelet-apheresed** donors. *Riv Emoter Immunematol* 27:218-224, 1980

Gelabert A, Puig L, Maragall S, Monteaguido J, Castillo R: Coagulative alterations during massive **plasmapheresis**. In Sieberth HG (cd): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 71-75

Glickner WM, Sieberth HG, Dienst C, Vaith P, Mitrenga D, Kindler 3: Elimination kinetics of antibodies and immune complexes in membrane plasma separation. In Sieberth HG (cd): "Plasma Exchange. **Plasmapheresis - Plasmaseparation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 121-124

Grgicevic D, Pistotnik M, Pende B: Observation of the changes of plasma proteins after long term **plasmapheresis**. *Dev Biol Stand* 48:279-286, 1980

Grob PJ, Gmlr J, Von Felten A, Frey-Wertstein M, Hartmann S, Gartmann 3: Plasma exchange and non-specific immune parameters. Comparison of two **methods**. In Sieberth HG (ad): "Plasma Exchange. **Plasmapheresis - Plasma-Separation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 113-119

Keller AJ, Urbaniak SJ: Intensive plasma exchange on the cell separator: Effects on serum **immunoglobulins** and complement components. *Plasma Ther Transfus Technol* 1:1-10, 1980

Lundsgaard-Hansen P: Donor safety in plasmapheresis. *Dev Biol Stand* 48:287-295, 1980

Rawer P, Sommerlad K-H, Goretzki K, Leber HW: Elimination of plasma proteins during plasma separation using either **centrifugation** or membrane filtration and selective removal of **immunoglobulin G** and **immune** complexes with immobilised protein A. In Sieberth HG (ad): "Plasma Exchange. **Plasmapheresis - Plasma-separation**." Stuttgart: F. K. Schattauer Verlag, 1980, pp 65-70

Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S: Infectious complications with **plasmapheresis** in rapidly progressive **glomerulonephritis**. *JAMA* 244:2423-2426, 1980

Bussel A: Etudes des incidents ● t accidents observes au cours de 250 **echanges plasmatiques**. Lea **Echanges Plasmatiques: Pratique, Resultats** et Perspectives. Bois Guillaume, March 1979

Bussard CM: The effects of intensive **plasmapheresis** on plasma constituents in donors and patients. **PhD d'issertation**, University Bern, 1979

Cohen E: Possible immunological effects of long term **plasmapheresis**. In Warner WL (cd): "Plasma Forum. A **Public Exchange of Views Regarding Plasmapheresis**." American Blood Resources Association, 1979, pp 5-20

Glassman AB: Immune responses: The rationale for **plasmapheresis**. *Plasma Ther Transfus Technol* 1:13, 1979

Kinney NJ, Tarter R, Varga E, Varga V, Sugarman AA, Milson S: Safety of repeated weekly hemoperfusion. *Clin Res* 27:420A, 1979

Sideman S, Hoffer E: **Biocompatibility** and safety evaluation of hemoperfusion devices. In Sideman S, Chang TMS (eds): "**Hemoperfusion Workshop-Beit Oren**." Samuel Newman Institute for Advanced Studies in Science and Technology, Israel, 1979

Sutton DMC, Cardella CJ, Uldall PR: Some observations on the complications of intensive plasma exchange. Boston: **Haemonetics Research** Institute, 1979

Engle WD, Jacobs JF, Swatz RD, Duff TE, Kelsch RC, Lane GA, Baublis 3W: Severe **coagulopathy** complicating charcoal **hemoperfusion** in children with **Reye** syndrome. *J Pediatr* 93:972-974, 1978

Gibson TP, Atkinson AJ: Effect of changes in **intercompartment** rate constants on drug removal during **hemoperfusion**. *J Pharmacol Sci* **67**:1178, 1978

Fennimore 3, Kolthammer JC, Lang SM: Evaluation of **hemoperfusion** systems in vitro methods related to performance and safety. In Kenedi RM, Courtney J, Gaylor JDS, Gilchrist T (eds): "Artificial Organs." London: **Macmillan Press**, 1977, pp148-157

Gilcher RO, Hashiba U: Automated **plasmapheresis** (coagulation studies). Boston: Haemonetics Advance Comportment Seminar, 1977

Lundsgaard-Hansen P: Volume **limitations** of **plasmapheresis**. *Vox Sang* **32**:20-25, 1977

Lynch RE, BuseImeier TJ: Charcoal **hemoperfusion** - induced thrombocytopenia, **leukopenia**, and serum chemistry alteration. *Kidney Int* **12**:484, 1977

Rossen RD, Hersh EM, Sharp JT, McCredie KB, Gyorkey F, Suki WN, Eknayan G, Reisberg MA: Effect of plasma exchange on circulating **immunocomplexes** and antibody formation in patients treated with **cyclophosphamide** and prednisone. *Am J Med* **63**:674, 1977

Scharschmidt BF, Martin JF, Shapiro LJ: The use of calcium chelating agents and **prostaglandin** E1 to eliminate platelet and white blood cell losses resulting from **hemoperfusion** through **uncoated** charcoal **albumin-agarose gel** and **neutral** and cation exchange resin. *J Lab Clin Med* **89**:110-119, 1977

Friedman BA, et al: Plasmapheresis-induced **hemodilution** and its effects on serum constituents. *Transfusion* **16**:155-161, 1976

Koepke JA, Wu KK, Hoak JC, Thompson 3S: Effects of long term **plasmapheresis** on plasma proteins. *Transfusion* **16**:191-192, 1976

Rimon O: Selective removal of **metabolites** from the blood serum by **hemoperfusion**. Thesis, **Technicon, Haifa**, 1976 (In Hebrew)

Winchester JF, Mackay JM, Forbes CD, Blakely E, Prentice CRM, Kennedy AC: Hemostatic **changes** induced in vitro by activated charcoal **hemoperfusion**. *Throm Diath* **34**:587, 1975

Konstantinov VN, et al: The effect of repeated **plasmapheresis** on the donors' organism. *Probl Gematol Pereliv Krovi* **16**:25-27, 1971 (In Russian)

Ad Hoc committee: Safeguards for plasma **donors in plasmapheresis** programs. *JAMA* **213**:743, 1970

Cohen MA, Oberman HA: Safety and long **term** effects of plasmapheresis. *Transfusion* **10**:58, 1970

Oishi M: Studies on the regeneration of blood **clotting** factors **following acute plasmapheresis**. *Acta Haematol Jap* **33**:226-244, 1970 (In Japanese)

Pacitti C, et al: Metabolic effects caused by blood protein restoration after **plasmapheresis**. *Arch Fisiol* **67**:215-223, 1969 (In Italian)

Daszynski 3, Klenowska Z: Preliminary investigations upon **plasmapheresis** in blood donors. *Pol Med J* **6**:857, 1967

Kliman A, Carbone PP, Gaydos LA, Freireich EJ: Effects of intensive **plasmapheresis** on normal blood donors. *Blood* **23**:647-656, 1964

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. XV: Technical Aspects

- Agishi T:** Double filtration plasmapheresis and immunoadsorption: Technical aspects. In Bayer J +1, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology." Basal: S. Karger, 1982, pp 47-56
- Borberg H:** Technical aspects of cell-plasma separation and the elimination of plasma-components ex vivo. In Bayer 3+1, Borberg H, Fuchs Ch, Nagel GA (eds): "Plasmapheresis in Immunology and Oncology." Basal: S. Karger, 1982, pp 11-18
- Leonard EF:** The Shear-rate filtration rate relationship of membranes for plasmapheresis. In "International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: Int Soc Artif Organs, 1982, p 22
- Randerson DH, et al:** Mass transfer in membrane plasma exchange. Artif Organs 6:43-49, 1982
- Kawai T, Yamagishi Y, Narita Y, Yuda M, Chiba A:** Some pertinent factors involving blood viscosity. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 41-46
- Marinone G, et al:** Bone marrow erythroblastic recovery after plasmapheresis in acquired pure red cell anemia. Case report. Haematologica (Pavia) 66:796-802, 1981
- Mielke CH Jr, et al:** Technical and therapeutic applications of plasma exchange. Prog Clin Biol Res 6:123-143, 1981
- Quellhorst E, et al:** How to prevent vascular instability: Haemofiltration. Proc Eur Dial Transplant Assoc 18:243-249, 1981
- Takahashi I, Otsubo O, Horiuchi T, Nozaki H, Yanagisawa T, Maeda T, Seo S, Yagata K, Inou T:** Fundamental studies related to plasma exchange. In Oda T (ed): "Therapeutic Plasmapheresis." Stuttgart: F. K. Schattauer Verlag, 1981, pp 35-40
- Wenk RE, Masucol E, Brewer MK:** Automated suspension of washed erythrocytes in fresh-frozen plasma for exchange transfusion. Obtaining a desired hematocrit. Transfusion 21:690-692, 1981
- Wood L, et al:** The role of continuous-flow blood fraction separators in clinical practice. S Afr Med J 59:99-104, 1981
- Das PC, Smit-Sibinga ChTS:** Replacement fluid in plasma exchange. Lancet 2:644, 1980
- Kleinman S, Thompson-Breton R, Rifkind S, Goldfinger D:** Exchange red blood cell pheresis in the management of complications of sickle cell anemia. Plasma Ther Transfus Technol 1:27, 1980
- ARC Blood Services**
Bibliography Supplement 2
TPB XV-2
- Levine DJ:** Calculation of volumes for exchange transfusions. JPediatr 97:870, 1980
- Schurek HG, Heyde C vd, Velte H, Deicher H, Marghescu S, Stolte H:** Different application of plasma exchange. Optimal adaption of exchange procedure. Nieren-u. Hochdruckkrankh 9:149, 1980
- Yamazaki Z, Inoue N, Fujimori Y, Takahama T, Wada T, Oda T, Ida K, Kataoka K, Fujisaki Y:** Biocompatibility of plasma separator of an improved cellulose acetate hollow fiber. In Sieberth HG (ed): "Plasma Exchange. Plasmapheresis - Plasma-separation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 45-51
- Nosé Y, Malchesky PS:** Therapeutic applications of plasmapheresis. In Warner WL (ed): "Plasma Forum. A Public Exchange of Views Regarding Plasmapheresis." American Blood Resources Association, 1979, pp 47-60
- Buchholz DH, Bove JR, Charette R:** Plasmapheresis using IBM 2991 blood cell processor. Transfusion 18:269-273, 1978
- Gibson TP, Atkinson AJ:** Effects of changes in intercompartment rate constants on drug removal during hemoperfusion. J Pharmacol Sci 67:1178-1179, 1978
- Maher J:** Interrelation of hemoperfusion plasma clearance and half life. In Chang TMS (ed): "Artificial Kidney, Artificial Liver, and Artificial Cells." New York: Plenum press, 1978, pp 297-300
- Panlilio AL, et al:** Pheresis techniques in therapeutic procedures and preparation of blood products. J Term Mad Assoc 71:181-184, 1978
- Suaudeau 3, Kolobow T, Vaillancourt R, Carvalho A, Ito Y, Erdmann AJ:** The Ito "flow-through" centrifuge: A new device for long-term (24 hours) plasmapheresis without platelet deterioration. Transfusion 18:312-319, 1978
- Thompson GR:** Clinical application of plasma exchange. IBM Medical Review, 1978
- Schmidt R, Falkenhagen D, Holtz M, Obsten B, Kroger E, Glasel E, Gottschall ST, Ahrend KF, Bremer H, Tiess D, Klunkmann H:** Harnoperfusion-Experimentelle und Klinische Ergebnisse. Dtsch Gesundh-Wesen 32:2117-2122, 1977 (In German)
- Farreles FB, Summers T, Belcher C, Bayer WL:** Plasma exchange with plasma protein fraction and lactated Ringers solution using the continuous flow cell separator. Infusionstherapie 2:273-277, 1975
- Rosenbaum JL:** Biocompatibility of resin haemoperfusion. In Williams RS, Murray-Lyons IM (eds): "Artificial Liver Support." New York: Pittman Press, 1975, p 118
- Ayme G, et al:** An improved technique for polyacrylamide gel electrophoresis: Application for the study of serum proteins during plasmapheresis. Prog Immunobiol Stand 4:434-443, 1970 (In French)
- Anderson SB, Rossing N:** Metabolism of albumin and G globulin during albumin infusions and during plasmapheresis. Scand J Clin Lab Invest 20:183-184, 1967

AMERICAN RED CROSS BLOOD SERVICES

Supplement 2

Therapeutic Pheresis Bibliography No. XVI: Alternative Methodologies

- Agishi T, Kaneko I, Hasuo Y, Ota K, Amemiya H, Sugino N, Abe M: **Automatic control apparatus for membrane plasmapheresis.** In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 1
- Bambauer R, Jutzler GA, Keller HE, Stolz D: Clinical experience with a technically simplified **plasmapheresis** system. In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 3
- Bambauer R, Jutzler GA, Stolz D, Ranger A, Doenecke P: **Detoxification: Using a technically simplified plasma filtration system.** In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 4
- Butylin Vi, et al: Use of the **ISL-3** artificial **circulation** apparatus for performing **hemosorption.** *Klin Khir* 1:63-64, 1982 (In Russian)
- Dmitriev M, et al: Evaluation of variants in the approach to vessels in the **hemosorption** operation in relation to the treatment regimen and procedure. *Anesteziol Reanimatol* 1:35-37, 1982 (English abstract)
- Falkenhagen D, Gottschall S, Esther G, Courtney JM, Klinkmann H: In vitro assessment of **charcoal** and resin **hemoadsorbents.** *Contrib Nephrol* 29:23-33, 1982
- Falkenhagen D, Schmitt E, Schneider P, Behm E, Tessenow W, Klinkmann H: **Plasma-absorption** - an alternative way to treat intoxications? In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 11
- Gurland HG, Nosé Y, Asanuma Y, Blumenstein M, Malchesky PS, Samtleben W, Schmidt B, Zawicki h **Membrane-plasma filtration.** In Bayer J-H, Borberg H, Fuchs Ch, Nagel GA (eds): **"Plasmapheresis in Immunology and Oncology."** Basel: S. Karger, 1982, pp 2-10
- Khatri BO: A **technique** for easy vascular access in patients **undergoing plasmapheresis.** *J Clin Apheresis* 1:55, 1982
- Kimura G, et al: A computerized model to analyze **transcellular** fluid shift during **hemofiltration.** *Artif Organs* 6:31-36, 1982
- Krakauer RS, Asanuma Y, Zawicki I, Calabrese L, Malchesky P, Nae Y: **Circulating immune complexes** in rheumatoid arthritis: Selective removal by **cryogelation** with membrane filtration. *Arch Intern Med* 142:395-397, 1982

ARC Blood Services
Bibliography Supplement 2
TPB XVI-2

- Leonard EF: The Shear-rate filtration rate relationship of membranes for **plasmapheresis.** In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 22
- Lopot F, et al: **Haemofiltration** - a new method of treatment for chronic renal failure. *Cas Lek Cesk* 121:210-213, 1982 (English abstract)
- Lysaght MJ: Factors governing mass transport in filters for membrane **plasmapheresis.** In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 25
- Malchesky PS: **Membrane plasma separation.** In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 27
- Millward BL, Hoeltge GA: The historical **development** of automated **hemapheresis.** *J Clin Apheresis* 1:25-32, 1982
- O'Neil GD, Karp DD, Hansen LE, Martel J, Gorgone BC, Ervin TJ: Preliminary results of **thrombocytapheresis** using a surge pump. **Boston: Haemonetics Advanced Component Seminar**, 1982 (abstract)
- Pourrat JP, Sanchez V, Espanan P, Dueymes JM, Conte 33: On-line **separation** of plasma **proteins** by convective **electrophoresis:** An alternative to plasma-exchange. **Boston: Haemonetics Advanced Component Seminar**, 1982 (abstract)
- Rawer P, Sommerlad K-H, Goretzky K, Leber HW: A comparative **study** of the efficacy of two methods of **plasmapheresis: Centrifugation** with ACD or heparin and membrane filtration with two **different cellulose diacetate** hollow-fiber membranes. In Bayer J-H, Borbert H, Fuchs Ch, Nagel GA (eds): **"Plasmapheresis in Immunology and Oncology."** Basel: S. Karger, 1982, pp 28-36
- Schreiner GE: Clinical **hemoperfusion.** *Contrib Nephrol* 29:7-10, 1982
- Shettigar UR, et al: **Portable artificial kidney** with advantages of hemodialysis, hereof **filtration**, and hemoperfusion. *Artif Organs* 6:17-23, 1982
- Sueoka A, Wojcicki J, Malchesky P, Need Y: PVA membranes for plasma separation. In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 42
- Vanholder R, DeClippelle M, Wulfrank, Deschrijver A, Ringoir S: **Unipuncture membrane plasmapheresis.** In **"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques."** Cleveland: **Int Soc Artif Organs**, 1982, p 46
- Asanuma Y, et al: **Chronic ambulatory liver support** by membrane **plasmapheresis** with on-line detoxification. *Trans Am Soc Artif Intern Organs* 27:416-422, 1981
- Bussel A: Comparative study of the various technics used in plasma exchange. *Rev Fr Transfus Immunohematol* 24:691-699, 1981 (In French)
- Cavalier 3: **General parameters** in the technology of plasma filtration using a membrane. *Rev Fr Transfus Immunohematol* 24:633-641, 1981 (In French)

Chmiel H: **Technologische Aspekte zur Membranplasmapherese.** In Gurland HJ, Heinze V, Lee HA (eds): **therapeutic Plasma Exchange.** New York: Springer-Verlag, 1981, pp 15-21 (In German)

Cunio JE, Anderson WW: Continuous flow plasma exchange utilizing "single needle" techniques. **Trans Am Soc Artif Intern Organs** 27:550-553, 1981

Elghouzzi MH, et al: Technical, immunological and clinical study of the performance of blood filtration using Erypur filters. **Rev Fr Transfus Immunohematol** 24:579-595, 1981 (English abstract)

Gajdós Ph, Simon N, Elkharrat D, Goulon M: Testing a cellulose diacetate membrane for plasma exchange. **Nouv Presse Med** 10:3469-3471, 1981 (English abstract)

Hughes RD, et al: Selection of an adsorbent and hemoperfusion column design. **Int J Artif Organs** 4:224-229, 1981

Inoue N, Yamazaki i& Yoshiba M, Ichikawa K, Sakai T, Oda T, Sanjo T, Wada T, Inoue J, Saoshiro T, Horiuchi T, Ide K, Fujisaki Y: Plasma exchange using membrane plasmapheresis in the treatment of acute hepatic failure. **Artif Organs** 10:557, 1981

Kanamono T, Iwata H, Yasuhara N, Takahashi S, Satoh K, Ohishi Y, Nakagawa M, Yamanaka N, Kohyama M, Saitoh A, Ota K: Long-term experience of plasma exchange using hemo-filter. in Oda T (cd): **"Therapeutic Plasmapheresis."** Stuttgart: F. K. Schattauer Verlag, 1981, pp 139-144

Kaneko I, Agishi T, Hasuo Y, Era K, Ota K, Abe M: Automatic controlling system for double filtration plasmapheresis. **Artif Organs** 10:284, 1981 (In Japanese)

Kayashima K, et al: Simple on-line filters for the therapeutic removal of lymphocytes from blood. **Trans Am Soc Artif Intern Organs** 27:559-562, 1981

Kourilsky O, et al: Plasma exchange by membrane filtration. Experience of the Tenon Hospital. **Rev Fr Transfus Immunohematol** 24:643-655, 1981 (In French)

Mathez D, et al: A new plasma exchange technique: Coagulation studies. **Nouv Rev Fr Hematol** 23:285-289, 1981 (English abstract)

Nosé Y, Malchesky PS: Therapeutic membrane plasmapheresis. In Oda T (cd): **"Therapeutic Plasmapheresis."** Stuttgart: F. K. Schattauer Verlag, 1981, pp 3-14

Pierides AM, et al: Two year experience with over 500 sessions of postdilution hemofiltration. **Trans Am Soc Artif Intern Organa** 27:618-622, 1981

Pineda AA, Taswell HF: Selective plasma component removal: Alternatives to plasma exchange. **Artif Organs** 5:234-240, 1981

Piskin E, et al: The best coating material for hemoperfusion: Comparison of cellulose nitrate with cellulose acetate and derivatives. **Int J Artif Organs** 4:86-88, 1981

Radcliffe DR, et al: Sorption kinetics in haemoperfusion columns. part 2: Modelling column Performance. **Mad Biol Eng Comput** 19:627-637, 1981

Radcliffe DR, et al: sorption kinetics in haemoperfusion columns. Part 1: Estimation of mass-transfer parameters. **Med Biol Eng Comput** 19:617-626, 1981

Ramperez P, et al: Economic preparation of sterile pyrogen free infusate for haemofiltration. **Proc Eur Dial Transplant Assoc** 18:293-296, 1981

Sakai S, Matsumoto A, Nishimuta A, Imamura N, Amemiya M, Fujimaki H, Nakamura M, Ochiai H, Miyahara T: Plasmapheresis @ W two hollow fibers of cellulose-diacetate membrane of different pore size. In Oda T (ad): **"Therapeutic Plasmapheresis."** Stuttgart: F. K. Schattauer Verlag, 1981, pp 177-183

Schindhelm K, et al: Mass transfer characteristics of plasma filtration membranes. **Trans Am Soc Artif Intern Organa** 27:554-558, 1981

Shaldon S, et al: Mixed hemofiltration (MHF): 18 months experience with ultrashort treatment time. **Trans Am Soc Artif Intern Organa** 27:610-612, 1981

Shimizu H, Hoayoa R, Yoshida S, Eiraku K, Nishimura K: Efficiency of blood cell separation and clinical evaluation of IBM 2997 CFCS. **Artif Organs** 10:316, 1981 (In Japanese)

Shimo K, Suzuta T, Suzuki M, Nosé Y: Basic and clinical studies on continuous cryofiltration: A new treatment for rheumatoid arthritis. **Rheumachi** 21:61, 1981

Shinoda A, et al: Accessible plasma exchange using membrana filter - a successfully treated case of TTP with repeated plasma exchanges. **Artif Organs** 5:248-253, 1981

Simon P, et al: Plasma exchange using filtration. Experience at the apropos of 21 patients. **Rev Fr Transfus Immunohematol** 24:671-690, 1981 (In French)

smith JW, Wyaenbeek AJ, Krakauer RS: Plasmapheresis I: Membrane filtration methods. **Plasma Ther Transfus Technol** 2:53-60, 1981

Solomon BA: Membrane separations: Technological principles and issues. **Trans Am Soc Artif Intern Organs** 27:345-350, 1981

Verrier Jones J: Centrifugal separation of plasma: Techniques and applications. **Trans Am Soc Artif Intern Organa** 27:351-355, 1981

Werynaki A, Malchesky PS, Sueoka A, Asanuma Y, Smith JW, Kayashirna K, Herpy E, Sato H, Nosé Y: Membrane plasma separation: Toward improved clinical operation. **Trans Am Soc Artif Intern Organs** 27:539-543, 1981

Zhang X: Regress in hemofiltration research. **Chung Hua Nei Ko Tsa Chih** 20:439-442, 1981 (In Chinese)

Agishi T, Kaneko S, Hasuo Y, Sanaka T, Ota K, Amemika H, Sugino N: Double filtration plasmapheresis with no or minimal amount of blood derivative for substitution. In Sieberth HG (ad): **"Plasma Exchange. Plasmapheresis - Plasma-separation."** Stuttgart: F. K. Schattauer Verlag, 1980, pp 53-57

Asaba H, Lofquist B, Wehle B, Bergstrom J: Plasma exchange with a membrane plasma filter (plasmaflo). **Nieren-u. Hochdruckkrankht** 9:136, 1980

Blaha M, et al: Case report of hyperviscosity syndrome treatment with plasma exchange using the "Aminco" separator. *Vnitr Lek* 26:786-791, 1980 (In Czechoslovakian)

Brunner G, Harstick K, Holloway CJ: Agarose-encapsulated absorbents: A new material for haemoperfusion. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification," Part L Washington: Hemisphere Publishing Corporation, 1980, pp 37-44

Chang TMS: Present status and prospective of artificial cells in hemoperfusion. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification." Washington, DC: Hemisphere Publishing Corporation, 1980, pp 93-104

Burton BT, Chang TMS, Nose Y, Rosenbaum 3L, Sideman S: Panel Discussion: Resent and future of hemoperfusion. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification." Washington, DC: Hemisphere Publishing Corporation, 1980, pp 399-401

Farrell PC, Schindhelm K, Roberts CG: Membrane plasma separation. In Sieberth HG (cd): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 37-44

Gibson TP: Pharmacokinetic determinants of the efficacy of hemoperfusion. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification," Part I. Washington: Hemisphere Publishing Corporation, 1980, pp 207-216

Inoue N, Yoshida M, Yamazaki Z, Sakai T, Sanjo K, Okada K, Oda T, Wada T, Inoue T: Continuous flow membrane plasmapheresis utilizing cellulose acetate hollow fiber in hepatic failure. In Brunner G, Schmidt FW (eds): "Artificial Liver support." New York: Springer Verlag, 1980, p 175

Kaneko I, Agishi T, Hasuo Y, Hoshimo T, Era K, Ota K, Abe M, Hayasaka Y, Kawai S, Yamane T: Technical feasibility of double filtration plasmapheresis. *Artif Organs* 9:443, 1980 (In Japanese)

Mor LA, Sideman S, Mor L, Brandes JM: Analysis of hemoperfusion columns: Selective removal of protein-bound metabolites. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification," Part I. Washington: Hemisphere Publishing Corporation, 1980, pp 175-188

Nakabayashi N, Masuhara E, Nakagawa S, Koshikawa S, Nakashima T, Takakura K: Preparation of poly-hema coated spherical activated charcoal for direct hemoperfusion. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification." Washington, DC: Hemisphere Publishing Corporation, 1980, pp 57-61

Odaka M, Hirasawa H, Kobayashi H, Ohkawa M, Soeda K, Tabata Y, Soma M, Sato H: Clinical and fundamental studies of cellulose coated bead-shaped charcoal haemoperfusion in chronic renal failure. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification." Washington, DC: Hemisphere Publishing Corporation, 1980, pp 45-55

Santleben W, Hillebrand G, Krumme D, Gurland HJ: Membrane plasma separation: Clinical experience with more than 120 plasma exchanges. In Sieberth HG (cd): "Plasma Exchange. Plasmapheresis - Plasmaseparation." Stuttgart: F. K. Schattauer Verlag, 1980, pp 175-178

Sideman S, Hoffer E, Better OS, Lupovitch S: Development of a hemoperfusion system for phosphate removal. In Sideman S, Chang TMS (eds): "Hemoperfusion. Kidney and Liver Support and Detoxification," Part L Washington: Hemisphere Publishing Corporation, 1980, pp 81-89

Asanuma Y, Smith JW, Malchesky PS, Hermann RE, Carey WD, Nose Y: Pre-clinical evaluation of membrane plasmapheresis with on-line bilirubin removal. *Artif Organs* (in press), 1979

Chang TMS: Assessment of clinical trials of charcoal hemoperfusion in uremic patients. *Nephrol* 11:111-119, 1979

Cooney DD, Daly JS: Mass transfer characteristics of hollow-fiber dialyzers and hemoperfusion devices. *Artif Organs* 3:253-258, 1979

Garciape 33, Redondor M, Torresra A, Mendezpe ML, Meceirac B, Buenogom 3: Hemoperfusion over sorbent materials. *Rev Clin Res* 152:331-335, 1979

Grabensee BH, Gobel K, Hofmann E, Schnurr E, Schroder E: Tierexperimentelle untersuchungen zur Behandlung Schwere Schlamittelvergiftungen mit Hamoperfusion durch Adsorberharz. *Verh Dtsch Ges Inn Med* 80:1571, 1979

Malchesky PS, Asanuma Y, Smith JW, Zawicki I, Nose Y: Membrane plasmapheresis with on-line plasma treatment. *Artif Organs* 3:359, 1979

Nakabayashi N, Masuhara E, Nakagawa S, Koshikawa S: Encapsulation of spherical activated charcoals with Poly-Hema for direct hemoperfusion. *Kobunsh-Ron* 36:279-286, 1979

Rossi PL: Therapeutic value of the cell separator: Review and case reports. *Minerva Med* 70:1289-1298, 1979

Smith JW, Asanuma Y, Suwa S, Harasaki H, Zawicki I, Malchesky PS, Nose Y: Blood compatibility studies of hollow fiber plasma filtration for hepatic assist. *Trans Am Soc Artif Intern Organs* 25:476, 1979

Tijssen J, Bantjes A, van Doorn AWJ, Feijen J, van Dijk B, Vonk CR, Dijkhuis JC: A hemoperfusion column based on carbon granules coated with an ultrathin membrane of cellulose acetate. *Artif Organs* 3:11, 1979

Uldall RP, Dyck RF, Woods F, Merchant N, Martin GS, Cardella CJ, Sutton D, de Veber GA: Subclavian cannula for temporary vascular access for haemodialysis or plasmapheresis. *Dial Transplant* 9:963, 1979

Amano I, Kano H, Takahira H, Yamamoto Y, Itoh K, Iwatsuki S, Maeda K, Ohta K: Hepatic assist system using bead-type charcoal. In Chang TMS (cd): "Artificial Kidney, Artificial Liver, and Artificial Cells." New York: Plenum Press, 1978, pp 89-98

Chang TMS: Adsorbent **hemoperfusion** - general discussion. In **Chang TMS** (cd): "Artificial Kidney, Artificial Liver, and Artificial Cells." New York: Plenum Press, 1978, pp 301-304

Chang TMS: A 1978 perspective of adsorbent **hemoperfusion**, artificial organs. *Artif Organs* 2:363-366, 1977

Cooney DD, Infantolino W, Kane R: Comparative studies of **hemoperfusion** devices. 1. In vitro clearance characteristics. *Biomater Med Devices Artif Organs* 6:199-213, 1978

Grabensee BH, Königshausen TH, Schnurr E: **Behandlung** Schwerer Schlafmittelver-giftungen durch **extrakorporale hamoperfusion**. *Dtsch Med Wochenschr* 101:158-162, 1978

Gundermann KJ, Lie TS: **Möglichkeiten** zur Vermeidung der Adsorption **physiologische substanzen** bei der Aktivkohlehamoperf usion. *Res Exp Med (Berl)* 173: 105-111, 1978

Hampel G, Widdop B, Goulding R: Adsorptive capacities of **hemoperfusion** devices in clinical use. *Artif Organs* 2:363-366, 1978

Hellwig G, Chmiel H: Theoretical concepts of adsorbents for **hemoperfusion**. Haemoperfusion, **Dialysate** and **Diafiltrate** Purification Symposium, Tutzing, Germany, 1978 (abstract)

Hughes RD, Ton HY, Langley PG, Silk DBA, Williams R: The use of an in vitro **hemoperfusion** circuit to evaluate the blood compatibility of **albumin-coated amberlite XAD-7** resin. *Int J Artif Organs* 1:129, 1978

Inoue N, Yamazaki Z, Sakai T, Fujiwara K, Oda T, Sanjo K, Wada T, Abe T, Furuta T, Inagaki K, Kominami N, Kataoka K, Fujisaki Y: Clinical application of a new method for **plasmapheresis** using cellulose acetate **hollow** fiber as a plasma separator. *Artif Organs* 7:1095, 1978

Klein E, Holland FF, Eberle K, Marton FC, Cabasso I: **Sorbent** filled hollow fibers for **hemoperfusion**. *Trans Am Soc Artif Intern Organs* 24:127-130, 1978

Kulpmann WR, Oelleric M, Blume V, Schmidt E, Barthels M: In vitro evaluation of adsorbents used in **hemoperfusion**. *Klin Wochenschr* 56:1171-1178, 1978

Lawyer C, Aitchison J, Sutton J, Beunett W: Treatment of **theophylline neurotoxicity** with resin **hemoperfusion**. *Ann Intern Med* 88:516-517, 1978

Losgen H, Brunner G, Holloway CJ, Buttelmann, B, Husmann S, Scharff P, Siehoff A: Large **agarose** beads for **extracorporeal** detoxification systems. I. Preparation and some properties of the large beads in haemoperfusion. *Biomater Med Devices Artif Organs* 6:151-173, 1978

Maini R: Plasmapheresis/dialysis through high porosity protein **permeable** membrane with sorbent detoxification. Haemoperfusion, **Dialysate**, and **Diafiltrate** Purification Symposium, Tutzing, Germany, 1978 (abstract)

Martin AM, Gibbons JK, Oduro A, Herbert R: Clinical experience with cellulose coated carbon **haemoperfusion**. In **Chang TMS** (cd): "Artificial Kidney, Artificial Liver, and Artificial Cells." New York: Plenum Press, 1978, pp 143-151

Piatkiewicz W, Malchesky PS, Ouchi A, Asanuma Y, Nose Y: Mechanical aspects of the plasma separation by **microporous** membrane filters. *Proc Annu Conf Eng Med Biol* 23:300, 1978

Silk DBA, Williams R: Experiences in the treatment of **fulminant** hepatic failure by conservative therapy, charcoal **hemoperfusion**, and **polyacrylonitrile hemodialysis**. *Int J Artif Organs* 1:29, 1978

Silk DBA, Williams R: Treatment of **fulminant** hepatic failure with charcoal **haemoperfusion** and **polyacrylonitrile haemodialysis**. In **Chang TMS** (cd): "Artificial Kidney, Artificial Liver, and Artificial Cells." New York: Plenum Press, 1978, pp 125-134

Suaudeau J, Kolobow T, Vaillancourt R, Carvalho A, Ito Y, Erdmann AJ: The Ito "flow-through" centrifuge: A new device for long-term (24 hours) **plasmapheresis** without platelet deterioration. *Transfusion* 18:312-319, 1978

Trafford A, Ireland R, Evans R: The use of **hemoperfusion** as an adjunct to **hemodialysis**. *Artif Organs* 3:249-253, 1978

Winchester JF, Gelfand MC, Knepshild JH, Schreiner GE: Present and future uses of **hemoperfusion** with **sorbents**. *Artif Organs* 2:353-358, 1978

Winchester JF, Gelfand MC, Knepshild JH, Schreiner GE: Present and future uses of **sorbent hemoperfusion**. **Hemoperfusion, Dialysate and Diafiltrate** Purification Symposium, Tutzing, Germany, 1978

Winchester JF, Mackay JM, Forbes CD, Courtney JM, Gilchrist T, Rentice CRM: Hemostatic changes induced in vitro by **hemoperfusion** over activated charcoal. *Artif Organs* 2:293, 1978

Yamazaki Z, Fujimori Y, Sanjo K, Kojima Y, Sugiura M, Wada T, Inoue N, Sakai T, Oda T, Kominami N, Fujisaki U, Kataoka K: New artificial liver support system (plasma-perfusion detoxification) for hepatic coma. *Artif Organs* 2 (suppl):273, 1978

Berk PD: A computer simulation study relating to the treatment of **fulminant** hepatic failure by **hemoperfusion**. *Proc Soc Exp Biol Med* 155:535-539, 1977

Castro LA, Hampel G, Gebhardt R, Fateh A, Gurland HJ: **Combination** of **hemodialysis** and **hemoperfusion** in a single hollow-fiber unit for treatment of **uremia**. In **Chang TMS** (cd): "Artificial Kidney, Artificial Liver and Artificial Cells." New York: Plenum Press, 1977, pp 193-197

Chang TMS: Criteria, evaluation and perspectives of some charcoal **hemoperfusion** systems. 3 *Dial Transplant* 5:50-54, 1977

Chang TMS: Criteria, evaluation, and prospective of various **microencapsulated** charcoal **hemoperfusion** systems. 3 *Dial Transplant* 6:21, 1977

Chang TMS, Chirito E, Barre P, Cole C, Lister C, Resurrection E: Clinical evaluation of the clearance profiles of a portable compact dialysate-free system incorporating microencapsulated charcoal hemoperfusion for blood purification with ultrafiltration for fluid removal. *J Dial* 1:239-259, 1977

Denti E, Walker JM, Brancaccio D, Tessore V: Evaluation of novel sorbent systems for joint hemodialysis and hemoperfusion. *Med Instrum* 11:212, 1977

Gilcher RO, Hashiba U: Automated plasmapheresis (coagulation studies). Haemotetics Advanced Component Seminar, Boston, MA, 1977

Holland FF, Donnan A, Gidden HE, Klein E: Methods of measurement of mass transfer rates and capacities of hemoperfusion cartridges. *Trans Am Soc Artif Intern Organs* 23:573-581, 1977

Malchesky PS, Ouchi K, Piatkiewicz W, Nosé Y: Recent developments in the design of an extracorporeal system for total hepatic assist. NIH Conference on Fulminant Hepatic Failure, Bethesda, February 1977

Martin AM, Gibbons 3K, Honsson E, Trinder P: The clinical use of carbon haemoperfusion column. In Kenedi RM, Courtney JM, Gaylor JDS, Gilchrist T (eds): "Artificial Organs." London: Macmillan Press, 1977, p 196

Ouchi K, Malchesky PS, Piatkiewicz W, Herrmann RE, Nosé Y: Improved hemoperfusion sorbent and plasma filtration system for hepatic assist. *Proc ACEMB* 19:439, 1977

Oules R, Asaba H, Neuhauser M, Yajiel V, Gunnarsson B, Bergstrom J, Furst P: Removal of uremic small and middle molecules and free amino acids by carbon hemoperfusion. *Trans Am Soc Artif Intern Organs* 23:583, 1977

Siemsen AW: Augmentation of hemodialysis by charcoal hemoperfusion. *Kidney Int* 12:490, 1977

Chang TMS, Chirito E, Barre P, Resurrection E: The use of ACAC micro-encapsulate charcoal hemoperfusion in series with Amicon ultrafiltration for patients with chronic renal failure. *Trans Am Soc Artif Intern Organs* 5:15, 1976

Malchesky PS, Vames WG, Nokoff R, Nosé Y: The charcoal capillary hemoperfusion system. *Proc Eur Dial Transplant Assoc* 13:242, 1976

Odaka M, Tabata Y, Kobayashi H, Nomura Y, Soma H, Hirasawa H, Sata H, Suenage E, Nageta K: Three-hour maintenance dialysis combining direct haemoperfusion and haemodialysis. *Proc Eur Dial Transplant Assoc* 13:257, 1976

Temple AR, Walker 3, Done GA: A comparative evaluation of activated charcoal hemoperfusion devices. Meeting of the AM Acad Clin Toxicol. The Am Assoc Poison Control Centers and the Can Acad Clin Toxicol, Seattle, WA, 1976

Walker JM, Denti E, Wagenen RV, Andrade JD: Evaluation and selection of activated carbon for hemoperfusion. *Kidney Int* 10: 3320-3327, 1976

Yamazaki Z, Fujimoto Y, Sanjo K, Kojima Y, Sugiyama M, Wada T, Inoue N, Oda T, Kominami N, Fujisaki U, Kataoka K: New artificial liver support system (plasma perfusion detoxification) for hepatic coma. *Artif Organs* 5:227, 1976 (In Japanese)

Chang TMS: Biocompatible microencapsulated (coated) charcoal for hemoperfusion in patients. In Williams R (cd): "Artificial Support Systems for Acute Hepatic Failure." London: Whitefriars Press, 1975, pp 94-103

Chang TMS, Chirito E, Barre P, Cole C, Hewish M: Clinical performance characteristics of a new combined system for simultaneous hemoperfusion-hemodialysis-ultrafiltration in series. *Trans Am Soc Artif Intern Organs* 21:502-508, 1975

Dunea G, Rizvi 2A, Anicama HG, Mamdani BH, Majurkar SD: Charcoal hemoperfusion: In-vivo and in-vitro studies. *Am Soc Nephrol* 8:28, 1975

Farrales FB, Summers T, Belcher C, Bayer WL: Plasma exchange with plasma protein fraction and lactated Ringer's solution using the continuous flow cell separator. *Infusionstherapie* 2:273-277, 1975

Isakov IUF, Lopukhin UM, Burkov IV, Mashkov OA, Lutsky I, Mosharov OP, Kazyukov VD, Isotov BN, Macheret NA: First experience with the use of extracorporeal hemoperfusion through activated charcoal in children. *Eksp Khir Anesteziol* 4:52, 1975

Ito Y, Suaudeau J, Bowman RL: New flow-through centrifuge without rotating seals applied to plasmapheresis. *Science* 189:999-1000, 1975

Maini R: Hemoperfusion over ion-exchange resins and polymeric absorbents. *Int 3 Artif Organs* 1:196-201, 1975

Scharschmidt BF, Martin 3F, Shapiro L3, Plotz PH, Berk PD: Use of calcium chelating agents and protaglandin E1 (PGE1) to eliminate platelet losses during hemoperfusion through various absorbents. *Gastroenterology* 69:A64, 1975

Weston MJ, Mellon PJ, Langley PG, Hughes RD, Dunlop EH, Gazzard BG, Williams R: Resin column perfusion with whole blood or plasma separated by the continuous flow centrifuge. *Clin Sci Molec Med* 48:187-192, 1975

Winchester 3F, Apiliga MT, Mackay J, Kennedy AC: Haemodialysis with charcoal haemoperfusion. *Proc Eur Dial Transplant Assoc* 12:526-533, 1975

Davis TA, Cowsar DR, Harrison SD, Tanquari AC: Artificial carbon fibers for hemoperfusion. *Trans Am Soc Artif Intern Organs* 20:356, 1974

Gilchrist T, Honsson E, Martin AM, Naucler L, Cameron A, Courtney JM: Development of the Strathclyde hemoperfusion system. In Williams R, Murray-Lyons IM (eds): "Artificial Liver, Artificial Kidney, and Artificial Ceils." London: Pittman Medical, 1974, p 319

Hill JB, Palaia FL, Horres CR: The design of a charcoal haemoperfusion system. In Kenedi RM, Courtney JM, Gaylor JDS, Gilchrist T (eds): "Artificial organs." London: Macmillan Press, 1974, p 123

Courtney JM, Gilchrist T, Walker JM, Edwards RO: A new coated adsorbent for blood perfusion. Digest 10th Int Conf Med Biol Eng, Dresden, Germany, 1973

Holland FF, **Donnaud A**, Giddeon HE, **Klein E**: Methods of measurement of mass transfer rates and capacities of **hemoperfusion** cartridges. **Trans Am Soc Artif Intern Organs** **18:573-582**, 1973

Andrade JD, van **Wagenen R**, **Chen C**, Ghamavian M, **Voider 3**, Kirkham R, **Koli WR**: Coated absorbents for dire blood perfusion. **Trans Am Soc Artif Intern Organs** **18:473-483**, 1972

Evenson MA, de **Vos D**: Direct contact (**membraneless**) **haemoperfusion** through oils. **Clin Chem** **18:554-562**, 1972

Andrade JD, **Kunimoto K**, van **Wagene R**, **Kastigir B**, **Gough S**, **Kolff WJ**: Coated **adsorbents** for direct blood perfusion **Hema/activated** charcoal. **Trans Am Soc Artif Intern Organs** **17:222-228**, 1971

Chang TMS, **Pent A**, **Johnson LJ**, **Malave N**: Response to intermittent **extracorporeal** perfusion through shunts containing semipermeable **microcapsules**. **Trans Am Soc Artif Intern organs** **15:163-168**, 1968

Pozniakow VA, et al: Method and technic of **plasmapheresis** by use of glass flasks. **Probl Gematol Pereliv Krovi** **13:62-63**, 1968 (In Russian)

Moore RJ, **Lehman TH**, **Hodges CV**: Treatment of acute hyperkalaemia utilizing **extracorporeal** perfusion of **blood** through cation-exchange resin columns. **Surg Gynaecol Obstet** **112:67-74**, 1961

Therapeutic **Pheresis** Bibliography No. XVII: Texts, Symposia

Beyer 3-H, **Borberg H**, **Fuchs Ch**, **Nagel GA (eds)**: "**Plasmapheresis** in Immunology and Oncology." **Basel: S. Karger**, 1982

Bonomini V, **Chang TMS (eds)**: "**Hemoperfusion**." **Basel: S. Karger**, 1982 (Listed in Bibliography as **Contrib Nephrol**, Vol. 29)

Horiuchi T, **Kambic H**, **Takatani S**, **Nose Y**: Topics in plasmapheresis: A bibliography of therapeutic applications and new techniques. Cleveland: **Charles E. Spahr** Information Center of the International Center for Artificial Organs and Transplantation, 1982

"International Symposium on Plasmapheresis: Therapeutic Applications and New Techniques." Cleveland: **Int Soc Artif Organs**, 1982 (collection of abstracts)

Gurland JG, **Heinze V**, **Lee HA (eds)**: therapeutic Plasma Exchange." New York: Springer-Verlag, 1981

Ota T (ad): therapeutic **Plasmapheresis**." Stuttgart: F. K. **Schattauer Verlag**, 1981

Serrou B, **Rosenfield C (ads)**: 'Immune Complexes and Plasma Exchanges in Patients with Cancer.' New York: **Elsevier/North Holland Biomedical Press**, 1981

Sideman S, **Chang TMS (eds)**: "**Hemoperfusion**. Kidney and Liver Support and Detoxification," Part L Washington: Hemisphere Publishing Corporation, 1980

References

References

1. Abel, J., Rowntree, L. G., and Turner, B. B., "Plasma Removal With Return of Corpuscles," *J. Pharmacol. Exp. Ther.* 5:625-641, 1914.
2. Altman, L. K., "Bloodletting Is Revived for a Wide Variety of Modern Ills," *New York Times*, sec. C., p. 1, Apr. 27, 1982.
3. Altman, S. H., and Blendon, R. (eds.), *Medical Technology: The Culprit Behind Health Care Costs*, proceedings of the 1977 Sun Valley Forum on National Health, DHEW publication No. (PHS) 79-3216 (Washington, D. C.: Government Printing Office, August 1977).
4. American College of Physicians, Clinical Efficacy Assessment Project, "Apheresis for the Treatment of Goodpasture's Syndrome, Systemic Lupus Erythematosus, Membranous and Proliferative Glomerulonephritides, Multiple Sclerosis, Potentially Life-Threatening Complications of Rheumatic Diseases, and Thrombotic Thrombocytopenic Purpura," unpublished draft statement, Philadelphia, Pa., July 20, 1982.
5. American Medical Association, Council on Scientific and Medical Affairs, Apheresis Panel, "Minutes of the Apheresis Panel," Chicago, Ill., June 19, 1982.
6. American Society of Hematology, "On the Use of Apheresis for Treatment of Hematologic Disorders," prepared for the National Center for Health Care Technology, Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., September 1981.
7. American Society of Hematology, "Statement by the American Society of Hematology on the Use of Apheresis for Treatment of Hematologic Disorders," unpublished, Thorofare, N. J., 1981.
8. Anthony, J., Baxter Travenol Laboratories, Inc., Deerfield, Ill., personal communication, December 1982.
9. Arthritis Foundation, "Recommendations of the Arthritis Foundation and the American Rheumatism Association on Plasmapheresis in Rheumatic Diseases," unpublished, Atlanta, Ga., February 1981.
10. Asbury, A., Fisher, R., McKhann, G. M., et al., "Guillain-Barré Syndrome: Is There a Role for Plasmapheresis?" *Neurology* 30:1112, 1980.
11. Beattie, T. J., Murphy, A. V., Willoughby, M. L. N., et al., "Plasmapheresis in the Hemolytic-Uraemic Syndrome in Children," *Br. Med. J.* 282:1667-1668, 1981.
12. Berkman, E., "Issues in Therapeutic Apheresis," editorial, *N. Engl. J. Med.* 306(23):1418-1420, 1982.
13. Borberg, H., "Problems of Plasma Exchange Therapy," in *Therapeutic Plasma Exchange*, H. J. Gurland, V. Heinze, and H. A. Lee (eds.) (Berlin: Springer-Verlag, 1981).
14. Bowman, J. M., Peddle, L. J., and Anderson, C., "Plasmapheresis in Severe Rh-iso-immunization," *Vox Sang.* 15:272, 1968.
15. Brettle, R. P., Gross, M., Legg, N. J., et al., "Treatment of Acute Polyneuropathy by Plasma Exchange," letter, *Lancet* 2:1100, 1971.
16. Bucu, M., Blue Cross-Blue Shield Association, Chicago, Ill., letter to Travenol Laboratories, Inc., Deerfield, Ill., Oct. 27, 1982.
17. Bunker, J. P., Hinkle, D., and McDermott, W. v., "Surgical Innovation and Its Evaluation," *science* 200:937-941, 1978.
18. Burton, R., *Anatomy of Melancholy* (New York: Vintage Books, Random House, 1977).
19. Center for the Analysis of Health Practices, Harvard School of Public Health, "Impact on Health Costs of NCHCT Recommendations for Nonreimbursement for Medical Procedures," prepared for the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Apr. 15, 1981.
20. Ciarkowski, A. A., Food and Drug Administration, Department of Health and Human Services, Silver Spring, Md., personal communication, August 1982.
21. Ciarkowski, A. A., Food and Drug Administration, Department of Health and Human Services, Silver Spring, Md., personal communication, December 1982.
22. Ciuryla, V. T., E. I. du Pont de Nemours & Co., Inc., Wilmington, Del., personal communication, December 1982.
23. Cobcroft, R., Tamagnini, G., and Dorrnandy, K. M., "Serial Plasmapheresis in a Hemophiliac With Antibodies to Factor VIII," *J. Clin. Pathol.* 30:763-765, 1977.
24. Collins, R. M., Cobe Laboratories, Inc., Lakewood, Colo., personal communication, December 1982.
25. Cook, T. D., and Campbell, D. T., *Quasi-Experimentation: Design and Analysis of Research in Field Settings* (Chicago: Rand McNally, 1979).
26. Cook, T. D., Tindall R. A. S., Walker, J., et al., "Plasma Exchange as a Treatment of Acute and Chronic Idiopathic Autoimmune Polyneuropathy: Limited Success," *Neurology* 30:361, 1980.
27. Corachan, M., Talonu, T., Oldfield, E., et al., "Treatment of Acute Severe Guillain-Barré Syndrome by Plasmapheresis," *Papua New Guinea Med. J.* 23:146-147, 1980.

28. Cotter, D., Office of Health Technology Assessment, Department of Health and Human Services, Rockville, Md., personal communication, March 1983.
29. Cotter, D., Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., personal communication, July 1982.
30. Dau, P. C., Children's Hospital, San Francisco, Calif., 1981, as reported by Travenol Laboratories, Inc., Deerfield, Ill., personal communication, December 1982.
31. Dau, P. C., Miller, R. G., and Denys, E. H., "Experience With Plasmapheresis in 153 Neurologic Patients," *Int. J. Artif. Org.* 5(1):37-46, 1982.
32. Douma, A. J., American Medical Association, Chicago, Ill., personal communication, August 1982.
33. Durward, W. F., Burnett, A. K., Watkins, R., et al., "Plasma Exchange in Guillain-Barré Syndrome," *Br. Med. J.* 283:794, 1981.
34. Edelson, E., "Cleansing the Blood," *Science* 82 (American Association for the Advancement of Science, Washington, D.C.), 3(8):72-77, October 1982.
35. Edmondson, F. W., Travenol Laboratories, Inc., Deerfield, Ill., personal communication, July 1982.
36. Edson, J. R., McArthur, J. R., Branda, R. F., et al., "Successful Management of a Subdural Hematoma in a Hemophiliac With an Anti-Factor VIII Antibody," *Blood* 41:113-122, 1973.
37. Erskine, J. G., Burnett, A. K., Walker, I. D., et al., "Plasma Exchange in Non-Hemophiliac Patients With Inhibitors to Factor VIII," *Br. Med. J.* 283:760, 1981.
38. *Federal Register*, 46(116):31770, June 17, 1981.
39. Food and Drug Administration, Department of Health and Human Services, "Apheresis: Medical Therapy for the 80s," unpublished internal document (no date, Rockville, Md.) sent to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., May 26, 1982.
40. Foreman, R. M., National Kidney Foundation, Inc., New York, letter to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., no date.
41. Friedman, L., American Red Cross, Bethesda, Md., personal communication, December 1982.
42. Frost & Sullivan, Inc., "In-Vivo Hemodetoxification and Hemoprocessing Markets in the U.S.," unpublished, New York, June 1981.
43. Goldstein, M., National Institute of Neurological and Communication Disorders and Stroke, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., personal communication, December 1982.
44. Grady, D., "Pumping Plasma," *Discover*, pp. 70-72, November 1980.
45. Gross, M. L. P., Sweny, P., and Legg, N. J., "Successful Plasmapheresis in the Miller-Fisher Syndrome," *Br. Med. J.* 282:1159, 1981.
46. Haemonetics Research Institute, "Guidelines for Therapeutic Apheresis," unpublished, Braintree, Mass., 1980.
47. Hamburger, M. I., Washington, D. C., personal communication, November 1982.
48. Hamburger, M. I., letter to Stephen HeySe, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., no date.
49. Hamburger, M. I., State University of New York, Stony Brook, N. Y., personal communication, January 1983.
50. Harden, L. B., Bluck R. S., and Salcedo, J. R., "Simultaneous Hemodialysis and Exchange Transfusion in Hemolytic Uremic Syndrome," *Clin. Pediatr.* 19:640-642, 1980.
51. Health Care Financing Administration, Department of Health and Human Services, *Medicare Hospital Manual*, Coverage Issues Appendix, Sec. 35-50: Pheresis, Baltimore, Md., revision of Dec. 9, 1980.
52. Health Care Financing Administration, Department of Health and Human Services, *Medicare Hospital Manual*, Coverage Issues Appendix: Sec. 35-50: Pheresis, Baltimore, Md., Sept. 15, 1981.
53. Health Policy Alternatives, Inc., "Public and Private Payer Views on Reimbursement for Therapeutic Apheresis," unpublished, Washington, D. C., Jan. 20, 1982.
54. Heyse, S. P., National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., memorandum on "Coverage of Plasmapheresis," to Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., Feb. 11, 1981.
55. HeySe, S. P., National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., memorandum on "Medicare Coverage Instruction on Pheresis," to Deputy Director, Office of Coverage Policy, Bu-

- reau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., Apr. 2, 1981.
56. Heyse, S. P., National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., memorandum on "Plasmapheresis—Your Memorandum of October 24, 1980," to Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., Nov. 6, 1980.
 57. Heyse, S. P., National Institutes for Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., personal communication, December 1982.
 58. Heyse, S. P., National Institutes for Arthritis, Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., personal communication, July 1982.
 59. Heyse, S. P., Renault, P. R., and Perry, S., "National Center for Health Care Technology Assessment of Therapeutic Apheresis for Rheumatoid Arthritis, 1981," *J. Clin. Apheresis* 1:50-54, 1982.
 60. Hiatt, B., "Mutation Studies Go High-Tech.," *Research News* (University of Michigan), 33(6/7), June/July 1982.
 61. Hollis, T., Blue Cross-Blue Shield of Massachusetts, Boston, Mass., personal communication, February 1983.
 62. Hughes, R. A. C., Newsom-Davis, J., Armitage, P., et al., letter, *Br. Med. J.* 282:2056, 1981.
 63. Hughes, R. A. C., Newsom-Davis, J. M., Perkin, G. D., et al., "Controlled Trial of Prenisolone in Acute Polyneuropathy," *Lancet* 2:750-753, 1978.
 64. Irvine, A. T., and Tibbles, J., "Treatment of Fisher's Variant of Guillain-Barré Syndrome by Exchange Transfusion," *J. Can. Sci. Neurol.* 8:49-50, 1981.
 65. Isselbacher, K. J., *Harrison's Principles of Internal Medicine*, 9th ed. (New York: McGraw-Hill, 1980).
 66. Jones, J. V., Claugh, J. D., Klinenberg, J. R., et al., "The Role of Therapeutic Plasmapheresis in the Rheumatic Diseases," *J. Lab. Med.* 97:589-598, 1981.
 67. Jones, J. V., "Plasmapheresis in SLE," *Clinics in Rheum. Dis.* 8(1):243-260, 1982.
 68. Jones, J. V., et al., "Rape and Heresy," *Plasma Therapy* (Laux Co., Inc., Harvard, Mass.) 1(4):3-4, 1980.
 69. Jones, R. J., American Medical Association, Chicago, 111., letter to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., June 1, 1981.
 70. Kambic, H., and Nosé, Y., *Plasmapheresis: Historical Perspective, Therapeutic Applications, and New Frontiers* (Cleveland, Ohio: International Center for Artificial Organs and Transplantation, 1982).
 71. Kaplan, B. S., and Drummond, K. N., "The Hemolytic-Uremic Syndrome is a Syndrome," *N. Engl. J. Med.* 298:964-966, 1978.
 72. Kingsley, G. F., Haemonetics Corp., Braintree, Mass., letter to the National Center for Health Care Technology, Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., Sept. 14, 1981.
 73. LeCocq, J., "Therapeutic Apheresis Update: Report on the International Symposium on Plasmapheresis," unpublished, Montgomery Securities, San Francisco, June 15, 1982.
 74. Levy, J., Immunogenetics, Sherman Oaks, Calif., personal communication, January 1983.
 75. Levy, J., Immunogenetics, Sherman Oaks, Calif., letter to P. Renault, National Center for Health Care Technology, Office of the Assistant Secretary for Health, Department of Health and Human Services, Rockville, Md., July 14, 1980.
 76. Levy, R. L., Newkirk, R., and Ochoa, J., "Treating Chronic Relapsing Guillain-Barré Syndrome by Plasma Exchange," *Lancet* 2:259-260, 1979.
 77. Littlewood, R., and Bajada, S., "Successful Plasmapheresis in the Miller-Fisher Syndrome," *Br. Med. J.* 282:778, 1981.
 78. Maisey, D. N., and Olczak, S. A., "Successful Plasmapheresis in the Miller-Fisher Syndrome," *Br. Med. J.* 282:2055, 1981.
 79. Martini, J. A., Blue Cross/Blue Shield of Massachusetts, Boston, Mass., letter to S. P. Heyse, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Aug. 3, 1981.
 80. Marwick, C., "New Blood Washing Therapy: Catching on Big Despite Lack of Controlled Studies," *Med. World N.* 22:47-59, June 8, 1981.
 81. Mayr, U., Rumpl, E., Hackl, J. M., et al., "Treatment of Guillain-Barré Syndrome by Plasma Exchange, in *Plasma Exchange Therapy*, H. Borberg and P. Reuther (eds.) (Stuttgart: Georg Thieme Verlag, 1981).
 82. Mishler, J. M., Blood Resources Branch, Division of Blood Diseases and Resources, memorandum on "Apheresis" to Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., Feb. 13, 1981.

83. Mishler, J. M., Blood Resources Branch, Division of Blood Diseases and Resources, memorandum on "Therapeutic Apheresis," to Director, National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Md., Mar. 2, 1981.
84. Misiani, R., Trevisan, F., Marchesi, D., et. al., "Plasmapheresis and Plasma Infusion in the Treatment of Hemolytic-Uremic Syndrome," *Hemostasis, Prostaglandins and Renal Disease* (New York: Raven Press, 1980).
85. Murt, H., "Therapeutic Plasmapheresis: A Medical Innovation in Search of Applications," unpublished, School of Public Health, University of Michigan, Ann Arbor, Mich., 1982.
86. National Center for Health Care Technology, "Apheresis in the Treatment of Rheumatoid Arthritis," *Assessment Report Series*, vol. 1, No. 6, Department of Health and Human Services, 1981.
87. National Institutes of Health—Progress Report, "Plasmapheresis Treatment of Acute Guillain-Barré," grant No. 1R01-NS 17053-01, 1981.
88. Nightingale, S. L., Acting Associate Commissioner for Health Affairs, Food and Drug Administration, memorandum on "Apheresis in the Treatment of Disease," to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., July 29, 1981.
89. Norris, F. H., Denys, E. H., and Mielke, C. H., "Plasmapheresis in Amyotrophic Lateral Sclerosis," in *Plasmapheresis and the Immunobiology of Myasthenia Gravis*, P. Dau (ed.) (Boston: Houghton Mifflin Professional Publishers, 1979).
90. Nosé, Y., and Malchesky, P. S., "Therapeutic Application of Plasmapheresis," *Plasma Q.* 1(4), 1979.
91. Office of Health Research, Statistics, and Technology, "Apheresis for Multiple Sclerosis," *Assessment Report Series*, vol. 2, No. 11, Department of Health and Human Services, Rockville, Md., 1982.
92. Office of Health Research, Statistics, and Technology, "Plasmapheresis and Plasma Exchange for Treatment of Thrombotic Thrombocytopenic Purpura," *Assessment Report Series*, vol. 2, No. 13, Department of Health and Human Services, Rockville, Md., 1982.
93. Office of Health Research, Statistics, and Technology, "Rheumatoid Vasculitis Therapeutic Apheresis," *Assessment Report Series*, vol. 2, No. 8, Department of Health and Human Services, Rockville, Md., 1982.
94. Office of Health Technology Assessment, "Apheresis for the Treatment of Goodpasture's Syndrome and Membranous Proliferative Glomerulonephritides," *Assessment Report Series*, vol. 3, Nos. 2 and 3, Department of Health and Human Services, Rockville, Md., 1983.
95. Office of Technology Assessment, U.S. Congress, *Assessing the Efficacy and Safety of Medical Technologies*, Washington, D. C., OTA-H-75, September 1978.
96. Office of Technology Assessment, U.S. Congress, *Development of Medical Technology: Opportunities for Assessment*, OTA-H-34, Washington, D. C., August 1976.
97. Office of Technology Assessment, U.S. Congress, "The Impacts of Randomized Clinical Trials on Health Policy and Medical Practice," preliminary draft, Washington, D. C., March 1983.
98. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology*, OTA-H-126, Washington, D. C., August 1980.
99. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology/Background Paper #1: Methodological Issues and Literature Review*, OTA-BP-H-5, Washington, D. C., September 1980.
100. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology/Background Paper #2: Case Studies of Medical Technologies*, 17 individually published case studies, Washington, D. C., 1980-1982.
101. Office of Technology Assessment, U.S. Congress, *The Implications of Cost-Effectiveness Analysis of Medical Technology/Background Paper #3: The Efficacy and Cost Effectiveness of Psychotherapy*, OTA-BP-H-6, Washington, D. C., October 1980.
102. Office of Technology Assessment, U.S. Congress, *Medical Technology and the Costs of the Medicare Program/Health Technology Case Study #22: The Effectiveness and Costs of Alcoholism Treatment*, OTA-HCS-22, Washington, D. C., March 1983.
103. Office of Technology Assessment, U.S. Congress, "The National Center for Health Care Technology and Medical Technology Assessment Policy," unpublished staff paper, Washington, D. C., March 17, 1981.
104. Office of Technology Assessment, U.S. Congress, *Strategies for Medical Technology Assessment*,

- OTA-H-181, Washington, D. C., September 1982.
105. Oldham, Robert K., National Cancer Institute, National Institutes of Health, Bethesda, Md., personal communication, December 1982.
 106. Parries, B., Duke, V. E., Simon, N. M., et al., "Adult Hemolytic-Uremic Syndrome Successfully Treated With Plasma Exchange," *Plasma Therapy* 3:57-61, 1981.
 107. Pease, E. A., "Report From NCHCT: Evaluation of Therapeutic Apheresis for Rheumatoid Arthritis," *J. A.M.A.* 246(10):1053, 1981.
 108. Phillips L. Scoville Associates, *Therapeutic PZasmapheresis: Review and Market Forecast*, Greenville, S. C., February 1981.
 109. Piller, G., Hocker, P., Ludwig, E., et al., "Plasmapheresis: Its Role in the Management of Inhibitor Patients," in *Workshop on Inhibitors of Factors VIII and IX, January 26th and 27th, 1976* (Vienna: Facultas-Verlas, 1977).
 110. Pineda, A. A., Brzica, S. M., and Taswell, H. F., "Continuous-, and Semicontinuous-Flow Blood Centrifuge Systems: Therapeutic Applications With Plasma-, Platelet-, Lympha-, and Eosinpheresis," *Transfusion* 17:407-416, 1977.
 111. Pintado, T., Taswell, H. F., and Bowie, E. J., "Treatment of Life-Threatening Hemorrhage Due to Acquired Factor VIII Inhibitor," *Blood* 46:535-541, 1975.
 112. Powell, L. C., "Intense Plasmapheresis in the Pregnant Rh-Sensitized Woman," *Am. J. Obstet. Gynecol.* 101:153, 1968.
 113. Rettig, R. A., "End-Stage Renal Disease and the 'Cost' of Medical Technology," in *Medical Technology: The Culprit Behind Health Care Costs*, proceedings of the 1977 Sun Valley Forum on National Health, S. H. Altman and R. Blendon (eds.), DHEW publication No. (PHS) 79-3216 (Washington, D. C.: U.S. Government Printing Office, August 1977).
 114. Révész, T., Mátyus, J., Goldschmidt, B., et al., "Control of Life-Threatening Bleeding by Combined Plasmapheresis and Immunosuppressive Treatment in a Hemophiliac With Inhibitors," *Arch. Dis. Child.* 55:641-643, 1980.
 115. Riegelman, R. K., "Plasmapheresis in Guillain-Barré Syndrome," prepared for the Office of Technology Assessment, U.S. Congress, September 1982.
 116. Robbins, F., "Assessing the Consequences of Biomedical Research," in *Medical Technology: The Culprit Behind Health Care Costs*, proceedings of the 1977 Sun Valley Forum on National Health, S. H. Altman and R. Blendon (eds.), DHEW publication No. (PHS) 79-3216 (Washington, D. C.: U.S. Government Printing Office, August 1977).
 117. L. F. Rothschild, Unterberg, Towbin, "Therapeutic Apheresis," unpublished, New York, Sept. 11, 1981.
 118. Rothwell, R. S., Davis, P., Gordon, P. A., et al., "A Controlled Study of Plasma Exchange in the Treatment of Severe Rheumatoid Arthritis," *Arth. & Rheumat.* 23:785-790, 1980.
 119. Rumpl, E., et al., "Treatment of Guillain-Barré Syndrome by Plasma Exchange," *J. Neurol.* 225: 207-217, 1981.
 120. Samtleben, W., Blumenstein, M., Liebl, L., et al., "Membrane Plasma Separates for Treatment of Immunologically Medicated Disease," *Trans. Am. Soc. of Artif. Int. Org.* 26:12-16, 1980.
 121. Sandier, G. S., American Red Cross, Washington, D. C., personal communication, December 1982.
 122. Saxe, L., and Fine, M., *Social Experiments: Methods for Design and Evaluation* (Beverly Hills, Calif.: Sage Publications, Inc., 1981).
 123. Schooneman, F., Janet, C., Streiff, F., et al., "Plasma Exchange in Guillain-Barré Syndrome: Ten Cases," *Plasma Ther.* 2:117-121, 1981.
 124. Schweitzer, S., and Foxman, B. H., UCLA School of Public Health, "The Effect of Third Party Reimbursement on Expenditures for Medical Care," prepared at the request of the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Sept. 15, 1981.
 125. Scoville, P., Greenville, S. C., personal communication, December 1982.
 126. Seger, R., Joller, P., and Baerlocher, K., "Hemolytic-Uremic Syndrome Associated With Neuraminidase-Producing Micro-Organisms: Treatment by Plasma Exchange," *Helv. Paediatr. Act.* 35:359-367, 1980.
 127. Simon, T., "Overview of the Efficacy of Therapeutic Apheresis," presented at Plasma Forum V, Washington, D. C., June 1982.
 128. Simon, T., United Blood Services, Albuquerque, N. M., letter to S. P. Heyse, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Sept. 11, 1981.
 129. Slocombe, G. W., Newland, A. C., and Colvin, M. P., "The Role of Intensive Plasma Exchange in the Prevention and Management of Haemorrhage in Patients With Inhibitors to Factor VIII," *Br. J. Haematol.* 47:577-585, 1981.
 130. Sutton, D. M. C., Cardella, C. J., Udall, P. R.,

- et al., "Complications of Intensive Plasma Exchange," *Plasma Ther.* 2:19-23, 1981.
131. Sweny, P., Winning, A., Gross, M., et al., "Plasmapheresis in the Haemolytic-Uraemic Syndrome in Children," *Br. Med. J.* 282:2137, 1981.
 132. Taft, E. G., and Baldwin, S. T., "Plasma Exchange Transfusion," *Semin. Thromb. Hemostas.* 7:15-21, 1981.
 133. Thomas, L., *Lives of a Cell* (New York: Viking Press, 1974).
 134. Valbonesi, M., Mosconi, L., Garelli, S., et al., "Successful Treatment by Plasma Exchange in Guillain-Barré Syndrome With Immune Complexes," *Vox Sang.* 38:181-184, 1980.
 135. Viatel, P., Chenais, F., Dechelette, D., et al., "Adult Hemolytic Uremic Syndrome Successfully Treated With Plasma Exchange," *Kidney Int.* 15:453, 1979.
 136. Vibert, G. J., Parker-Hannifin Corp., Irvine, Calif., personal communication, August 1982.
 137. Waldenstrom, J. G., "Plasmapheresis—Bloodletting Revived and Refined," *Acta Med. Scand.* 208:1-4, 1980.
 138. Wallace, D. J., Goldfinger, D., and Gatti, R., "Plasmapheresis and Lymphoplasmapheresis in the Management of Rheumatoid Arthritis," *Arth. & Rheumat.* 22:703-710, 1979.
 139. Wallace, D. J., Goldfinger, D., Lowe, C., et al., "A Double-Blind, Controlled Study of Lymphoplasmapheresis Versus Sham Apheresis in Rheumatoid Arthritis," *N. Engl. J. Med.* 306(23):1406-1410, 1982.
 140. Wallace, D. J., Goldfinger, D., Thompson-Breton, R., et al., "Advances in the Use of Therapeutic Pheresis for the Management of Rheumatic Diseases," *Sem. Arth. & Rheumat.* 10:81-91, 1980.
 141. Warner, K. E., "A 'Desperation-Reaction' Model of Medical Diffusion," *Health Serv. Res.* 10:369-383, 1975.
 142. Warner, W. L. (ed.), *Plasma Forum IV: February 11-13, 1981*, American Blood Resources Association, no city, no date.
 143. Wensley, R. T., Stevens, R. F., Burn, A. M., et al., "Plasma Exchange and Human Factor VIII Concentrate in Managing Hemophilia A With Factor VIII Inhibitors," *Br. Med. J.* 281:1388-1389, 1980.
 144. Wenz, B., and Barland, P., "Therapeutic Intensive Plasmapheresis," *Sem. Hematol.* 18(2):147-162, 1981.
 145. Wohlreich, J. J., Travenol Laboratories, Inc., letter to the National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Sept. 14, 1981.
 146. Wortman, P. M., and Murt, H. (in collaboration with Bruce Friedman), "Plasmapheresis for Hemolytic-Uremic Syndrome and Factor VIII Inhibitor," prepared for the Office of Technology Assessment, U.S. Congress, October 1982.
 147. Wortman, P. M., and Saxe, L., "The Assessment of Medical Technology: Methodological Considerations," prepared for the Office of Technology Assessment, U.S. Congress, Appendix C in *Strategies for Medical Technology Assessment*, OTA-H-181, Washington, D. C., September 1981.
 148. Wyngaarden, J. B., and Smith, L. H. (eds.), *Cecil Textbook of Medicine*, 16th ed. (Philadelphia, Pa.: W. B. Saunders Co., 1982).
 149. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Coverage of Apheresis" to Associate Director for Medical and Scientific Evaluation, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., May 11, 1981.
 150. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Coverage of Plasmapheresis," to Director, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Jan. 13, 1981.
 151. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Baltimore, Md., memorandum on "Medicare Coverage Instructions on Pheresis," to Director, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Dec. 12, 1980.
 152. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "NCHCT Regarding Plasmapheresis in the Treatment of Rheumatoid Arthritis," to Associate Director for Medical and Scientific Evaluation, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., June 15, 1981.
 153. Young, D. A., Deputy Director, Office of Coverage Policy, Bureau of Program Policy, Health

Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Medicare Coverage Instructions on Pheresis," to Director, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Mar. 11, 1981.

154. Young, D. A., Office of Coverage Policy, Bureau

of Program Policy, Health Care Financing Administration, Department of Health and Human Services, Baltimore, Md., memorandum on "Plasmapheresis—Memorandum of August 25, 1980" to Associate Director for Medical and Scientific Evaluation, National Center for Health Care Technology, Department of Health and Human Services, Rockville, Md., Oct. 24, 1980.

0